{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For Johnson and Johnson, in 2022 Q1, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  |  |  |  |  |  |  | \n |  | \n\u2611 |  | Quarterly Report Pursuant to Section\u00a013 or 15(d) of the Securities Exchange Act of 1934  |  |  |  |  |  |  |  | \n |  | \n\u2610 |  | Transition Report Pursuant to Section\u00a013 or 15(d) of the Securities Exchange Act of 1934for the transition period from\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0to  |  |  |  |  |  |  |  | \nNew Jersey |  | 22-1024240\n(State or other jurisdiction ofincorporation or organization) |  | (I.R.S. EmployerIdentification No.)  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Large accelerated filer | \u2611 | Accelerated filer | \u2610\n | Non-accelerated filer | \u2610 | Smaller reporting company | \u2610\n | Emerging growth company | \u2610 |  |   |  |  |  |  |  |  |  | \nTitle of each class | Trading Symbol | Name of each exchange on which registered\nCommon Stock, Par Value $1.00 | JNJ | New York Stock Exchange\n0.650% Notes Due May 2024 | JNJ24C | New York Stock Exchange\n5.50% Notes Due November 2024 | JNJ24BP | New York Stock Exchange\n1.150% Notes Due November 2028 | JNJ28 | New York Stock Exchange\n1.650% Notes Due May 2035 | JNJ35 | New York Stock Exchange  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Page\n |  |  | No.\nPart I \u2014 Financial Information |  |  | 1\n |  |  | \nItem\u00a01. Financial Statements (unaudited) |  |  | 1\n |  |  | \nConsolidated Balance Sheets \u2014April3, 2022and January2, 2022 |  |  | 1\n |  |  | \nConsolidated Statements of Earnings for the FiscalFirstQuartersEndedApril3, 2022andApril4, 2021 |  |  | 2\n |  |  | \n |  |  | \n |  |  | \nConsolidated Statements of Comprehensive Income for the FiscalFirstQuartersEndedApril3, 2022andApril4, 2021 |  |  | 3\n |  |  | \nConsolidated Statements of Equity for the FiscalFirstQuarters EndedApril3, 2022andApril4, 2021 |  |  | 4\n |  |  | \nConsolidated Statements of Cash Flows for the FiscalThreeMonths EndedApril3, 2022andApril4, 2021 |  |  | 5\n |  |  | \nNotes to Consolidated Financial Statements |  |  | 6\n |  |  | \n |  |  | \n |  |  | \nItem\u00a02. Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations |  |  | 42\n |  |  | \nItem\u00a03. Quantitative and Qualitative Disclosures About Market Risk |  |  | 53\n |  |  | \nItem\u00a04. Controls and Procedures |  |  | 54\n |  |  | \nPart II \u2014 Other Information |  |  | 54\n |  |  | \nItem\u00a01 - Legal Proceedings |  |  | 54\n |  |  | \nItem\u00a02 - Unregistered Sales of Equity Securities and Use of Proceeds |  |  | 55\n |  |  | \nItem\u00a06 - Exhibits |  |  | 56\n |  |  | \nSignatures |  |  | 57\n\n\n\n\n\n\n\n  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | April 3, 2022 |  | January 2, 2022\nASSETS\nCurrent assets: |  |  |  | \nCash and cash equivalents |  | $ | 10,463 |  |  | 14,487 | \nMarketable securities |  | 19,925 |  |  | 17,121 | \nAccounts receivable, trade, less allowances for doubtful accounts and credit losses $234(2021, $230) |  | 15,594 |  |  | 15,283 | \nInventories (Note 2) |  | 10,990 |  |  | 10,387 | \nPrepaid expenses and other |  | 3,452 |  |  | 3,701 | \n |  |  |  | \nTotal current assets |  | 60,424 |  |  | 60,979 | \nProperty, plant and equipment at cost |  | 47,702 |  |  | 47,679 | \nLess: accumulated depreciation |  | (29,001) |  |  | (28,717) | \nProperty, plant and equipment, net |  | 18,701 |  |  | 18,962 | \nIntangible assets, net (Note 3) |  | 44,420 |  |  | 46,392 | \nGoodwill (Note 3) |  | 34,935 |  |  | 35,246 | \nDeferred taxes on income (Note 5) |  | 9,936 |  |  | 10,223 | \nOther assets |  | 9,939 |  |  | 10,216 | \nTotal assets |  | $ | 178,355 |  |  | 182,018 | \nLIABILITIES AND SHAREHOLDERS\u2019 EQUITY\nCurrent liabilities: |  |  |  | \nLoans and notes payable |  | $ | 4,297 |  |  | 3,766 | \nAccounts payable |  | 9,309 |  |  | 11,055 | \nAccrued liabilities |  | 13,006 |  |  | 13,612 | \nAccrued rebates, returns and promotions |  | 12,972 |  |  | 12,095 | \nAccrued compensation and employee related obligations |  | 2,098 |  |  | 3,586 | \nAccrued taxes on income (Note 5) |  | 1,708 |  |  | 1,112 | \nTotal current liabilities |  | 43,390 |  |  | 45,226 | \nLong-term debt (Note 4) |  | 28,851 |  |  | 29,985 | \nDeferred taxes on income (Note 5) |  | 6,424 |  |  | 7,487 | \nEmployee related obligations (Note 6) |  | 8,739 |  |  | 8,898 | \nLong-term taxes payable (Note 5) |  | 5,745 |  |  | 5,713 | \nOther liabilities |  | 10,497 |  |  | 10,686 | \nTotal liabilities |  | $ | 103,646 |  |  | 107,995 | \nCommitments and Contingencies (Note 11) |  |  |  | \nShareholders\u2019 equity: |  |  |  | \nCommon stock \u2014 par value $1.00per share (authorized4,320,000,000shares; issued3,119,843,000shares) |  | $ | 3,120 |  |  | 3,120 | \nAccumulated other comprehensive income (loss) (Note 7) |  | (13,757) |  |  | (13,058) | \nRetained earnings |  | 124,380 |  |  | 123,060 | \nLess: common stock held in treasury, at cost (490,459,000and490,878,000shares) |  | 39,034 |  |  | 39,099 | \nTotal shareholders\u2019 equity |  | 74,709 |  |  | 74,023 | \nTotal liabilities and shareholders' equity |  | $ | 178,355 |  |  | 182,018 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal First Quarter Ended\n |  | April 3,2022 |  | Percentto Sales |  | April 4,2021 |  | Percentto Sales\nSales to customers (Note 9) |  | $ | 23,426 |  |  | 100.0 | % |  | $ | 22,321 |  |  | 100.0 | %\nCost of products sold |  | 7,598 |  |  | 32.4 |  |  | 7,063 |  |  | 31.7 | \nGross profit |  | 15,828 |  |  | 67.6 |  |  | 15,258 |  |  | 68.3 | \nSelling, marketing and administrative expenses |  | 5,938 |  |  | 25.4 |  |  | 5,432 |  |  | 24.3 | \nResearch and development expense |  | 3,462 |  |  | 14.8 |  |  | 3,178 |  |  | 14.2 | \nIn-process research and development |  | 610 |  |  | 2.6 |  |  | \u2014 |  |  | \u2014 | \nInterest income |  | (22) |  |  | (0.1) |  |  | (15) |  |  | (0.1) | \nInterest expense, net of portion capitalized |  | 10 |  |  | 0.0 |  |  | 63 |  |  | 0.3 | \nOther (income) expense, net |  | (102) |  |  | (0.4) |  |  | (882) |  |  | (3.9) | \nRestructuring (Note 12) |  | 70 |  |  | 0.3 |  |  | 53 |  |  | 0.2 | \nEarnings before provision for taxes on income |  | 5,862 |  |  | 25.0 |  |  | 7,429 |  |  | 33.3 | \nProvision for taxes on income (Note 5) |  | 713 |  |  | 3.0 |  |  | 1,232 |  |  | 5.5 | \nNET EARNINGS |  | $ | 5,149 |  |  | 22.0 | % |  | $ | 6,197 |  |  | 27.8 | %\n |  |  |  |  |  |  |  | \nNET EARNINGS PER SHARE (Note 8) |  |  |  |  |  |  |  | \nBasic |  | $ | 1.96 |  |  |  |  | $ | 2.35 |  |  | \nDiluted |  | $ | 1.93 |  |  |  |  | $ | 2.32 |  |  | \n |  |  |  |  |  |  |  | \nAVG. SHARES OUTSTANDING |  |  |  |  |  |  |  | \nBasic |  | 2,629.2 |  |  |  |  | 2,631.6 |  |  | \nDiluted |  | 2,666.5 |  |  |  |  | 2,672.7 |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Fiscal First Quarter Ended |  | \n | April 3, 2022 |  | April 4, 2021 |  |  |  | \n |  |  |  |  |  |  | \nNet earnings | $ | 5,149 |  |  | 6,197 |  |  |  |  | \n |  |  |  |  |  |  | \nOther comprehensive income (loss), net of tax |  |  |  |  |  |  | \nForeign currency translation | (554) |  |  | 276 |  |  |  |  | \n |  |  |  |  |  |  | \nSecurities: |  |  |  |  |  |  | \nUnrealized holding gain (loss) arising during period | (13) |  |  | \u2014 |  |  |  |  | \nReclassifications to earnings | \u2014 |  |  | \u2014 |  |  |  |  | \n |  |  |  |  |  |  | \nNet change | (13) |  |  | \u2014 |  |  |  |  | \n |  |  |  |  |  |  | \nEmployee benefit plans: |  |  |  |  |  |  | \nPrior service cost amortization during period | (53) |  |  | (41) |  |  |  |  | \nGain (loss) amortization during period | 217 |  |  | 274 |  |  |  |  | \n |  |  |  |  |  |  | \nNet change | 164 |  |  | 233 |  |  |  |  | \n |  |  |  |  |  |  | \nDerivatives & hedges: |  |  |  |  |  |  | \nUnrealized gain (loss) arising during period | (195) |  |  | (522) |  |  |  |  | \nReclassifications to earnings | (101) |  |  | (73) |  |  |  |  | \nNet change | (296) |  |  | (595) |  |  |  |  | \n |  |  |  |  |  |  | \nOther comprehensive income (loss) | (699) |  |  | (86) |  |  |  |  | \n |  |  |  |  |  |  | \nComprehensive income | $ | 4,450 |  |  | 6,111 |  |  |  |  | \n |  |  |  |  |  |  |   |  | \nThe tax effects in other comprehensive income for the fiscal first quarter were as follows for 2022 and 2021, respectively: Foreign Currency Translation: $145million and $319million; Securities: $3million in 2022; Employee Benefit Plans: $19million and $66million; Derivatives & Hedges: $78million and $157million.\n\n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Total |  | RetainedEarnings |  | AccumulatedOtherComprehensiveIncome |  | Common StockIssued Amount |  | TreasuryStockAmount\nBalance, January 2, 2022 | $ | 74,023 |  |  | 123,060 |  |  | (13,058) |  |  | 3,120 |  |  | (39,099) | \nNet earnings | 5,149 |  |  | 5,149 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nCash dividends paid ($1.06per share) | (2,787) |  |  | (2,787) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nEmployee compensation and stock option plans | 600 |  |  | (1,042) |  |  | \u2014 |  |  | \u2014 |  |  | 1,642 | \nRepurchase of common stock | (1,577) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1,577) | \n |  |  |  |  |  |  |  |  | \nOther comprehensive income (loss), net of tax | (699) |  |  | \u2014 |  |  | (699) |  |  | \u2014 |  |  | \u2014 | \nBalance, April 3, 2022 | $ | 74,709 |  |  | 124,380 |  |  | (13,757) |  |  | 3,120 |  |  | (39,034) | \n |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n\n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Total |  | RetainedEarnings |  | AccumulatedOtherComprehensiveIncome |  | Common StockIssued Amount |  | TreasuryStockAmount\nBalance, January 3, 2021 | $ | 63,278 |  |  | 113,890 |  |  | (15,242) |  |  | 3,120 |  |  | (38,490) | \n |  |  |  |  |  |  |  |  | \nNet earnings | 6,197 |  |  | 6,197 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nCash dividends paid ($1.01per share) | (2,659) |  |  | (2,659) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nEmployee compensation and stock option plans | 542 |  |  | (920) |  |  | \u2014 |  |  | \u2014 |  |  | 1,462 | \nRepurchase of common stock | (1,438) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1,438) | \n |  |  |  |  |  |  |  |  | \nOther comprehensive income (loss), net of tax | (86) |  |  | \u2014 |  |  | (86) |  |  | \u2014 |  |  | \u2014 | \nBalance, April 4, 2021 | $ | 65,834 |  |  | 116,508 |  |  | (15,328) |  |  | 3,120 |  |  | (38,466) | \n |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n\n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Three Months Ended\n |  | April 3,2022 |  | April 4,2021\nCASH FLOWS FROM OPERATING ACTIVITIES |  |  |  | \nNet earnings |  | $ | 5,149 |  |  | 6,197 | \nAdjustments to reconcile net earnings to cash flows from operating activities: |  |  |  | \nDepreciation and amortization of property and intangibles |  | 1,769 |  |  | 1,894 | \nStock based compensation |  | 278 |  |  | 307 | \n |  |  |  | \n |  |  |  | \nAsset write-downs |  | 610 |  |  | 14 | \n |  |  |  | \nNet gain on sale of assets/businesses |  | (168) |  |  | (580) | \n |  |  |  | \nDeferred tax provision |  | (926) |  |  | (730) | \nCredit losses and accounts receivable allowances |  | 6 |  |  | (13) | \nChanges in assets and liabilities, net of effects from acquisitions and divestitures: |  |  |  | \nIncrease in accounts receivable |  | (427) |  |  | (1,604) | \nIncrease in inventories |  | (600) |  |  | (695) | \nDecrease in accounts payable and accrued liabilities |  | (2,817) |  |  | (2,336) | \nDecrease in other current and non-current assets |  | 995 |  |  | 2,522 | \nIncrease/(Decrease) in other current and non-current liabilities |  | 110 |  |  | (902) | \n |  |  |  | \nNET CASH FLOWS FROM OPERATING ACTIVITIES |  | 3,979 |  |  | 4,074 | \n |  |  |  | \nCASH FLOWS FROM INVESTING ACTIVITIES |  |  |  | \nAdditions to property, plant and equipment |  | (607) |  |  | (677) | \nProceeds from the disposal of assets/businesses, net (Note 10) |  | 248 |  |  | 603 | \nAcquisitions, net of cash acquired (Note 10) |  | (252) |  |  | \u2014 | \nPurchases of investments |  | (9,018) |  |  | (5,994) | \nSales of investments |  | 6,303 |  |  | 5,233 | \nCredit support agreements activity, net |  | (249) |  |  | 751 | \nOther (primarily licenses and milestones) |  | (59) |  |  | (101) | \n |  |  |  | \nNET CASH USED BY INVESTING ACTIVITIES |  | (3,634) |  |  | (185) | \n |  |  |  | \nCASH FLOWS FROM FINANCING ACTIVITIES |  |  |  | \nDividends to shareholders |  | (2,787) |  |  | (2,659) | \nRepurchase of common stock |  | (1,577) |  |  | (1,438) | \nProceeds from short-term debt |  | 3,019 |  |  | 23 | \nRepayment of short-term debt |  | (856) |  |  | (475) | \nProceeds from long-term debt, net of issuance costs |  | \u2014 |  |  | 1 | \nRepayment of long-term debt |  | (2,132) |  |  | (1,001) | \nProceeds from the exercise of stock options/employee withholding tax on stock awards, net |  | 321 |  |  | 236 | \nCredit support agreements activity, net |  | (235) |  |  | 212 | \nOther |  | (138) |  |  | (24) | \n |  |  |  | \nNET CASH USED BY FINANCING ACTIVITIES |  | (4,385) |  |  | (5,125) | \n |  |  |  | \nEffect of exchange rate changes on cash and cash equivalents |  | 16 |  |  | (78) | \nDecrease in cash and cash equivalents |  | (4,024) |  |  | (1,314) | \nCash and Cash equivalents, beginning of period |  | 14,487 |  |  | 13,985 | \nCASH AND CASH EQUIVALENTS, END OF PERIOD |  | $ | 10,463 |  |  | 12,671 | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \nAcquisitions |  |  |  | \nFair value of assets acquired |  | $ | 255 |  |  | \u2014 | \nFair value of liabilities assumed and noncontrolling interests |  | (3) |  |  | \u2014 | \nNet cash paid for acquisitions |  | $ | 252 |  |  | \u2014 | \n |  |  |  | \n |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | April 3, 2022 |  | January 2, 2022\nRaw materials and supplies |  | $ | 1,679 |  |  | 1,592 | \nGoods in process |  | 2,629 |  |  | 2,287 | \nFinished goods |  | 6,682 |  |  | 6,508 | \nTotal inventories |  | $ | 10,990 |  |  | 10,387 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | April 3, 2022 |  | January 2, 2022\nIntangible assets with definite lives: |  |  |  | \nPatents and trademarks \u2014 gross |  | $ | 37,960 |  |  | 38,572 | \nLess accumulated amortization |  | (20,492) |  |  | (20,088) | \nPatents and trademarks \u2014 net |  | 17,468 |  |  | 18,484 | \nCustomer relationships and other intangibles \u2014 gross |  | 22,910 |  |  | 23,011 | \nLess accumulated amortization |  | (12,147) |  |  | (11,925) | \nCustomer relationships and other intangibles\u00a0\u2014 net(1) |  | 10,763 |  |  | 11,086 | \nIntangible assets with indefinite lives: |  |  |  | \nTrademarks |  | 6,947 |  |  | 6,985 | \nPurchased in-process research and development(2) |  | 9,242 |  |  | 9,837 | \nTotal intangible assets with indefinite lives |  | 16,189 |  |  | 16,822 | \nTotal intangible assets \u2014 net |  | $ | 44,420 |  |  | 46,392 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | Consumer Health |  | Pharmaceutical |  | MedTech |  | Total\nGoodwill at January 2, 2022 |  | $ | 9,810 |  |  | 10,580 |  |  | 14,856 |  |  | 35,246 | \nGoodwill, related to acquisitions |  | \u2014 |  |  | \u2014 |  |  | 73 |  |  | 73 | \n |  |  |  |  |  |  |  | \nCurrency translation/Other |  | (195) |  |  | (170) |  |  | (19) |  |  | (384) | \nGoodwill at April 3, 2022 |  | $ | 9,615 |  |  | 10,410 |  |  | 14,910 |  |  | 34,935 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  |  |  |  |  | \n2022 |  | 2023 |  | 2024 |  | 2025 |  | 2026\n$4,600 |  | 4,600 |  | 4,400 |  | 3,600 |  | 3,000  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | \n | April 3, 2022 | April 4, 2021\n(Dollars in Millions) | Sales | Cost of Products Sold | R&D Expense | Interest (Income) Expense | Other (Income)  Expense | Sales | Cost of Products Sold | R&D Expense | Interest (Income) Expense | Other (Income)  Expense\n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \nThe effects of fair value, net investment and cash flow hedging: |  |  |  |  |  |  |  |  |  | \nGain (Loss) on fair value hedging relationship: |  |  |  |  |  |  |  |  |  | \nInterest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nHedged items | $ | \u2014 |  | \u2014 |  | \u2014 |  | (531) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 | \nDerivatives designated as hedging instruments | \u2014 |  | \u2014 |  | \u2014 |  | 531 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nGain (Loss) on net investment hedging relationship: |  |  |  |  |  |  |  |  |  | \nCross currency interest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing | \u2014 |  | \u2014 |  | \u2014 |  | 45 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 40 |  | \u2014 | \nAmount of gain or (loss) recognized in AOCI | \u2014 |  | \u2014 |  | \u2014 |  | 45 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 40 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nGain (Loss) on cash flow hedging relationship: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) reclassified from AOCI into income | (17) |  | (52) |  | 23 |  | \u2014 |  | (18) |  | 17 |  | 34 |  | (113) |  | \u2014 |  | 3 | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in AOCI | 22 |  | (94) |  | 33 |  | \u2014 |  | (73) |  | (3) |  | (193) |  | (76) |  | \u2014 |  | 17 | \n |  |  |  |  |  |  |  |  |  | \nCross currency interest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) reclassified from AOCI into income | \u2014 |  | \u2014 |  | \u2014 |  | 120 |  | \u2014 |  | \u2014 |  |  | \u2014 |  | 92 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in AOCI | $ | \u2014 |  | \u2014 |  | \u2014 |  | (128) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (307) |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | \n |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLine item in the Consolidated Balance Sheet in which the hedged item is included |  | Carrying Amount of the Hedged Liability |  | Cumulative Amount of Fair Value Hedging Gain/ (Loss)  Included in the Carrying Amount of the Hedged Liability\n |  | \n(Dollars in Millions) |  | April 3, 2022 |  | January 2, 2022 |  | April 3, 2022 |  | January 2, 2022\n |  |  |  |  |  |  |  | \nLong-term Debt |  | 9,313 |  |  | 9,793 |  |  | (694) |  |  | (142) | \n |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | \n |  |  |  | Gain/(Loss)Recognized InIncome on Derivative |  | \n(Dollars in Millions) |  | Location of Gain /(Loss) Recognized in Income on Derivative |  | Fiscal First Quarter Ended |  | \nDerivatives Not Designated as Hedging Instruments |  |  |  | April 3, 2022 |  | April 4, 2021 |  |  |  | \nForeign Exchange Contracts |  | Other (income) expense |  | $ | 29 |  |  | (16) |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n\n |  | Gain/(Loss)Recognized InAccumulatedOCI |  | Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income |  | Gain/(Loss)                                                                                                                                                                                                                                  Reclassified FromAccumulated OCIInto Income\n(Dollars in Millions) |  | April 3, 2022 |  | April 4, 2021 |  |  |  | April 3, 2022 |  | April 4, 2021\nDebt |  | $ | 68 |  |  | 209 |  |  | Interest (income) expense |  | \u2014 |  |  | \u2014 | \nCross Currency interest rate swaps |  | $ | 560 |  |  | 361 |  |  | Interest (income) expense |  | \u2014 |  |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n\n |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | January 2, 2022 |  |  |  |  |  | April 3, 2022 |  | \n |  | Carrying Value |  | Changes in Fair Value Reflected in Net Income(1) |  | Sales/ Purchases/Other(2) |  | Carrying Value |  | Non Current Other Assets\nEquity Investments with readily determinable value |  | $ | 1,884 |  |  | (402) |  |  | (30) |  |  | 1,452 |  |  | 1,452 | \n |  |  |  |  |  |  |  |  |  | \nEquity Investments without readily determinable value |  | $ | 500 |  |  | (5) |  |  | 10 |  |  | 505 |  |  | 505 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | April 3, 2022 |  |  |  | January 2, 2022\n(Dollars in Millions) |  | Level 1 |  | Level 2 |  | Level 3 |  | Total |  | Total(1)\nDerivatives designated as hedging instruments: |  |  |  |  |  |  |  |  |  | \nAssets: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts |  | $ | \u2014 |  |  | 742 |  |  | \u2014 |  |  | 742 |  |  | 540 | \nInterest rate contracts(2) |  | \u2014 |  |  | 975 |  |  | \u2014 |  |  | 975 |  |  | 796 | \n |  |  |  |  |  |  |  |  |  | \nTotal |  | \u2014 |  |  | 1,717 |  |  | \u2014 |  |  | 1,717 |  |  | 1,336 | \nLiabilities: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts |  | \u2014 |  |  | 1,058 |  |  | \u2014 |  |  | 1,058 |  |  | 881 | \nInterest rate contracts(2) |  | \u2014 |  |  | 1,652 |  |  | \u2014 |  |  | 1,652 |  |  | 979 | \n |  |  |  |  |  |  |  |  |  | \nTotal |  | \u2014 |  |  | 2,710 |  |  | \u2014 |  |  | 2,710 |  |  | 1,860 | \nDerivatives not designated as hedging instruments: |  |  |  |  |  |  |  |  |  | \nAssets: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts |  | \u2014 |  |  | 36 |  |  | \u2014 |  |  | 36 |  |  | 24 | \nLiabilities: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts |  | \u2014 |  |  | 68 |  |  | \u2014 |  |  | 68 |  |  | 28 | \nOther Investments: |  |  |  |  |  |  |  |  |  | \nEquity investments(3) |  | 1,452 |  |  | \u2014 |  |  | \u2014 |  |  | 1,452 |  |  | 1,884 | \nDebt securities(4) |  | \u2014 |  |  | 19,583 |  |  | \u2014 |  |  | 19,583 |  |  | 19,727 | \nOther Liabilities |  |  |  |  |  |  |  |  |  | \nContingent consideration(5) |  | $ | \u2014 |  |  | \u2014 |  |  | 486 |  |  | 486 |  |  | 533 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \nGross to Net Derivative Reconciliation |  | April 3, 2022 |  | January 2, 2022\n(Dollars in Millions) |  |  |  | \nTotal Gross Assets |  | $ | 1,753 |  |  | 1,360 | \nCredit Support Agreement (CSA) |  | (1,655) |  |  | (1,285) | \nTotal Net Asset |  | 98 |  |  | 75 | \n |  |  |  | \nTotal Gross Liabilities |  | 2,778 |  |  | 1,888 | \nCredit Support Agreement (CSA) |  | (2,709) |  |  | (1,855) | \nTotal Net Liabilities |  | $ | 69 |  |  | 33 | \n |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | \n |  | April 3, 2022 |  | April 4, 2021\n(Dollars in Millions) |  |  |  | \nBeginning Balance |  | $ | 533 |  |  | $ | 633 | \nChanges in estimated fair value(6) |  | (47) |  |  | 15 | \nAdditions |  | \u2014 |  |  | \u2014 | \nPayments |  | \u2014 |  |  | (48) | \nEnding Balance |  | $ | 486 |  |  | $ | 600 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) | Carrying Amount |  |  |  | Gain/( Loss) |  | Estimated Fair Value |  | Cash & Cash Equivalents |  | Current Marketable Securities\nCash | $ | 3,128 |  |  |  |  | \u2014 |  |  | 3,128 |  |  | 3,128 |  |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |  | \nNon-U.S. sovereign securities(1) | 329 |  |  |  |  | \u2014 |  |  | 329 |  |  | \u2014 |  |  | 329 | \nU.S. reverse repurchase agreements | 1,449 |  |  |  |  | \u2014 |  |  | 1,449 |  |  | 1,449 |  |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |  | \nCorporate debt securities(1) | 3,557 |  |  |  |  | (6) |  |  | 3,551 |  |  | 540 |  |  | 3,017 | \nMoney market funds | 1,579 |  |  |  |  | \u2014 |  |  | 1,579 |  |  | 1,579 |  |  | \u2014 | \nTime deposits(1) | 763 |  |  |  |  | \u2014 |  |  | 763 |  |  | 763 |  |  | \u2014 | \nSubtotal | 10,805 |  |  |  |  | (6) |  |  | 10,799 |  |  | 7,459 |  |  | 3,346 | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | Unrealized Loss |  |  |  |  |  | \nU.S. Gov't securities | 19,354 |  |  |  |  | (19) |  |  | 19,335 |  |  | 2,968 |  |  | 16,367 | \nOther sovereign securities | 3 |  |  |  |  | \u2014 |  |  | 3 |  |  | \u2014 |  |  | 3 | \nCorporate debt securities | 246 |  |  |  |  | (1) |  |  | 245 |  |  | 36 |  |  | 209 | \nSubtotal available for sale debt(2) | $ | 19,603 |  |  |  |  | (20) |  |  | 19,583 |  |  | 3,004 |  |  | 16,579 | \nTotal cash, cash equivalents and current marketable securities | $ | 30,408 |  |  |  |  | (26) |  |  | 30,382 |  |  | 10,463 |  |  | 19,925 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | Cost Basis |  | Fair Value\nDue within one year |  | $ | 19,585 |  |  | 19,564 | \nDue after one year through five years |  | 19 |  |  | 19 | \nDue after five years through ten years |  | \u2014 |  |  | \u2014 | \nTotal debt securities |  | $ | 19,604 |  |  | 19,583 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | Carrying Amount |  | Estimated Fair Value\n |  |  |  | \nFinancial Liabilities |  |  |  | \n |  |  |  | \nCurrent Debt |  | $ | 4,297 |  |  | 4,298 | \n |  |  |  | \nNon-Current Debt |  |  |  | \n6.73% Debentures due 2023 |  | 250 |  |  | 266 | \n3.375% Notes due 2023 |  | 802 |  |  | 820 | \n |  |  |  | \n0.650% Notes due 2024 (750MM Euro 1.1311) |  | 824 |  |  | 829 | \n5.50% Notes due 2024 (500 MM GBP 1.3485) |  | 654 |  |  | 713 | \n2.625% Notes due 2025 |  | 749 |  |  | 762 | \n |  |  |  | \n0.55% Notes due 2025 |  | 950 |  |  | 886 | \n2.45% Notes due 2026 |  | 1,995 |  |  | 1,981 | \n2.95% Notes due 2027 |  | 930 |  |  | 934 | \n |  |  |  | \n0.95% Notes due 2027 |  | 1,436 |  |  | 1,307 | \n2.90%\u00a0Notes due 2028 |  | 1,496 |  |  | 1,489 | \n1.150% Notes due 2028 (750MM Euro 1.1311) |  | 826 |  |  | 829 | \n6.95% Notes due 2029 |  | 298 |  |  | 379 | \n |  |  |  | \n1.30% Notes due 2030 |  | 1,672 |  |  | 1,486 | \n4.95% Debentures due 2033 |  | 498 |  |  | 590 | \n4.375% Notes due 2033 |  | 855 |  |  | 959 | \n1.650% Notes due 2035 (1.5B Euro 1.1311) |  | 1,654 |  |  | 1,687 | \n3.55% Notes due 2036 |  | 917 |  |  | 947 | \n5.95% Notes due 2037 |  | 993 |  |  | 1,288 | \n3.625% Notes due 2037 |  | 1,416 |  |  | 1,463 | \n3.40%\u00a0Notes due 2038 |  | 992 |  |  | 999 | \n5.85% Debentures due 2038 |  | 697 |  |  | 901 | \n4.50% Debentures due 2040 |  | 540 |  |  | 617 | \n |  |  |  | \n2.10% Notes due 2040 |  | 914 |  |  | 777 | \n4.85% Notes due 2041 |  | 297 |  |  | 342 | \n4.50% Notes due 2043 |  | 496 |  |  | 565 | \n3.70% Notes due 2046 |  | 1,975 |  |  | 2,097 | \n3.75% Notes due 2047 |  | 906 |  |  | 969 | \n3.50% Notes due 2048 |  | 743 |  |  | 766 | \n2.25% Notes due 2050 |  | 914 |  |  | 759 | \n2.45% Notes due 2060 |  | 1,155 |  |  | 942 | \nOther |  | 7 |  |  | 7 | \nTotal Non-Current Debt |  | $ | 28,851 |  |  | 29,356 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal First Quarter Ended |  | \n |  | Retirement Plans |  | Other Benefit Plans |  |  |  | \n(Dollars in Millions) |  | April 3, 2022 |  | April 4, 2021 |  | April 3, 2022 |  | April 4, 2021 |  |  |  |  |  |  |  | \nService cost |  | $ | 321 |  |  | 353 |  |  | 80 |  |  | 77 |  |  |  |  |  |  |  |  | \nInterest cost |  | 230 |  |  | 193 |  |  | 26 |  |  | 20 |  |  |  |  |  |  |  |  | \nExpected return on plan assets |  | (699) |  |  | (680) |  |  | (2) |  |  | (2) |  |  |  |  |  |  |  |  | \nAmortization of prior service cost/(credit) |  | (46) |  |  | (45) |  |  | (1) |  |  | (8) |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nRecognized actuarial losses |  | 162 |  |  | 314 |  |  | 30 |  |  | 38 |  |  |  |  |  |  |  |  | \nCurtailments and settlements |  | 1 |  |  | 1 |  |  | \u2014 |  |  | \u2014 |  |  |  |  |  |  |  |  | \nNet periodic benefit cost/(credit) |  | $ | (31) |  |  | 136 |  |  | 133 |  |  | 125 |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  | Foreign |  | Gain/(Loss) |  | Employee |  | Gain/(Loss) |  | Total Accumulated\n |  | Currency |  | On |  | Benefit |  | On Derivatives |  | Other Comprehensive\n(Dollars in Millions) |  | Translation |  | Securities |  | Plans |  | & Hedges |  | Income (Loss)\nJanuary 2, 2022 |  | $ | (10,017) |  |  | (3) |  |  | (2,702) |  |  | (336) |  |  | (13,058) | \nNet change |  | (554) |  |  | (13) |  |  | 164 |  |  | (296) |  |  | (699) | \n |  |  |  |  |  |  |  |  |  | \nApril 3, 2022 |  | $ | (10,571) |  |  | (16) |  |  | (2,538) |  |  | (632) |  |  | (13,757) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal First Quarter Ended |  | \n(Shares in Millions) |  | April 3, 2022 |  | April 4, 2021 |  |  |  | \nBasic net earnings per share |  | $ | 1.96 |  |  | 2.35 |  |  |  |  | \nAverage shares outstanding \u2014 basic |  | 2,629.2 |  |  | 2,631.6 |  |  |  |  | \nPotential shares exercisable under stock option plans |  | 140.1 |  |  | 128.4 |  |  |  |  | \nLess: shares which could be repurchased under treasury stock method |  | (102.8) |  |  | (87.3) |  |  |  |  | \n |  |  |  |  |  |  |  | \nAverage shares outstanding \u2014 diluted |  | 2,666.5 |  |  | 2,672.7 |  |  |  |  | \nDiluted net earnings per share |  | $ | 1.93 |  |  | 2.32 |  |  |  |  |   |  |  |  |  |  |  |  | \n\n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal First Quarter Ended |  | \n(Dollars in Millions) |  | April 3,2022 |  | April 4,2021 |  | PercentChange |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nCONSUMER HEALTH |  |  |  |  |  |  |  |  |  |  |  | \nOTC(1) |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | $ | 670 |  |  | 599 |  |  | 11.8 | % |  |  |  |  |  | \nInternational |  | 791 |  |  | 673 |  |  | 17.5 |  |  |  |  |  |  | \nWorldwide |  | 1,461 |  |  | 1,273 |  |  | 14.8 |  |  |  |  |  |  | \nSkin Health/Beauty |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 544 |  |  | 634 |  |  | (14.2) |  |  |  |  |  |  | \nInternational |  | 468 |  |  | 529 |  |  | (11.6) |  |  |  |  |  |  | \nWorldwide |  | 1,012 |  |  | 1,163 |  |  | (13.0) |  |  |  |  |  |  | \nOral Care |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 143 |  |  | 163 |  |  | (12.6) |  |  |  |  |  |  | \nInternational |  | 223 |  |  | 254 |  |  | (12.0) |  |  |  |  |  |  | \nWorldwide |  | 366 |  |  | 417 |  |  | (12.2) |  |  |  |  |  |  | \nBaby Care |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 85 |  |  | 96 |  |  | (11.5) |  |  |  |  |  |  | \nInternational |  | 270 |  |  | 293 |  |  | (7.7) |  |  |  |  |  |  | \nWorldwide |  | 355 |  |  | 389 |  |  | (8.6) |  |  |  |  |  |  | \nWomen's Health |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 3 |  |  | 3 |  |  | 7.2 |  |  |  |  |  |  | \nInternational |  | 224 |  |  | 219 |  |  | 2.5 |  |  |  |  |  |  | \nWorldwide |  | 228 |  |  | 222 |  |  | 2.6 |  |  |  |  |  |  | \nWound Care/Other |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 112 |  |  | 115 |  |  | (3.3) |  |  |  |  |  |  | \nInternational |  | 52 |  |  | 61 |  |  | (15.3) |  |  |  |  |  |  | \nWorldwide |  | 164 |  |  | 177 |  |  | (7.4) |  |  |  |  |  |  | \nTOTAL CONSUMER HEALTH |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,557 |  |  | 1,611 |  |  | (3.4) |  |  |  |  |  |  | \nInternational |  | 2,029 |  |  | 2,030 |  |  | 0.0 |  |  |  |  |  | \nWorldwide |  | 3,586 |  |  | 3,641 |  |  | (1.5) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPHARMACEUTICAL |  |  |  |  |  |  |  |  |  |  |  | \nImmunology |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 2,501 |  |  | 2,413 |  |  | 3.7 |  |  |  |  |  |  | \nInternational |  | 1,617 |  |  | 1,501 |  |  | 7.7 |  |  |  |  |  |  | \nWorldwide |  | 4,119 |  |  | 3,914 |  |  | 5.2 |  |  |  |  |  |  | \nREMICADE |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 358 |  |  | 489 |  |  | (26.8) |  |  |  |  |  |  | \nU.S. Exports |  | 80 |  |  | 57 |  |  | 40.5 |  |  |  |  |  |  | \nInternational |  | 225 |  |  | 232 |  |  | (2.6) |  |  |  |  |  |  | \nWorldwide |  | 663 |  |  | 777 |  |  | (14.7) |  |  |  |  |  |  | \nSIMPONI / SIMPONI ARIA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 287 |  |  | 255 |  |  | 12.5 |  |  |  |  |  |  | \nInternational |  | 283 |  |  | 307 |  |  | (7.6) |  |  |  |  |  |  | \nWorldwide |  | 571 |  |  | 562 |  |  | 1.5 |  |  |  |  |  |  | \nSTELARA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,379 |  |  | 1,331 |  |  | 3.6 |  |  |  |  |  |  | \nInternational |  | 909 |  |  | 817 |  |  | 11.2 |  |  |  |  |  |  | \nWorldwide |  | 2,288 |  |  | 2,148 |  |  | 6.5 |  |  |  |  |  |  | \nTREMFYA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 391 |  |  | 274 |  |  | 42.7 |  |  |  |  |  |  | \nInternational |  | 199 |  |  | 143 |  |  | 38.8 |  |  |  |  |  |  | \nWorldwide |  | 590 |  |  | 418 |  |  | 41.3 |  |  |  |  |  |  | \nOTHER IMMUNOLOGY |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 6 |  |  | 7 |  |  | (3.2) |  |  |  |  |  |  | \nInternational |  | 0 |  |  | 2 |  |  | * |  |  |  |  |  | \nWorldwide |  | 6 |  |  | 8 |  |  | (22.0) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nInfectious Diseases |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 461 |  |  | 512 |  |  | (10.0) |  |  |  |  |  |  | \nInternational |  | 836 |  |  | 485 |  |  | 72.3 |  |  |  |  |  |  | \nWorldwide |  | 1,297 |  |  | 998 |  |  | 30.0 |  |  |  |  |  |  | \nCOVID-19 VACCINE |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 75 |  |  | 100 |  |  | (24.9) |  |  |  |  |  |  | \nInternational |  | 382 |  |  | 0 |  | * |  |  |  |  |  | \nWorldwide |  | 457 |  |  | 100 |  |  | * |  |  |  |  |  | \nEDURANT / rilpivirine |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 9 |  |  | 10 |  |  | (12.6) |  |  |  |  |  |  | \nInternational |  | 239 |  |  | 233 |  |  | 2.5 |  |  |  |  |  |  | \nWorldwide |  | 248 |  |  | 243 |  |  | 1.8 |  |  |  |  |  |  | \nPREZISTA / PREZCOBIX /REZOLSTA / SYMTUZA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 369 |  |  | 380 |  |  | (3.1) |  |  |  |  |  |  | \nInternational |  | 132 |  |  | 166 |  |  | (20.3) |  |  |  |  |  |  | \nWorldwide |  | 501 |  |  | 546 |  |  | (8.3) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nOTHER INFECTIOUS DISEASES(1) |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 8 |  |  | 21 |  |  | (62.5) |  |  |  |  |  |  | \nInternational |  | 83 |  |  | 87 |  |  | (3.8) |  |  |  |  |  |  | \nWorldwide |  | 91 |  |  | 108 |  |  | (15.3) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nNeuroscience |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 843 |  |  | 771 |  |  | 9.3 |  |  |  |  |  |  | \nInternational |  | 898 |  |  | 943 |  |  | (4.8) |  |  |  |  |  |  | \nWorldwide |  | 1,741 |  |  | 1,715 |  |  | 1.5 |  |  |  |  |  |  | \nCONCERTA / methylphenidate |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 35 |  |  | 47 |  |  | (26.5) |  |  |  |  |  |  | \nInternational |  | 122 |  |  | 123 |  |  | (1.3) |  |  |  |  |  |  | \nWorldwide |  | 157 |  |  | 171 |  |  | (8.3) |  |  |  |  |  |  | \nINVEGA SUSTENNA / XEPLION / INVEGA   TRINZA / TREVICTA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 661 |  |  | 589 |  |  | 12.2 |  |  |  |  |  |  | \nInternational |  | 387 |  |  | 376 |  |  | 3.0 |  |  |  |  |  |  | \nWorldwide |  | 1,048 |  |  | 965 |  |  | 8.6 |  |  |  |  |  |  | \nRISPERDAL CONSTA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 63 |  |  | 67 |  |  | (6.4) |  |  |  |  |  |  | \nInternational |  | 66 |  |  | 89 |  |  | (26.1) |  |  |  |  |  |  | \nWorldwide |  | 129 |  |  | 157 |  |  | (17.6) |  |  |  |  |  |  | \nOTHER NEUROSCIENCE(1) |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 84 |  |  | 67 |  |  | 25.5 |  |  |  |  |  |  | \nInternational |  | 323 |  |  | 355 |  |  | (8.9) |  |  |  |  |  |  | \nWorldwide |  | 408 |  |  | 422 |  |  | (3.5) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nOncology |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,582 |  |  | 1,377 |  |  | 14.9 |  |  |  |  |  |  | \nInternational |  | 2,369 |  |  | 2,193 |  |  | 8.0 |  |  |  |  |  |  | \nWorldwide |  | 3,950 |  |  | 3,570 |  |  | 10.6 |  |  |  |  |  |  | \nDARZALEX |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 953 |  |  | 691 |  |  | 37.9 |  |  |  |  |  |  | \nInternational |  | 903 |  |  | 674 |  |  | 34.0 |  |  |  |  |  |  | \nWorldwide |  | 1,856 |  |  | 1,365 |  |  | 36.0 |  |  |  |  |  |  | \nERLEADA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 206 |  |  | 171 |  |  | 20.3 |  |  |  |  |  |  | \nInternational |  | 194 |  |  | 90 |  |  | * |  |  |  |  |  | \nWorldwide |  | 400 |  |  | 261 |  |  | 53.0 |  |  |  |  |  |  | \nIMBRUVICA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 370 |  |  | 444 |  |  | (16.7) |  |  |  |  |  |  | \nInternational |  | 668 |  |  | 680 |  |  | (1.8) |  |  |  |  |  |  | \nWorldwide |  | 1,038 |  |  | 1,125 |  |  | (7.7) |  |  |  |  |  |  | \nZYTIGA/abiraterone acetate |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 19 |  |  | 50 |  |  | (62.1) |  |  |  |  |  |  | \nInternational |  | 520 |  |  | 588 |  |  | (11.6) |  |  |  |  |  |  | \nWorldwide |  | 539 |  |  | 638 |  |  | (15.6) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nOTHER ONCOLOGY |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 34 |  |  | 21 |  |  | 63.1 |  |  |  |  |  |  | \nInternational |  | 84 |  |  | 161 |  |  | (47.7) |  |  |  |  |  |  | \nWorldwide |  | 118 |  |  | 182 |  |  | (35.1) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nPulmonary Hypertension |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 572 |  |  | 573 |  |  | (0.2) |  |  |  |  |  |  | \nInternational |  | 279 |  |  | 288 |  |  | (2.9) |  |  |  |  |  |  | \nWorldwide |  | 852 |  |  | 861 |  |  | (1.1) |  |  |  |  |  |  | \nOPSUMIT |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 273 |  |  | 272 |  |  | 0.5 |  |  |  |  |  |  | \nInternational |  | 170 |  |  | 179 |  |  | (4.8) |  |  |  |  |  |  | \nWorldwide |  | 443 |  |  | 450 |  |  | (1.6) |  |  |  |  |  |  | \nUPTRAVI |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 269 |  |  | 259 |  |  | 3.9 |  |  |  |  |  |  | \nInternational |  | 56 |  |  | 46 |  |  | 20.9 |  |  |  |  |  |  | \nWorldwide |  | 325 |  |  | 305 |  |  | 6.5 |  |  |  |  |  |  | \nOTHER PULMONARY HYPERTENSION |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 30 |  |  | 42 |  |  | (29.0) |  |  |  |  |  |  | \nInternational |  | 53 |  |  | 63 |  |  | (15.2) |  |  |  |  |  |  | \nWorldwide |  | 83 |  |  | 105 |  |  | (20.8) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nCardiovascular / Metabolism / Other |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 672 |  |  | 799 |  |  | (15.8) |  |  |  |  |  |  | \nInternational |  | 238 |  |  | 245 |  |  | (3.0) |  |  |  |  |  |  | \nWorldwide |  | 910 |  |  | 1,044 |  |  | (12.8) |  |  |  |  |  |  | \nXARELTO |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 508 |  |  | 589 |  |  | (13.8) |  |  |  |  |  |  | \nInternational |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  |  |  |  |  | \nWorldwide |  | 508 |  |  | 589 |  |  | (13.8) |  |  |  |  |  |  | \nINVOKANA / INVOKAMET |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 60 |  |  | 87 |  |  | (30.7) |  |  |  |  |  |  | \nInternational |  | 68 |  |  | 63 |  |  | 7.5 |  |  |  |  |  |  | \nWorldwide |  | 128 |  |  | 150 |  |  | (14.6) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nOTHER(1,2) |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 104 |  |  | 122 |  |  | (14.9) |  |  |  |  |  |  | \nInternational |  | 170 |  |  | 182 |  |  | (6.6) |  |  |  |  |  |  | \nWorldwide |  | 274 |  |  | 305 |  |  | (10.0) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nTOTAL PHARMACEUTICAL |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 6,632 |  |  | 6,446 |  |  | 2.9 |  |  |  |  |  |  | \nInternational |  | 6,237 |  |  | 5,655 |  |  | 10.3 |  |  |  |  |  |  | \nWorldwide |  | 12,869 |  |  | 12,101 |  |  | 6.3 |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nMEDTECH(3) |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nInterventional Solutions |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 494 |  |  | 434 |  |  | 13.8 |  |  |  |  |  |  | \nInternational |  | 597 |  |  | 514 |  |  | 16.2 |  |  |  |  |  |  | \nWorldwide |  | 1,092 |  |  | 949 |  |  | 15.1 |  |  |  |  |  |  | \nOrthopaedics |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,289 |  |  | 1,249 |  |  | 3.2 |  |  |  |  |  |  | \nInternational |  | 899 |  |  | 864 |  |  | 4.1 |  |  |  |  |  |  | \nWorldwide |  | 2,188 |  |  | 2,113 |  |  | 3.5 |  |  |  |  |  |  | \nHIPS |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 225 |  |  | 209 |  |  | 7.3 |  |  |  |  |  |  | \nInternational |  | 164 |  |  | 146 |  |  | 12.2 |  |  |  |  |  |  | \nWorldwide |  | 389 |  |  | 356 |  |  | 9.3 |  |  |  |  |  |  | \nKNEES |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 201 |  |  | 185 |  |  | 8.6 |  |  |  |  |  |  | \nInternational |  | 138 |  |  | 132 |  |  | 4.1 |  |  |  |  |  |  | \nWorldwide |  | 339 |  |  | 317 |  |  | 6.7 |  |  |  |  |  |  | \nTRAUMA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 475 |  |  | 450 |  |  | 5.5 |  |  |  |  |  |  | \nInternational |  | 273 |  |  | 282 |  |  | (3.3) |  |  |  |  |  |  | \nWorldwide |  | 748 |  |  | 733 |  |  | 2.1 |  |  |  |  |  |  | \nSPINE, SPORTS & OTHER |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 387 |  |  | 404 |  |  | (4.1) |  |  |  |  |  |  | \nInternational |  | 324 |  |  | 303 |  |  | 7.0 |  |  |  |  |  |  | \nWorldwide |  | 712 |  |  | 707 |  |  | 0.6 |  |  |  |  |  |  | \nSurgery |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 921 |  |  | 898 |  |  | 2.5 |  |  |  |  |  |  | \nInternational |  | 1,513 |  |  | 1,474 |  |  | 2.7 |  |  |  |  |  |  | \nWorldwide |  | 2,434 |  |  | 2,372 |  |  | 2.6 |  |  |  |  |  |  | \nADVANCED |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 417 |  |  | 405 |  |  | 3.0 |  |  |  |  |  |  | \nInternational |  | 729 |  |  | 713 |  |  | 2.2 |  |  |  |  |  |  | \nWorldwide |  | 1,146 |  |  | 1,118 |  |  | 2.5 |  |  |  |  |  |  | \nGENERAL |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 504 |  |  | 493 |  |  | 2.1 |  |  |  |  |  |  | \nInternational |  | 784 |  |  | 761 |  |  | 3.1 |  |  |  |  |  |  | \nWorldwide |  | 1,288 |  |  | 1,254 |  |  | 2.7 |  |  |  |  |  |  | \nVision |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 521 |  |  | 472 |  |  | 10.4 |  |  |  |  |  |  | \nInternational |  | 736 |  |  | 673 |  |  | 9.4 |  |  |  |  |  |  | \nWorldwide |  | 1,257 |  |  | 1,145 |  |  | 9.8 |  |  |  |  |  |  | \nCONTACT LENSES / OTHER |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 400 |  |  | 371 |  |  | 7.7 |  |  |  |  |  |  | \nInternational |  | 511 |  |  | 486 |  |  | 5.1 |  |  |  |  |  |  | \nWorldwide |  | 910 |  |  | 857 |  |  | 6.2 |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nSURGICAL |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 121 |  |  | 101 |  |  | 20.2 |  |  |  |  |  |  | \nInternational |  | 226 |  |  | 187 |  |  | 20.5 |  |  |  |  |  |  | \nWorldwide |  | 347 |  |  | 288 |  |  | 20.4 |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nTOTAL MEDTECH |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 3,225 |  |  | 3,054 |  |  | 5.6 |  |  |  |  |  |  | \nInternational |  | 3,746 |  |  | 3,525 |  |  | 6.3 |  |  |  |  |  |  | \nWorldwide |  | 6,971 |  |  | 6,579 |  |  | 5.9 |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nWORLDWIDE |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 11,414 |  |  | 11,111 |  |  | 2.7 |  |  |  |  |  |  | \nInternational |  | 12,012 |  |  | 11,210 |  |  | 7.2 |  |  |  |  |  |  | \nWorldwide |  | $ | 23,426 |  |  | 22,321 |  |  | 5.0 | % |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal First Quarter Ended |  |  | \n(Dollars in Millions) |  | April 3,2022 |  | April 4,2021 |  | PercentChange |  |  |  |  |  |  |  |  |  |  | \nConsumer Health(1) |  | $ | 686 |  |  | 842 |  |  | (18.5)% |  |  |  |  |  |  |  |  |  |  | \nPharmaceutical(2) |  | 3,924 |  |  | 5,169 |  |  | (24.1) |  |  |  |  |  |  |  |  |  |  | \nMedTech(3) |  | 1,477 |  |  | 1,629 |  |  | (9.3) |  |  |  |  |  |  |  |  |  |  | \nSegment earnings before provision for taxes |  | 6,087 |  |  | 7,640 |  |  | (20.3) |  |  |  |  |  |  |  |  |  |  | \nLess: Expense not allocated to segments(4) |  | 123 |  |  | 211 |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLess: Consumer Health separation costs |  | 102 |  |  | \u2014 |  |  |  |  |  |  |  |  |  |  |  |  |  | \nWorldwide income before tax |  | $ | 5,862 |  |  | 7,429 |  |  | (21.1)% |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal First Quarter Ended |  | \n(Dollars in Millions) |  | April 3, 2022 |  | April 4, 2021 |  | PercentChange |  |  |  |  |  | \nUnited States |  | $ | 11,414 |  |  | 11,111 |  |  | 2.7 | % |  |  |  |  |  | \nEurope |  | 6,024 |  |  | 5,414 |  |  | 11.3 |  |  |  |  |  |  | \nWestern Hemisphere, excluding U.S. |  | 1,482 |  |  | 1,424 |  |  | 4.1 |  |  |  |  |  |  | \nAsia-Pacific, Africa |  | 4,506 |  |  | 4,372 |  |  | 3.1 |  |  |  |  |  |  | \nTotal |  | $ | 23,426 |  |  | 22,321 |  |  | 5.0 | % |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) | Severance | Asset Write-offs/Sales |  | Other(2) | Total\nReserve balance, January 2, 2022 | $ | 112 |  | \u2014 |  |  | 25 |  | 137 | \n |  |  |  |  | \nCurrent year activity: |  |  |  |  | \nCharges | \u2014 |  | (23) |  |  | 95 |  | 72 | \nCash settlements | (10) |  | 35 |  | (3) |  | (107) |  | (82) | \nSettled non cash | \u2014 |  | (12) |  |  | \u2014 |  | (12) | \n |  |  |  |  | \n |  |  |  |  | \nReserve balance, April 3, 2022(1) | $ | 102 |  | \u2014 |  |  | 13 |  | 115 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | April 3, 2022 |  | April 4, 2021 |  | TotalChange |  | OperationsChange |  | CurrencyChange\nOTC(1) |  | $ | 1,461 |  |  | $ | 1,273 |  |  | 14.8 | % |  | 17.1 | % |  | (2.3) | %\nSkin Health/Beauty |  | 1,012 |  |  | 1,163 |  |  | (13.0) |  |  | (11.0) |  |  | (2.0) | \nOral Care |  | 366 |  |  | 417 |  |  | (12.2) |  |  | (10.2) |  |  | (2.0) | \nBaby Care |  | 355 |  |  | 389 |  |  | (8.6) |  |  | (6.4) |  |  | (2.2) | \nWomen\u2019s Health |  | 228 |  |  | 222 |  |  | 2.6 |  |  | 8.3 |  |  | (5.7) | \nWound Care/Other |  | 164 |  |  | 177 |  |  | (7.4) |  |  | (7.2) |  |  | (0.2) | \nTotal Consumer Health Sales |  | $ | 3,586 |  |  | $ | 3,641 |  |  | (1.5) | % |  | 0.8 | % |  | (2.3) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | April 3, 2022 |  | April 4, 2021 |  | TotalChange |  | OperationsChange |  | CurrencyChange\nImmunology |  | $ | 4,119 |  |  | $ | 3,914 |  |  | 5.2 | % |  | 7.5 | % |  | (2.3) | %\nREMICADE |  | 663 |  |  | 777 |  |  | (14.7) |  |  | (14.2) |  |  | (0.5) | \nSIMPONI/ SIMPONI ARIA |  | 571 |  |  | 562 |  |  | 1.5 |  |  | 4.7 |  |  | (3.2) | \nSTELARA |  | 2,288 |  |  | 2,148 |  |  | 6.5 |  |  | 9.0 |  |  | (2.5) | \nTREMFYA |  | 590 |  |  | 418 |  |  | 41.3 |  |  | 44.5 |  |  | (3.2) | \nOther Immunology |  | 6 |  |  | 8 |  |  | (22.0) |  |  | (22.0) |  |  | 0.0\nInfectious Diseases |  | 1,297 |  |  | 998 |  |  | 30.0 |  |  | 33.1 |  |  | (3.1) | \nCOVID-19 VACCINE |  | 457 |  |  | 100 |  |  | * |  | * |  | *\nEDURANT/rilpivirine |  | 248 |  |  | 243 |  |  | 1.8 |  |  | 9.6 |  |  | (7.8) | \nPREZISTA/ PREZCOBIX/ REZOLSTA/SYMTUZA |  | 501 |  |  | 546 |  |  | (8.3) |  |  | (6.9) |  |  | (1.4) | \nOther Infectious Diseases(2) |  | 91 |  |  | 108 |  |  | (15.3) |  |  | (11.0) |  |  | (4.3) | \nNeuroscience |  | 1,741 |  |  | 1,715 |  |  | 1.5 |  |  | 5.0 |  |  | (3.5) | \nCONCERTA/ methylphenidate |  | 157 |  |  | 171 |  |  | (8.3) |  |  | (4.8) |  |  | (3.5) | \nINVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/TREVICTA |  | 1,048 |  |  | 965 |  |  | 8.6 |  |  | 11.3 |  |  | (2.7) | \nRISPERDAL CONSTA |  | 129 |  |  | 157 |  |  | (17.6) |  |  | (13.9) |  |  | (3.7) | \nOther Neuroscience(2) |  | 408 |  |  | 422 |  |  | (3.5) |  |  | 1.7 |  |  | (5.2) | \nOncology |  | 3,950 |  |  | 3,570 |  |  | 10.6 |  |  | 14.9 |  |  | (4.3) | \nDARZALEX |  | 1,856 |  |  | 1,365 |  |  | 36.0 |  |  | 40.3 |  |  | (4.3) | \nERLEADA |  | 400 |  |  | 261 |  |  | 53.0 |  |  | 57.5 |  |  | (4.5) | \nIMBRUVICA |  | 1,038 |  |  | 1,125 |  |  | (7.7) |  |  | (3.9) |  |  | (3.8) | \nZYTIGA/ abiraterone acetate |  | 539 |  |  | 638 |  |  | (15.6) |  |  | (10.1) |  |  | (5.5) | \nOther Oncology |  | 118 |  |  | 182 |  |  | (35.1) |  |  | (32.3) |  |  | (2.8) | \nPulmonary Hypertension |  | 852 |  |  | 861 |  |  | (1.1) |  |  | 1.2 |  |  | (2.3) | \nOPSUMIT |  | 443 |  |  | 450 |  |  | (1.6) |  |  | 1.1 |  |  | (2.7) | \nUPTRAVI |  | 325 |  |  | 305 |  |  | 6.5 |  |  | 7.7 |  |  | (1.2) | \nOther Pulmonary Hypertension |  | 83 |  |  | 105 |  |  | (20.8) |  |  | (16.8) |  |  | (4.0) | \nCardiovascular / Metabolism / Other |  | 910 |  |  | 1,044 |  |  | (12.8) |  |  | (11.9) |  |  | (0.9) | \nXARELTO |  | 508 |  |  | 589 |  |  | (13.8) |  |  | (13.8) |  |  | \u2014 | \nINVOKANA/ INVOKAMET |  | 128 |  |  | 150 |  |  | (14.6) |  |  | (13.1) |  |  | (1.5) | \nOther(1,2) |  | 274 |  |  | 305 |  |  | (10.0) |  |  | (7.5) |  |  | (2.5) | \nTotal Pharmaceutical Sales |  | $ | 12,869 |  |  | $ | 12,101 |  |  | 6.3 | % |  | 9.3 | % |  | (3.0) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | April 3, 2022 |  | April 4, 2021 |  | TotalChange |  | OperationsChange |  | CurrencyChange\nSurgery |  | $ | 2,434 |  |  | $ | 2,372 |  |  | 2.6 | % |  | 5.0 | % |  | (2.4) | %\nAdvanced |  | 1,146 |  |  | 1,118 |  |  | 2.5 |  |  | 4.5 |  |  | (2.0) | \nGeneral |  | 1,288 |  |  | 1,254 |  |  | 2.7 |  |  | 5.5 |  |  | (2.8) | \nOrthopaedics |  | 2,188 |  |  | 2,113 |  |  | 3.5 |  |  | 5.6 |  |  | (2.1) | \nHips |  | 389 |  |  | 356 |  |  | 9.3 |  |  | 11.3 |  |  | (2.0) | \nKnees |  | 339 |  |  | 317 |  |  | 6.7 |  |  | 8.8 |  |  | (2.1) | \nTrauma |  | 748 |  |  | 733 |  |  | 2.1 |  |  | 4.2 |  |  | (2.1) | \nSpine, Sports & Other |  | 712 |  |  | 707 |  |  | 0.6 |  |  | 2.7 |  |  | (2.1) | \nVision |  | 1,257 |  |  | 1,145 |  |  | 9.8 |  |  | 13.9 |  |  | (4.1) | \nContact Lenses/Other |  | 910 |  |  | 857 |  |  | 6.2 |  |  | 10.6 |  |  | (4.4) | \nSurgical |  | 347 |  |  | 288 |  |  | 20.4 |  |  | 23.8 |  |  | (3.4) | \nInterventional Solutions |  | 1,092 |  |  | 949 |  |  | 15.1 |  |  | 17.4 |  |  | (2.3) | \n |  |  |  |  |  |  |  |  |  | \nTotal MedTech Sales |  | $ | 6,971 |  |  | $ | 6,579 |  |  | 5.9 | % |  | 8.5 | % |  | (2.6) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nFiscal First Quarter |  |  |  |  |  | \n(Dollars in Billions)(Income)/Expense |  | 2022 |  | 2021 |  | Change\nChanges in the fair value of securities |  | $ | 0.4 |  |  | 0.0 |  |  | 0.4 | \nAcquisition, integration and divestiture related(1) |  | 0.0 |  |  | (0.5) |  |  | 0.5 | \nConsumer Health separation costs |  | 0.1 |  |  | 0.0 |  |  | 0.1 | \nEmployee benefit plan related |  | (0.3) |  |  | (0.2) |  |  | (0.1) | \nOther |  | (0.3) |  |  | (0.2) |  |  | (0.1) | \n |  |  |  |  |  | \n |  |  |  |  |  | \nTotal Other (Income) Expense, Net |  | $ | (0.1) |  |  | $ | (0.9) |  |  | $ | 0.8 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Income Before Tax |  | Segment Sales |  | Percent of Segment Sales\n(Dollars in Millions) |  | April 3, 2022 |  | April 4, 2021 |  | April 3, 2022 |  | April 4, 2021 |  | April 3, 2022 |  | April 4, 2021\nConsumer Health |  | $ | 686 |  |  | $ | 842 |  |  | $ | 3,586 |  |  | $ | 3,641 |  |  | 19.1 | % |  | 23.1 | %\nPharmaceutical |  | 3,924 |  |  | 5,169 |  |  | 12,869 |  |  | 12,101 |  |  | 30.5 |  |  | 42.7 | \nMedTech |  | 1,477 |  |  | 1,629 |  |  | 6,971 |  |  | 6,579 |  |  | 21.2 |  |  | 24.8 | \nSegment earnings before tax |  | 6,087 |  |  | 7,640 |  |  | 23,426 |  |  | 22,321 |  |  | 26.0 |  |  | 34.2 | \nLess: Expenses not allocated to segments(1) |  | 123 |  |  | 211 |  |  |  |  |  |  |  |  | \nLess: Consumer Health separation costs |  | 102 |  |  | \u2014 |  |  |  |  |  |  |  |  | \nWorldwide income before tax |  | $ | 5,862 |  |  | $ | 7,429 |  |  | $ | 23,426 |  |  | $ | 22,321 |  |  | 25.0 | % |  | 33.3 | %  |  |  |  |  | \n(Dollars In Billions) | \n$ | 14.5 |  | Q4 2021 Cash and cash equivalents balance\n4.0 |  | cash generated from operating activities\n(3.6) |  | net cash used by investing activities\n(4.4) |  | net cash used by financing activities\n | \n$ | 10.5 |  | Q1 2022 Cash and cash equivalents balance  |  |  |  |  | \n(Dollars In Billions) | \n$ | 5.1 |  | Net Earnings\n1.6 |  | non-cash expenses and other adjustments primarily for depreciation and amortization, stock-based compensation, asset write-downs and credit losses and accounts receivable allowances partially offset by the deferred tax provision and net gain on sale of assets/businesses\n | \n(1.0) |  | an increase in accounts receivable and inventories\n | \n(2.8) |  | a decrease in accounts payable and accrued liabilities\n1.0 |  | a decrease in other current and non-current assets\n0.1 |  | an increase in other current and non-current liabilities\n$ | 4.0 |  | Cash Flow from operations  |  |  |  |  | \n(Dollars In Billions) | \n$ | (0.6) |  | additions to property, plant and equipment\n0.2 |  | proceeds from the disposal of assets/businesses, net\n(0.3) |  | acquisitions, net of cash acquired and other\n(2.7) |  | net purchases of investments\n | \n(0.2) |  | credit support agreements activity, net\n | \n$ | (3.6) |  | Net cash used for investing activities  |  |  |  |  | \n(Dollars In Billions) | \n$ | (2.8) |  | dividends to shareholders\n(1.6) |  | repurchase of common stock\n0.0 | net repayment of short and long term debt\n0.3 |  | proceeds from stock options exercised/employee withholding tax on stock awards, net\n(0.2) |  | credit support agreements activity, net\n(0.1) |  | other and rounding\n$ | (4.4) |  | Net cash used for financing activities  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nFiscal Month Period |  | Total Numberof Shares Purchased(1) |  | Avg. PricePer Share |  | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs |  | Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs\nJanuary 3, 2022 through January 30, 2022 |  | 918,500 |  |  | 170.99 |  |  |  |  | \u2014\nJanuary 31, 2022 through February 27, 2022 |  | 4,728,073 |  |  | 168.98 |  |  |  |  | \u2014\nFebruary 28, 2022 through April 3, 2022 |  | 3,596,956 |  |  | 172.58 |  |  |  |  | \u2014\nTotal |  | 9,243,529 |  |  |  |  |  |  |   |  |  |  |  |  |  |  | \nEX-101.INS |  | Instance Document - the instance document does not appear in the Interactive Data File because its                XBRL tags are embedded within the Inline XBRL document\nEX-101.SCH |  | Inline XBRL Taxonomy Extension Schema\nEX-101.CAL |  | Inline XBRL Taxonomy Extension Calculation Linkbase\nEX-101.LAB |  | Inline XBRL Taxonomy Extension Label Linkbase\nEX-101.PRE |  | Inline XBRL Taxonomy Extension Presentation Linkbase\nEX-101.DEF |  | Inline XBRL Taxonomy Extension Definition Document\n |  | \nExhibit 104: |  | Cover Page Interactive Data File\u2013\u2013the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.\n |  |   |  |  |  |  | \n | JOHNSON & JOHNSON(Registrant)\n | \nDate: April 29, 2022 | By /s/ J. J. WOLK\n | J. J. WOLK\n | Executive Vice President, Chief Financial Officer (Principal Financial Officer)\n | \nDate: April 29, 2022 | By /s/\u00a0R. J. DECKER Jr.\n | R. J. DECKER Jr.\n | Controller (Principal Accounting Officer)"}]}
{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For Johnson and Johnson, in 2022 Q2, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  |  |  |  |  |  |  | \n |  | \n\u2611 |  | Quarterly Report Pursuant to Section\u00a013 or 15(d) of the Securities Exchange Act of 1934  |  |  |  |  |  |  |  | \n |  | \n\u2610 |  | Transition Report Pursuant to Section\u00a013 or 15(d) of the Securities Exchange Act of 1934for the transition period from\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0to  |  |  |  |  |  |  |  | \nNew Jersey |  | 22-1024240\n(State or other jurisdiction ofincorporation or organization) |  | (I.R.S. EmployerIdentification No.)  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Large accelerated filer | \u2611 | Accelerated filer | \u2610\n | Non-accelerated filer | \u2610 | Smaller reporting company | \u2610\n | Emerging growth company | \u2610 |  |   |  |  |  |  |  |  |  | \nTitle of each class | Trading Symbol | Name of each exchange on which registered\nCommon Stock, Par Value $1.00 | JNJ | New York Stock Exchange\n0.650% Notes Due May 2024 | JNJ24C | New York Stock Exchange\n5.50% Notes Due November 2024 | JNJ24BP | New York Stock Exchange\n1.150% Notes Due November 2028 | JNJ28 | New York Stock Exchange\n1.650% Notes Due May 2035 | JNJ35 | New York Stock Exchange  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Page\n |  |  | No.\nPart I \u2014 Financial Information |  |  | 1\n |  |  | \nItem\u00a01. Financial Statements (unaudited) |  |  | 1\n |  |  | \nConsolidated Balance Sheets \u2014April3, 2022and January2, 2022 |  |  | 1\n |  |  | \nConsolidated Statements of Earnings for the FiscalFirstQuartersEndedApril3, 2022andApril4, 2021 |  |  | 2\n |  |  | \n |  |  | \n |  |  | \nConsolidated Statements of Comprehensive Income for the FiscalFirstQuartersEndedApril3, 2022andApril4, 2021 |  |  | 3\n |  |  | \nConsolidated Statements of Equity for the FiscalFirstQuarters EndedApril3, 2022andApril4, 2021 |  |  | 4\n |  |  | \nConsolidated Statements of Cash Flows for the FiscalThreeMonths EndedApril3, 2022andApril4, 2021 |  |  | 5\n |  |  | \nNotes to Consolidated Financial Statements |  |  | 6\n |  |  | \n |  |  | \n |  |  | \nItem\u00a02. Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations |  |  | 42\n |  |  | \nItem\u00a03. Quantitative and Qualitative Disclosures About Market Risk |  |  | 53\n |  |  | \nItem\u00a04. Controls and Procedures |  |  | 54\n |  |  | \nPart II \u2014 Other Information |  |  | 54\n |  |  | \nItem\u00a01 - Legal Proceedings |  |  | 54\n |  |  | \nItem\u00a02 - Unregistered Sales of Equity Securities and Use of Proceeds |  |  | 55\n |  |  | \nItem\u00a06 - Exhibits |  |  | 56\n |  |  | \nSignatures |  |  | 57\n\n\n\n\n\n\n\n  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | April 3, 2022 |  | January 2, 2022\nASSETS\nCurrent assets: |  |  |  | \nCash and cash equivalents |  | $ | 10,463 |  |  | 14,487 | \nMarketable securities |  | 19,925 |  |  | 17,121 | \nAccounts receivable, trade, less allowances for doubtful accounts and credit losses $234(2021, $230) |  | 15,594 |  |  | 15,283 | \nInventories (Note 2) |  | 10,990 |  |  | 10,387 | \nPrepaid expenses and other |  | 3,452 |  |  | 3,701 | \n |  |  |  | \nTotal current assets |  | 60,424 |  |  | 60,979 | \nProperty, plant and equipment at cost |  | 47,702 |  |  | 47,679 | \nLess: accumulated depreciation |  | (29,001) |  |  | (28,717) | \nProperty, plant and equipment, net |  | 18,701 |  |  | 18,962 | \nIntangible assets, net (Note 3) |  | 44,420 |  |  | 46,392 | \nGoodwill (Note 3) |  | 34,935 |  |  | 35,246 | \nDeferred taxes on income (Note 5) |  | 9,936 |  |  | 10,223 | \nOther assets |  | 9,939 |  |  | 10,216 | \nTotal assets |  | $ | 178,355 |  |  | 182,018 | \nLIABILITIES AND SHAREHOLDERS\u2019 EQUITY\nCurrent liabilities: |  |  |  | \nLoans and notes payable |  | $ | 4,297 |  |  | 3,766 | \nAccounts payable |  | 9,309 |  |  | 11,055 | \nAccrued liabilities |  | 13,006 |  |  | 13,612 | \nAccrued rebates, returns and promotions |  | 12,972 |  |  | 12,095 | \nAccrued compensation and employee related obligations |  | 2,098 |  |  | 3,586 | \nAccrued taxes on income (Note 5) |  | 1,708 |  |  | 1,112 | \nTotal current liabilities |  | 43,390 |  |  | 45,226 | \nLong-term debt (Note 4) |  | 28,851 |  |  | 29,985 | \nDeferred taxes on income (Note 5) |  | 6,424 |  |  | 7,487 | \nEmployee related obligations (Note 6) |  | 8,739 |  |  | 8,898 | \nLong-term taxes payable (Note 5) |  | 5,745 |  |  | 5,713 | \nOther liabilities |  | 10,497 |  |  | 10,686 | \nTotal liabilities |  | $ | 103,646 |  |  | 107,995 | \nCommitments and Contingencies (Note 11) |  |  |  | \nShareholders\u2019 equity: |  |  |  | \nCommon stock \u2014 par value $1.00per share (authorized4,320,000,000shares; issued3,119,843,000shares) |  | $ | 3,120 |  |  | 3,120 | \nAccumulated other comprehensive income (loss) (Note 7) |  | (13,757) |  |  | (13,058) | \nRetained earnings |  | 124,380 |  |  | 123,060 | \nLess: common stock held in treasury, at cost (490,459,000and490,878,000shares) |  | 39,034 |  |  | 39,099 | \nTotal shareholders\u2019 equity |  | 74,709 |  |  | 74,023 | \nTotal liabilities and shareholders' equity |  | $ | 178,355 |  |  | 182,018 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal First Quarter Ended\n |  | April 3,2022 |  | Percentto Sales |  | April 4,2021 |  | Percentto Sales\nSales to customers (Note 9) |  | $ | 23,426 |  |  | 100.0 | % |  | $ | 22,321 |  |  | 100.0 | %\nCost of products sold |  | 7,598 |  |  | 32.4 |  |  | 7,063 |  |  | 31.7 | \nGross profit |  | 15,828 |  |  | 67.6 |  |  | 15,258 |  |  | 68.3 | \nSelling, marketing and administrative expenses |  | 5,938 |  |  | 25.4 |  |  | 5,432 |  |  | 24.3 | \nResearch and development expense |  | 3,462 |  |  | 14.8 |  |  | 3,178 |  |  | 14.2 | \nIn-process research and development |  | 610 |  |  | 2.6 |  |  | \u2014 |  |  | \u2014 | \nInterest income |  | (22) |  |  | (0.1) |  |  | (15) |  |  | (0.1) | \nInterest expense, net of portion capitalized |  | 10 |  |  | 0.0 |  |  | 63 |  |  | 0.3 | \nOther (income) expense, net |  | (102) |  |  | (0.4) |  |  | (882) |  |  | (3.9) | \nRestructuring (Note 12) |  | 70 |  |  | 0.3 |  |  | 53 |  |  | 0.2 | \nEarnings before provision for taxes on income |  | 5,862 |  |  | 25.0 |  |  | 7,429 |  |  | 33.3 | \nProvision for taxes on income (Note 5) |  | 713 |  |  | 3.0 |  |  | 1,232 |  |  | 5.5 | \nNET EARNINGS |  | $ | 5,149 |  |  | 22.0 | % |  | $ | 6,197 |  |  | 27.8 | %\n |  |  |  |  |  |  |  | \nNET EARNINGS PER SHARE (Note 8) |  |  |  |  |  |  |  | \nBasic |  | $ | 1.96 |  |  |  |  | $ | 2.35 |  |  | \nDiluted |  | $ | 1.93 |  |  |  |  | $ | 2.32 |  |  | \n |  |  |  |  |  |  |  | \nAVG. SHARES OUTSTANDING |  |  |  |  |  |  |  | \nBasic |  | 2,629.2 |  |  |  |  | 2,631.6 |  |  | \nDiluted |  | 2,666.5 |  |  |  |  | 2,672.7 |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Fiscal First Quarter Ended |  | \n | April 3, 2022 |  | April 4, 2021 |  |  |  | \n |  |  |  |  |  |  | \nNet earnings | $ | 5,149 |  |  | 6,197 |  |  |  |  | \n |  |  |  |  |  |  | \nOther comprehensive income (loss), net of tax |  |  |  |  |  |  | \nForeign currency translation | (554) |  |  | 276 |  |  |  |  | \n |  |  |  |  |  |  | \nSecurities: |  |  |  |  |  |  | \nUnrealized holding gain (loss) arising during period | (13) |  |  | \u2014 |  |  |  |  | \nReclassifications to earnings | \u2014 |  |  | \u2014 |  |  |  |  | \n |  |  |  |  |  |  | \nNet change | (13) |  |  | \u2014 |  |  |  |  | \n |  |  |  |  |  |  | \nEmployee benefit plans: |  |  |  |  |  |  | \nPrior service cost amortization during period | (53) |  |  | (41) |  |  |  |  | \nGain (loss) amortization during period | 217 |  |  | 274 |  |  |  |  | \n |  |  |  |  |  |  | \nNet change | 164 |  |  | 233 |  |  |  |  | \n |  |  |  |  |  |  | \nDerivatives & hedges: |  |  |  |  |  |  | \nUnrealized gain (loss) arising during period | (195) |  |  | (522) |  |  |  |  | \nReclassifications to earnings | (101) |  |  | (73) |  |  |  |  | \nNet change | (296) |  |  | (595) |  |  |  |  | \n |  |  |  |  |  |  | \nOther comprehensive income (loss) | (699) |  |  | (86) |  |  |  |  | \n |  |  |  |  |  |  | \nComprehensive income | $ | 4,450 |  |  | 6,111 |  |  |  |  | \n |  |  |  |  |  |  |   |  | \nThe tax effects in other comprehensive income for the fiscal first quarter were as follows for 2022 and 2021, respectively: Foreign Currency Translation: $145million and $319million; Securities: $3million in 2022; Employee Benefit Plans: $19million and $66million; Derivatives & Hedges: $78million and $157million.\n\n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Total |  | RetainedEarnings |  | AccumulatedOtherComprehensiveIncome |  | Common StockIssued Amount |  | TreasuryStockAmount\nBalance, January 2, 2022 | $ | 74,023 |  |  | 123,060 |  |  | (13,058) |  |  | 3,120 |  |  | (39,099) | \nNet earnings | 5,149 |  |  | 5,149 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nCash dividends paid ($1.06per share) | (2,787) |  |  | (2,787) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nEmployee compensation and stock option plans | 600 |  |  | (1,042) |  |  | \u2014 |  |  | \u2014 |  |  | 1,642 | \nRepurchase of common stock | (1,577) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1,577) | \n |  |  |  |  |  |  |  |  | \nOther comprehensive income (loss), net of tax | (699) |  |  | \u2014 |  |  | (699) |  |  | \u2014 |  |  | \u2014 | \nBalance, April 3, 2022 | $ | 74,709 |  |  | 124,380 |  |  | (13,757) |  |  | 3,120 |  |  | (39,034) | \n |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n\n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Total |  | RetainedEarnings |  | AccumulatedOtherComprehensiveIncome |  | Common StockIssued Amount |  | TreasuryStockAmount\nBalance, January 3, 2021 | $ | 63,278 |  |  | 113,890 |  |  | (15,242) |  |  | 3,120 |  |  | (38,490) | \n |  |  |  |  |  |  |  |  | \nNet earnings | 6,197 |  |  | 6,197 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nCash dividends paid ($1.01per share) | (2,659) |  |  | (2,659) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nEmployee compensation and stock option plans | 542 |  |  | (920) |  |  | \u2014 |  |  | \u2014 |  |  | 1,462 | \nRepurchase of common stock | (1,438) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1,438) | \n |  |  |  |  |  |  |  |  | \nOther comprehensive income (loss), net of tax | (86) |  |  | \u2014 |  |  | (86) |  |  | \u2014 |  |  | \u2014 | \nBalance, April 4, 2021 | $ | 65,834 |  |  | 116,508 |  |  | (15,328) |  |  | 3,120 |  |  | (38,466) | \n |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n\n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Three Months Ended\n |  | April 3,2022 |  | April 4,2021\nCASH FLOWS FROM OPERATING ACTIVITIES |  |  |  | \nNet earnings |  | $ | 5,149 |  |  | 6,197 | \nAdjustments to reconcile net earnings to cash flows from operating activities: |  |  |  | \nDepreciation and amortization of property and intangibles |  | 1,769 |  |  | 1,894 | \nStock based compensation |  | 278 |  |  | 307 | \n |  |  |  | \n |  |  |  | \nAsset write-downs |  | 610 |  |  | 14 | \n |  |  |  | \nNet gain on sale of assets/businesses |  | (168) |  |  | (580) | \n |  |  |  | \nDeferred tax provision |  | (926) |  |  | (730) | \nCredit losses and accounts receivable allowances |  | 6 |  |  | (13) | \nChanges in assets and liabilities, net of effects from acquisitions and divestitures: |  |  |  | \nIncrease in accounts receivable |  | (427) |  |  | (1,604) | \nIncrease in inventories |  | (600) |  |  | (695) | \nDecrease in accounts payable and accrued liabilities |  | (2,817) |  |  | (2,336) | \nDecrease in other current and non-current assets |  | 995 |  |  | 2,522 | \nIncrease/(Decrease) in other current and non-current liabilities |  | 110 |  |  | (902) | \n |  |  |  | \nNET CASH FLOWS FROM OPERATING ACTIVITIES |  | 3,979 |  |  | 4,074 | \n |  |  |  | \nCASH FLOWS FROM INVESTING ACTIVITIES |  |  |  | \nAdditions to property, plant and equipment |  | (607) |  |  | (677) | \nProceeds from the disposal of assets/businesses, net (Note 10) |  | 248 |  |  | 603 | \nAcquisitions, net of cash acquired (Note 10) |  | (252) |  |  | \u2014 | \nPurchases of investments |  | (9,018) |  |  | (5,994) | \nSales of investments |  | 6,303 |  |  | 5,233 | \nCredit support agreements activity, net |  | (249) |  |  | 751 | \nOther (primarily licenses and milestones) |  | (59) |  |  | (101) | \n |  |  |  | \nNET CASH USED BY INVESTING ACTIVITIES |  | (3,634) |  |  | (185) | \n |  |  |  | \nCASH FLOWS FROM FINANCING ACTIVITIES |  |  |  | \nDividends to shareholders |  | (2,787) |  |  | (2,659) | \nRepurchase of common stock |  | (1,577) |  |  | (1,438) | \nProceeds from short-term debt |  | 3,019 |  |  | 23 | \nRepayment of short-term debt |  | (856) |  |  | (475) | \nProceeds from long-term debt, net of issuance costs |  | \u2014 |  |  | 1 | \nRepayment of long-term debt |  | (2,132) |  |  | (1,001) | \nProceeds from the exercise of stock options/employee withholding tax on stock awards, net |  | 321 |  |  | 236 | \nCredit support agreements activity, net |  | (235) |  |  | 212 | \nOther |  | (138) |  |  | (24) | \n |  |  |  | \nNET CASH USED BY FINANCING ACTIVITIES |  | (4,385) |  |  | (5,125) | \n |  |  |  | \nEffect of exchange rate changes on cash and cash equivalents |  | 16 |  |  | (78) | \nDecrease in cash and cash equivalents |  | (4,024) |  |  | (1,314) | \nCash and Cash equivalents, beginning of period |  | 14,487 |  |  | 13,985 | \nCASH AND CASH EQUIVALENTS, END OF PERIOD |  | $ | 10,463 |  |  | 12,671 | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \nAcquisitions |  |  |  | \nFair value of assets acquired |  | $ | 255 |  |  | \u2014 | \nFair value of liabilities assumed and noncontrolling interests |  | (3) |  |  | \u2014 | \nNet cash paid for acquisitions |  | $ | 252 |  |  | \u2014 | \n |  |  |  | \n |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | April 3, 2022 |  | January 2, 2022\nRaw materials and supplies |  | $ | 1,679 |  |  | 1,592 | \nGoods in process |  | 2,629 |  |  | 2,287 | \nFinished goods |  | 6,682 |  |  | 6,508 | \nTotal inventories |  | $ | 10,990 |  |  | 10,387 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | April 3, 2022 |  | January 2, 2022\nIntangible assets with definite lives: |  |  |  | \nPatents and trademarks \u2014 gross |  | $ | 37,960 |  |  | 38,572 | \nLess accumulated amortization |  | (20,492) |  |  | (20,088) | \nPatents and trademarks \u2014 net |  | 17,468 |  |  | 18,484 | \nCustomer relationships and other intangibles \u2014 gross |  | 22,910 |  |  | 23,011 | \nLess accumulated amortization |  | (12,147) |  |  | (11,925) | \nCustomer relationships and other intangibles\u00a0\u2014 net(1) |  | 10,763 |  |  | 11,086 | \nIntangible assets with indefinite lives: |  |  |  | \nTrademarks |  | 6,947 |  |  | 6,985 | \nPurchased in-process research and development(2) |  | 9,242 |  |  | 9,837 | \nTotal intangible assets with indefinite lives |  | 16,189 |  |  | 16,822 | \nTotal intangible assets \u2014 net |  | $ | 44,420 |  |  | 46,392 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | Consumer Health |  | Pharmaceutical |  | MedTech |  | Total\nGoodwill at January 2, 2022 |  | $ | 9,810 |  |  | 10,580 |  |  | 14,856 |  |  | 35,246 | \nGoodwill, related to acquisitions |  | \u2014 |  |  | \u2014 |  |  | 73 |  |  | 73 | \n |  |  |  |  |  |  |  | \nCurrency translation/Other |  | (195) |  |  | (170) |  |  | (19) |  |  | (384) | \nGoodwill at April 3, 2022 |  | $ | 9,615 |  |  | 10,410 |  |  | 14,910 |  |  | 34,935 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  |  |  |  |  | \n2022 |  | 2023 |  | 2024 |  | 2025 |  | 2026\n$4,600 |  | 4,600 |  | 4,400 |  | 3,600 |  | 3,000  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | \n | April 3, 2022 | April 4, 2021\n(Dollars in Millions) | Sales | Cost of Products Sold | R&D Expense | Interest (Income) Expense | Other (Income)  Expense | Sales | Cost of Products Sold | R&D Expense | Interest (Income) Expense | Other (Income)  Expense\n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \nThe effects of fair value, net investment and cash flow hedging: |  |  |  |  |  |  |  |  |  | \nGain (Loss) on fair value hedging relationship: |  |  |  |  |  |  |  |  |  | \nInterest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nHedged items | $ | \u2014 |  | \u2014 |  | \u2014 |  | (531) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 | \nDerivatives designated as hedging instruments | \u2014 |  | \u2014 |  | \u2014 |  | 531 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nGain (Loss) on net investment hedging relationship: |  |  |  |  |  |  |  |  |  | \nCross currency interest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing | \u2014 |  | \u2014 |  | \u2014 |  | 45 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 40 |  | \u2014 | \nAmount of gain or (loss) recognized in AOCI | \u2014 |  | \u2014 |  | \u2014 |  | 45 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 40 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nGain (Loss) on cash flow hedging relationship: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) reclassified from AOCI into income | (17) |  | (52) |  | 23 |  | \u2014 |  | (18) |  | 17 |  | 34 |  | (113) |  | \u2014 |  | 3 | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in AOCI | 22 |  | (94) |  | 33 |  | \u2014 |  | (73) |  | (3) |  | (193) |  | (76) |  | \u2014 |  | 17 | \n |  |  |  |  |  |  |  |  |  | \nCross currency interest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) reclassified from AOCI into income | \u2014 |  | \u2014 |  | \u2014 |  | 120 |  | \u2014 |  | \u2014 |  |  | \u2014 |  | 92 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in AOCI | $ | \u2014 |  | \u2014 |  | \u2014 |  | (128) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (307) |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | \n |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLine item in the Consolidated Balance Sheet in which the hedged item is included |  | Carrying Amount of the Hedged Liability |  | Cumulative Amount of Fair Value Hedging Gain/ (Loss)  Included in the Carrying Amount of the Hedged Liability\n |  | \n(Dollars in Millions) |  | April 3, 2022 |  | January 2, 2022 |  | April 3, 2022 |  | January 2, 2022\n |  |  |  |  |  |  |  | \nLong-term Debt |  | 9,313 |  |  | 9,793 |  |  | (694) |  |  | (142) | \n |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | \n |  |  |  | Gain/(Loss)Recognized InIncome on Derivative |  | \n(Dollars in Millions) |  | Location of Gain /(Loss) Recognized in Income on Derivative |  | Fiscal First Quarter Ended |  | \nDerivatives Not Designated as Hedging Instruments |  |  |  | April 3, 2022 |  | April 4, 2021 |  |  |  | \nForeign Exchange Contracts |  | Other (income) expense |  | $ | 29 |  |  | (16) |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n\n |  | Gain/(Loss)Recognized InAccumulatedOCI |  | Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income |  | Gain/(Loss)                                                                                                                                                                                                                                  Reclassified FromAccumulated OCIInto Income\n(Dollars in Millions) |  | April 3, 2022 |  | April 4, 2021 |  |  |  | April 3, 2022 |  | April 4, 2021\nDebt |  | $ | 68 |  |  | 209 |  |  | Interest (income) expense |  | \u2014 |  |  | \u2014 | \nCross Currency interest rate swaps |  | $ | 560 |  |  | 361 |  |  | Interest (income) expense |  | \u2014 |  |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n\n |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | January 2, 2022 |  |  |  |  |  | April 3, 2022 |  | \n |  | Carrying Value |  | Changes in Fair Value Reflected in Net Income(1) |  | Sales/ Purchases/Other(2) |  | Carrying Value |  | Non Current Other Assets\nEquity Investments with readily determinable value |  | $ | 1,884 |  |  | (402) |  |  | (30) |  |  | 1,452 |  |  | 1,452 | \n |  |  |  |  |  |  |  |  |  | \nEquity Investments without readily determinable value |  | $ | 500 |  |  | (5) |  |  | 10 |  |  | 505 |  |  | 505 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | April 3, 2022 |  |  |  | January 2, 2022\n(Dollars in Millions) |  | Level 1 |  | Level 2 |  | Level 3 |  | Total |  | Total(1)\nDerivatives designated as hedging instruments: |  |  |  |  |  |  |  |  |  | \nAssets: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts |  | $ | \u2014 |  |  | 742 |  |  | \u2014 |  |  | 742 |  |  | 540 | \nInterest rate contracts(2) |  | \u2014 |  |  | 975 |  |  | \u2014 |  |  | 975 |  |  | 796 | \n |  |  |  |  |  |  |  |  |  | \nTotal |  | \u2014 |  |  | 1,717 |  |  | \u2014 |  |  | 1,717 |  |  | 1,336 | \nLiabilities: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts |  | \u2014 |  |  | 1,058 |  |  | \u2014 |  |  | 1,058 |  |  | 881 | \nInterest rate contracts(2) |  | \u2014 |  |  | 1,652 |  |  | \u2014 |  |  | 1,652 |  |  | 979 | \n |  |  |  |  |  |  |  |  |  | \nTotal |  | \u2014 |  |  | 2,710 |  |  | \u2014 |  |  | 2,710 |  |  | 1,860 | \nDerivatives not designated as hedging instruments: |  |  |  |  |  |  |  |  |  | \nAssets: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts |  | \u2014 |  |  | 36 |  |  | \u2014 |  |  | 36 |  |  | 24 | \nLiabilities: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts |  | \u2014 |  |  | 68 |  |  | \u2014 |  |  | 68 |  |  | 28 | \nOther Investments: |  |  |  |  |  |  |  |  |  | \nEquity investments(3) |  | 1,452 |  |  | \u2014 |  |  | \u2014 |  |  | 1,452 |  |  | 1,884 | \nDebt securities(4) |  | \u2014 |  |  | 19,583 |  |  | \u2014 |  |  | 19,583 |  |  | 19,727 | \nOther Liabilities |  |  |  |  |  |  |  |  |  | \nContingent consideration(5) |  | $ | \u2014 |  |  | \u2014 |  |  | 486 |  |  | 486 |  |  | 533 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \nGross to Net Derivative Reconciliation |  | April 3, 2022 |  | January 2, 2022\n(Dollars in Millions) |  |  |  | \nTotal Gross Assets |  | $ | 1,753 |  |  | 1,360 | \nCredit Support Agreement (CSA) |  | (1,655) |  |  | (1,285) | \nTotal Net Asset |  | 98 |  |  | 75 | \n |  |  |  | \nTotal Gross Liabilities |  | 2,778 |  |  | 1,888 | \nCredit Support Agreement (CSA) |  | (2,709) |  |  | (1,855) | \nTotal Net Liabilities |  | $ | 69 |  |  | 33 | \n |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | \n |  | April 3, 2022 |  | April 4, 2021\n(Dollars in Millions) |  |  |  | \nBeginning Balance |  | $ | 533 |  |  | $ | 633 | \nChanges in estimated fair value(6) |  | (47) |  |  | 15 | \nAdditions |  | \u2014 |  |  | \u2014 | \nPayments |  | \u2014 |  |  | (48) | \nEnding Balance |  | $ | 486 |  |  | $ | 600 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) | Carrying Amount |  |  |  | Gain/( Loss) |  | Estimated Fair Value |  | Cash & Cash Equivalents |  | Current Marketable Securities\nCash | $ | 3,128 |  |  |  |  | \u2014 |  |  | 3,128 |  |  | 3,128 |  |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |  | \nNon-U.S. sovereign securities(1) | 329 |  |  |  |  | \u2014 |  |  | 329 |  |  | \u2014 |  |  | 329 | \nU.S. reverse repurchase agreements | 1,449 |  |  |  |  | \u2014 |  |  | 1,449 |  |  | 1,449 |  |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |  | \nCorporate debt securities(1) | 3,557 |  |  |  |  | (6) |  |  | 3,551 |  |  | 540 |  |  | 3,017 | \nMoney market funds | 1,579 |  |  |  |  | \u2014 |  |  | 1,579 |  |  | 1,579 |  |  | \u2014 | \nTime deposits(1) | 763 |  |  |  |  | \u2014 |  |  | 763 |  |  | 763 |  |  | \u2014 | \nSubtotal | 10,805 |  |  |  |  | (6) |  |  | 10,799 |  |  | 7,459 |  |  | 3,346 | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | Unrealized Loss |  |  |  |  |  | \nU.S. Gov't securities | 19,354 |  |  |  |  | (19) |  |  | 19,335 |  |  | 2,968 |  |  | 16,367 | \nOther sovereign securities | 3 |  |  |  |  | \u2014 |  |  | 3 |  |  | \u2014 |  |  | 3 | \nCorporate debt securities | 246 |  |  |  |  | (1) |  |  | 245 |  |  | 36 |  |  | 209 | \nSubtotal available for sale debt(2) | $ | 19,603 |  |  |  |  | (20) |  |  | 19,583 |  |  | 3,004 |  |  | 16,579 | \nTotal cash, cash equivalents and current marketable securities | $ | 30,408 |  |  |  |  | (26) |  |  | 30,382 |  |  | 10,463 |  |  | 19,925 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | Cost Basis |  | Fair Value\nDue within one year |  | $ | 19,585 |  |  | 19,564 | \nDue after one year through five years |  | 19 |  |  | 19 | \nDue after five years through ten years |  | \u2014 |  |  | \u2014 | \nTotal debt securities |  | $ | 19,604 |  |  | 19,583 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | Carrying Amount |  | Estimated Fair Value\n |  |  |  | \nFinancial Liabilities |  |  |  | \n |  |  |  | \nCurrent Debt |  | $ | 4,297 |  |  | 4,298 | \n |  |  |  | \nNon-Current Debt |  |  |  | \n6.73% Debentures due 2023 |  | 250 |  |  | 266 | \n3.375% Notes due 2023 |  | 802 |  |  | 820 | \n |  |  |  | \n0.650% Notes due 2024 (750MM Euro 1.1311) |  | 824 |  |  | 829 | \n5.50% Notes due 2024 (500 MM GBP 1.3485) |  | 654 |  |  | 713 | \n2.625% Notes due 2025 |  | 749 |  |  | 762 | \n |  |  |  | \n0.55% Notes due 2025 |  | 950 |  |  | 886 | \n2.45% Notes due 2026 |  | 1,995 |  |  | 1,981 | \n2.95% Notes due 2027 |  | 930 |  |  | 934 | \n |  |  |  | \n0.95% Notes due 2027 |  | 1,436 |  |  | 1,307 | \n2.90%\u00a0Notes due 2028 |  | 1,496 |  |  | 1,489 | \n1.150% Notes due 2028 (750MM Euro 1.1311) |  | 826 |  |  | 829 | \n6.95% Notes due 2029 |  | 298 |  |  | 379 | \n |  |  |  | \n1.30% Notes due 2030 |  | 1,672 |  |  | 1,486 | \n4.95% Debentures due 2033 |  | 498 |  |  | 590 | \n4.375% Notes due 2033 |  | 855 |  |  | 959 | \n1.650% Notes due 2035 (1.5B Euro 1.1311) |  | 1,654 |  |  | 1,687 | \n3.55% Notes due 2036 |  | 917 |  |  | 947 | \n5.95% Notes due 2037 |  | 993 |  |  | 1,288 | \n3.625% Notes due 2037 |  | 1,416 |  |  | 1,463 | \n3.40%\u00a0Notes due 2038 |  | 992 |  |  | 999 | \n5.85% Debentures due 2038 |  | 697 |  |  | 901 | \n4.50% Debentures due 2040 |  | 540 |  |  | 617 | \n |  |  |  | \n2.10% Notes due 2040 |  | 914 |  |  | 777 | \n4.85% Notes due 2041 |  | 297 |  |  | 342 | \n4.50% Notes due 2043 |  | 496 |  |  | 565 | \n3.70% Notes due 2046 |  | 1,975 |  |  | 2,097 | \n3.75% Notes due 2047 |  | 906 |  |  | 969 | \n3.50% Notes due 2048 |  | 743 |  |  | 766 | \n2.25% Notes due 2050 |  | 914 |  |  | 759 | \n2.45% Notes due 2060 |  | 1,155 |  |  | 942 | \nOther |  | 7 |  |  | 7 | \nTotal Non-Current Debt |  | $ | 28,851 |  |  | 29,356 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal First Quarter Ended |  | \n |  | Retirement Plans |  | Other Benefit Plans |  |  |  | \n(Dollars in Millions) |  | April 3, 2022 |  | April 4, 2021 |  | April 3, 2022 |  | April 4, 2021 |  |  |  |  |  |  |  | \nService cost |  | $ | 321 |  |  | 353 |  |  | 80 |  |  | 77 |  |  |  |  |  |  |  |  | \nInterest cost |  | 230 |  |  | 193 |  |  | 26 |  |  | 20 |  |  |  |  |  |  |  |  | \nExpected return on plan assets |  | (699) |  |  | (680) |  |  | (2) |  |  | (2) |  |  |  |  |  |  |  |  | \nAmortization of prior service cost/(credit) |  | (46) |  |  | (45) |  |  | (1) |  |  | (8) |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nRecognized actuarial losses |  | 162 |  |  | 314 |  |  | 30 |  |  | 38 |  |  |  |  |  |  |  |  | \nCurtailments and settlements |  | 1 |  |  | 1 |  |  | \u2014 |  |  | \u2014 |  |  |  |  |  |  |  |  | \nNet periodic benefit cost/(credit) |  | $ | (31) |  |  | 136 |  |  | 133 |  |  | 125 |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  | Foreign |  | Gain/(Loss) |  | Employee |  | Gain/(Loss) |  | Total Accumulated\n |  | Currency |  | On |  | Benefit |  | On Derivatives |  | Other Comprehensive\n(Dollars in Millions) |  | Translation |  | Securities |  | Plans |  | & Hedges |  | Income (Loss)\nJanuary 2, 2022 |  | $ | (10,017) |  |  | (3) |  |  | (2,702) |  |  | (336) |  |  | (13,058) | \nNet change |  | (554) |  |  | (13) |  |  | 164 |  |  | (296) |  |  | (699) | \n |  |  |  |  |  |  |  |  |  | \nApril 3, 2022 |  | $ | (10,571) |  |  | (16) |  |  | (2,538) |  |  | (632) |  |  | (13,757) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal First Quarter Ended |  | \n(Shares in Millions) |  | April 3, 2022 |  | April 4, 2021 |  |  |  | \nBasic net earnings per share |  | $ | 1.96 |  |  | 2.35 |  |  |  |  | \nAverage shares outstanding \u2014 basic |  | 2,629.2 |  |  | 2,631.6 |  |  |  |  | \nPotential shares exercisable under stock option plans |  | 140.1 |  |  | 128.4 |  |  |  |  | \nLess: shares which could be repurchased under treasury stock method |  | (102.8) |  |  | (87.3) |  |  |  |  | \n |  |  |  |  |  |  |  | \nAverage shares outstanding \u2014 diluted |  | 2,666.5 |  |  | 2,672.7 |  |  |  |  | \nDiluted net earnings per share |  | $ | 1.93 |  |  | 2.32 |  |  |  |  |   |  |  |  |  |  |  |  | \n\n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal First Quarter Ended |  | \n(Dollars in Millions) |  | April 3,2022 |  | April 4,2021 |  | PercentChange |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nCONSUMER HEALTH |  |  |  |  |  |  |  |  |  |  |  | \nOTC(1) |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | $ | 670 |  |  | 599 |  |  | 11.8 | % |  |  |  |  |  | \nInternational |  | 791 |  |  | 673 |  |  | 17.5 |  |  |  |  |  |  | \nWorldwide |  | 1,461 |  |  | 1,273 |  |  | 14.8 |  |  |  |  |  |  | \nSkin Health/Beauty |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 544 |  |  | 634 |  |  | (14.2) |  |  |  |  |  |  | \nInternational |  | 468 |  |  | 529 |  |  | (11.6) |  |  |  |  |  |  | \nWorldwide |  | 1,012 |  |  | 1,163 |  |  | (13.0) |  |  |  |  |  |  | \nOral Care |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 143 |  |  | 163 |  |  | (12.6) |  |  |  |  |  |  | \nInternational |  | 223 |  |  | 254 |  |  | (12.0) |  |  |  |  |  |  | \nWorldwide |  | 366 |  |  | 417 |  |  | (12.2) |  |  |  |  |  |  | \nBaby Care |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 85 |  |  | 96 |  |  | (11.5) |  |  |  |  |  |  | \nInternational |  | 270 |  |  | 293 |  |  | (7.7) |  |  |  |  |  |  | \nWorldwide |  | 355 |  |  | 389 |  |  | (8.6) |  |  |  |  |  |  | \nWomen's Health |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 3 |  |  | 3 |  |  | 7.2 |  |  |  |  |  |  | \nInternational |  | 224 |  |  | 219 |  |  | 2.5 |  |  |  |  |  |  | \nWorldwide |  | 228 |  |  | 222 |  |  | 2.6 |  |  |  |  |  |  | \nWound Care/Other |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 112 |  |  | 115 |  |  | (3.3) |  |  |  |  |  |  | \nInternational |  | 52 |  |  | 61 |  |  | (15.3) |  |  |  |  |  |  | \nWorldwide |  | 164 |  |  | 177 |  |  | (7.4) |  |  |  |  |  |  | \nTOTAL CONSUMER HEALTH |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,557 |  |  | 1,611 |  |  | (3.4) |  |  |  |  |  |  | \nInternational |  | 2,029 |  |  | 2,030 |  |  | 0.0 |  |  |  |  |  | \nWorldwide |  | 3,586 |  |  | 3,641 |  |  | (1.5) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPHARMACEUTICAL |  |  |  |  |  |  |  |  |  |  |  | \nImmunology |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 2,501 |  |  | 2,413 |  |  | 3.7 |  |  |  |  |  |  | \nInternational |  | 1,617 |  |  | 1,501 |  |  | 7.7 |  |  |  |  |  |  | \nWorldwide |  | 4,119 |  |  | 3,914 |  |  | 5.2 |  |  |  |  |  |  | \nREMICADE |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 358 |  |  | 489 |  |  | (26.8) |  |  |  |  |  |  | \nU.S. Exports |  | 80 |  |  | 57 |  |  | 40.5 |  |  |  |  |  |  | \nInternational |  | 225 |  |  | 232 |  |  | (2.6) |  |  |  |  |  |  | \nWorldwide |  | 663 |  |  | 777 |  |  | (14.7) |  |  |  |  |  |  | \nSIMPONI / SIMPONI ARIA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 287 |  |  | 255 |  |  | 12.5 |  |  |  |  |  |  | \nInternational |  | 283 |  |  | 307 |  |  | (7.6) |  |  |  |  |  |  | \nWorldwide |  | 571 |  |  | 562 |  |  | 1.5 |  |  |  |  |  |  | \nSTELARA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,379 |  |  | 1,331 |  |  | 3.6 |  |  |  |  |  |  | \nInternational |  | 909 |  |  | 817 |  |  | 11.2 |  |  |  |  |  |  | \nWorldwide |  | 2,288 |  |  | 2,148 |  |  | 6.5 |  |  |  |  |  |  | \nTREMFYA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 391 |  |  | 274 |  |  | 42.7 |  |  |  |  |  |  | \nInternational |  | 199 |  |  | 143 |  |  | 38.8 |  |  |  |  |  |  | \nWorldwide |  | 590 |  |  | 418 |  |  | 41.3 |  |  |  |  |  |  | \nOTHER IMMUNOLOGY |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 6 |  |  | 7 |  |  | (3.2) |  |  |  |  |  |  | \nInternational |  | 0 |  |  | 2 |  |  | * |  |  |  |  |  | \nWorldwide |  | 6 |  |  | 8 |  |  | (22.0) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nInfectious Diseases |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 461 |  |  | 512 |  |  | (10.0) |  |  |  |  |  |  | \nInternational |  | 836 |  |  | 485 |  |  | 72.3 |  |  |  |  |  |  | \nWorldwide |  | 1,297 |  |  | 998 |  |  | 30.0 |  |  |  |  |  |  | \nCOVID-19 VACCINE |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 75 |  |  | 100 |  |  | (24.9) |  |  |  |  |  |  | \nInternational |  | 382 |  |  | 0 |  | * |  |  |  |  |  | \nWorldwide |  | 457 |  |  | 100 |  |  | * |  |  |  |  |  | \nEDURANT / rilpivirine |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 9 |  |  | 10 |  |  | (12.6) |  |  |  |  |  |  | \nInternational |  | 239 |  |  | 233 |  |  | 2.5 |  |  |  |  |  |  | \nWorldwide |  | 248 |  |  | 243 |  |  | 1.8 |  |  |  |  |  |  | \nPREZISTA / PREZCOBIX /REZOLSTA / SYMTUZA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 369 |  |  | 380 |  |  | (3.1) |  |  |  |  |  |  | \nInternational |  | 132 |  |  | 166 |  |  | (20.3) |  |  |  |  |  |  | \nWorldwide |  | 501 |  |  | 546 |  |  | (8.3) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nOTHER INFECTIOUS DISEASES(1) |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 8 |  |  | 21 |  |  | (62.5) |  |  |  |  |  |  | \nInternational |  | 83 |  |  | 87 |  |  | (3.8) |  |  |  |  |  |  | \nWorldwide |  | 91 |  |  | 108 |  |  | (15.3) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nNeuroscience |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 843 |  |  | 771 |  |  | 9.3 |  |  |  |  |  |  | \nInternational |  | 898 |  |  | 943 |  |  | (4.8) |  |  |  |  |  |  | \nWorldwide |  | 1,741 |  |  | 1,715 |  |  | 1.5 |  |  |  |  |  |  | \nCONCERTA / methylphenidate |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 35 |  |  | 47 |  |  | (26.5) |  |  |  |  |  |  | \nInternational |  | 122 |  |  | 123 |  |  | (1.3) |  |  |  |  |  |  | \nWorldwide |  | 157 |  |  | 171 |  |  | (8.3) |  |  |  |  |  |  | \nINVEGA SUSTENNA / XEPLION / INVEGA   TRINZA / TREVICTA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 661 |  |  | 589 |  |  | 12.2 |  |  |  |  |  |  | \nInternational |  | 387 |  |  | 376 |  |  | 3.0 |  |  |  |  |  |  | \nWorldwide |  | 1,048 |  |  | 965 |  |  | 8.6 |  |  |  |  |  |  | \nRISPERDAL CONSTA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 63 |  |  | 67 |  |  | (6.4) |  |  |  |  |  |  | \nInternational |  | 66 |  |  | 89 |  |  | (26.1) |  |  |  |  |  |  | \nWorldwide |  | 129 |  |  | 157 |  |  | (17.6) |  |  |  |  |  |  | \nOTHER NEUROSCIENCE(1) |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 84 |  |  | 67 |  |  | 25.5 |  |  |  |  |  |  | \nInternational |  | 323 |  |  | 355 |  |  | (8.9) |  |  |  |  |  |  | \nWorldwide |  | 408 |  |  | 422 |  |  | (3.5) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nOncology |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,582 |  |  | 1,377 |  |  | 14.9 |  |  |  |  |  |  | \nInternational |  | 2,369 |  |  | 2,193 |  |  | 8.0 |  |  |  |  |  |  | \nWorldwide |  | 3,950 |  |  | 3,570 |  |  | 10.6 |  |  |  |  |  |  | \nDARZALEX |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 953 |  |  | 691 |  |  | 37.9 |  |  |  |  |  |  | \nInternational |  | 903 |  |  | 674 |  |  | 34.0 |  |  |  |  |  |  | \nWorldwide |  | 1,856 |  |  | 1,365 |  |  | 36.0 |  |  |  |  |  |  | \nERLEADA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 206 |  |  | 171 |  |  | 20.3 |  |  |  |  |  |  | \nInternational |  | 194 |  |  | 90 |  |  | * |  |  |  |  |  | \nWorldwide |  | 400 |  |  | 261 |  |  | 53.0 |  |  |  |  |  |  | \nIMBRUVICA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 370 |  |  | 444 |  |  | (16.7) |  |  |  |  |  |  | \nInternational |  | 668 |  |  | 680 |  |  | (1.8) |  |  |  |  |  |  | \nWorldwide |  | 1,038 |  |  | 1,125 |  |  | (7.7) |  |  |  |  |  |  | \nZYTIGA/abiraterone acetate |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 19 |  |  | 50 |  |  | (62.1) |  |  |  |  |  |  | \nInternational |  | 520 |  |  | 588 |  |  | (11.6) |  |  |  |  |  |  | \nWorldwide |  | 539 |  |  | 638 |  |  | (15.6) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nOTHER ONCOLOGY |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 34 |  |  | 21 |  |  | 63.1 |  |  |  |  |  |  | \nInternational |  | 84 |  |  | 161 |  |  | (47.7) |  |  |  |  |  |  | \nWorldwide |  | 118 |  |  | 182 |  |  | (35.1) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nPulmonary Hypertension |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 572 |  |  | 573 |  |  | (0.2) |  |  |  |  |  |  | \nInternational |  | 279 |  |  | 288 |  |  | (2.9) |  |  |  |  |  |  | \nWorldwide |  | 852 |  |  | 861 |  |  | (1.1) |  |  |  |  |  |  | \nOPSUMIT |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 273 |  |  | 272 |  |  | 0.5 |  |  |  |  |  |  | \nInternational |  | 170 |  |  | 179 |  |  | (4.8) |  |  |  |  |  |  | \nWorldwide |  | 443 |  |  | 450 |  |  | (1.6) |  |  |  |  |  |  | \nUPTRAVI |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 269 |  |  | 259 |  |  | 3.9 |  |  |  |  |  |  | \nInternational |  | 56 |  |  | 46 |  |  | 20.9 |  |  |  |  |  |  | \nWorldwide |  | 325 |  |  | 305 |  |  | 6.5 |  |  |  |  |  |  | \nOTHER PULMONARY HYPERTENSION |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 30 |  |  | 42 |  |  | (29.0) |  |  |  |  |  |  | \nInternational |  | 53 |  |  | 63 |  |  | (15.2) |  |  |  |  |  |  | \nWorldwide |  | 83 |  |  | 105 |  |  | (20.8) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nCardiovascular / Metabolism / Other |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 672 |  |  | 799 |  |  | (15.8) |  |  |  |  |  |  | \nInternational |  | 238 |  |  | 245 |  |  | (3.0) |  |  |  |  |  |  | \nWorldwide |  | 910 |  |  | 1,044 |  |  | (12.8) |  |  |  |  |  |  | \nXARELTO |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 508 |  |  | 589 |  |  | (13.8) |  |  |  |  |  |  | \nInternational |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  |  |  |  |  | \nWorldwide |  | 508 |  |  | 589 |  |  | (13.8) |  |  |  |  |  |  | \nINVOKANA / INVOKAMET |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 60 |  |  | 87 |  |  | (30.7) |  |  |  |  |  |  | \nInternational |  | 68 |  |  | 63 |  |  | 7.5 |  |  |  |  |  |  | \nWorldwide |  | 128 |  |  | 150 |  |  | (14.6) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nOTHER(1,2) |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 104 |  |  | 122 |  |  | (14.9) |  |  |  |  |  |  | \nInternational |  | 170 |  |  | 182 |  |  | (6.6) |  |  |  |  |  |  | \nWorldwide |  | 274 |  |  | 305 |  |  | (10.0) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nTOTAL PHARMACEUTICAL |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 6,632 |  |  | 6,446 |  |  | 2.9 |  |  |  |  |  |  | \nInternational |  | 6,237 |  |  | 5,655 |  |  | 10.3 |  |  |  |  |  |  | \nWorldwide |  | 12,869 |  |  | 12,101 |  |  | 6.3 |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nMEDTECH(3) |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nInterventional Solutions |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 494 |  |  | 434 |  |  | 13.8 |  |  |  |  |  |  | \nInternational |  | 597 |  |  | 514 |  |  | 16.2 |  |  |  |  |  |  | \nWorldwide |  | 1,092 |  |  | 949 |  |  | 15.1 |  |  |  |  |  |  | \nOrthopaedics |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,289 |  |  | 1,249 |  |  | 3.2 |  |  |  |  |  |  | \nInternational |  | 899 |  |  | 864 |  |  | 4.1 |  |  |  |  |  |  | \nWorldwide |  | 2,188 |  |  | 2,113 |  |  | 3.5 |  |  |  |  |  |  | \nHIPS |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 225 |  |  | 209 |  |  | 7.3 |  |  |  |  |  |  | \nInternational |  | 164 |  |  | 146 |  |  | 12.2 |  |  |  |  |  |  | \nWorldwide |  | 389 |  |  | 356 |  |  | 9.3 |  |  |  |  |  |  | \nKNEES |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 201 |  |  | 185 |  |  | 8.6 |  |  |  |  |  |  | \nInternational |  | 138 |  |  | 132 |  |  | 4.1 |  |  |  |  |  |  | \nWorldwide |  | 339 |  |  | 317 |  |  | 6.7 |  |  |  |  |  |  | \nTRAUMA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 475 |  |  | 450 |  |  | 5.5 |  |  |  |  |  |  | \nInternational |  | 273 |  |  | 282 |  |  | (3.3) |  |  |  |  |  |  | \nWorldwide |  | 748 |  |  | 733 |  |  | 2.1 |  |  |  |  |  |  | \nSPINE, SPORTS & OTHER |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 387 |  |  | 404 |  |  | (4.1) |  |  |  |  |  |  | \nInternational |  | 324 |  |  | 303 |  |  | 7.0 |  |  |  |  |  |  | \nWorldwide |  | 712 |  |  | 707 |  |  | 0.6 |  |  |  |  |  |  | \nSurgery |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 921 |  |  | 898 |  |  | 2.5 |  |  |  |  |  |  | \nInternational |  | 1,513 |  |  | 1,474 |  |  | 2.7 |  |  |  |  |  |  | \nWorldwide |  | 2,434 |  |  | 2,372 |  |  | 2.6 |  |  |  |  |  |  | \nADVANCED |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 417 |  |  | 405 |  |  | 3.0 |  |  |  |  |  |  | \nInternational |  | 729 |  |  | 713 |  |  | 2.2 |  |  |  |  |  |  | \nWorldwide |  | 1,146 |  |  | 1,118 |  |  | 2.5 |  |  |  |  |  |  | \nGENERAL |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 504 |  |  | 493 |  |  | 2.1 |  |  |  |  |  |  | \nInternational |  | 784 |  |  | 761 |  |  | 3.1 |  |  |  |  |  |  | \nWorldwide |  | 1,288 |  |  | 1,254 |  |  | 2.7 |  |  |  |  |  |  | \nVision |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 521 |  |  | 472 |  |  | 10.4 |  |  |  |  |  |  | \nInternational |  | 736 |  |  | 673 |  |  | 9.4 |  |  |  |  |  |  | \nWorldwide |  | 1,257 |  |  | 1,145 |  |  | 9.8 |  |  |  |  |  |  | \nCONTACT LENSES / OTHER |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 400 |  |  | 371 |  |  | 7.7 |  |  |  |  |  |  | \nInternational |  | 511 |  |  | 486 |  |  | 5.1 |  |  |  |  |  |  | \nWorldwide |  | 910 |  |  | 857 |  |  | 6.2 |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nSURGICAL |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 121 |  |  | 101 |  |  | 20.2 |  |  |  |  |  |  | \nInternational |  | 226 |  |  | 187 |  |  | 20.5 |  |  |  |  |  |  | \nWorldwide |  | 347 |  |  | 288 |  |  | 20.4 |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nTOTAL MEDTECH |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 3,225 |  |  | 3,054 |  |  | 5.6 |  |  |  |  |  |  | \nInternational |  | 3,746 |  |  | 3,525 |  |  | 6.3 |  |  |  |  |  |  | \nWorldwide |  | 6,971 |  |  | 6,579 |  |  | 5.9 |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nWORLDWIDE |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 11,414 |  |  | 11,111 |  |  | 2.7 |  |  |  |  |  |  | \nInternational |  | 12,012 |  |  | 11,210 |  |  | 7.2 |  |  |  |  |  |  | \nWorldwide |  | $ | 23,426 |  |  | 22,321 |  |  | 5.0 | % |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal First Quarter Ended |  |  | \n(Dollars in Millions) |  | April 3,2022 |  | April 4,2021 |  | PercentChange |  |  |  |  |  |  |  |  |  |  | \nConsumer Health(1) |  | $ | 686 |  |  | 842 |  |  | (18.5)% |  |  |  |  |  |  |  |  |  |  | \nPharmaceutical(2) |  | 3,924 |  |  | 5,169 |  |  | (24.1) |  |  |  |  |  |  |  |  |  |  | \nMedTech(3) |  | 1,477 |  |  | 1,629 |  |  | (9.3) |  |  |  |  |  |  |  |  |  |  | \nSegment earnings before provision for taxes |  | 6,087 |  |  | 7,640 |  |  | (20.3) |  |  |  |  |  |  |  |  |  |  | \nLess: Expense not allocated to segments(4) |  | 123 |  |  | 211 |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLess: Consumer Health separation costs |  | 102 |  |  | \u2014 |  |  |  |  |  |  |  |  |  |  |  |  |  | \nWorldwide income before tax |  | $ | 5,862 |  |  | 7,429 |  |  | (21.1)% |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal First Quarter Ended |  | \n(Dollars in Millions) |  | April 3, 2022 |  | April 4, 2021 |  | PercentChange |  |  |  |  |  | \nUnited States |  | $ | 11,414 |  |  | 11,111 |  |  | 2.7 | % |  |  |  |  |  | \nEurope |  | 6,024 |  |  | 5,414 |  |  | 11.3 |  |  |  |  |  |  | \nWestern Hemisphere, excluding U.S. |  | 1,482 |  |  | 1,424 |  |  | 4.1 |  |  |  |  |  |  | \nAsia-Pacific, Africa |  | 4,506 |  |  | 4,372 |  |  | 3.1 |  |  |  |  |  |  | \nTotal |  | $ | 23,426 |  |  | 22,321 |  |  | 5.0 | % |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) | Severance | Asset Write-offs/Sales |  | Other(2) | Total\nReserve balance, January 2, 2022 | $ | 112 |  | \u2014 |  |  | 25 |  | 137 | \n |  |  |  |  | \nCurrent year activity: |  |  |  |  | \nCharges | \u2014 |  | (23) |  |  | 95 |  | 72 | \nCash settlements | (10) |  | 35 |  | (3) |  | (107) |  | (82) | \nSettled non cash | \u2014 |  | (12) |  |  | \u2014 |  | (12) | \n |  |  |  |  | \n |  |  |  |  | \nReserve balance, April 3, 2022(1) | $ | 102 |  | \u2014 |  |  | 13 |  | 115 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | April 3, 2022 |  | April 4, 2021 |  | TotalChange |  | OperationsChange |  | CurrencyChange\nOTC(1) |  | $ | 1,461 |  |  | $ | 1,273 |  |  | 14.8 | % |  | 17.1 | % |  | (2.3) | %\nSkin Health/Beauty |  | 1,012 |  |  | 1,163 |  |  | (13.0) |  |  | (11.0) |  |  | (2.0) | \nOral Care |  | 366 |  |  | 417 |  |  | (12.2) |  |  | (10.2) |  |  | (2.0) | \nBaby Care |  | 355 |  |  | 389 |  |  | (8.6) |  |  | (6.4) |  |  | (2.2) | \nWomen\u2019s Health |  | 228 |  |  | 222 |  |  | 2.6 |  |  | 8.3 |  |  | (5.7) | \nWound Care/Other |  | 164 |  |  | 177 |  |  | (7.4) |  |  | (7.2) |  |  | (0.2) | \nTotal Consumer Health Sales |  | $ | 3,586 |  |  | $ | 3,641 |  |  | (1.5) | % |  | 0.8 | % |  | (2.3) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | April 3, 2022 |  | April 4, 2021 |  | TotalChange |  | OperationsChange |  | CurrencyChange\nImmunology |  | $ | 4,119 |  |  | $ | 3,914 |  |  | 5.2 | % |  | 7.5 | % |  | (2.3) | %\nREMICADE |  | 663 |  |  | 777 |  |  | (14.7) |  |  | (14.2) |  |  | (0.5) | \nSIMPONI/ SIMPONI ARIA |  | 571 |  |  | 562 |  |  | 1.5 |  |  | 4.7 |  |  | (3.2) | \nSTELARA |  | 2,288 |  |  | 2,148 |  |  | 6.5 |  |  | 9.0 |  |  | (2.5) | \nTREMFYA |  | 590 |  |  | 418 |  |  | 41.3 |  |  | 44.5 |  |  | (3.2) | \nOther Immunology |  | 6 |  |  | 8 |  |  | (22.0) |  |  | (22.0) |  |  | 0.0\nInfectious Diseases |  | 1,297 |  |  | 998 |  |  | 30.0 |  |  | 33.1 |  |  | (3.1) | \nCOVID-19 VACCINE |  | 457 |  |  | 100 |  |  | * |  | * |  | *\nEDURANT/rilpivirine |  | 248 |  |  | 243 |  |  | 1.8 |  |  | 9.6 |  |  | (7.8) | \nPREZISTA/ PREZCOBIX/ REZOLSTA/SYMTUZA |  | 501 |  |  | 546 |  |  | (8.3) |  |  | (6.9) |  |  | (1.4) | \nOther Infectious Diseases(2) |  | 91 |  |  | 108 |  |  | (15.3) |  |  | (11.0) |  |  | (4.3) | \nNeuroscience |  | 1,741 |  |  | 1,715 |  |  | 1.5 |  |  | 5.0 |  |  | (3.5) | \nCONCERTA/ methylphenidate |  | 157 |  |  | 171 |  |  | (8.3) |  |  | (4.8) |  |  | (3.5) | \nINVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/TREVICTA |  | 1,048 |  |  | 965 |  |  | 8.6 |  |  | 11.3 |  |  | (2.7) | \nRISPERDAL CONSTA |  | 129 |  |  | 157 |  |  | (17.6) |  |  | (13.9) |  |  | (3.7) | \nOther Neuroscience(2) |  | 408 |  |  | 422 |  |  | (3.5) |  |  | 1.7 |  |  | (5.2) | \nOncology |  | 3,950 |  |  | 3,570 |  |  | 10.6 |  |  | 14.9 |  |  | (4.3) | \nDARZALEX |  | 1,856 |  |  | 1,365 |  |  | 36.0 |  |  | 40.3 |  |  | (4.3) | \nERLEADA |  | 400 |  |  | 261 |  |  | 53.0 |  |  | 57.5 |  |  | (4.5) | \nIMBRUVICA |  | 1,038 |  |  | 1,125 |  |  | (7.7) |  |  | (3.9) |  |  | (3.8) | \nZYTIGA/ abiraterone acetate |  | 539 |  |  | 638 |  |  | (15.6) |  |  | (10.1) |  |  | (5.5) | \nOther Oncology |  | 118 |  |  | 182 |  |  | (35.1) |  |  | (32.3) |  |  | (2.8) | \nPulmonary Hypertension |  | 852 |  |  | 861 |  |  | (1.1) |  |  | 1.2 |  |  | (2.3) | \nOPSUMIT |  | 443 |  |  | 450 |  |  | (1.6) |  |  | 1.1 |  |  | (2.7) | \nUPTRAVI |  | 325 |  |  | 305 |  |  | 6.5 |  |  | 7.7 |  |  | (1.2) | \nOther Pulmonary Hypertension |  | 83 |  |  | 105 |  |  | (20.8) |  |  | (16.8) |  |  | (4.0) | \nCardiovascular / Metabolism / Other |  | 910 |  |  | 1,044 |  |  | (12.8) |  |  | (11.9) |  |  | (0.9) | \nXARELTO |  | 508 |  |  | 589 |  |  | (13.8) |  |  | (13.8) |  |  | \u2014 | \nINVOKANA/ INVOKAMET |  | 128 |  |  | 150 |  |  | (14.6) |  |  | (13.1) |  |  | (1.5) | \nOther(1,2) |  | 274 |  |  | 305 |  |  | (10.0) |  |  | (7.5) |  |  | (2.5) | \nTotal Pharmaceutical Sales |  | $ | 12,869 |  |  | $ | 12,101 |  |  | 6.3 | % |  | 9.3 | % |  | (3.0) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | April 3, 2022 |  | April 4, 2021 |  | TotalChange |  | OperationsChange |  | CurrencyChange\nSurgery |  | $ | 2,434 |  |  | $ | 2,372 |  |  | 2.6 | % |  | 5.0 | % |  | (2.4) | %\nAdvanced |  | 1,146 |  |  | 1,118 |  |  | 2.5 |  |  | 4.5 |  |  | (2.0) | \nGeneral |  | 1,288 |  |  | 1,254 |  |  | 2.7 |  |  | 5.5 |  |  | (2.8) | \nOrthopaedics |  | 2,188 |  |  | 2,113 |  |  | 3.5 |  |  | 5.6 |  |  | (2.1) | \nHips |  | 389 |  |  | 356 |  |  | 9.3 |  |  | 11.3 |  |  | (2.0) | \nKnees |  | 339 |  |  | 317 |  |  | 6.7 |  |  | 8.8 |  |  | (2.1) | \nTrauma |  | 748 |  |  | 733 |  |  | 2.1 |  |  | 4.2 |  |  | (2.1) | \nSpine, Sports & Other |  | 712 |  |  | 707 |  |  | 0.6 |  |  | 2.7 |  |  | (2.1) | \nVision |  | 1,257 |  |  | 1,145 |  |  | 9.8 |  |  | 13.9 |  |  | (4.1) | \nContact Lenses/Other |  | 910 |  |  | 857 |  |  | 6.2 |  |  | 10.6 |  |  | (4.4) | \nSurgical |  | 347 |  |  | 288 |  |  | 20.4 |  |  | 23.8 |  |  | (3.4) | \nInterventional Solutions |  | 1,092 |  |  | 949 |  |  | 15.1 |  |  | 17.4 |  |  | (2.3) | \n |  |  |  |  |  |  |  |  |  | \nTotal MedTech Sales |  | $ | 6,971 |  |  | $ | 6,579 |  |  | 5.9 | % |  | 8.5 | % |  | (2.6) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nFiscal First Quarter |  |  |  |  |  | \n(Dollars in Billions)(Income)/Expense |  | 2022 |  | 2021 |  | Change\nChanges in the fair value of securities |  | $ | 0.4 |  |  | 0.0 |  |  | 0.4 | \nAcquisition, integration and divestiture related(1) |  | 0.0 |  |  | (0.5) |  |  | 0.5 | \nConsumer Health separation costs |  | 0.1 |  |  | 0.0 |  |  | 0.1 | \nEmployee benefit plan related |  | (0.3) |  |  | (0.2) |  |  | (0.1) | \nOther |  | (0.3) |  |  | (0.2) |  |  | (0.1) | \n |  |  |  |  |  | \n |  |  |  |  |  | \nTotal Other (Income) Expense, Net |  | $ | (0.1) |  |  | $ | (0.9) |  |  | $ | 0.8 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Income Before Tax |  | Segment Sales |  | Percent of Segment Sales\n(Dollars in Millions) |  | April 3, 2022 |  | April 4, 2021 |  | April 3, 2022 |  | April 4, 2021 |  | April 3, 2022 |  | April 4, 2021\nConsumer Health |  | $ | 686 |  |  | $ | 842 |  |  | $ | 3,586 |  |  | $ | 3,641 |  |  | 19.1 | % |  | 23.1 | %\nPharmaceutical |  | 3,924 |  |  | 5,169 |  |  | 12,869 |  |  | 12,101 |  |  | 30.5 |  |  | 42.7 | \nMedTech |  | 1,477 |  |  | 1,629 |  |  | 6,971 |  |  | 6,579 |  |  | 21.2 |  |  | 24.8 | \nSegment earnings before tax |  | 6,087 |  |  | 7,640 |  |  | 23,426 |  |  | 22,321 |  |  | 26.0 |  |  | 34.2 | \nLess: Expenses not allocated to segments(1) |  | 123 |  |  | 211 |  |  |  |  |  |  |  |  | \nLess: Consumer Health separation costs |  | 102 |  |  | \u2014 |  |  |  |  |  |  |  |  | \nWorldwide income before tax |  | $ | 5,862 |  |  | $ | 7,429 |  |  | $ | 23,426 |  |  | $ | 22,321 |  |  | 25.0 | % |  | 33.3 | %  |  |  |  |  | \n(Dollars In Billions) | \n$ | 14.5 |  | Q4 2021 Cash and cash equivalents balance\n4.0 |  | cash generated from operating activities\n(3.6) |  | net cash used by investing activities\n(4.4) |  | net cash used by financing activities\n | \n$ | 10.5 |  | Q1 2022 Cash and cash equivalents balance  |  |  |  |  | \n(Dollars In Billions) | \n$ | 5.1 |  | Net Earnings\n1.6 |  | non-cash expenses and other adjustments primarily for depreciation and amortization, stock-based compensation, asset write-downs and credit losses and accounts receivable allowances partially offset by the deferred tax provision and net gain on sale of assets/businesses\n | \n(1.0) |  | an increase in accounts receivable and inventories\n | \n(2.8) |  | a decrease in accounts payable and accrued liabilities\n1.0 |  | a decrease in other current and non-current assets\n0.1 |  | an increase in other current and non-current liabilities\n$ | 4.0 |  | Cash Flow from operations  |  |  |  |  | \n(Dollars In Billions) | \n$ | (0.6) |  | additions to property, plant and equipment\n0.2 |  | proceeds from the disposal of assets/businesses, net\n(0.3) |  | acquisitions, net of cash acquired and other\n(2.7) |  | net purchases of investments\n | \n(0.2) |  | credit support agreements activity, net\n | \n$ | (3.6) |  | Net cash used for investing activities  |  |  |  |  | \n(Dollars In Billions) | \n$ | (2.8) |  | dividends to shareholders\n(1.6) |  | repurchase of common stock\n0.0 | net repayment of short and long term debt\n0.3 |  | proceeds from stock options exercised/employee withholding tax on stock awards, net\n(0.2) |  | credit support agreements activity, net\n(0.1) |  | other and rounding\n$ | (4.4) |  | Net cash used for financing activities  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nFiscal Month Period |  | Total Numberof Shares Purchased(1) |  | Avg. PricePer Share |  | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs |  | Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs\nJanuary 3, 2022 through January 30, 2022 |  | 918,500 |  |  | 170.99 |  |  |  |  | \u2014\nJanuary 31, 2022 through February 27, 2022 |  | 4,728,073 |  |  | 168.98 |  |  |  |  | \u2014\nFebruary 28, 2022 through April 3, 2022 |  | 3,596,956 |  |  | 172.58 |  |  |  |  | \u2014\nTotal |  | 9,243,529 |  |  |  |  |  |  |   |  |  |  |  |  |  |  | \nEX-101.INS |  | Instance Document - the instance document does not appear in the Interactive Data File because its                XBRL tags are embedded within the Inline XBRL document\nEX-101.SCH |  | Inline XBRL Taxonomy Extension Schema\nEX-101.CAL |  | Inline XBRL Taxonomy Extension Calculation Linkbase\nEX-101.LAB |  | Inline XBRL Taxonomy Extension Label Linkbase\nEX-101.PRE |  | Inline XBRL Taxonomy Extension Presentation Linkbase\nEX-101.DEF |  | Inline XBRL Taxonomy Extension Definition Document\n |  | \nExhibit 104: |  | Cover Page Interactive Data File\u2013\u2013the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.\n |  |   |  |  |  |  | \n | JOHNSON & JOHNSON(Registrant)\n | \nDate: April 29, 2022 | By /s/ J. J. WOLK\n | J. J. WOLK\n | Executive Vice President, Chief Financial Officer (Principal Financial Officer)\n | \nDate: April 29, 2022 | By /s/\u00a0R. J. DECKER Jr.\n | R. J. DECKER Jr.\n | Controller (Principal Accounting Officer)"}]}
{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For Johnson and Johnson, in 2022 Q3, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  |  |  |  |  |  |  | \n |  | \n\u2611 |  | Quarterly Report Pursuant to Section\u00a013 or 15(d) of the Securities Exchange Act of 1934  |  |  |  |  |  |  |  | \n |  | \n\u2610 |  | Transition Report Pursuant to Section\u00a013 or 15(d) of the Securities Exchange Act of 1934for the transition period from\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0to  |  |  |  |  |  |  |  | \nNew Jersey |  | 22-1024240\n(State or other jurisdiction ofincorporation or organization) |  | (I.R.S. EmployerIdentification No.)  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Large accelerated filer | \u2611 | Accelerated filer | \u2610\n | Non-accelerated filer | \u2610 | Smaller reporting company | \u2610\n | Emerging growth company | \u2610 |  |   |  |  |  |  |  |  |  | \nTitle of each class | Trading Symbol | Name of each exchange on which registered\nCommon Stock, Par Value $1.00 | JNJ | New York Stock Exchange\n0.650% Notes Due May 2024 | JNJ24C | New York Stock Exchange\n5.50% Notes Due November 2024 | JNJ24BP | New York Stock Exchange\n1.150% Notes Due November 2028 | JNJ28 | New York Stock Exchange\n1.650% Notes Due May 2035 | JNJ35 | New York Stock Exchange  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Page\n |  |  | No.\nPart I \u2014 Financial Information |  |  | 1\n |  |  | \nItem\u00a01. Financial Statements (unaudited) |  |  | 1\n |  |  | \nConsolidated Balance Sheets \u2014October2, 2022 and January 2, 2022 |  |  | 1\n |  |  | \nConsolidated Statements of Earnings for the FiscalThirdQuarters EndedOctober2, 2022 andOctober3, 2021 |  |  | 2\n |  |  | \nConsolidated Statements of Earnings for the FiscalNineMonths EndedOctober2, 2022 andOctober3, 2021 |  |  | 3\n |  |  | \nConsolidated Statements of Comprehensive Income for the FiscalThirdQuarters and FiscalNineMonths EndedOctober2, 2022 andOctober3, 2021 |  |  | 4\n |  |  | \nConsolidated Statements of Equity for the FiscalThirdQuarters and FiscalNineMonths EndedOctober2, 2022 andOctober3, 2021 |  |  | 5\n |  |  | \nConsolidated Statements of Cash Flows for the FiscalNineMonths EndedOctober2, 2022 andOctober3, 2021 |  |  | 7\n |  |  | \nNotes to Consolidated Financial Statements |  |  | 8\n |  |  | \n |  |  | \n |  |  | \nItem\u00a02. Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations |  |  | 47\n |  |  | \nItem\u00a03. Quantitative and Qualitative Disclosures About Market Risk |  |  | 65\n |  |  | \nItem\u00a04. Controls and Procedures |  |  | 65\n |  |  | \nPart II \u2014 Other Information |  |  | 65\n |  |  | \nItem\u00a01 - Legal Proceedings |  |  | 65\n |  |  | \nItem\u00a02 - Unregistered Sales of Equity Securities and Use of Proceeds |  |  | 66\n |  |  | \nItem\u00a06 - Exhibits |  |  | 67\n |  |  | \nSignatures |  |  | 68\n\n\n\n\n\n\n\n  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | October 2, 2022 |  | January 2, 2022\nASSETS\nCurrent assets: |  |  |  | \nCash and cash equivalents |  | $ | 11,355 |  |  | 14,487 | \nMarketable securities |  | 22,724 |  |  | 17,121 | \nAccounts receivable, trade, less allowances $201(2021, $230) |  | 15,890 |  |  | 15,283 | \nInventories (Note 2) |  | 11,675 |  |  | 10,387 | \nPrepaid expenses and other |  | 3,592 |  |  | 3,701 | \n |  |  |  | \nTotal current assets |  | 65,236 |  |  | 60,979 | \nProperty, plant and equipment at cost |  | 46,681 |  |  | 47,679 | \nLess: accumulated depreciation |  | (28,529) |  |  | (28,717) | \nProperty, plant and equipment, net |  | 18,152 |  |  | 18,962 | \nIntangible assets, net (Note 3) |  | 40,336 |  |  | 46,392 | \nGoodwill (Note 3) |  | 33,383 |  |  | 35,246 | \nDeferred taxes on income (Note 5) |  | 9,392 |  |  | 10,223 | \nOther assets |  | 8,625 |  |  | 10,216 | \nTotal assets |  | $ | 175,124 |  |  | 182,018 | \nLIABILITIES AND SHAREHOLDERS\u2019 EQUITY\nCurrent liabilities: |  |  |  | \nLoans and notes payable |  | $ | 4,424 |  |  | 3,766 | \nAccounts payable |  | 10,153 |  |  | 11,055 | \nAccrued liabilities |  | 11,953 |  |  | 13,612 | \nAccrued rebates, returns and promotions |  | 14,021 |  |  | 12,095 | \nAccrued compensation and employee related obligations |  | 3,006 |  |  | 3,586 | \nAccrued taxes on income (Note 5) |  | 1,986 |  |  | 1,112 | \nTotal current liabilities |  | 45,543 |  |  | 45,226 | \nLong-term debt (Note 4) |  | 27,603 |  |  | 29,985 | \nDeferred taxes on income (Note 5) |  | 4,946 |  |  | 7,487 | \nEmployee related obligations (Note 6) |  | 8,353 |  |  | 8,898 | \nLong-term taxes payable (Note 5) |  | 4,162 |  |  | 5,713 | \nOther liabilities |  | 9,918 |  |  | 10,686 | \nTotal liabilities |  | $ | 100,525 |  |  | 107,995 | \nCommitments and Contingencies (Note 11) |  |  |  | \nShareholders\u2019 equity: |  |  |  | \nCommon stock \u2014 par value $1.00per share (authorized4,320,000,000shares; issued3,119,843,000shares) |  | $ | 3,120 |  |  | 3,120 | \nAccumulated other comprehensive income (loss) (Note 7) |  | (15,292) |  |  | (13,058) | \nRetained earnings |  | 127,917 |  |  | 123,060 | \nLess: common stock held in treasury, at cost (502,961,000and490,878,000shares) |  | 41,146 |  |  | 39,099 | \nTotal shareholders\u2019 equity |  | 74,599 |  |  | 74,023 | \nTotal liabilities and shareholders' equity |  | $ | 175,124 |  |  | 182,018 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Third Quarter Ended\n |  | October 2,2022 |  | Percentto Sales |  | October 3,2021 |  | Percentto Sales\nSales to customers (Note 9) |  | $ | 23,791 |  |  | 100.0 | % |  | $ | 23,338 |  |  | 100.0 | %\nCost of products sold |  | 7,807 |  |  | 32.8 |  |  | 7,250 |  |  | 31.1 | \nGross profit |  | 15,984 |  |  | 67.2 |  |  | 16,088 |  |  | 68.9 | \nSelling, marketing and administrative expenses |  | 6,089 |  |  | 25.6 |  |  | 6,000 |  |  | 25.7 | \nResearch and development expense |  | 3,597 |  |  | 15.1 |  |  | 3,422 |  |  | 14.7 | \nIn-process research and development |  | \u2014 |  |  | \u2014 |  |  | 900 |  |  | 3.9 | \nInterest income |  | (150) |  |  | (0.6) |  |  | (13) |  |  | (0.1) | \nInterest expense, net of portion capitalized |  | 51 |  |  | 0.2 |  |  | 20 |  |  | 0.1 | \nOther (income) expense, net |  | 493 |  |  | 2.1 |  |  | 1,850 |  |  | 7.9 | \nRestructuring (Note 12) |  | 82 |  |  | 0.3 |  |  | 60 |  |  | 0.2 | \nEarnings before provision for taxes on income |  | 5,822 |  |  | 24.5 |  |  | 3,849 |  |  | 16.5 | \nProvision for taxes on income (Note 5) |  | 1,364 |  |  | 5.8 |  |  | 182 |  |  | 0.8 | \nNET EARNINGS |  | $ | 4,458 |  |  | 18.7 | % |  | $ | 3,667 |  |  | 15.7 | %\n |  |  |  |  |  |  |  | \nNET EARNINGS PER SHARE (Note 8) |  |  |  |  |  |  |  | \nBasic |  | $ | 1.70 |  |  |  |  | $ | 1.39 |  |  | \nDiluted |  | $ | 1.68 |  |  |  |  | $ | 1.37 |  |  | \n |  |  |  |  |  |  |  | \nAVG. SHARES OUTSTANDING |  |  |  |  |  |  |  | \nBasic |  | 2,627.9 |  |  |  |  | 2,632.6 |  |  | \nDiluted |  | 2,661.3 |  |  |  |  | 2,674.9 |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n |  | Fiscal Nine Months Ended\n |  | October 2,2022 |  | Percentto Sales |  | October 3,2021 |  | Percentto Sales\nSales to customers (Note 9) |  | $ | 71,237 |  |  | 100.0 | % |  | $ | 68,971 |  |  | 100.0 | %\nCost of products sold |  | 23,324 |  |  | 32.7 |  |  | 21,900 |  |  | 31.8 | \nGross profit |  | 47,913 |  |  | 67.3 |  |  | 47,071 |  |  | 68.2 | \nSelling, marketing and administrative expenses |  | 18,253 |  |  | 25.7 |  |  | 17,505 |  |  | 25.4 | \nResearch and development expense |  | 10,762 |  |  | 15.1 |  |  | 9,994 |  |  | 14.5 | \nIn-process research and development |  | 610 |  |  | 0.9 |  |  | 900 |  | 1.3\nInterest income |  | (236) |  |  | (0.3) |  |  | (40) |  |  | (0.1) | \nInterest expense, net of portion capitalized |  | 99 |  |  | 0.1 |  |  | 123 |  |  | 0.2 | \nOther (income) expense, net |  | 664 |  |  | 0.9 |  |  | 480 |  |  | 0.7 | \nRestructuring (Note 12) |  | 237 |  |  | 0.3 |  |  | 169 |  |  | 0.2 | \nEarnings before provision for taxes on income |  | 17,524 |  |  | 24.6 |  |  | 17,940 |  |  | 26.0 | \nProvision for taxes on income (Note 5) |  | 3,103 |  |  | 4.4 |  |  | 1,798 |  |  | 2.6 | \nNET EARNINGS |  | $ | 14,421 |  |  | 20.2 | % |  | $ | 16,142 |  |  | 23.4 | %\n |  |  |  |  |  |  |  | \nNET EARNINGS PER SHARE (Note 8) |  |  |  |  |  |  |  | \nBasic |  | $ | 5.49 |  |  |  |  | $ | 6.13 |  |  | \nDiluted |  | $ | 5.41 |  |  |  |  | $ | 6.04 |  |  | \n |  |  |  |  |  |  |  | \nAVG. SHARES OUTSTANDING |  |  |  |  |  |  |  | \nBasic |  | 2,628.9 |  |  |  |  | 2,632.2 |  |  | \nDiluted |  | 2,667.5 |  |  |  |  | 2,674.6 |  |  | \n |  |  |  |  |  |  |  | \nSee Notes to Consolidated Financial Statements  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended\n | October 2, 2022 |  | October 3, 2021 |  | October 2, 2022 |  | October 3, 2021\n |  |  |  |  |  |  | \nNet earnings | $ | 4,458 |  |  | 3,667 |  |  | $ | 14,421 |  |  | 16,142 | \n |  |  |  |  |  |  | \nOther comprehensive income (loss), net of tax |  |  |  |  |  |  | \nForeign currency translation | (1,252) |  |  | (382) |  |  | (1,957) |  |  | (241) | \n |  |  |  |  |  |  | \nSecurities: |  |  |  |  |  |  | \nUnrealized holding gain (loss) arising during period | (2) |  |  | \u2014 |  |  | (35) |  |  | (1) | \nReclassifications to earnings | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \n |  |  |  |  |  |  | \nNet change | (2) |  |  | \u2014 |  |  | (35) |  |  | (1) | \n |  |  |  |  |  |  | \nEmployee benefit plans: |  |  |  |  |  |  | \nPrior service cost amortization during period | (37) |  |  | (40) |  |  | (110) |  |  | (122) | \nGain (loss) amortization during period | 151 |  |  | 273 |  |  | 454 |  |  | 822 | \n |  |  |  |  |  |  | \nNet change | 114 |  |  | 233 |  |  | 344 |  |  | 700 | \n |  |  |  |  |  |  | \nDerivatives & hedges: |  |  |  |  |  |  | \nUnrealized gain (loss) arising during period | (204) |  |  | 67 |  |  | (254) |  |  | (55) | \nReclassifications to earnings | (105) |  |  | (233) |  |  | (332) |  |  | (576) | \nNet change | (309) |  |  | (166) |  |  | (586) |  |  | (631) | \n |  |  |  |  |  |  | \nOther comprehensive income (loss) | (1,449) |  |  | (315) |  |  | (2,234) |  |  | (173) | \n |  |  |  |  |  |  | \nComprehensive income | $ | 3,009 |  |  | 3,352 |  |  | $ | 12,187 |  |  | 15,969 | \n |  |  |  |  |  |  |   |  | \nThe tax effects in other comprehensive income for the fiscal third quarter were as follows for 2022 and 2021, respectively: Foreign Currency Translation: $181million and $86million; Employee Benefit Plans: $33million and $65million; Derivatives & Hedges: $82million and $43million.\n\nThe tax effects in other comprehensive income for the fiscal nine months were as follows for 2022 and 2021, respectively: Foreign Currency Translation: $859million and $315million; Securities: $9million in 2022; Employee Benefit Plans: $98million and $197million; Derivatives & Hedges: $155million and $167million.  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Total |  | RetainedEarnings |  | AccumulatedOtherComprehensiveIncome |  | Common StockIssued Amount |  | TreasuryStockAmount\nBalance, July 3, 2022 | $ | 76,357 |  |  | 126,216 |  |  | (13,843) |  |  | 3,120 |  |  | (39,136) | \nNet earnings | 4,458 |  |  | 4,458 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nCash dividends paid ($1.13per share) | (2,970) |  |  | (2,970) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nEmployee compensation and stock option plans | 368 |  |  | 213 |  |  | \u2014 |  |  | \u2014 |  |  | 155 | \nRepurchase of common stock | (2,165) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (2,165) | \n |  |  |  |  |  |  |  |  | \nOther comprehensive income (loss), net of tax | (1,449) |  |  | \u2014 |  |  | (1,449) |  |  | \u2014 |  |  | \u2014 | \nBalance, October 2, 2022 | $ | 74,599 |  |  | 127,917 |  |  | (15,292) |  |  | 3,120 |  |  | (41,146) | \n |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n\n | Total |  | RetainedEarnings |  | AccumulatedOtherComprehensiveIncome |  | Common StockIssued Amount |  | TreasuryStockAmount\nBalance, January 2, 2022 | $ | 74,023 |  |  | 123,060 |  |  | (13,058) |  |  | 3,120 |  |  | (39,099) | \nNet earnings | 14,421 |  |  | 14,421 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nCash dividends paid ($3.32per share) | (8,728) |  |  | (8,728) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nEmployee compensation and stock option plans | 1,832 |  |  | (836) |  |  | \u2014 |  |  | \u2014 |  |  | 2,668 | \nRepurchase of common stock | (4,715) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (4,715) | \n |  |  |  |  |  |  |  |  | \nOther comprehensive income (loss), net of tax | (2,234) |  |  | \u2014 |  |  | (2,234) |  |  | \u2014 |  |  | \u2014 | \nBalance, October 2, 2022 | $ | 74,599 |  |  | 127,917 |  |  | (15,292) |  |  | 3,120 |  |  | (41,146) | \n |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Total |  | RetainedEarnings |  | AccumulatedOtherComprehensiveIncome |  | Common StockIssued Amount |  | TreasuryStockAmount\nBalance, July 4, 2021 | $ | 69,580 |  |  | 120,154 |  |  | (15,100) |  |  | 3,120 |  |  | (38,594) | \n |  |  |  |  |  |  |  |  | \nNet earnings | 3,667 |  |  | 3,667 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nCash dividends paid ($1.06per share) | (2,791) |  |  | (2,791) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nEmployee compensation and stock option plans | 522 |  |  | 62 |  |  | \u2014 |  |  | \u2014 |  |  | 460 | \nRepurchase of common stock | (391) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (391) | \n |  |  |  |  |  |  |  |  | \nOther comprehensive income (loss), net of tax | (315) |  |  | \u2014 |  |  | (315) |  |  | \u2014 |  |  | \u2014 | \nBalance, October 3, 2021 | $ | 70,272 |  |  | 121,092 |  |  | (15,415) |  |  | 3,120 |  |  | (38,525) | \n |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n\n | Total |  | RetainedEarnings |  | AccumulatedOtherComprehensiveIncome |  | Common StockIssued Amount |  | TreasuryStockAmount\nBalance, January 3, 2021 | $ | 63,278 |  |  | 113,890 |  |  | (15,242) |  |  | 3,120 |  |  | (38,490) | \n |  |  |  |  |  |  |  |  | \nNet earnings | 16,142 |  |  | 16,142 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nCash dividends paid ($3.13per share) | (8,241) |  |  | (8,241) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nEmployee compensation and stock option plans | 1,726 |  |  | (699) |  |  | \u2014 |  |  | \u2014 |  |  | 2,425 | \nRepurchase of common stock | (2,460) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (2,460) | \n |  |  |  |  |  |  |  |  | \nOther comprehensive income (loss), net of tax | (173) |  |  | \u2014 |  |  | (173) |  |  | \u2014 |  |  | \u2014 | \nBalance, October 3, 2021 | $ | 70,272 |  |  | 121,092 |  |  | (15,415) |  |  | 3,120 |  |  | (38,525) | \n |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Nine Months Ended\n |  | October 2,2022 |  | October 3,2021\nCASH FLOWS FROM OPERATING ACTIVITIES |  |  |  | \nNet earnings |  | $ | 14,421 |  |  | 16,142 | \nAdjustments to reconcile net earnings to cash flows from operating activities: |  |  |  | \nDepreciation and amortization of property and intangibles |  | 5,198 |  |  | 5,547 | \nStock based compensation |  | 925 |  |  | 920 | \n |  |  |  | \n |  |  |  | \nAsset write-downs |  | 787 |  |  | 964 | \n |  |  |  | \nNet gain on sale of assets/businesses |  | (213) |  |  | (601) | \n |  |  |  | \nDeferred tax provision |  | (2,488) |  |  | (2,564) | \nCredit losses and accounts receivable allowances |  | (14) |  |  | (60) | \nChanges in assets and liabilities, net of effects from acquisitions and divestitures: |  |  |  | \nIncrease in accounts receivable |  | (1,591) |  |  | (1,818) | \nIncrease in inventories |  | (1,877) |  |  | (1,178) | \nIncrease in accounts payable and accrued liabilities |  | 141 |  |  | 182 | \nDecrease in other current and non-current assets |  | 4,563 |  |  | 2,082 | \nDecrease in other current and non-current liabilities |  | (4,008) |  |  | (1,938) | \n |  |  |  | \nNET CASH FLOWS FROM OPERATING ACTIVITIES |  | 15,844 |  |  | 17,678 | \n |  |  |  | \nCASH FLOWS FROM INVESTING ACTIVITIES |  |  |  | \nAdditions to property, plant and equipment |  | (2,422) |  |  | (2,237) | \nProceeds from the disposal of assets/businesses, net (Note 10) |  | 322 |  |  | 666 | \nAcquisitions, net of cash acquired (Note 10) |  | (522) |  |  | \u2014 | \nPurchases of investments |  | (31,163) |  |  | (18,843) | \nSales of investments |  | 26,324 |  |  | 16,809 | \nCredit support agreements activity, net |  | (305) |  |  | 696 | \nOther (primarily licenses and milestones) |  | (208) |  |  | (414) | \n |  |  |  | \nNET CASH USED BY INVESTING ACTIVITIES |  | (7,974) |  |  | (3,323) | \n |  |  |  | \nCASH FLOWS FROM FINANCING ACTIVITIES |  |  |  | \nDividends to shareholders |  | (8,728) |  |  | (8,241) | \nRepurchase of common stock |  | (4,715) |  |  | (2,460) | \nProceeds from short-term debt |  | 7,099 |  |  | 1,283 | \nRepayment of short-term debt |  | (4,808) |  |  | (821) | \nProceeds from long-term debt, net of issuance costs |  | 1 |  |  | 3 | \nRepayment of long-term debt |  | (2,133) |  |  | (1,452) | \nProceeds from the exercise of stock options/employee withholding tax on stock awards, net |  | 907 |  |  | 808 | \nCredit support agreements activity, net |  | 1,678 |  |  | 168 | \nOther |  | 128 |  |  | 101 | \n |  |  |  | \nNET CASH USED BY FINANCING ACTIVITIES |  | (10,571) |  |  | (10,611) | \n |  |  |  | \nEffect of exchange rate changes on cash and cash equivalents |  | (431) |  |  | (125) | \n(Decrease)/Increase in cash and cash equivalents |  | (3,132) |  |  | 3,619 | \nCash and Cash equivalents, beginning of period |  | 14,487 |  |  | 13,985 | \nCASH AND CASH EQUIVALENTS, END OF PERIOD |  | $ | 11,355 |  |  | 17,604 | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \nAcquisitions |  |  |  | \nFair value of assets acquired |  | $ | 620 |  |  | \u2014 | \nFair value of liabilities assumed and noncontrolling interests |  | (98) |  |  | \u2014 | \nNet cash paid for acquisitions |  | $ | 522 |  |  | \u2014 | \n |  |  |  | \n |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | October 2, 2022 |  | January 2, 2022\nRaw materials and supplies |  | $ | 1,730 |  |  | 1,592 | \nGoods in process |  | 2,106 |  |  | 2,287 | \nFinished goods |  | 7,839 |  |  | 6,508 | \nTotal inventories |  | $ | 11,675 |  |  | 10,387 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | October 2, 2022 |  | January 2, 2022\nIntangible assets with definite lives: |  |  |  | \nPatents and trademarks \u2014 gross(1) |  | $ | 35,132 |  |  | 38,572 | \nLess accumulated amortization |  | (20,116) |  |  | (20,088) | \nPatents and trademarks \u2014 net |  | 15,016 |  |  | 18,484 | \nCustomer relationships and other intangibles \u2014 gross |  | 22,302 |  |  | 23,011 | \nLess accumulated amortization |  | (12,406) |  |  | (11,925) | \nCustomer relationships and other intangibles\u00a0\u2014 net(2) |  | 9,896 |  |  | 11,086 | \nIntangible assets with indefinite lives: |  |  |  | \nTrademarks |  | 6,648 |  |  | 6,985 | \nPurchased in-process research and development(3) |  | 8,776 |  |  | 9,837 | \nTotal intangible assets with indefinite lives |  | 15,424 |  |  | 16,822 | \nTotal intangible assets \u2014 net |  | $ | 40,336 |  |  | 46,392 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | Consumer Health |  | Pharmaceutical |  | MedTech |  | Total\nGoodwill at January 2, 2022 |  | $ | 9,810 |  |  | 10,580 |  |  | 14,856 |  |  | 35,246 | \nGoodwill, related to acquisitions |  | \u2014 |  |  | \u2014 |  |  | 195 |  |  | 195 | \n |  |  |  |  |  |  |  | \nCurrency translation/Other |  | (1,037) |  |  | (920) |  |  | (101) |  |  | (2,058) | \nGoodwill at October 2, 2022 |  | $ | 8,773 |  |  | 9,660 |  |  | 14,950 |  |  | 33,383 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  |  |  |  |  | \n2022 |  | 2023 |  | 2024 |  | 2025 |  | 2026\n$4,300 |  | 4,300 |  | 4,100 |  | 3,400 |  | 2,800  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | October 2, 2022 | October 3, 2021\n(Dollars in Millions) | Sales | Cost of Products Sold | R&D Expense | Interest (Income) Expense | Other (Income)  Expense | Sales | Cost of Products Sold | R&D Expense | Interest (Income) Expense | Other (Income)  Expense\n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \nThe effects of fair value, net investment and cash flow hedging: |  |  |  |  |  |  |  |  |  | \nGain (Loss) on fair value hedging relationship: |  |  |  |  |  |  |  |  |  | \nInterest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nHedged items | $ | \u2014 |  | \u2014 |  | \u2014 |  | (322) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (62) |  | \u2014 | \nDerivatives designated as hedging instruments | \u2014 |  | \u2014 |  | \u2014 |  | 322 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 62 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nGain (Loss) on net investment hedging relationship: |  |  |  |  |  |  |  |  |  | \nCross currency interest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing | \u2014 |  | \u2014 |  | \u2014 |  | 13 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 34 |  | \u2014 | \nAmount of gain or (loss) recognized in AOCI | \u2014 |  | \u2014 |  | \u2014 |  | 13 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 34 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nGain (Loss) on cash flow hedging relationship: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) reclassified from AOCI into income | (20) |  | (83) |  | 53 |  | \u2014 |  | 22 |  | (3) |  | 58 |  | 8 |  | \u2014 |  | 19 | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in AOCI | (45) |  | (94) |  | 91 |  | \u2014 |  | 36 |  | (35) |  | (155) |  | 37 |  | \u2014 |  | 42 | \n |  |  |  |  |  |  |  |  |  | \nCross currency interest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) reclassified from AOCI into income | \u2014 |  | \u2014 |  | \u2014 |  | 120 |  | \u2014 |  | \u2014 |  |  | \u2014 |  | 117 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in AOCI | $ | \u2014 |  | \u2014 |  | \u2014 |  | (205) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 144 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | October 2, 2022 | October 3, 2021\n(Dollars in Millions) | Sales | Cost of Products Sold | R&D Expense | Interest (Income) Expense | Other (Income)  Expense | Sales | Cost of Products Sold | R&D Expense | Interest (Income) Expense | Other (Income)  Expense\n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \nThe effects of fair value, net investment and cash flow hedging: |  |  |  |  |  |  |  |  |  | \nGain (Loss) on fair value hedging relationship: |  |  |  |  |  |  |  |  |  | \nInterest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nHedged items | $ | \u2014 |  | \u2014 |  | \u2014 |  | (1,094) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (56) |  | \u2014 | \nDerivatives designated as hedging instruments | \u2014 |  | \u2014 |  | \u2014 |  | 1,094 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 56 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nGain (Loss) on net investment hedging relationship: |  |  |  |  |  |  |  |  |  | \nCross currency interest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing | \u2014 |  | \u2014 |  | \u2014 |  | 102 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 115 |  | \u2014 | \nAmount of gain or (loss) recognized in AOCI | \u2014 |  | \u2014 |  | \u2014 |  | 102 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 115 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nGain (Loss) on cash flow hedging relationship: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) reclassified from AOCI into income | (54) |  | (141) |  | 118 |  | \u2014 |  | (35) |  | 25 |  | 106 |  | (1) |  | \u2014 |  | 24 | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in AOCI | (48) |  | (153) |  | 193 |  | \u2014 |  | (75) |  | (41) |  | (398) |  | 80 |  | \u2014 |  | 67 | \n |  |  |  |  |  |  |  |  |  | \nCross currency interest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) reclassified from AOCI into income | \u2014 |  | \u2014 |  | \u2014 |  | 342 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 307 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in AOCI | $ | \u2014 |  | \u2014 |  | \u2014 |  | (273) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 122 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLine item in the Consolidated Balance Sheet in which the hedged item is included |  | Carrying Amount of the Hedged Liability |  | Cumulative Amount of Fair Value Hedging Gain/ (Loss)  Included in the Carrying Amount of the Hedged Liability\n |  | \n(Dollars in Millions) |  | October 2, 2022 |  | January 2, 2022 |  | October 2, 2022 |  | January 2, 2022\n |  |  |  |  |  |  |  | \nLong-term Debt |  | $ | 8,668 |  |  | 9,793 |  |  | (1,430) |  |  | (142) | \n |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | \n |  |  |  | Gain/(Loss)Recognized InIncome on Derivative | Gain/(Loss)Recognized InIncome on Derivative | \n(Dollars in Millions) |  | Location of Gain /(Loss) Recognized in Income on Derivative |  | Fiscal Third Quarter Ended | Fiscal Nine Months Ended | \nDerivatives Not Designated as Hedging Instruments |  |  |  | October 2, 2022 |  | October 3, 2021 | October 2, 2022 |  | October 3, 2021 | \nForeign Exchange Contracts |  | Other (income) expense |  | $ | 109 |  |  | (13) |  | 211 |  |  | (50) |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n\n |  | Gain/(Loss)Recognized InAccumulatedOCI |  | Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income |  | Gain/(Loss)                                                                                                                                                                                                                                  Reclassified FromAccumulated OCIInto Income\n(Dollars in Millions) |  | October 2, 2022 |  | October 3, 2021 |  |  |  | October 2, 2022 |  | October 3, 2021\nDebt |  | $ | 208 |  |  | 115 |  |  | Interest (income) expense |  | \u2014 |  |  | \u2014 | \nCross Currency interest rate swaps |  | $ | 261 |  |  | 141 |  |  | Interest (income) expense |  | \u2014 |  |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n\n |  | Gain/(Loss)Recognized InAccumulated OCI |  | Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income |  | Gain/(Loss)                                                                                                                                                                                                                                  Reclassified FromAccumulated OCIInto Income\n(Dollars in Millions) |  | October 2, 2022 |  | October 3, 2021 |  |  |  | October 2, 2022 |  | October 3, 2021\nDebt |  | $ | 478 |  |  | 279 |  |  | Interest (income) expense |  | \u2014 |  |  | \u2014 | \nCross Currency interest rate swaps |  | $ | 1,134 |  |  | 432 |  |  | Interest (income) expense |  | \u2014 |  |  | \u2014 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | January 2, 2022 |  |  |  |  |  | October 2, 2022 |  | \n |  | Carrying Value |  | Changes in Fair Value Reflected in Net Income(1) |  | Sales/ Purchases/Other(2) |  | Carrying Value |  | Non Current Other Assets\nEquity Investments with readily determinable value |  | $ | 1,884 |  |  | (607) |  |  | (755) |  |  | 522 |  |  | 522 | \n |  |  |  |  |  |  |  |  |  | \nEquity Investments without readily determinable value |  | $ | 500 |  |  | (29) |  |  | 60 |  |  | 531 |  |  | 531 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | October 2, 2022 |  |  |  | January 2, 2022\n(Dollars in Millions) |  | Level 1 |  | Level 2 |  | Level 3 |  | Total |  | Total(1)\nDerivatives designated as hedging instruments: |  |  |  |  |  |  |  |  |  | \nAssets: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts |  | $ | \u2014 |  |  | 1,942 |  |  | \u2014 |  |  | 1,942 |  |  | 540 | \nInterest rate contracts(2) |  | \u2014 |  |  | 2,533 |  |  | \u2014 |  |  | 2,533 |  |  | 796 | \n |  |  |  |  |  |  |  |  |  | \nTotal |  | \u2014 |  |  | 4,475 |  |  | \u2014 |  |  | 4,475 |  |  | 1,336 | \nLiabilities: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts |  | \u2014 |  |  | 1,881 |  |  | \u2014 |  |  | 1,881 |  |  | 881 | \nInterest rate contracts(2) |  | \u2014 |  |  | 1,884 |  |  | \u2014 |  |  | 1,884 |  |  | 979 | \n |  |  |  |  |  |  |  |  |  | \nTotal |  | \u2014 |  |  | 3,765 |  |  | \u2014 |  |  | 3,765 |  |  | 1,860 | \nDerivatives not designated as hedging instruments: |  |  |  |  |  |  |  |  |  | \nAssets: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts |  | \u2014 |  |  | 178 |  |  | \u2014 |  |  | 178 |  |  | 24 | \nLiabilities: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts |  | \u2014 |  |  | 68 |  |  | \u2014 |  |  | 68 |  |  | 28 | \nOther Investments: |  |  |  |  |  |  |  |  |  | \nEquity investments(3) |  | 522 |  |  | \u2014 |  |  | \u2014 |  |  | 522 |  |  | 1,884 | \nDebt securities(4) |  | \u2014 |  |  | 22,124 |  |  | \u2014 |  |  | 22,124 |  |  | 19,727 | \nOther Liabilities |  |  |  |  |  |  |  |  |  | \nContingent consideration(5) |  | $ | \u2014 |  |  | \u2014 |  |  | 525 |  |  | 525 |  |  | 533 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \nGross to Net Derivative Reconciliation |  | October 2, 2022 |  | January 2, 2022\n(Dollars in Millions) |  |  |  | \nTotal Gross Assets |  | $ | 4,653 |  |  | 1,360 | \nCredit Support Agreement (CSA) |  | (4,440) |  |  | (1,285) | \nTotal Net Asset |  | 213 |  |  | 75 | \n |  |  |  | \nTotal Gross Liabilities |  | 3,833 |  |  | 1,888 | \nCredit Support Agreement (CSA) |  | (3,636) |  |  | (1,855) | \nTotal Net Liabilities |  | $ | 197 |  |  | 33 | \n |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | \n |  | October 2, 2022 |  | October 3, 2021\n(Dollars in Millions) |  |  |  | \nBeginning Balance |  | $ | 533 |  |  | $ | 633 | \nChanges in estimated fair value(6) |  | (85) |  |  | 28 | \nAdditions |  | 89 |  |  | \u2014 | \nPayments |  | (12) |  |  | (48) | \nEnding Balance |  | $ | 525 |  |  | $ | 613 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) | Carrying Amount |  |  |  | Gain/( Loss) |  | Estimated Fair Value |  | Cash & Cash Equivalents |  | Current Marketable Securities\nCash | $ | 4,037 |  |  |  |  | \u2014 |  |  | 4,037 |  |  | 4,037 |  |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |  | \nNon-U.S. sovereign securities(1) | 389 |  |  |  |  |  |  | 389 |  |  | 89 |  |  | 300 | \nU.S. reverse repurchase agreements | 2,541 |  |  |  |  | \u2014 |  |  | 2,541 |  |  | 2,541 |  |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |  | \nCorporate debt securities(1) | 2,544 |  |  |  |  | (5) |  |  | 2,539 |  |  |  |  | 2,544 | \nMoney market funds | 1,516 |  |  |  |  | \u2014 |  |  | 1,516 |  |  | 1,516 |  |  | \u2014 | \nTime deposits(1) | 928 |  |  |  |  | \u2014 |  |  | 928 |  |  | 928 |  |  | \u2014 | \nSubtotal | 11,955 |  |  |  |  | (5) |  |  | 11,950 |  |  | 9,111 |  |  | 2,844 | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | Unrealized Loss |  |  |  |  |  | \nU.S. Gov't securities | 21,930 |  |  |  |  | (48) |  |  | 21,882 |  |  | 2,189 |  |  | 19,693 | \n |  |  |  |  |  |  |  |  |  |  | \nCorporate debt securities | 243 |  |  |  |  | (1) |  |  | 242 |  |  | 55 |  |  | 187 | \nSubtotal available for sale debt(2) | $ | 22,173 |  |  |  |  | (49) |  |  | 22,124 |  |  | 2,244 |  |  | 19,880 | \nTotal cash, cash equivalents and current marketable securities | $ | 34,128 |  |  |  |  | (54) |  |  | 34,074 |  |  | 11,355 |  |  | 22,724 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | Cost Basis |  | Fair Value\nDue within one year |  | $ | 22,153 |  |  | 22,104 | \nDue after one year through five years |  | 20 |  |  | 20 | \nDue after five years through ten years |  | \u2014 |  |  | \u2014 | \nTotal debt securities |  | $ | 22,173 |  |  | 22,124 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | Carrying Amount |  | Estimated Fair Value\n |  |  |  | \nFinancial Liabilities |  |  |  | \n |  |  |  | \nCurrent Debt |  | $ | 4,424 |  |  | 4,422 | \n |  |  |  | \nNon-Current Debt |  |  |  | \n6.73% Debentures due 2023 |  | 250 |  |  | 256 | \n3.375% Notes due 2023 |  | 802 |  |  | 797 | \n |  |  |  | \n0.650% Notes due 2024 (750MM Euro0.9712) |  | 722 |  |  | 702 | \n5.50% Notes due 2024 (500MM GBP1.0908) |  | 544 |  |  | 548 | \n2.625% Notes due 2025 |  | 749 |  |  | 721 | \n0.550% Notes due 2025 |  | 922 |  |  | 826 | \n |  |  |  | \n2.45% Notes due 2026 |  | 1,996 |  |  | 1,868 | \n2.95% Notes due 2027 |  | 877 |  |  | 829 | \n |  |  |  | \n0.95% Notes due 2027 |  | 1,396 |  |  | 1,185 | \n2.90%\u00a0Notes due 2028 |  | 1,496 |  |  | 1,379 | \n1.150% Notes due 2028 (750MM Euro0.9712) |  | 724 |  |  | 649 | \n6.95% Notes due 2029 |  | 298 |  |  | 342 | \n1.30% Notes due 2030 |  | 1,606 |  |  | 1,276 | \n4.95% Debentures due 2033 |  | 498 |  |  | 507 | \n4.375% Notes due 2033 |  | 855 |  |  | 820 | \n1.650% Notes due 2035 (1.5B Euro0.9712) |  | 1,450 |  |  | 1,181 | \n3.55% Notes due 2036 |  | 841 |  |  | 726 | \n5.95% Notes due 2037 |  | 993 |  |  | 1,074 | \n3.625% Notes due 2037 |  | 1,334 |  |  | 1,154 | \n3.40%\u00a0Notes due 2038 |  | 992 |  |  | 822 | \n5.85% Debentures due 2038 |  | 697 |  |  | 747 | \n4.50% Debentures due 2040 |  | 540 |  |  | 506 | \n2.10% Notes due 2040 |  | 827 |  |  | 551 | \n4.85% Notes due 2041 |  | 297 |  |  | 291 | \n4.50% Notes due 2043 |  | 496 |  |  | 457 | \n3.70% Notes due 2046 |  | 1,976 |  |  | 1,626 | \n3.75% Notes due 2047 |  | 811 |  |  | 668 | \n3.50% Notes due 2048 |  | 743 |  |  | 593 | \n2.25% Notes due 2050 |  | 809 |  |  | 500 | \n2.45% Notes due 2060 |  | 1,054 |  |  | 619 | \nOther |  | 8 |  |  | 12 | \nTotal Non-Current Debt |  | $ | 27,603 |  |  | 24,232 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended\n |  | Retirement Plans |  | Other Benefit Plans |  | Retirement Plans |  | Other Benefit Plans\n(Dollars in Millions) |  | October 2, 2022 |  | October 3, 2021 |  | October 2, 2022 |  | October 3, 2021 |  | October 2, 2022 |  | October 3, 2021 |  | October 2, 2022 |  | October 3, 2021\nService cost |  | $ | 313 |  |  | 339 |  |  | 80 |  |  | 78 |  |  | 953 |  |  | 1,019 |  |  | 240 |  |  | 232 | \nInterest cost |  | 226 |  |  | 192 |  |  | 26 |  |  | 20 |  |  | 685 |  |  | 578 |  |  | 79 |  |  | 61 | \nExpected return on plan assets |  | (683) |  |  | (661) |  |  | (2) |  |  | (1) |  |  | (2,075) |  |  | (1,988) |  |  | (6) |  |  | (5) | \nAmortization of prior service cost/(credit) |  | (46) |  |  | (46) |  |  | (1) |  |  | (8) |  |  | (138) |  |  | (136) |  |  | (4) |  |  | (23) | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nRecognized actuarial losses |  | 163 |  |  | 314 |  |  | 30 |  |  | 38 |  |  | 492 |  |  | 944 |  |  | 91 |  |  | 113 | \nCurtailments and settlements |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 1 |  |  | 1 |  |  | \u2014 |  |  | \u2014 | \nNet periodic benefit cost/(credit) |  | $ | (27) |  |  | 138 |  |  | 133 |  |  | 127 |  |  | (82) |  |  | 418 |  |  | 400 |  |  | 378 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  | Foreign |  | Gain/(Loss) |  | Employee |  | Gain/(Loss) |  | Total Accumulated\n |  | Currency |  | On |  | Benefit |  | On Derivatives |  | Other Comprehensive\n(Dollars in Millions) |  | Translation |  | Securities |  | Plans |  | & Hedges |  | Income (Loss)\nJanuary 2, 2022 |  | $ | (10,017) |  |  | (3) |  |  | (2,702) |  |  | (336) |  |  | (13,058) | \nNet change |  | (1,957) |  |  | (35) |  |  | 344 |  |  | (586) |  |  | (2,234) | \n |  |  |  |  |  |  |  |  |  | \nOctober 2, 2022 |  | $ | (11,974) |  |  | (38) |  |  | (2,358) |  |  | (922) |  |  | (15,292) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended\n(Shares in Millions) |  | October 2, 2022 |  | October 3, 2021 |  | October 2, 2022 |  | October 3, 2021\nBasic net earnings per share |  | $ | 1.70 |  |  | 1.39 |  |  | 5.49 |  |  | 6.13 | \nAverage shares outstanding \u2014 basic |  | 2,627.9 |  |  | 2,632.6 |  |  | 2,628.9 |  |  | 2,632.2 | \nPotential shares exercisable under stock option plans |  | 140.1 |  |  | 138.3 |  |  | 141.1 |  |  | 139.1 | \nLess: shares which could be repurchased under treasury stock method |  | (106.7) |  |  | (96.0) |  |  | (102.5) |  |  | (96.7) | \n |  |  |  |  |  |  |  | \nAverage shares outstanding \u2014 diluted |  | 2,661.3 |  |  | 2,674.9 |  |  | 2,667.5 |  |  | 2,674.6 | \nDiluted net earnings per share |  | $ | 1.68 |  |  | 1.37 |  |  | 5.41 |  |  | 6.04 |   |  |  |  |  |  |  |  | \n\n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended\n(Dollars in Millions) |  | October 2,2022 |  | October 3,2021 |  | PercentChange |  | October 2,2022 |  | October 3,2021 |  | Percent Change\n |  |  |  |  |  |  |  |  |  |  |  | \nCONSUMER HEALTH(1) |  |  |  |  |  |  |  |  |  |  |  | \nOTC |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | $ | 695 |  |  | 686 |  |  | 1.4 | % |  | $ | 2,028 |  |  | 1,960 |  |  | 3.5 | %\nInternational |  | 825 |  |  | 798 |  |  | 3.4 |  |  | 2,434 |  |  | 2,223 |  |  | 9.5 | \nWorldwide |  | 1,519 |  |  | 1,484 |  |  | 2.5 |  |  | 4,462 |  |  | 4,183 |  |  | 6.7 | \nSkin Health/Beauty |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 591 |  |  | 569 |  |  | 3.7 |  |  | 1,764 |  |  | 1,862 |  |  | (5.3) | \nInternational |  | 535 |  |  | 555 |  |  | (3.6) |  |  | 1,500 |  |  | 1,595 |  |  | (6.0) | \nWorldwide |  | 1,126 |  |  | 1,124 |  |  | 0.1 |  |  | 3,264 |  |  | 3,457 |  |  | (5.6) | \nOral Care |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 158 |  |  | 150 |  |  | 5.2 |  |  | 471 |  |  | 478 |  |  | (1.5) | \nInternational |  | 217 |  |  | 248 |  |  | (12.4) |  |  | 664 |  |  | 762 |  |  | (12.8) | \nWorldwide |  | 375 |  |  | 398 |  |  | (5.8) |  |  | 1,135 |  |  | 1,240 |  |  | (8.5) | \nBaby Care |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 91 |  |  | 95 |  |  | (4.0) |  |  | 264 |  |  | 288 |  |  | (8.2) | \nInternational |  | 283 |  |  | 296 |  |  | (4.5) |  |  | 840 |  |  | 879 |  |  | (4.4) | \nWorldwide |  | 375 |  |  | 391 |  |  | (4.3) |  |  | 1,105 |  |  | 1,167 |  |  | (5.4) | \nWomen's Health |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 2 |  |  | 3 |  |  | (22.0) |  |  | 9 |  |  | 9 |  |  | (2.8) | \nInternational |  | 222 |  |  | 229 |  |  | (2.7) |  |  | 674 |  |  | 675 |  |  | (0.1) | \nWorldwide |  | 225 |  |  | 232 |  |  | (3.0) |  |  | 684 |  |  | 684 |  |  | (0.1) | \nWound Care/Other |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 122 |  |  | 122 |  |  | (0.2) |  |  | 366 |  |  | 390 |  |  | (6.0) | \nInternational |  | 53 |  |  | 61 |  |  | (11.4) |  |  | 170 |  |  | 186 |  |  | (8.2) | \nWorldwide |  | 176 |  |  | 182 |  |  | (3.9) |  |  | 537 |  |  | 575 |  |  | (6.7) | \nTOTAL CONSUMER HEALTH |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,659 |  |  | 1,625 |  |  | 2.1 |  |  | 4,903 |  |  | 4,987 |  |  | (1.7) | \nInternational |  | 2,136 |  |  | 2,187 |  |  | (2.3) |  |  | 6,283 |  |  | 6,320 |  |  | (0.6) | \nWorldwide |  | 3,795 |  |  | 3,812 |  |  | (0.4) |  |  | 11,186 |  |  | 11,307 |  |  | (1.1) | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPHARMACEUTICAL(1) |  |  |  |  |  |  |  |  |  |  |  | \nImmunology |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 2,876 |  |  | 2,771 |  |  | 3.8 |  |  | 8,230 |  |  | 7,932 |  |  | 3.8 | \nInternational |  | 1,411 |  |  | 1,480 |  |  | (4.7) |  |  | 4,587 |  |  | 4,464 |  |  | 2.8 | \nWorldwide |  | 4,287 |  |  | 4,250 |  |  | 0.9 |  |  | 12,817 |  |  | 12,395 |  |  | 3.4 | \nREMICADE |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 350 |  |  | 480 |  |  | (27.0) |  |  | 1,099 |  |  | 1,508 |  |  | (27.1) | \nU.S. Exports |  | 39 |  |  | 47 |  |  | (16.9) |  |  | 163 |  |  | 197 |  |  | (17.2) | \nInternational |  | 169 |  |  | 234 |  |  | (27.8) |  |  | 606 |  |  | 721 |  |  | (16.0) | \nWorldwide |  | 558 |  |  | 761 |  |  | (26.6) |  |  | 1,868 |  |  | 2,426 |  |  | (23.0) | \nSIMPONI / SIMPONI ARIA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 298 |  |  | 295 |  |  | 0.9 |  |  | 886 |  |  | 840 |  |  | 5.4 | \nInternational |  | 248 |  |  | 276 |  |  | (10.4) |  |  | 797 |  |  | 877 |  |  | (9.2) | \nWorldwide |  | 545 |  |  | 571 |  |  | (4.6) |  |  | 1,682 |  |  | 1,717 |  |  | (2.0) | \nSTELARA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,655 |  |  | 1,569 |  |  | 5.5 |  |  | 4,766 |  |  | 4,396 |  |  | 8.4 | \nInternational |  | 794 |  |  | 809 |  |  | (1.9) |  |  | 2,571 |  |  | 2,404 |  |  | 6.9 | \nWorldwide |  | 2,449 |  |  | 2,378 |  |  | 3.0 |  |  | 7,336 |  |  | 6,800 |  |  | 7.9 | \nTREMFYA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 530 |  |  | 376 |  |  | 40.7 |  |  | 1,303 |  |  | 975 |  |  | 33.6 | \nInternational |  | 200 |  |  | 161 |  |  | 24.6 |  |  | 613 |  |  | 459 |  |  | 33.7 | \nWorldwide |  | 729 |  |  | 537 |  |  | 35.9 |  |  | 1,916 |  |  | 1,434 |  |  | 33.6 | \nOTHER IMMUNOLOGY |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 5 |  |  | 3 |  |  | * |  | 14 |  |  | 15 |  |  | (3.5) | \nInternational |  | 0 |  | 0 |  | * |  | 0 |  | 3 |  |  | *\nWorldwide |  | 5 |  |  | 3 |  |  | * |  | 14 |  |  | 18 |  |  | (19.3) | \n |  |  |  |  |  |  |  |  |  |  |  | \nInfectious Diseases |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 390 |  |  | 679 |  |  | (42.7) |  |  | 1,266 |  |  | 1,635 |  |  | (22.6) | \nInternational |  | 905 |  |  | 698 |  |  | 29.7 |  |  | 2,642 |  |  | 1,758 |  |  | 50.3 | \nWorldwide |  | 1,295 |  |  | 1,378 |  |  | (6.0) |  |  | 3,908 |  |  | 3,394 |  |  | 15.2 | \nCOVID-19 VACCINE |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 0 |  | 270 |  |  | * |  | 120 |  |  | 421 |  |  | (71.5) | \nInternational |  | 489 |  |  | 233 |  |  | * |  | 1,370 |  |  | 346 |  |  | *\nWorldwide |  | 489 |  |  | 502 |  |  | (2.7) |  | 1,490 |  |  | 766 |  |  | *\nEDURANT / rilpivirine |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 9 |  |  | 12 |  |  | (27.1) |  |  | 27 |  |  | 31 |  |  | (14.5) | \nInternational |  | 237 |  |  | 247 |  |  | (4.2) |  |  | 691 |  |  | 733 |  |  | (5.7) | \nWorldwide |  | 245 |  |  | 259 |  |  | (5.2) |  |  | 718 |  |  | 764 |  |  | (6.1) | \nPREZISTA / PREZCOBIX /REZOLSTA / SYMTUZA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 372 |  |  | 380 |  |  | (2.2) |  |  | 1,096 |  |  | 1,128 |  |  | (2.9) | \nInternational |  | 112 |  |  | 137 |  |  | (17.9) |  |  | 354 |  |  | 440 |  |  | (19.5) | \nWorldwide |  | 485 |  |  | 517 |  |  | (6.4) |  |  | 1,450 |  |  | 1,568 |  |  | (7.5) | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nOTHER INFECTIOUS DISEASES |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 10 |  |  | 18 |  |  | (46.4) |  |  | 24 |  |  | 55 |  |  | (57.2) | \nInternational |  | 68 |  |  | 82 |  |  | (17.1) |  |  | 228 |  |  | 240 |  |  | (5.0) | \nWorldwide |  | 77 |  |  | 99 |  |  | (22.4) |  |  | 251 |  |  | 295 |  |  | (14.8) | \n |  |  |  |  |  |  |  |  |  |  |  | \nNeuroscience |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 919 |  |  | 835 |  |  | 10.0 |  |  | 2,658 |  |  | 2,448 |  |  | 8.6 | \nInternational |  | 763 |  |  | 845 |  |  | (9.9) |  |  | 2,498 |  |  | 2,751 |  |  | (9.2) | \nWorldwide |  | 1,681 |  |  | 1,680 |  |  | 0.0 |  | 5,156 |  |  | 5,199 |  |  | (0.8) | \nCONCERTA / methylphenidate |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 41 |  |  | 35 |  |  | 19.3 |  |  | 114 |  |  | 117 |  |  | (2.2) | \nInternational |  | 117 |  |  | 122 |  |  | (4.4) |  |  | 362 |  |  | 372 |  |  | (2.6) | \nWorldwide |  | 158 |  |  | 157 |  |  | 0.8 |  |  | 476 |  |  | 489 |  |  | (2.5) | \nINVEGA SUSTENNA / XEPLION / INVEGA   TRINZA / TREVICTA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 684 |  |  | 648 |  |  | 5.3 |  |  | 2,036 |  |  | 1,882 |  |  | 8.1 | \nInternational |  | 348 |  |  | 355 |  |  | (2.3) |  |  | 1,097 |  |  | 1,111 |  |  | (1.3) | \nWorldwide |  | 1,031 |  |  | 1,004 |  |  | 2.6 |  |  | 3,132 |  |  | 2,994 |  |  | 4.6 | \nRISPERDAL CONSTA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 67 |  |  | 71 |  |  | (6.1) |  |  | 195 |  |  | 210 |  |  | (7.1) | \nInternational |  | 52 |  |  | 69 |  |  | (24.2) |  |  | 178 |  |  | 242 |  |  | (26.3) | \nWorldwide |  | 119 |  |  | 140 |  |  | (14.9) |  |  | 373 |  |  | 452 |  |  | (17.4) | \nOTHER NEUROSCIENCE |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 127 |  |  | 81 |  |  | 57.2 |  |  | 313 |  |  | 239 |  |  | 31.1 | \nInternational |  | 246 |  |  | 298 |  |  | (17.9) |  |  | 861 |  |  | 1,026 |  |  | (16.2) | \nWorldwide |  | 374 |  |  | 379 |  |  | (1.9) |  |  | 1,174 |  |  | 1,265 |  |  | (7.3) | \n |  |  |  |  |  |  |  |  |  |  |  | \nOncology |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,812 |  |  | 1,525 |  |  | 18.8 |  |  | 5,073 |  |  | 4,364 |  |  | 16.2 | \nInternational |  | 2,252 |  |  | 2,140 |  |  | 5.2 |  |  | 6,983 |  |  | 6,406 |  |  | 9.0 | \nWorldwide |  | 4,064 |  |  | 3,665 |  |  | 10.9 |  |  | 12,056 |  |  | 10,770 |  |  | 11.9 | \nDARZALEX |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,097 |  |  | 841 |  |  | 30.3 |  |  | 3,071 |  |  | 2,302 |  |  | 33.4 | \nInternational |  | 955 |  |  | 739 |  |  | 29.3 |  |  | 2,823 |  |  | 2,076 |  |  | 36.0 | \nWorldwide |  | 2,052 |  |  | 1,580 |  |  | 29.8 |  |  | 5,894 |  |  | 4,378 |  |  | 34.6 | \nERLEADA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 254 |  |  | 214 |  |  | 19.1 |  |  | 693 |  | 578 |  | 20.0 | \nInternational |  | 235 |  |  | 130 |  |  | * |  | 647 |  | 329 |  | *\nWorldwide |  | 490 |  |  | 344 |  |  | 42.2 |  |  | 1,340 |  |  | 907 |  | 47.7 | \nIMBRUVICA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 353 |  |  | 413 |  |  | (14.6) |  |  | 1,072 |  |  | 1,311 |  |  | (18.3) | \nInternational |  | 559 |  |  | 654 |  |  | (14.6) |  |  | 1,847 |  |  | 1,996 |  |  | (7.5) | \nWorldwide |  | 911 |  |  | 1,066 |  |  | (14.6) |  |  | 2,918 |  |  | 3,307 |  |  | (11.8) | \nZYTIGA/abiraterone acetate |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 16 |  |  | 25 |  |  | (33.1) |  |  | 54 |  |  | 96 |  |  | (43.4) | \nInternational |  | 440 |  |  | 523 |  |  | (15.9) |  |  | 1,446 |  |  | 1,653 |  |  | (12.5) | \nWorldwide |  | 456 |  |  | 548 |  |  | (16.7) |  |  | 1,500 |  |  | 1,749 |  |  | (14.2) | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nOTHER ONCOLOGY |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 92 |  |  | 32 |  |  | * |  | 183 |  |  | 76 |  |  | *\nInternational |  | 64 |  |  | 94 |  |  | (32.1) |  |  | 220 |  |  | 352 |  |  | (37.5) | \nWorldwide |  | 155 |  |  | 126 |  |  | 23.1 |  |  | 403 |  |  | 428 |  |  | (5.9) | \n |  |  |  |  |  |  |  |  |  |  |  | \nPulmonary Hypertension |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 604 |  |  | 610 |  |  | (1.1) |  |  | 1,736 |  |  | 1,778 |  |  | (2.4) | \nInternational |  | 247 |  |  | 258 |  |  | (3.8) |  |  | 810 |  |  | 821 |  |  | (1.3) | \nWorldwide |  | 852 |  |  | 868 |  |  | (1.9) |  |  | 2,547 |  |  | 2,599 |  |  | (2.0) | \nOPSUMIT |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 289 |  |  | 299 |  |  | (3.4) |  |  | 827 |  |  | 861 |  |  | (4.0) | \nInternational |  | 152 |  |  | 159 |  |  | (4.7) |  |  | 495 |  |  | 510 |  |  | (3.0) | \nWorldwide |  | 441 |  |  | 458 |  |  | (3.9) |  |  | 1,322 |  |  | 1,371 |  |  | (3.6) | \nUPTRAVI |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 283 |  |  | 265 |  |  | 6.6 |  |  | 824 |  |  | 792 |  |  | 3.9 | \nInternational |  | 50 |  |  | 44 |  |  | 14.2 |  |  | 162 |  |  | 135 |  |  | 20.4 | \nWorldwide |  | 333 |  |  | 309 |  |  | 7.7 |  |  | 986 |  |  | 927 |  |  | 6.3 | \nOTHER PULMONARY HYPERTENSION |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 33 |  |  | 47 |  |  | (29.5) |  |  | 86 |  |  | 125 |  |  | (31.3) | \nInternational |  | 46 |  |  | 54 |  |  | (15.7) |  |  | 154 |  |  | 176 |  |  | (13.0) | \nWorldwide |  | 78 |  |  | 101 |  |  | (22.1) |  |  | 239 |  |  | 301 |  |  | (20.5) | \n |  |  |  |  |  |  |  |  |  |  |  | \nCardiovascular / Metabolism / Other |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 837 |  |  | 800 |  |  | 4.5 |  |  | 2,266 |  |  | 2,379 |  |  | (4.8) | \nInternational |  | 198 |  |  | 241 |  |  | (17.5) |  |  | 651 |  |  | 727 |  |  | (10.4) | \nWorldwide |  | 1,034 |  |  | 1,041 |  |  | (0.6) |  |  | 2,916 |  |  | 3,106 |  |  | (6.1) | \nXARELTO |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 689 |  |  | 636 |  |  | 8.4 |  |  | 1,806 |  |  | 1,794 |  |  | 0.7 | \nInternational |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nWorldwide |  | 689 |  |  | 636 |  |  | 8.4 |  |  | 1,806 |  |  | 1,794 |  |  | 0.7 | \nINVOKANA / INVOKAMET |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 49 |  |  | 66 |  |  | (25.8) |  |  | 164 |  |  | 249 |  |  | (34.1) | \nInternational |  | 60 |  |  | 67 |  |  | (11.0) |  |  | 193 |  |  | 194 |  |  | (0.6) | \nWorldwide |  | 109 |  |  | 133 |  |  | (18.4) |  |  | 357 |  |  | 443 |  |  | (19.5) | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nOTHER(2) |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 98 |  |  | 98 |  |  | (0.1) |  |  | 295 |  |  | 336 |  |  | (12.2) | \nInternational |  | 138 |  |  | 173 |  |  | (20.0) |  |  | 458 |  |  | 533 |  |  | (14.0) | \nWorldwide |  | 236 |  |  | 271 |  |  | (12.8) |  |  | 753 |  |  | 869 |  |  | (13.3) | \n |  |  |  |  |  |  |  |  |  |  |  | \nTOTAL PHARMACEUTICAL |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 7,438 |  |  | 7,221 |  |  | 3.0 |  |  | 21,229 |  |  | 20,536 |  |  | 3.4 | \nInternational |  | 5,776 |  |  | 5,661 |  |  | 2.0 |  |  | 18,171 |  |  | 16,927 |  |  | 7.3 | \nWorldwide |  | 13,214 |  |  | 12,882 |  |  | 2.6 |  |  | 39,400 |  |  | 37,463 |  |  | 5.2 | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nMEDTECH(3) |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nInterventional Solutions |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 547 |  |  | 444 |  |  | 23.2 |  |  | 1,566 |  |  | 1,353 |  |  | 15.7 | \nInternational |  | 513 |  |  | 513 |  |  | 0.0 |  | 1,636 |  |  | 1,599 |  |  | 2.3 | \nWorldwide |  | 1,060 |  |  | 957 |  |  | 10.8 |  |  | 3,202 |  |  | 2,952 |  |  | 8.5 | \nOrthopaedics |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,309 |  |  | 1,249 |  |  | 4.8 |  |  | 3,936 |  |  | 3,821 |  |  | 3.0 | \nInternational |  | 785 |  |  | 843 |  |  | (6.9) |  |  | 2,504 |  |  | 2,611 |  |  | (4.1) | \nWorldwide |  | 2,095 |  |  | 2,093 |  |  | 0.1 |  |  | 6,440 |  |  | 6,433 |  |  | 0.1 | \nHIPS |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 228 |  |  | 209 |  |  | 9.1 |  |  | 693 |  |  | 651 |  |  | 6.5 | \nInternational |  | 124 |  |  | 146 |  |  | (15.1) |  |  | 437 |  |  | 451 |  |  | (3.3) | \nWorldwide |  | 352 |  |  | 355 |  |  | (0.9) |  |  | 1,129 |  |  | 1,102 |  |  | 2.5 | \nKNEES |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 203 |  |  | 184 |  |  | 9.8 |  |  | 620 |  |  | 579 |  |  | 6.9 | \nInternational |  | 115 |  |  | 131 |  |  | (12.8) |  |  | 386 |  |  | 403 |  |  | (4.4) | \nWorldwide |  | 317 |  |  | 316 |  |  | 0.4 |  |  | 1,005 |  |  | 983 |  |  | 2.3 | \nTRAUMA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 473 |  |  | 455 |  |  | 3.8 |  |  | 1,412 |  |  | 1,352 |  |  | 4.4 | \nInternational |  | 244 |  |  | 260 |  |  | (6.0) |  |  | 749 |  |  | 805 |  |  | (7.0) | \nWorldwide |  | 717 |  |  | 715 |  |  | 0.2 |  |  | 2,161 |  |  | 2,157 |  |  | 0.2 | \nSPINE, SPORTS & OTHER |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 406 |  |  | 401 |  |  | 1.3 |  |  | 1,211 |  |  | 1,239 |  |  | (2.2) | \nInternational |  | 303 |  |  | 306 |  |  | (1.1) |  |  | 933 |  |  | 952 |  |  | (2.0) | \nWorldwide |  | 708 |  |  | 706 |  |  | 0.3 |  |  | 2,144 |  |  | 2,190 |  |  | (2.1) | \nSurgery |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 984 |  |  | 948 |  |  | 3.7 |  |  | 2,897 |  |  | 2,881 |  |  | 0.5 | \nInternational |  | 1,439 |  |  | 1,457 |  |  | (1.2) |  |  | 4,410 |  |  | 4,418 |  |  | (0.2) | \nWorldwide |  | 2,422 |  |  | 2,405 |  |  | 0.7 |  |  | 7,306 |  |  | 7,299 |  |  | 0.1 | \nADVANCED |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 457 |  |  | 440 |  |  | 3.8 |  |  | 1,328 |  |  | 1,304 |  |  | 1.8 | \nInternational |  | 701 |  |  | 705 |  |  | (0.4) |  |  | 2,132 |  |  | 2,126 |  |  | 0.3 | \nWorldwide |  | 1,158 |  |  | 1,144 |  |  | 1.2 |  |  | 3,460 |  |  | 3,430 |  |  | 0.9 | \nGENERAL |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 527 |  |  | 508 |  |  | 3.6 |  |  | 1,569 |  |  | 1,577 |  |  | (0.5) | \nInternational |  | 737 |  |  | 752 |  |  | (2.0) |  |  | 2,277 |  |  | 2,292 |  |  | (0.6) | \nWorldwide |  | 1,264 |  |  | 1,261 |  |  | 0.3 |  |  | 3,846 |  |  | 3,869 |  |  | (0.6) | \nVision |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 517 |  |  | 475 |  |  | 8.8 |  |  | 1,534 |  |  | 1,414 |  |  | 8.5 | \nInternational |  | 689 |  |  | 714 |  |  | (3.5) |  |  | 2,170 |  |  | 2,103 |  |  | 3.2 | \nWorldwide |  | 1,206 |  |  | 1,189 |  |  | 1.4 |  |  | 3,704 |  |  | 3,517 |  |  | 5.3 | \nCONTACT LENSES / OTHER |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 405 |  |  | 359 |  |  | 12.6 |  |  | 1,179 |  |  | 1,082 |  |  | 9.0 | \nInternational |  | 503 |  |  | 522 |  |  | (3.6) |  |  | 1,533 |  |  | 1,525 |  |  | 0.5 | \nWorldwide |  | 908 |  |  | 882 |  |  | 3.0 |  |  | 2,712 |  |  | 2,607 |  |  | 4.0 | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nSURGICAL |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 112 |  |  | 117 |  |  | (3.2) |  |  | 355 |  |  | 333 |  |  | 6.8 | \nInternational |  | 186 |  |  | 191 |  |  | (3.3) |  |  | 637 |  |  | 577 |  |  | 10.3 | \nWorldwide |  | 298 |  |  | 308 |  |  | (3.2) |  |  | 992 |  |  | 910 |  |  | 9.0 | \n |  |  |  |  |  |  |  |  |  |  |  | \nTOTAL MEDTECH |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 3,356 |  |  | 3,117 |  |  | 7.7 |  |  | 9,932 |  |  | 9,470 |  |  | 4.9 | \nInternational |  | 3,426 |  |  | 3,527 |  |  | (2.9) |  |  | 10,719 |  |  | 10,731 |  |  | (0.1) | \nWorldwide |  | 6,782 |  |  | 6,644 |  |  | 2.1 |  |  | 20,651 |  |  | 20,201 |  |  | 2.2 | \n |  |  |  |  |  |  |  |  |  |  |  | \nWORLDWIDE |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 12,453 |  |  | 11,963 |  |  | 4.1 |  |  | 36,064 |  |  | 34,993 |  |  | 3.1 | \nInternational |  | 11,338 |  |  | 11,375 |  |  | (0.3) |  |  | 35,173 |  |  | 33,978 |  |  | 3.5 | \nWorldwide |  | $ | 23,791 |  |  | 23,338 |  |  | 1.9 | % |  | $ | 71,237 |  |  | 68,971 |  |  | 3.3 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended | \n(Dollars in Millions) |  | October 2,2022 |  | October 3,2021 |  | PercentChange |  | October 2,2022 |  | October 3,2021 |  | PercentChange |  |  |  |  | \nConsumer Health(1) |  | $ | 809 |  |  | (577) |  |  | ** |  | $ | 2,279 |  |  | 1,131 |  |  | ** |  |  |  |  | \nPharmaceutical(2) |  | 4,249 |  |  | 4,200 |  |  | 1.2 |  |  | 12,593 |  |  | 13,663 |  |  | (7.8) |  |  |  |  |  | \nMedTech(3) |  | 1,124 |  |  | 423 |  |  | ** |  | 3,742 |  |  | 3,798 |  |  | (1.5) |  |  |  |  |  | \nSegment earnings before provision for taxes |  | 6,182 |  |  | 4,046 |  |  | 52.8 |  |  | 18,614 |  |  | 18,592 |  |  | 0.1 |  |  |  |  |  | \nLess: Expense not allocated to segments(4) |  | 111 |  |  | 197 |  |  |  |  | 471 |  |  | 652 |  |  |  |  |  |  |  | \nLess: Consumer Health separation costs |  | 249 |  |  | \u2014 |  |  |  |  | 619 |  |  | \u2014 |  |  |  |  |  |  |  | \nWorldwide income before tax |  | $ | 5,822 |  |  | 3,849 |  |  | 51.3 | % |  | $ | 17,524 |  |  | 17,940 |  |  | (2.3) | % |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended\n(Dollars in Millions) |  | October 2, 2022 |  | October 3, 2021 |  | PercentChange |  | October 2, 2022 |  | October 3, 2021 |  | Percent Change\nUnited States |  | $ | 12,453 |  |  | 11,963 |  |  | 4.1 | % |  | $ | 36,064 |  |  | 34,993 |  |  | 3.1 | %\nEurope |  | 5,524 |  |  | 5,587 |  |  | (1.1) |  |  | 17,633 |  |  | 16,669 |  |  | 5.8 | \nWestern Hemisphere, excluding U.S. |  | 1,562 |  |  | 1,500 |  |  | 4.1 |  |  | 4,580 |  |  | 4,291 |  |  | 6.7 | \nAsia-Pacific, Africa |  | 4,252 |  |  | 4,288 |  |  | (0.9) |  |  | 12,960 |  |  | 13,018 |  |  | (0.4) | \nTotal |  | $ | 23,791 |  |  | 23,338 |  |  | 1.9 | % |  | $ | 71,237 |  |  | 68,971 |  |  | 3.3 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) | Severance | Asset Write-offs/Sales |  | Other(2) | Total\nReserve balance, January 2, 2022 | $ | 112 |  | \u2014 |  |  | 25 |  | 137 | \n |  |  |  |  | \nCurrent year activity: |  |  |  |  | \nCharges | \u2014 |  | (4) |  |  | 327 |  | 323 | \nCash settlements | (28) |  | 35 |  | (3) |  | (317) |  | (310) | \nSettled non cash | \u2014 |  | (31) |  |  | \u2014 |  | (31) | \n |  |  |  |  | \n |  |  |  |  | \nReserve balance, October 2, 2022(1) | $ | 84 |  | \u2014 |  |  | 35 |  | 119 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | October 2, 2022 |  | October 3, 2021 |  | TotalChange |  | OperationsChange |  | CurrencyChange\nOTC(1) |  | $ | 4,462 |  |  | $ | 4,183 |  |  | 6.7 | % |  | 10.3 | % |  | (3.6) | %\nSkin Health/Beauty |  | 3,264 |  |  | 3,457 |  |  | (5.6) |  |  | (2.2) |  |  | (3.4) | \nOral Care |  | 1,135 |  |  | 1,240 |  |  | (8.5) |  |  | (5.0) |  |  | (3.5) | \nBaby Care |  | 1,105 |  |  | 1,167 |  |  | (5.4) |  |  | (1.5) |  |  | (3.9) | \nWomen\u2019s Health |  | 684 |  |  | 684 |  |  | (0.1) |  |  | 7.8 |  |  | (7.9) | \nWound Care/Other |  | 537 |  |  | 575 |  |  | (6.7) |  |  | (5.8) |  |  | (0.9) | \nTotal Consumer Health Sales |  | $ | 11,186 |  |  | $ | 11,307 |  |  | (1.1) | % |  | 2.6 | % |  | (3.7) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | October 2, 2022 |  | October 3, 2021 |  | TotalChange |  | OperationsChange |  | CurrencyChange\nOTC(1) |  | $ | 1,519 |  |  | $ | 1,484 |  |  | 2.5 | % |  | 7.2 | % |  | (4.7) | %\nSkin Health/Beauty |  | 1,126 |  |  | 1,124 |  |  | 0.1 |  |  | 5.0 |  |  | (4.9) | \nOral Care |  | 375 |  |  | 398 |  |  | (5.8) |  |  | (0.7) |  |  | (5.1) | \nBaby Care |  | 375 |  |  | 391 |  |  | (4.3) |  |  | 1.6 |  |  | (5.9) | \nWomen\u2019s Health |  | 225 |  |  | 232 |  |  | (3.0) |  |  | 7.9 |  |  | (10.9) | \nWound Care/Other |  | 176 |  |  | 182 |  |  | (3.9) |  |  | (2.5) |  |  | (1.4) | \nTotal Consumer Health Sales |  | $ | 3,795 |  |  | $ | 3,812 |  |  | (0.4) | % |  | 4.7 | % |  | (5.1) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | October 2, 2022 |  | October 3, 2021 |  | TotalChange |  | OperationsChange |  | CurrencyChange\nImmunology |  | $ | 12,817 |  |  | $ | 12,395 |  |  | 3.4 | % |  | 7.1 | % |  | (3.7) | %\nREMICADE |  | 1,868 |  |  | 2,426 |  |  | (23.0) |  |  | (21.8) |  |  | (1.2) | \nSIMPONI/ SIMPONI ARIA |  | 1,682 |  |  | 1,717 |  |  | (2.0) |  |  | 2.9 |  |  | (4.9) | \nSTELARA |  | 7,336 |  |  | 6,800 |  |  | 7.9 |  |  | 11.9 |  |  | (4.0) | \nTREMFYA |  | 1,916 |  |  | 1,434 |  |  | 33.6 |  |  | 38.5 |  |  | (4.9) | \nOther Immunology |  | 14 |  |  | 18 |  |  | (19.3) |  |  | (19.3) |  |  | 0.0\nInfectious Diseases |  | 3,908 |  |  | 3,394 |  |  | 15.2 |  |  | 23.9 |  |  | (8.7) | \nCOVID-19 VACCINE |  | 1,490 |  |  | 766 |  |  | * |  | * |  | *\nEDURANT/rilpivirine |  | 718 |  |  | 764 |  |  | (6.1) |  |  | 4.0 |  |  | (10.1) | \nPREZISTA/ PREZCOBIX/ REZOLSTA/ SYMTUZA |  | 1,450 |  |  | 1,568 |  |  | (7.5) |  |  | (5.2) |  |  | (2.3) | \nOther Infectious Diseases(2) |  | 251 |  |  | 295 |  |  | (14.8) |  |  | (10.6) |  |  | (4.2) | \nNeuroscience |  | 5,156 |  |  | 5,199 |  |  | (0.8) |  |  | 3.7 |  |  | (4.5) | \nCONCERTA/methylphenidate |  | 476 |  |  | 489 |  |  | (2.5) |  |  | 4.4 |  |  | (6.9) | \nINVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA |  | 3,132 |  |  | 2,994 |  |  | 4.6 |  |  | 8.6 |  |  | (4.0) | \nRISPERDAL CONSTA |  | 373 |  |  | 452 |  |  | (17.4) |  |  | (12.4) |  |  | (5.0) | \nOther Neuroscience(2) |  | 1,174 |  |  | 1,265 |  |  | (7.3) |  |  | (2.4) |  |  | (4.9) | \nOncology |  | 12,056 |  |  | 10,770 |  |  | 11.9 |  |  | 19.0 |  |  | (7.1) | \nDARZALEX |  | 5,894 |  |  | 4,378 |  |  | 34.6 |  |  | 41.6 |  |  | (7.0) | \nERLEADA |  | 1,340 |  |  | 907 |  | 47.7 |  |  | 54.9 |  |  | (7.2) | \nIMBRUVICA |  | 2,918 |  |  | 3,307 |  |  | (11.8) |  |  | (6.1) |  |  | (5.7) | \nZYTIGA/ abiraterone acetate |  | 1,500 |  |  | 1,749 |  |  | (14.2) |  |  | (4.2) |  |  | (10.0) | \nOther Oncology |  | 403 |  |  | 428 |  |  | (5.9) |  |  | (0.8) |  |  | (5.1) | \nPulmonary Hypertension |  | 2,547 |  |  | 2,599 |  |  | (2.0) |  |  | 1.7 |  |  | (3.7) | \nOPSUMIT |  | 1,322 |  |  | 1,371 |  |  | (3.6) |  |  | 0.7 |  |  | (4.3) | \nUPTRAVI |  | 986 |  |  | 927 |  |  | 6.3 |  |  | 8.0 |  |  | (1.7) | \nOther Pulmonary Hypertension |  | 239 |  |  | 301 |  |  | (20.5) |  |  | (13.5) |  |  | (7.0) | \nCardiovascular / Metabolism / Other |  | 2,916 |  |  | 3,106 |  |  | (6.1) |  |  | (4.5) |  |  | (1.6) | \nXARELTO |  | 1,806 |  |  | 1,794 |  |  | 0.7 |  |  | 0.7 |  |  | \u2014 | \nINVOKANA/ INVOKAMET |  | 357 |  |  | 443 |  |  | (19.5) |  |  | (16.6) |  |  | (2.9) | \n |  |  |  |  |  |  |  |  |  | \nOther(1,2) |  | 753 |  |  | 869 |  |  | (13.3) |  |  | (9.2) |  |  | (4.1) | \nTotal Pharmaceutical Sales |  | $ | 39,400 |  |  | $ | 37,463 |  |  | 5.2 | % |  | 10.2 | % |  | (5.0) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | October 2, 2022 |  | October 3, 2021 |  | TotalChange |  | OperationsChange |  | CurrencyChange\nImmunology |  | $ | 4,287 |  |  | $ | 4,250 |  |  | 0.9 | % |  | 5.6 | % |  | (4.7) | %\nREMICADE |  | 558 |  |  | 761 |  |  | (26.6) |  |  | (25.1) |  |  | (1.5) | \nSIMPONI/ SIMPONI ARIA |  | 545 |  |  | 571 |  |  | (4.6) |  |  | 1.9 |  |  | (6.5) | \nSTELARA |  | 2,449 |  |  | 2,378 |  |  | 3.0 |  |  | 8.0 |  |  | (5.0) | \nTREMFYA |  | 729 |  |  | 537 |  |  | 35.9 |  |  | 41.9 |  |  | (6.0) | \nOther Immunology |  | 5 |  |  | 3 |  |  | * |  | * |  | *\nInfectious Diseases |  | 1,295 |  |  | 1,378 |  |  | (6.0) |  |  | 3.8 |  |  | (9.8) | \nCOVID-19 VACCINE |  | 489 |  |  | 502 |  |  | (2.7) |  |  | 13.1 |  |  | (15.8) | \nEDURANT/rilpivirine |  | 245 |  |  | 259 |  |  | (5.2) |  |  | 8.2 |  |  | (13.4) | \nPREZISTA/ PREZCOBIX/ REZOLSTA/SYMTUZA |  | 485 |  |  | 517 |  |  | (6.4) |  |  | (3.3) |  |  | (3.1) | \nOther Infectious Diseases(2) |  | 77 |  |  | 99 |  |  | (22.4) |  |  | (17.2) |  |  | (5.2) | \nNeuroscience |  | 1,681 |  |  | 1,680 |  |  | 0.0 |  | 5.9 |  |  | (5.9) | \nCONCERTA/ methylphenidate |  | 158 |  |  | 157 |  |  | 0.8 |  |  | 10.5 |  |  | (9.7) | \nINVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/TREVICTA |  | 1,031 |  |  | 1,004 |  |  | 2.6 |  |  | 7.8 |  |  | (5.2) | \nRISPERDAL CONSTA |  | 119 |  |  | 140 |  |  | (14.9) |  |  | (8.6) |  |  | (6.3) | \nOther Neuroscience(2) |  | 374 |  |  | 379 |  |  | (1.9) |  |  | 4.3 |  |  | (6.2) | \nOncology |  | 4,064 |  |  | 3,665 |  |  | 10.9 |  |  | 20.0 |  |  | (9.1) | \nDARZALEX |  | 2,052 |  |  | 1,580 |  |  | 29.8 |  |  | 38.7 |  |  | (8.9) | \nERLEADA |  | 490 |  |  | 344 |  |  | 42.2 |  |  | 51.2 |  |  | (9.0) | \nIMBRUVICA |  | 911 |  |  | 1,066 |  |  | (14.6) |  |  | (7.2) |  |  | (7.4) | \nZYTIGA/ abiraterone acetate |  | 456 |  |  | 548 |  |  | (16.7) |  |  | (2.6) |  |  | (14.1) | \nOther Oncology |  | 155 |  |  | 126 |  |  | 23.1 |  |  | 30.2 |  |  | (7.1) | \nPulmonary Hypertension |  | 852 |  |  | 868 |  |  | (1.9) |  |  | 3.0 |  |  | (4.9) | \nOPSUMIT |  | 441 |  |  | 458 |  |  | (3.9) |  |  | 1.8 |  |  | (5.7) | \nUPTRAVI |  | 333 |  |  | 309 |  |  | 7.7 |  |  | 9.9 |  |  | (2.2) | \nOther Pulmonary Hypertension |  | 78 |  |  | 101 |  |  | (22.1) |  |  | (12.9) |  |  | (9.2) | \nCardiovascular / Metabolism / Other |  | 1,034 |  |  | 1,041 |  |  | (0.6) |  |  | 1.4 |  |  | (2.0) | \nXARELTO |  | 689 |  |  | 636 |  |  | 8.4 |  |  | 8.4 |  |  | \u2014 | \nINVOKANA/ INVOKAMET |  | 109 |  |  | 133 |  |  | (18.4) |  |  | (14.1) |  |  | (4.3) | \nOther(1,2) |  | 236 |  |  | 271 |  |  | (12.8) |  |  | (7.3) |  |  | (5.5) | \nTotal Pharmaceutical Sales |  | $ | 13,214 |  |  | $ | 12,882 |  |  | 2.6 | % |  | 9.0 | % |  | (6.4) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | October 2, 2022 |  | October 3, 2021 |  | TotalChange |  | OperationsChange |  | CurrencyChange\nSurgery |  | $ | 7,306 |  |  | $ | 7,299 |  |  | 0.1 | % |  | 4.6 | % |  | (4.5) | %\nAdvanced |  | 3,460 |  |  | 3,430 |  |  | 0.9 |  |  | 5.2 |  |  | (4.3) | \nGeneral |  | 3,846 |  |  | 3,869 |  |  | (0.6) |  |  | 4.1 |  |  | (4.7) | \nOrthopaedics |  | 6,440 |  |  | 6,433 |  |  | 0.1 |  |  | 3.5 |  |  | (3.4) | \nHips |  | 1,129 |  |  | 1,102 |  |  | 2.5 |  |  | 5.7 |  |  | (3.2) | \nKnees |  | 1,005 |  |  | 983 |  |  | 2.3 |  |  | 5.6 |  |  | (3.3) | \nTrauma |  | 2,161 |  |  | 2,157 |  |  | 0.2 |  |  | 3.6 |  |  | (3.4) | \nSpine, Sports & Other |  | 2,144 |  |  | 2,190 |  |  | (2.1) |  |  | 1.4 |  |  | (3.5) | \nVision |  | 3,704 |  |  | 3,517 |  |  | 5.3 |  |  | 11.1 |  |  | (5.8) | \nContact Lenses/Other |  | 2,712 |  |  | 2,607 |  |  | 4.0 |  |  | 10.2 |  |  | (6.2) | \nSurgical |  | 992 |  |  | 910 |  |  | 9.0 |  |  | 13.6 |  |  | (4.6) | \nInterventional Solutions |  | 3,202 |  |  | 2,952 |  |  | 8.5 |  |  | 13.2 |  |  | (4.7) | \nTotal MedTech Sales |  | $ | 20,651 |  |  | $ | 20,201 |  |  | 2.2 | % |  | 6.6 | % |  | (4.4) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | October 2, 2022 |  | October 3, 2021 |  | TotalChange |  | OperationsChange |  | CurrencyChange\nSurgery |  | $ | 2,422 |  |  | $ | 2,405 |  |  | 0.7 | % |  | 7.1 | % |  | (6.4) | %\nAdvanced |  | 1,158 |  |  | 1,144 |  |  | 1.2 |  |  | 7.5 |  |  | (6.3) | \nGeneral |  | 1,264 |  |  | 1,261 |  |  | 0.3 |  |  | 6.7 |  |  | (6.4) | \nOrthopaedics |  | 2,095 |  |  | 2,093 |  |  | 0.1 |  |  | 4.7 |  |  | (4.6) | \nHips |  | 352 |  |  | 355 |  |  | (0.9) |  |  | 3.5 |  |  | (4.4) | \nKnees |  | 317 |  |  | 316 |  |  | 0.4 |  |  | 4.9 |  |  | (4.5) | \nTrauma |  | 717 |  |  | 715 |  |  | 0.2 |  |  | 4.8 |  |  | (4.6) | \nSpine, Sports & Other |  | 708 |  |  | 706 |  |  | 0.3 |  |  | 5.2 |  |  | (4.9) | \nVision |  | 1,206 |  |  | 1,189 |  |  | 1.4 |  |  | 8.6 |  |  | (7.2) | \nContact Lenses/Other |  | 908 |  |  | 882 |  |  | 3.0 |  |  | 10.8 |  |  | (7.8) | \nSurgical |  | 298 |  |  | 308 |  |  | (3.2) |  |  | 2.3 |  |  | (5.5) | \nInterventional Solutions |  | 1,060 |  |  | 957 |  |  | 10.8 |  |  | 17.7 |  |  | (6.9) | \n |  |  |  |  |  |  |  |  |  | \nTotal MedTech Sales |  | $ | 6,782 |  |  | $ | 6,644 |  |  | 2.1 | % |  | 8.1 | % |  | (6.0) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nFiscal Nine Months |  |  |  |  |  | \n(Dollars in Billions)(Income)/Expense |  | 2022 |  | 2021 |  | Change\nChanges in the fair value of securities |  | $ | 0.7 |  |  | (0.3) |  |  | 1.0 | \nConsumer Health separation costs |  | 0.6 |  |  | 0.0 |  |  | 0.6 | \nLitigation related(1) |  | 0.6 |  |  | 2.1 |  |  | (1.5) | \nCOVID-19 Vaccine related costs |  | 0.2 |  |  | 0.0 |  |  | 0.2 | \nAcquisition, integration and divestiture related(2) |  | 0.0 |  |  | (0.5) |  |  | 0.5 | \nEmployee benefit plan related |  | (0.9) |  |  | (0.5) |  |  | (0.4) | \nOther |  | (0.5) |  |  | (0.3) |  |  | (0.2) | \nTotal Other (Income) Expense, Net |  | $ | 0.7 |  |  | 0.5 |  |  | 0.2 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nFiscal Third Quarter |  |  |  |  |  | \n(Dollars in Billions)(Income)/Expense |  | 2022 |  | 2021 |  | Change\nLitigation related(1) |  | $ | 0.2 |  |  | 2.1 |  |  | (1.9) | \n |  |  |  |  |  | \nConsumer Health separation costs |  | 0.2 |  |  | 0.0 |  |  | 0.2 | \nChanges in the fair value of securities |  | 0.2 |  |  | (0.1) |  |  | 0.3 | \nCOVID-19 Vaccine related costs |  | 0.2 |  |  | 0.0 |  |  | 0.2 | \nEmployee benefit plan related |  | (0.3) |  |  | (0.2) |  |  | (0.1) | \nOther |  | 0.0 |  |  | 0.1 |  |  | (0.1) | \n |  |  |  |  |  | \n |  |  |  |  |  | \nTotal Other (Income) Expense, Net |  | $ | 0.5 |  |  | 1.9 |  |  | (1.4) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Income Before Tax |  | Segment Sales |  | Percent of Segment Sales\n(Dollars in Millions) |  | October 2, 2022 |  | October 3, 2021 |  | October 2, 2022 |  | October 3, 2021 |  | October 2, 2022 |  | October 3, 2021\nConsumer Health(1) |  | $ | 2,279 |  |  | $ | 1,131 |  |  | $ | 11,186 |  |  | $ | 11,307 |  |  | 20.4 | % |  | 10.0 | %\nPharmaceutical(1) |  | 12,593 |  |  | 13,663 |  |  | 39,400 |  |  | 37,463 |  |  | 32.0 |  |  | 36.5 | \nMedTech |  | 3,742 |  |  | 3,798 |  |  | 20,651 |  |  | 20,201 |  |  | 18.1 |  |  | 18.8 | \nSegment earnings before tax |  | 18,614 |  |  | 18,592 |  |  | 71,237 |  |  | 68,971 |  |  | 26.1 |  |  | 27.0 | \nLess: Expenses not allocated to segments(2) |  | 471 |  |  | 652 |  |  |  |  |  |  |  |  | \nLess: Consumer Health separation costs |  | 619 |  |  | \u2014 |  |  |  |  |  |  |  |  | \nWorldwide income before tax |  | $ | 17,524 |  |  | $ | 17,940 |  |  | $ | 71,237 |  |  | $ | 68,971 |  |  | 24.6 | % |  | 26.0 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Income Before Tax |  | Segment Sales |  | Percent of Segment Sales\n(Dollars in Millions) |  | October 2, 2022 |  | October 3, 2021 |  | October 2, 2022 |  | October 3, 2021 |  | October 2, 2022 |  | October 3, 2021\nConsumer Health(1) |  | $ | 809 |  |  | $ | (577) |  |  | $ | 3,795 |  |  | $ | 3,812 |  |  | 21.3 | % |  | (15.1) | %\nPharmaceutical(1) |  | 4,249 |  |  | 4,200 |  |  | 13,214 |  |  | 12,882 |  |  | 32.2 |  |  | 32.6 | \nMedTech |  | 1,124 |  |  | 423 |  |  | 6,782 |  |  | 6,644 |  |  | 16.6 |  |  | 6.4 | \nSegment earnings before tax |  | 6,182 |  |  | 4,046 |  |  | 23,791 |  |  | 23,338 |  |  | 26.0 |  |  | 17.3 | \nLess: Expenses not allocated to segments(2) |  | 111 |  |  | 197 |  |  |  |  |  |  |  |  | \nLess: Consumer Health separation costs |  | 249 |  |  | \u2014 |  |  |  |  |  |  |  |  | \nWorldwide income before tax |  | $ | 5,822 |  |  | $ | 3,849 |  |  | $ | 23,791 |  |  | $ | 23,338 |  |  | 24.5 | % |  | 16.5 | %  |  |  |  |  | \n(Dollars In Billions) | \n$ | 14.5 |  | Q4 2021 Cash and cash equivalents balance\n15.8 |  | cash generated from operating activities\n(8.0) |  | net cash used by investing activities\n(10.6) |  | net cash used by financing activities\n | \n(0.3) |  | effect of exchange rate and rounding\n$ | 11.4 |  | Q3 2022 Cash and cash equivalents balance  |  |  |  |  | \n(Dollars In Billions) | \n$ | 14.4 |  | Net Earnings\n4.2 |  | non-cash expenses and other adjustments primarily for depreciation and amortization, stock-based compensation and asset write-downs partially offset by the deferred tax provision, net gain on sale of assets/businesses and credit losses and accounts receivable allowances\n | \n(3.5) |  | an increase in accounts receivable and inventories\n | \n0.1 |  | an increase in accounts payable and accrued liabilities\n4.6 |  | a decrease in other current and non-current assets\n(4.0) |  | a decrease in other current and non-current liabilities\n$ | 15.8 |  | Cash Flow from operations  |  |  |  |  | \n(Dollars In Billions) | \n$ | (2.4) |  | additions to property, plant and equipment\n0.3 |  | proceeds from the disposal of assets/businesses, net\n(0.5) |  | acquisitions, net of cash acquired and other\n(4.8) |  | net purchases of investments\n(0.3) |  | credit support agreements activity, net\n$ | (0.3) |  | Other and rounding\n | \n$ | (8.0) |  | Net cash used for investing activities  |  |  |  |  | \n(Dollars In Billions) | \n$ | (8.7) |  | dividends to shareholders\n(4.7) |  | repurchase of common stock\n0.2 | net proceeds from short and long term debt\n0.9 |  | proceeds from stock options exercised/employee withholding tax on stock awards, net\n1.7 |  | credit support agreements activity, net\n0.0 | other and rounding\n$ | (10.6) |  | Net cash used for financing activities  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nFiscal Month Period |  | Total Numberof Shares Purchased(1) |  | Avg. PricePer Share |  | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs(2) |  | Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs(3)\nJuly 4, 2022 through July 31, 2022 |  |  |  |  |  |  |  | \u2014\nAugust 1, 2022 through August 28, 2022 |  | 660,000 |  |  | 172.83 |  |  |  |  | \u2014\nAugust 29, 2022 through October 2, 2022 |  | 12,382,285 |  |  | 165.58 |  |  | 12,232,285 |  |  | \u2014\nTotal |  | 13,042,285 |  |  | 165.94 |  |  | 12,232,285 |  |  | 18,207,721 |   |  |  |  |  |  |  |  | \nEX-101.INS |  | Instance Document - the instance document does not appear in the Interactive Data File because its                XBRL tags are embedded within the Inline XBRL document\nEX-101.SCH |  | Inline XBRL Taxonomy Extension Schema\nEX-101.CAL |  | Inline XBRL Taxonomy Extension Calculation Linkbase\nEX-101.LAB |  | Inline XBRL Taxonomy Extension Label Linkbase\nEX-101.PRE |  | Inline XBRL Taxonomy Extension Presentation Linkbase\nEX-101.DEF |  | Inline XBRL Taxonomy Extension Definition Document\n |  | \nExhibit 104: |  | Cover Page Interactive Data File\u2013\u2013the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.\n |  |   |  |  |  |  | \n | JOHNSON & JOHNSON(Registrant)\n | \nDate: October 27, 2022 | By /s/ J. J. WOLK\n | J. J. WOLK\n | Executive Vice President, Chief Financial Officer (Principal Financial Officer)\n | \nDate: October 27, 2022 | By /s/\u00a0R. J. DECKER Jr.\n | R. J. DECKER Jr.\n | Controller (Principal Accounting Officer)"}]}
{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For Johnson and Johnson, in 2023 Q1, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  |  |  |  |  |  |  |  |  |  |  |  |  | \n  |  |  |  |  |  |  |  | \n |  | \n\u2611 |  | Quarterly Report Pursuant to Section\u00a013 or 15(d) of the Securities Exchange Act of 1934  |  |  |  |  |  |  |  | \n |  | \n\u2610 |  | Transition Report Pursuant to Section\u00a013 or 15(d) of the Securities Exchange Act of 1934for the transition period from\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0to  |  |  |  |  |  |  |  | \nNew Jersey |  | 22-1024240\n(State or other jurisdiction ofincorporation or organization) |  | (I.R.S. EmployerIdentification No.)  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Large accelerated filer | \u2611 | Accelerated filer | \u2610\n | Non-accelerated filer | \u2610 | Smaller reporting company | \u2610\n | Emerging growth company | \u2610 |  |   |  |  |  |  |  |  |  | \nTitle of each class | Trading Symbol | Name of each exchange on which registered\nCommon Stock, Par Value $1.00 | JNJ | New York Stock Exchange\n0.650% Notes Due May 2024 | JNJ24C | New York Stock Exchange\n5.50% Notes Due November 2024 | JNJ24BP | New York Stock Exchange\n1.150% Notes Due November 2028 | JNJ28 | New York Stock Exchange\n1.650% Notes Due May 2035 | JNJ35 | New York Stock Exchange  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Page\n |  |  | No.\nPart I \u2014 Financial Information |  |  | 1\n |  |  | \nItem\u00a01. Financial Statements (unaudited) |  |  | 1\n |  |  | \nConsolidated Balance Sheets \u2014 April 2, 2023 and January 1, 2023 |  |  | 1\n |  |  | \nConsolidated Statements of Earnings for the Fiscal First Quarters Ended April 2, 2023 and April 3, 2022 |  |  | 2\n |  |  | \n |  |  | \n |  |  | \nConsolidated Statements of Comprehensive Income for the Fiscal First Quarters Ended April 2, 2023 and April 3, 2022 |  |  | 3\n |  |  | \nConsolidated Statements of Equity for the Fiscal First Quarters Ended April 2, 2023 and April 3, 2022 |  |  | 4\n |  |  | \nConsolidated Statements of Cash Flows for the Fiscal Three Months Ended April 2, 2023 and April 3, 2022 |  |  | 5\n |  |  | \nNotes to Consolidated Financial Statements |  |  | 6\n |  |  | \n |  |  | \n |  |  | \nItem\u00a02. Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations |  |  | 38\n |  |  | \nItem\u00a03. Quantitative and Qualitative Disclosures About Market Risk |  |  | 49\n |  |  | \nItem\u00a04. Controls and Procedures |  |  | 49\n |  |  | \nPart II \u2014 Other Information |  |  | 50\n |  |  | \nItem\u00a01 - Legal Proceedings |  |  | 50\n |  |  | \nItem\u00a02 - Unregistered Sales of Equity Securities and Use of Proceeds |  |  | 50\n |  |  | \nItem\u00a06 - Exhibits |  |  | 51\n |  |  | \nSignatures |  |  | 52\n\n\n\n\n\n\n\n  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | April 2, 2023 |  | January 1, 2023\nASSETS\nCurrent assets: |  |  |  | \nCash and cash equivalents (Note 4) |  | $ | 19,170 |  |  | 14,127 | \nRestricted cash (Note 4) |  | 7,695 |  |  | \u2014 | \nMarketable securities |  | 5,443 |  |  | 9,392 | \nAccounts receivable, trade, less allowances $207(2022, $203) |  | 16,350 |  |  | 16,160 | \nInventories (Note 2) |  | 12,809 |  |  | 12,483 | \nPrepaid expenses and other |  | 2,921 |  |  | 3,132 | \n |  |  |  | \nTotal current assets |  | 64,388 |  |  | 55,294 | \nProperty, plant and equipment at cost |  | 50,367 |  |  | 49,253 | \nLess: accumulated depreciation |  | (30,193) |  |  | (29,450) | \nProperty, plant and equipment, net |  | 20,174 |  |  | 19,803 | \nIntangible assets, net (Note 3) |  | 47,448 |  |  | 48,325 | \nGoodwill (Note 3) |  | 45,575 |  |  | 45,231 | \nDeferred taxes on income (Note 5) |  | 8,817 |  |  | 9,123 | \nOther assets |  | 9,567 |  |  | 9,602 | \nTotal assets |  | $ | 195,969 |  |  | 187,378 | \nLIABILITIES AND SHAREHOLDERS\u2019 EQUITY\nCurrent liabilities: |  |  |  | \nLoans and notes payable |  | $ | 17,979 |  |  | 12,771 | \nAccounts payable |  | 9,909 |  |  | 11,703 | \nAccrued liabilities |  | 11,204 |  |  | 11,456 | \nAccrued rebates, returns and promotions |  | 14,784 |  |  | 14,417 | \nAccrued compensation and employee related obligations |  | 2,231 |  |  | 3,328 | \nAccrued taxes on income (Note 5) |  | 4,266 |  |  | 2,127 | \nTotal current liabilities |  | 60,373 |  |  | 55,802 | \nLong-term debt (Note 4) |  | 34,928 |  |  | 26,888 | \nDeferred taxes on income (Note 5) |  | 4,417 |  |  | 6,374 | \nEmployee related obligations (Note 6) |  | 6,665 |  |  | 6,767 | \nLong-term taxes payable (Note 5) |  | 4,296 |  |  | 4,306 | \nOther liabilities |  | 14,421 |  |  | 10,437 | \nTotal liabilities |  | $ | 125,100 |  |  | 110,574 | \nCommitments and Contingencies (Note 11) |  |  |  | \nShareholders\u2019 equity: |  |  |  | \nCommon stock \u2014 par value $1.00per share (authorized4,320,000,000shares; issued3,119,843,000shares) |  | $ | 3,120 |  |  | 3,120 | \nAccumulated other comprehensive income (loss) (Note 7) |  | (12,626) |  |  | (12,967) | \nRetained earnings and Additional paid-in capital |  | 124,558 |  |  | 128,345 | \nLess: common stock held in treasury, at cost (521,519,000and506,246,000shares) |  | 44,183 |  |  | 41,694 | \nTotal shareholders\u2019 equity |  | 70,869 |  |  | 76,804 | \nTotal liabilities and shareholders\u2019 equity |  | $ | 195,969 |  |  | 187,378 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal First Quarter Ended\n |  | April 2,2023 |  | Percentto Sales |  | April 3,2022 |  | Percentto Sales\nSales to customers (Note 9) |  | $ | 24,746 |  |  | 100.0 | % |  | $ | 23,426 |  |  | 100.0 | %\nCost of products sold |  | 8,395 |  |  | 33.9 |  |  | 7,598 |  |  | 32.4 | \nGross profit |  | 16,351 |  |  | 66.1 |  |  | 15,828 |  |  | 67.6 | \nSelling, marketing and administrative expenses |  | 6,138 |  |  | 24.8 |  |  | 5,938 |  |  | 25.4 | \nResearch and development expense |  | 3,563 |  |  | 14.4 |  |  | 3,462 |  |  | 14.8 | \nIn-process research and development |  | 49 |  |  | 0.2 |  |  | 610 |  |  | 2.6 | \nInterest income |  | (235) |  |  | (1.0) |  |  | (22) |  |  | (0.1) | \nInterest expense, net of portion capitalized |  | 215 |  |  | 0.9 |  |  | 10 |  |  | 0.0 | \nOther (income) expense, net |  | 7,228 |  |  | 29.2 |  |  | (102) |  |  | (0.4) | \nRestructuring |  | 130 |  |  | 0.6 |  |  | 70 |  |  | 0.3 | \nEarnings/(Loss) before provision for taxes on income |  | (737) |  |  | (3.0) |  |  | 5,862 |  |  | 25.0 | \nProvision for/(Benefit from) taxes on income (Note 5) |  | (669) |  |  | (2.7) |  |  | 713 |  |  | 3.0 | \nNET EARNINGS/(LOSS) |  | $ | (68) |  |  | (0.3) | % |  | $ | 5,149 |  |  | 22.0 | %\n |  |  |  |  |  |  |  | \nNET EARNINGS/(LOSS) PER SHARE (Note 8) |  |  |  |  |  |  |  | \nBasic |  | $ | (0.03) |  |  |  |  | $ | 1.96 |  |  | \nDiluted |  | $ | (0.03) |  |  |  |  | $ | 1.93 |  |  | \n |  |  |  |  |  |  |  | \nAVG. SHARES OUTSTANDING |  |  |  |  |  |  |  | \nBasic |  | 2,605.5 |  |  |  |  | 2,629.2 |  |  | \nDiluted |  | 2,605.5 |  |  |  |  | 2,666.5 |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Fiscal First Quarter Ended |  | \n | April 2, 2023 |  | April 3, 2022 |  |  |  | \n |  |  |  |  |  |  | \nNet earnings/(loss) | $ | (68) |  |  | 5,149 |  |  |  |  | \n |  |  |  |  |  |  | \nOther comprehensive income (loss), net of tax |  |  |  |  |  |  | \nForeign currency translation | (181) |  |  | (554) |  |  |  |  | \n |  |  |  |  |  |  | \nSecurities: |  |  |  |  |  |  | \nUnrealized holding gain (loss) arising during period | 17 |  |  | (13) |  |  |  |  | \nReclassifications to earnings | \u2014 |  |  | \u2014 |  |  |  |  | \n |  |  |  |  |  |  | \nNet change | 17 |  |  | (13) |  |  |  |  | \n |  |  |  |  |  |  | \nEmployee benefit plans: |  |  |  |  |  |  | \nPrior service cost amortization during period | (35) |  |  | (53) |  |  |  |  | \nGain (loss) amortization during period | (33) |  |  | 217 |  |  |  |  | \n |  |  |  |  |  |  | \nNet change | (68) |  |  | 164 |  |  |  |  | \n |  |  |  |  |  |  | \nDerivatives & hedges: |  |  |  |  |  |  | \nUnrealized gain (loss) arising during period | 570 |  |  | (195) |  |  |  |  | \nReclassifications to earnings | 3 |  |  | (101) |  |  |  |  | \nNet change | 573 |  |  | (296) |  |  |  |  | \n |  |  |  |  |  |  | \nOther comprehensive income (loss) | 341 |  |  | (699) |  |  |  |  | \n |  |  |  |  |  |  | \nComprehensive income | $ | 273 |  |  | 4,450 |  |  |  |  | \n |  |  |  |  |  |  |   |  | \nThe tax effects in other comprehensive income/(loss) for the fiscal first quarter were as follows for 2023 and 2022, respectively: Foreign Currency Translation: $234million and $145million; Securities: $5million and $3million; Employee Benefit Plans: $22million and $19million; Derivatives & Hedges: $154million and $78million.\n\n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Total |  | RetainedEarnings and Additional paid-in capital |  | AccumulatedOtherComprehensiveIncome |  | Common StockIssued Amount |  | TreasuryStockAmount\nBalance, January 1, 2023 | $ | 76,804 |  |  | 128,345 |  |  | (12,967) |  |  | 3,120 |  |  | (41,694) | \nNet earnings/(loss) | (68) |  |  | (68) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nCash dividends paid ($1.13per share) | (2,942) |  |  | (2,942) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nEmployee compensation and stock option plans | 295 |  |  | (777) |  |  | \u2014 |  |  | \u2014 |  |  | 1,072 | \nRepurchase of common stock | (3,537) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (3,537) | \nOther | (24) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (24) | \nOther comprehensive income (loss), net of tax | 341 |  |  | \u2014 |  |  | 341 |  |  | \u2014 |  |  | \u2014 | \nBalance, April 2, 2023 | $ | 70,869 |  |  | 124,558 |  |  | (12,626) |  |  | 3,120 |  |  | (44,183) | \n |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n\n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Total |  | RetainedEarnings and Additional paid-in capital |  | AccumulatedOtherComprehensiveIncome |  | Common StockIssued Amount |  | TreasuryStockAmount\nBalance, January 2, 2022 | $ | 74,023 |  |  | 123,060 |  |  | (13,058) |  |  | 3,120 |  |  | (39,099) | \n |  |  |  |  |  |  |  |  | \nNet earnings | 5,149 |  |  | 5,149 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nCash dividends paid ($1.06per share) | (2,787) |  |  | (2,787) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nEmployee compensation and stock option plans | 600 |  |  | (1,042) |  |  | \u2014 |  |  | \u2014 |  |  | 1,642 | \nRepurchase of common stock | (1,577) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1,577) | \n |  |  |  |  |  |  |  |  | \nOther comprehensive income (loss), net of tax | (699) |  |  | \u2014 |  |  | (699) |  |  | \u2014 |  |  | \u2014 | \nBalance, April 3, 2022 | $ | 74,709 |  |  | 124,380 |  |  | (13,757) |  |  | 3,120 |  |  | (39,034) | \n |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n\n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Three Months Ended\n |  | April 2,2023 |  | April 3,2022\nCASH FLOWS FROM OPERATING ACTIVITIES |  |  |  | \nNet (loss)/earnings |  | $ | (68) |  |  | 5,149 | \nAdjustments to reconcile net earnings to cash flows from operating activities: |  |  |  | \nDepreciation and amortization of property and intangibles |  | 1,880 |  |  | 1,769 | \nStock based compensation |  | 306 |  |  | 278 | \n |  |  |  | \n |  |  |  | \nAsset write-downs |  | 426 |  |  | 610 | \n |  |  |  | \nNet gain on sale of assets/businesses |  | (8) |  |  | (168) | \n |  |  |  | \nDeferred tax provision |  | (1,543) |  |  | (926) | \nCredit losses and accounts receivable allowances |  | 1 |  |  | 6 | \nChanges in assets and liabilities, net of effects from acquisitions and divestitures: |  |  |  | \nIncrease in accounts receivable |  | (54) |  |  | (427) | \nIncrease in inventories |  | (524) |  |  | (600) | \nDecrease in accounts payable and accrued liabilities |  | (2,572) |  |  | (2,817) | \n(Increase)/Decrease in other current and non-current assets |  | (915) |  |  | 995 | \nIncrease in other current and non-current liabilities |  | 6,328 |  |  | 110 | \n |  |  |  | \nNET CASH FLOWS FROM OPERATING ACTIVITIES |  | 3,257 |  |  | 3,979 | \n |  |  |  | \nCASH FLOWS FROM INVESTING ACTIVITIES |  |  |  | \nAdditions to property, plant and equipment |  | (863) |  |  | (607) | \nProceeds from the disposal of assets/businesses, net (Note 10) |  | 40 |  |  | 248 | \nAcquisitions, net of cash acquired (Note 10) |  | \u2014 |  |  | (252) | \nPurchases of investments |  | (3,774) |  |  | (9,018) | \nSales of investments |  | 7,766 |  |  | 6,303 | \nCredit support agreements activity, net |  | 158 |  |  | (249) | \nOther (primarily licenses and milestones) |  | (12) |  |  | (59) | \n |  |  |  | \nNET CASH FROM/(USED BY) INVESTING ACTIVITIES |  | 3,315 |  |  | (3,634) | \n |  |  |  | \nCASH FLOWS FROM FINANCING ACTIVITIES |  |  |  | \nDividends to shareholders |  | (2,942) |  |  | (2,787) | \nRepurchase of common stock |  | (3,537) |  |  | (1,577) | \nProceeds from short-term debt |  | 11,094 |  |  | 3,019 | \nRepayment of short-term debt |  | (5,388) |  |  | (856) | \nProceeds from long-term debt, net of issuance costs (Note 4) |  | 7,674 |  |  | \u2014 | \nRepayment of long-term debt |  | (500) |  |  | (2,132) | \nProceeds from the exercise of stock options/employee withholding tax on stock awards, net |  | (11) |  |  | 321 | \nCredit support agreements activity, net |  | (13) |  |  | (235) | \nOther |  | (239) |  |  | (138) | \n |  |  |  | \nNET CASH FROM/(USED BY) FINANCING ACTIVITIES |  | 6,138 |  |  | (4,385) | \n |  |  |  | \nEffect of exchange rate changes on cash and cash equivalents |  | 28 |  |  | 16 | \nIncrease/(Decrease) in cash, cash equivalents and restricted cash |  | 12,738 |  |  | (4,024) | \nCash and Cash equivalents beginning of period |  | 14,127 |  |  | 14,487 | \nCASH, CASH EQUIVALENTS AND RESTRICTED CASH, END OF PERIOD |  | $ | 26,865 |  |  | 10,463 | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \nAcquisitions |  |  |  | \nFair value of assets acquired |  | $ | \u2014 |  |  | 255 | \nFair value of liabilities assumed |  | \u2014 |  |  | (3) | \nNet cash paid for acquisitions |  | $ | \u2014 |  |  | 252 | \n |  |  |  | \n |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | April 2, 2023 |  | January 1, 2023\nRaw materials and supplies |  | $ | 2,267 |  |  | 2,070 | \nGoods in process |  | 1,866 |  |  | 1,700 | \nFinished goods |  | 8,676 |  |  | 8,713 | \nTotal inventories |  | $ | 12,809 |  |  | 12,483 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | April 2, 2023 |  | January 1, 2023\nIntangible assets with definite lives: |  |  |  | \nPatents and trademarks \u2014 gross |  | $ | 44,636 |  |  | 44,012 | \nLess accumulated amortization |  | (23,512) |  |  | (22,266) | \nPatents and trademarks \u2014 net |  | 21,124 |  |  | 21,746 | \nCustomer relationships and other intangibles \u2014 gross |  | 23,008 |  |  | 22,987 | \nLess accumulated amortization |  | (13,211) |  |  | (12,901) | \nCustomer relationships and other intangibles\u00a0\u2014 net(1) |  | 9,797 |  |  | 10,086 | \nIntangible assets with indefinite lives: |  |  |  | \nTrademarks |  | 6,843 |  |  | 6,807 | \nPurchased in-process research and development |  | 9,684 |  |  | 9,686 | \nTotal intangible assets with indefinite lives |  | 16,527 |  |  | 16,493 | \nTotal intangible assets \u2014 net |  | $ | 47,448 |  |  | 48,325 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | Consumer Health |  | Pharmaceutical |  | MedTech |  | Total\nGoodwill at January\u00a01, 2023 |  | $ | 9,184 |  |  | 10,184 |  |  | 25,863 |  |  | 45,231 | \nGoodwill, related to acquisitions |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \n |  |  |  |  |  |  |  | \nCurrency translation/Other |  | 49 |  |  | 124 |  |  | 171 |  | * | 344 | \nGoodwill at April\u00a02, 2023 |  | $ | 9,233 |  |  | 10,308 |  |  | 26,034 |  |  | 45,575 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  |  |  |  |  | \n2023 |  | 2024 |  | 2025 |  | 2026 |  | 2027\n$4,800 |  | 4,600 |  | 3,800 |  | 3,200 |  | 2,600  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | April 2, 2023 | April 3, 2022\n(Dollars in Millions) | Sales | Cost of Products Sold | R&D Expense | Interest (Income) Expense | Other (Income)  Expense | Sales | Cost of Products Sold | R&D Expense | Interest (Income) Expense | Other (Income)  Expense\n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \nThe effects of fair value, net investment and cash flow hedging: |  |  |  |  |  |  |  |  |  | \nGain (Loss) on fair value hedging relationship: |  |  |  |  |  |  |  |  |  | \nInterest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nHedged items | $ | \u2014 |  | \u2014 |  | \u2014 |  | (929) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (531) |  | \u2014 | \nDerivatives designated as hedging instruments | \u2014 |  | \u2014 |  | \u2014 |  | 929 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 531 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nGain (Loss) on net investment hedging relationship: |  |  |  |  |  |  |  |  |  | \nCross currency interest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing | \u2014 |  | \u2014 |  | \u2014 |  | 34 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 45 |  | \u2014 | \nAmount of gain or (loss) recognized in AOCI | \u2014 |  | \u2014 |  | \u2014 |  | 34 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 45 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nGain (Loss) on cash flow hedging relationship: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) reclassified from AOCI into income | 12 |  | (146) |  | (13) |  | \u2014 |  | 2 |  | (17) |  | (52) |  | 23 |  | \u2014 |  | (18) | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in AOCI | 24 |  | 145 |  | (36) |  | \u2014 |  | (14) |  | 22 |  | (94) |  | 33 |  | \u2014 |  | (73) | \n |  |  |  |  |  |  |  |  |  | \nCross currency interest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) reclassified from AOCI into income | \u2014 |  | \u2014 |  | \u2014 |  | 108 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 120 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in AOCI | $ | \u2014 |  | \u2014 |  | \u2014 |  | 417 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (128) |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLine item in the Consolidated Balance Sheet in which the hedged item is included |  | Carrying Amount of the Hedged Liability |  | Cumulative Amount of Fair Value Hedging Gain/ (Loss)  Included in the Carrying Amount of the Hedged Liability\n |  | \n(Dollars in Millions) |  | April 2, 2023 |  | January 1, 2023 |  | April 2, 2023 |  | January 1, 2023\n |  |  |  |  |  |  |  | \nLong-term Debt |  | $ | 8,860 |  |  | 8,665 |  |  | (1,214) |  |  | (1,435) | \n |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | \n |  |  |  | Gain/(Loss)Recognized InIncome on Derivative |  | \n(Dollars in Millions) |  | Location of Gain /(Loss) Recognized in Income on Derivative |  | Fiscal First Quarter Ended |  | \nDerivatives Not Designated as Hedging Instruments |  |  |  | April 2, 2023 |  | April 3, 2022 |  |  |  | \nForeign Exchange Contracts |  | Other (income) expense |  | $ | (31) |  |  | 29 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n\n |  | Gain/(Loss)Recognized InAccumulatedOCI |  | Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income |  | Gain/(Loss)                                                                                                                                                                                                                                  Reclassified FromAccumulated OCIInto Income\n(Dollars in Millions) |  | April 2, 2023 |  | April 3, 2022 |  |  |  | April 2, 2023 |  | April 3, 2022\nDebt |  | $ | (77) |  |  | 68 |  |  | Interest (income) expense |  | \u2014 |  |  | \u2014 | \nCross Currency interest rate swaps |  | $ | 690 |  |  | 560 |  |  | Interest (income) expense |  | \u2014 |  |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n\n |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | January 1, 2023 |  |  |  |  |  | April 2, 2023 |  | \n |  | Carrying Value |  | Changes in Fair Value Reflected in Net Income(1) |  | Sales/ Purchases/Other(2) |  | Carrying Value |  | Non Current Other Assets\nEquity Investments with readily determinable value |  | $ | 576 |  |  | (73) |  |  | 2 |  |  | 505 |  |  | 505 | \n |  |  |  |  |  |  |  |  |  | \nEquity Investments without readily determinable value |  | $ | 698 |  |  | (1) |  |  | 27 |  |  | 724 |  |  | 724 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | April 2, 2023 |  |  |  | January 1, 2023\n(Dollars in Millions) |  | Level 1 |  | Level 2 |  | Level 3 |  | Total |  | Total(1)\nDerivatives designated as hedging instruments: |  |  |  |  |  |  |  |  |  | \nAssets: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts |  | $ | \u2014 |  |  | 661 |  |  | \u2014 |  |  | 661 |  |  | 629 | \nInterest rate contracts(2) |  | \u2014 |  |  | 1,399 |  |  | \u2014 |  |  | 1,399 |  |  | 1,534 | \n |  |  |  |  |  |  |  |  |  | \nTotal |  | \u2014 |  |  | 2,060 |  |  | \u2014 |  |  | 2,060 |  |  | 2,163 | \nLiabilities: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts |  | \u2014 |  |  | 349 |  |  | \u2014 |  |  | 349 |  |  | 511 | \nInterest rate contracts(2) |  | \u2014 |  |  | 2,553 |  |  | \u2014 |  |  | 2,553 |  |  | 2,778 | \n |  |  |  |  |  |  |  |  |  | \nTotal |  | \u2014 |  |  | 2,902 |  |  | \u2014 |  |  | 2,902 |  |  | 3,289 | \nDerivatives not designated as hedging instruments: |  |  |  |  |  |  |  |  |  | \nAssets: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts |  | \u2014 |  |  | 32 |  |  | \u2014 |  |  | 32 |  |  | 38 | \nLiabilities: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts |  | \u2014 |  |  | 56 |  |  | \u2014 |  |  | 56 |  |  | 68 | \nOther Investments: |  |  |  |  |  |  |  |  |  | \nEquity investments(3) |  | 505 |  |  | \u2014 |  |  | \u2014 |  |  | 505 |  |  | 576 | \nDebt securities(4) |  | \u2014 |  |  | 8,942 |  |  | \u2014 |  |  | 8,942 |  |  | 10,487 | \nOther Liabilities |  |  |  |  |  |  |  |  |  | \nContingent consideration(5) |  | $ | \u2014 |  |  | \u2014 |  |  | 1,142 |  |  | 1,142 |  |  | 1,120 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \nGross to Net Derivative Reconciliation |  | April 2, 2023 |  | January 1, 2023\n(Dollars in Millions) |  |  |  | \nTotal Gross Assets |  | $ | 2,092 |  |  | 2,201 | \nCredit Support Agreement (CSA) |  | (2,028) |  |  | (2,176) | \nTotal Net Asset |  | 64 |  |  | 25 | \n |  |  |  | \nTotal Gross Liabilities |  | 2,958 |  |  | 3,357 | \nCredit Support Agreement (CSA) |  | (2,729) |  |  | (3,023) | \nTotal Net Liabilities |  | $ | 229 |  |  | 334 | \n |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | \n |  | April 2, 2023 |  | April 3, 2022\n(Dollars in Millions) |  |  |  | \nBeginning Balance |  | $ | 1,120 |  |  | 533 | \nChanges in estimated fair value(6) |  | 23 |  |  | (47) | \nAdditions |  | \u2014 |  |  | \u2014 | \nPayments |  | (1) |  |  | \u2014 | \nEnding Balance |  | $ | 1,142 |  |  | 486 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) | Carrying Amount |  |  |  | Gain/(Loss) |  | Estimated Fair Value |  | Cash & Cash Equivalents |  | Current Marketable Securities\nCash | $ | 4,674 |  |  |  |  | \u2014 |  |  | 4,674 |  |  | 4,674 |  |  | \u2014 | \nRestricted cash(1) | 7,695 |  |  |  |  | \u2014 |  |  | 7,695 |  |  | 7,695 |  |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |  | \nU.S. reverse repurchase agreements | 6,286 |  |  |  |  | \u2014 |  |  | 6,286 |  |  | 6,286 |  |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |  | \nCorporate debt securities(2) | 672 |  |  |  |  | \u2014 |  |  | 672 |  |  | 300 |  |  | 372 | \nMoney market funds | 3,364 |  |  |  |  | \u2014 |  |  | 3,364 |  |  | 3,364 |  |  | \u2014 | \nTime deposits(2) | 675 |  |  |  |  | \u2014 |  |  | 675 |  |  | 675 |  |  | \u2014 | \nSubtotal | 23,366 |  |  |  |  | \u2014 |  |  | 23,366 |  |  | 22,994 |  |  | 372 | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | Unrealized Loss |  |  |  |  |  | \nU.S. Gov\u2019t securities | 8,462 |  |  |  |  | (9) |  |  | 8,453 |  |  | 3,804 |  |  | 4,649 | \nU.S. Gov\u2019t Agencies | 185 |  |  |  |  | (3) |  |  | 182 |  |  | \u2014 |  |  | 182 | \nCorporate debt securities | 308 |  |  |  |  | (1) |  |  | 307 |  |  | 67 |  |  | 240 | \nSubtotal available for sale debt(3) | $ | 8,955 |  |  |  |  | (13) |  |  | 8,942 |  |  | 3,871 |  |  | 5,071 | \nTotal cash, cash equivalents, restricted cash and current marketable securities | $ | 32,321 |  |  |  |  | (13) |  |  | 32,308 |  |  | 26,865 |  |  | 5,443 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | Cost Basis |  | Fair Value\nDue within one year |  | $ | 8,901 |  |  | 8,889 | \nDue after one year through five years |  | 54 |  |  | 53 | \nDue after five years through ten years |  | \u2014 |  |  | \u2014 | \nTotal debt securities |  | $ | 8,955 |  |  | 8,942 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | Carrying Amount |  | Estimated Fair Value\n |  |  |  | \nFinancial Liabilities |  |  |  | \n |  |  |  | \nCurrent Debt |  | $ | 17,979 |  |  | 17,982 | \n |  |  |  | \nNon-Current Debt |  |  |  | \n |  |  |  | \n0.650% Notes due 2024 (750MM Euro1.0909) |  | 812 |  |  | 796 | \n5.50% Notes due 2024 (500MM GBP1.2359) |  | 617 |  |  | 626 | \n2.625% Notes due 2025 |  | 749 |  |  | 732 | \n0.55% Notes due 2025 |  | 936 |  |  | 920 | \n |  |  |  | \n2.45% Notes due 2026 |  | 1,997 |  |  | 1,924 | \n2.95% Notes due 2027 |  | 896 |  |  | 968 | \n |  |  |  | \n0.95% Notes due 2027 |  | 1,412 |  |  | 1,329 | \n2.90%\u00a0Notes due 2028 |  | 1,496 |  |  | 1,438 | \n1.150% Notes due 2028 (750MM Euro1.0909) |  | 814 |  |  | 737 | \n6.95% Notes due 2029 |  | 298 |  |  | 368 | \n1.30% Notes due 2030 |  | 1,628 |  |  | 1,469 | \n4.95% Debentures due 2033 |  | 498 |  |  | 543 | \n4.375% Notes due 2033 |  | 854 |  |  | 879 | \n1.650% Notes due 2035 (1.5B Euro1.0909) |  | 1,629 |  |  | 1,369 | \n3.55% Notes due 2036 |  | 864 |  |  | 933 | \n5.95% Notes due 2037 |  | 993 |  |  | 1,161 | \n3.625% Notes due 2037 |  | 1,359 |  |  | 1,389 | \n3.40%\u00a0Notes due 2038 |  | 992 |  |  | 896 | \n5.85% Debentures due 2038 |  | 697 |  |  | 806 | \n4.50% Debentures due 2040 |  | 540 |  |  | 551 | \n2.10% Notes due 2040 |  | 852 |  |  | 726 | \n4.85% Notes due 2041 |  | 297 |  |  | 311 | \n4.50% Notes due 2043 |  | 496 |  |  | 501 | \n3.70% Notes due 2046 |  | 1,976 |  |  | 1,785 | \n3.75% Notes due 2047 |  | 837 |  |  | 899 | \n3.50% Notes due 2048 |  | 743 |  |  | 651 | \n2.25% Notes due 2050 |  | 834 |  |  | 667 | \n2.45% Notes due 2060 |  | 1,080 |  |  | 819 | \n5.50% Debentures due 2025* |  | 748 |  |  | 775 | \n5.35% Debentures due 2026* |  | 747 |  |  | 776 | \n5.05% Debentures due 2028* |  | 993 |  |  | 1,038 | \n5.00% Debentures due 2030* |  | 992 |  |  | 1,033 | \n4.90% Debentures due 2033* |  | 1,240 |  |  | 1,271 | \n5.10% Debentures due 2043* |  | 741 |  |  | 774 | \n5.05% Debentures due 2053* |  | 1,476 |  |  | 1,540 | \n5.20% Debentures due 2063* |  | 738 |  |  | 776 | \nOther |  | 57 |  |  | 56 | \nTotal Non-Current Debt |  | $ | 34,928 |  |  | 34,232 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal First Quarter Ended |  | \n |  | Retirement Plans |  | Other Benefit Plans |  |  |  | \n(Dollars in Millions) |  | April 2, 2023 |  | April 3, 2022 |  | April 2, 2023 |  | April 3, 2022 |  |  |  |  |  |  |  | \nService cost |  | $ | 212 |  |  | 321 |  |  | 68 |  |  | 80 |  |  |  |  |  |  |  |  | \nInterest cost |  | 354 |  |  | 230 |  |  | 54 |  |  | 26 |  |  |  |  |  |  |  |  | \nExpected return on plan assets |  | (668) |  |  | (699) |  |  | (1) |  |  | (2) |  |  |  |  |  |  |  |  | \nAmortization of prior service cost/(credit) |  | (46) |  |  | (46) |  |  | \u2014 |  |  | (1) |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nRecognized actuarial (gains) losses |  | (50) |  |  | 162 |  |  | 6 |  |  | 30 |  |  |  |  |  |  |  |  | \nCurtailments and settlements |  | \u2014 |  |  | 1 |  |  | \u2014 |  |  | \u2014 |  |  |  |  |  |  |  |  | \nNet periodic benefit cost/(credit) |  | $ | (198) |  |  | (31) |  |  | 127 |  |  | 133 |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  | Foreign |  | Gain/(Loss) |  | Employee |  | Gain/(Loss) |  | Total Accumulated\n |  | Currency |  | On |  | Benefit |  | On Derivatives |  | Other Comprehensive\n(Dollars in Millions) |  | Translation |  | Securities |  | Plans |  | & Hedges |  | Income (Loss)\nJanuary 1, 2023 |  | $ | (11,813) |  |  | (27) |  |  | (897) |  |  | (230) |  |  | (12,967) | \nNet change |  | (181) |  |  | 17 |  |  | (68) |  |  | 573 |  |  | 341 | \n |  |  |  |  |  |  |  |  |  | \nApril 2, 2023 |  | $ | (11,994) |  |  | (10) |  |  | (965) |  |  | 343 |  |  | (12,626) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal First Quarter Ended |  | \n(Shares in Millions) |  | April 2, 2023 |  | April 3, 2022 |  |  |  | \nBasic net earnings/(loss) per share |  | $ | (0.03) |  |  | 1.96 |  |  |  |  | \nAverage shares outstanding \u2014 basic |  | 2,605.5 |  |  | 2,629.2 |  |  |  |  | \nPotential shares exercisable under stock option plans |  | \u2014 |  |  | 140.1 |  |  |  |  | \nLess: shares which could be repurchased under treasury stock method |  | \u2014 |  |  | (102.8) |  |  |  |  | \n |  |  |  |  |  |  |  | \nAverage shares outstanding \u2014 basic/diluted* |  | 2,605.5 |  |  | 2,666.5 |  |  |  |  | \nNet earnings/(loss) per share (basic/diluted)* |  | $ | (0.03) |  |  | 1.93 |  |  |  |  |   |  |  |  |  |  |  |  | \n\n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal First Quarter Ended |  | \n(Dollars in Millions) |  | April 2,2023 |  | April 3,2022 |  | PercentChange |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nCONSUMER HEALTH |  |  |  |  |  |  |  |  |  |  |  | \nOTC |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | $ | 745 |  |  | 670 |  |  | 11.0 | % |  |  |  |  |  | \nInternational |  | 897 |  |  | 791 |  |  | 13.5 |  |  |  |  |  |  | \nWorldwide |  | 1,642 |  |  | 1,461 |  |  | 12.4 |  |  |  |  |  |  | \nSkin Health/Beauty |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 617 |  |  | 544 |  |  | 13.4 |  |  |  |  |  |  | \nInternational |  | 493 |  |  | 468 |  |  | 5.3 |  |  |  |  |  |  | \nWorldwide |  | 1,110 |  |  | 1,012 |  |  | 9.7 |  |  |  |  |  |  | \nOral Care |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 159 |  |  | 143 |  |  | 11.6 |  |  |  |  |  |  | \nInternational |  | 202 |  |  | 223 |  |  | (9.6) |  |  |  |  |  |  | \nWorldwide |  | 361 |  |  | 366 |  |  | (1.3) |  |  |  |  |  |  | \nBaby Care |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 96 |  |  | 85 |  |  | 13.0 |  |  |  |  |  |  | \nInternational |  | 263 |  |  | 270 |  |  | (2.8) |  |  |  |  |  |  | \nWorldwide |  | 359 |  |  | 355 |  |  | 1.0 |  |  |  |  |  |  | \nWomen\u2019s Health |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 3 |  |  | 3 |  |  | 1.8 |  |  |  |  |  |  | \nInternational |  | 214 |  |  | 224 |  |  | (4.9) |  |  |  |  |  |  | \nWorldwide |  | 217 |  |  | 228 |  |  | (4.8) |  |  |  |  |  |  | \nWound Care/Other |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 115 |  |  | 112 |  |  | 2.6 |  |  |  |  |  |  | \nInternational |  | 49 |  |  | 52 |  |  | (6.0) |  |  |  |  |  |  | \nWorldwide |  | 164 |  |  | 164 |  |  | (0.1) |  |  |  |  |  |  | \nTOTAL CONSUMER HEALTH |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,735 |  |  | 1,557 |  |  | 11.4 |  |  |  |  |  |  | \nInternational |  | 2,117 |  |  | 2,029 |  |  | 4.4 |  |  |  |  |  |  | \nWorldwide |  | 3,852 |  |  | 3,586 |  |  | 7.4 |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPHARMACEUTICAL |  |  |  |  |  |  |  |  |  |  |  | \nImmunology |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 2,448 |  |  | 2,501 |  |  | (2.1) |  |  |  |  |  |  | \nInternational |  | 1,664 |  |  | 1,617 |  |  | 2.9 |  |  |  |  |  |  | \nWorldwide |  | 4,112 |  |  | 4,119 |  |  | (0.2) |  |  |  |  |  |  | \nREMICADE |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 276 |  |  | 358 |  |  | (22.8) |  |  |  |  |  |  | \nU.S. Exports |  | 41 |  |  | 80 |  |  | (48.8) |  |  |  |  |  |  | \nInternational |  | 170 |  |  | 225 |  |  | (24.4) |  |  |  |  |  |  | \nWorldwide |  | 487 |  |  | 663 |  |  | (26.5) |  |  |  |  |  |  | \nSIMPONI / SIMPONI ARIA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 271 |  |  | 287 |  |  | (5.6) |  |  |  |  |  |  | \nInternational |  | 266 |  |  | 283 |  |  | (6.1) |  |  |  |  |  |  | \nWorldwide |  | 537 |  |  | 571 |  |  | (5.8) |  |  |  |  |  |  | \nSTELARA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,451 |  |  | 1,379 |  |  | 5.2 |  |  |  |  |  |  | \nInternational |  | 993 |  |  | 909 |  |  | 9.3 |  |  |  |  |  |  | \nWorldwide |  | 2,444 |  |  | 2,288 |  |  | 6.8 |  |  |  |  |  |  | \nTREMFYA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 406 |  |  | 391 |  |  | 3.9 |  |  |  |  |  |  | \nInternational |  | 234 |  |  | 199 |  |  | 17.3 |  |  |  |  |  |  | \nWorldwide |  | 640 |  |  | 590 |  |  | 8.4 |  |  |  |  |  |  | \nOTHER IMMUNOLOGY |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 3 |  |  | 6 |  |  | (51.2) |  |  |  |  |  |  | \nInternational |  | 0 |  | 0 |  | \u2014 |  |  |  |  |  |  | \nWorldwide |  | 3 |  |  | 6 |  |  | (51.3) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nInfectious Diseases |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 392 |  |  | 461 |  |  | (14.9) |  |  |  |  |  |  | \nInternational |  | 1,193 |  |  | 836 |  |  | 42.8 |  |  |  |  |  |  | \nWorldwide |  | 1,586 |  |  | 1,297 |  |  | 22.3 |  |  |  |  |  |  | \nCOVID-19 VACCINE |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 0 |  | 75 |  |  | * |  |  |  |  |  | \nInternational |  | 747 |  |  | 382 |  |  | 95.6 |  |  |  |  |  |  | \nWorldwide |  | 747 |  |  | 457 |  |  | 63.4 |  |  |  |  |  |  | \nEDURANT / rilpivirine |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 9 |  |  | 9 |  |  | (1.4) |  |  |  |  |  |  | \nInternational |  | 271 |  |  | 239 |  |  | 13.4 |  |  |  |  |  |  | \nWorldwide |  | 280 |  |  | 248 |  |  | 12.8 |  |  |  |  |  |  | \nPREZISTA / PREZCOBIX /REZOLSTA / SYMTUZA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 378 |  |  | 369 |  |  | 2.5 |  |  |  |  |  |  | \nInternational |  | 99 |  |  | 132 |  |  | (25.2) |  |  |  |  |  |  | \nWorldwide |  | 477 |  |  | 501 |  |  | (4.8) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nOTHER INFECTIOUS DISEASES |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 5 |  |  | 8 |  |  | (33.1) |  |  |  |  |  |  | \nInternational |  | 77 |  |  | 83 |  |  | (7.6) |  |  |  |  |  |  | \nWorldwide |  | 82 |  |  | 91 |  |  | (9.8) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nNeuroscience |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 978 |  |  | 843 |  |  | 16.0 |  |  |  |  |  |  | \nInternational |  | 826 |  |  | 898 |  |  | (8.1) |  |  |  |  |  |  | \nWorldwide |  | 1,804 |  |  | 1,741 |  |  | 3.6 |  |  |  |  |  |  | \nCONCERTA / methylphenidate |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 70 |  |  | 35 |  |  | * |  |  |  |  |  | \nInternational |  | 136 |  |  | 122 |  |  | 11.4 |  |  |  |  |  |  | \nWorldwide |  | 206 |  |  | 157 |  |  | 31.4 |  |  |  |  |  |  | \nINVEGA SUSTENNA / XEPLION / INVEGA   TRINZA / TREVICTA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 713 |  |  | 661 |  |  | 7.9 |  |  |  |  |  |  | \nInternational |  | 331 |  |  | 387 |  |  | (14.6) |  |  |  |  |  |  | \nWorldwide |  | 1,044 |  |  | 1,048 |  |  | (0.4) |  |  |  |  |  |  | \nSPRAVATO |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 111 |  |  | 61 |  |  | 82.4 |  |  |  |  |  |  | \nInternational |  | 20 |  |  | 9 |  |  | * |  |  |  |  |  | \nWorldwide |  | 131 |  |  | 70 |  |  | 86.9 |  |  |  |  |  |  | \nOTHER NEUROSCIENCE(1) |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 84 |  |  | 86 |  |  | (3.5) |  |  |  |  |  |  | \nInternational |  | 339 |  |  | 380 |  |  | (10.7) |  |  |  |  |  |  | \nWorldwide |  | 423 |  |  | 467 |  |  | (9.4) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nOncology |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,889 |  |  | 1,582 |  |  | 19.4 |  |  |  |  |  |  | \nInternational |  | 2,223 |  |  | 2,369 |  |  | (6.1) |  |  |  |  |  |  | \nWorldwide |  | 4,112 |  |  | 3,950 |  |  | 4.1 |  |  |  |  |  |  | \nCARVYKTI |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 70 |  |  | \u2014 |  |  | * |  |  |  |  |  | \nInternational |  | 2 |  |  | \u2014 |  |  | * |  |  |  |  |  | \nWorldwide |  | 72 |  |  | \u2014 |  |  | * |  |  |  |  |  | \nDARZALEX |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,191 |  |  | 953 |  |  | 25.0 |  |  |  |  |  |  | \nInternational |  | 1,072 |  |  | 903 |  |  | 18.8 |  |  |  |  |  |  | \nWorldwide |  | 2,264 |  |  | 1,856 |  |  | 22.0 |  |  |  |  |  |  | \nERLEADA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 249 |  |  | 206 |  |  | 21.2 |  |  |  |  |  |  | \nInternational |  | 293 |  |  | 194 |  |  | 50.9 |  |  |  |  |  |  | \nWorldwide |  | 542 |  |  | 400 |  |  | 35.6 |  |  |  |  |  |  | \nIMBRUVICA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 270 |  |  | 370 |  |  | (27.1) |  |  |  |  |  |  | \nInternational |  | 557 |  |  | 668 |  |  | (16.6) |  |  |  |  |  |  | \nWorldwide |  | 827 |  |  | 1,038 |  |  | (20.3) |  |  |  |  |  |  | \nZYTIGA/abiraterone acetate |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 16 |  |  | 19 |  |  | (14.0) |  |  |  |  |  |  | \nInternational |  | 229 |  |  | 520 |  |  | (56.0) |  |  |  |  |  |  | \nWorldwide |  | 245 |  |  | 539 |  |  | (54.5) |  |  |  |  |  |  | \nOTHER ONCOLOGY |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 92 |  |  | 34 |  |  | * |  |  |  |  |  | \nInternational |  | 70 |  |  | 84 |  |  | (17.2) |  |  |  |  |  |  | \nWorldwide |  | 162 |  |  | 118 |  |  | 37.4 |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nPulmonary Hypertension |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 600 |  |  | 572 |  |  | 4.9 |  |  |  |  |  |  | \nInternational |  | 272 |  |  | 279 |  |  | (2.7) |  |  |  |  |  |  | \nWorldwide |  | 872 |  |  | 852 |  |  | 2.4 |  |  |  |  |  |  | \nOPSUMIT |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 273 |  |  | 273 |  |  | (0.1) |  |  |  |  |  |  | \nInternational |  | 167 |  |  | 170 |  |  | (1.6) |  |  |  |  |  |  | \nWorldwide |  | 440 |  |  | 443 |  |  | (0.7) |  |  |  |  |  |  | \nUPTRAVI |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 304 |  |  | 269 |  |  | 13.1 |  |  |  |  |  |  | \nInternational |  | 58 |  |  | 56 |  |  | 3.3 |  |  |  |  |  |  | \nWorldwide |  | 362 |  |  | 325 |  |  | 11.4 |  |  |  |  |  |  | \nOTHER PULMONARY HYPERTENSION |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 23 |  |  | 30 |  |  | (22.4) |  |  |  |  |  |  | \nInternational |  | 47 |  |  | 53 |  |  | (12.6) |  |  |  |  |  |  | \nWorldwide |  | 70 |  |  | 83 |  |  | (16.1) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nCardiovascular / Metabolism / Other |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 715 |  |  | 672 |  |  | 6.3 |  |  |  |  |  |  | \nInternational |  | 212 |  |  | 238 |  |  | (10.8) |  |  |  |  |  |  | \nWorldwide |  | 927 |  |  | 910 |  |  | 1.8 |  |  |  |  |  |  | \nXARELTO |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 578 |  |  | 508 |  |  | 13.7 |  |  |  |  |  |  | \nInternational |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  |  |  |  |  | \nWorldwide |  | 578 |  |  | 508 |  |  | 13.7 |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nOTHER(2) |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 137 |  |  | 164 |  |  | (16.7) |  |  |  |  |  |  | \nInternational |  | 212 |  |  | 238 |  |  | (10.8) |  |  |  |  |  |  | \nWorldwide |  | 349 |  |  | 402 |  |  | (13.2) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nTOTAL PHARMACEUTICAL |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 7,023 |  |  | 6,632 |  |  | 5.9 |  |  |  |  |  |  | \nInternational |  | 6,390 |  |  | 6,237 |  |  | 2.4 |  |  |  |  |  |  | \nWorldwide |  | 13,413 |  |  | 12,869 |  |  | 4.2 |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nMEDTECH |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nInterventional Solutions |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 863 |  |  | 494 |  |  | 74.5 |  |  |  |  |  |  | \nInternational |  | 640 |  |  | 597 |  |  | 7.1 |  |  |  |  |  |  | \nWorldwide |  | 1,503 |  |  | 1,092 |  |  | 37.6 |  |  |  |  |  |  | \nELECTROPHYSIOLOGY |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 571 |  |  | 470 |  |  | 21.4 |  |  |  |  |  |  | \nInternational |  | 522 |  |  | 532 |  |  | (1.8) |  |  |  |  |  |  | \nWorldwide |  | 1,092 |  |  | 1,002 |  |  | 9.1 |  |  |  |  |  |  | \nABIOMED(3) |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 264 |  |  | \u2014 |  |  | * |  |  |  |  |  | \nInternational |  | 60 |  |  | \u2014 |  |  | * |  |  |  |  |  | \nWorldwide |  | 324 |  |  | \u2014 |  |  | * |  |  |  |  |  | \nOTHER INTERVENTIONAL SOLUTIONS |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 28 |  |  | 24 |  |  | 17.4 |  |  |  |  |  |  | \nInternational |  | 58 |  |  | 65 |  |  | (11.7) |  |  |  |  |  |  | \nWorldwide |  | 87 |  |  | 90 |  |  | (3.9) |  |  |  |  |  |  | \nOrthopaedics |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,363 |  |  | 1,289 |  |  | 5.8 |  |  |  |  |  |  | \nInternational |  | 881 |  |  | 899 |  |  | (2.0) |  |  |  |  |  |  | \nWorldwide |  | 2,245 |  |  | 2,188 |  |  | 2.6 |  |  |  |  |  |  | \nHIPS |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 241 |  |  | 225 |  |  | 7.3 |  |  |  |  |  |  | \nInternational |  | 149 |  |  | 164 |  |  | (9.0) |  |  |  |  |  |  | \nWorldwide |  | 390 |  |  | 389 |  |  | 0.4 |  |  |  |  |  |  | \nKNEES |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 226 |  |  | 201 |  |  | 12.4 |  |  |  |  |  |  | \nInternational |  | 142 |  |  | 138 |  |  | 3.4 |  |  |  |  |  |  | \nWorldwide |  | 368 |  |  | 339 |  |  | 8.7 |  |  |  |  |  |  | \nTRAUMA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 491 |  |  | 475 |  |  | 3.2 |  |  |  |  |  |  | \nInternational |  | 267 |  |  | 273 |  |  | (2.4) |  |  |  |  |  |  | \nWorldwide |  | 757 |  |  | 748 |  |  | 1.2 |  |  |  |  |  |  | \nSPINE, SPORTS & OTHER |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 406 |  |  | 387 |  |  | 4.7 |  |  |  |  |  |  | \nInternational |  | 323 |  |  | 324 |  |  | (0.3) |  |  |  |  |  |  | \nWorldwide |  | 729 |  |  | 712 |  |  | 2.4 |  |  |  |  |  |  | \nSurgery |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 975 |  |  | 921 |  |  | 5.9 |  |  |  |  |  |  | \nInternational |  | 1,459 |  |  | 1,513 |  |  | (3.6) |  |  |  |  |  |  | \nWorldwide |  | 2,434 |  |  | 2,434 |  |  | 0.0 |  |  |  |  |  |  | \nADVANCED |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 444 |  |  | 417 |  |  | 6.5 |  |  |  |  |  |  | \nInternational |  | 673 |  |  | 729 |  |  | (7.6) |  |  |  |  |  |  | \nWorldwide |  | 1,118 |  |  | 1,146 |  |  | (2.5) |  |  |  |  |  |  | \nGENERAL |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 531 |  |  | 504 |  |  | 5.4 |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nInternational |  | 785 |  |  | 784 |  |  | 0.2 |  |  |  |  |  |  | \nWorldwide |  | 1,316 |  |  | 1,288 |  |  | 2.2 |  |  |  |  |  |  | \nVision |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 558 |  |  | 521 |  |  | 7.1 |  |  |  |  |  |  | \nInternational |  | 743 |  |  | 736 |  |  | 0.8 |  |  |  |  |  |  | \nWorldwide |  | 1,300 |  |  | 1,257 |  |  | 3.4 |  |  |  |  |  |  | \nCONTACT LENSES / OTHER |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 444 |  |  | 400 |  |  | 11.1 |  |  |  |  |  |  | \nInternational |  | 509 |  |  | 511 |  |  | (0.3) |  |  |  |  |  |  | \nWorldwide |  | 953 |  |  | 910 |  |  | 4.7 |  |  |  |  |  |  | \nSURGICAL |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 114 |  |  | 121 |  |  | (6.0) |  |  |  |  |  |  | \nInternational |  | 233 |  |  | 226 |  |  | 3.3 |  |  |  |  |  |  | \nWorldwide |  | 347 |  |  | 347 |  |  | 0.1 |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nTOTAL MEDTECH |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 3,759 |  |  | 3,225 |  |  | 16.6 |  |  |  |  |  |  | \nInternational |  | 3,722 |  |  | 3,746 |  |  | (0.6) |  |  |  |  |  |  | \nWorldwide |  | 7,481 |  |  | 6,971 |  |  | 7.3 |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nWORLDWIDE |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 12,517 |  |  | 11,414 |  |  | 9.7 |  |  |  |  |  |  | \nInternational |  | 12,229 |  |  | 12,012 |  |  | 1.8 |  |  |  |  |  |  | \nWorldwide |  | $ | 24,746 |  |  | 23,426 |  |  | 5.6 | % |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal First Quarter Ended |  |  | \n(Dollars in Millions) |  | April 2,2023 |  | April 3,2022 |  | PercentChange |  |  |  |  |  |  |  |  |  |  | \nConsumer Health(1) |  | $ | 776 |  |  | 686 |  |  | 13.1 | % |  |  |  |  |  |  |  |  |  |  | \nPharmaceutical(2) |  | 4,444 |  |  | 3,924 |  |  | 13.3 |  |  |  |  |  |  |  |  |  |  |  | \nMedTech(3) |  | 1,445 |  |  | 1,477 |  |  | (2.2) |  |  |  |  |  |  |  |  |  |  | \nSegment earnings before provision for taxes |  | 6,665 |  |  | 6,087 |  |  | 9.5 |  |  |  |  |  |  |  |  |  |  |  | \nLess: Expense not allocated to segments(4) |  | 7,102 |  |  | 123 |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLess: Consumer Health separation costs |  | 300 |  |  | 102 |  |  |  |  |  |  |  |  |  |  |  |  |  | \nWorldwide income/(loss) before tax |  | $ | (737) |  |  | 5,862 |  |  | * |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal First Quarter Ended |  | \n(Dollars in Millions) |  | April 2, 2023 |  | April 3, 2022 |  | PercentChange |  |  |  |  |  | \nUnited States |  | $ | 12,517 |  |  | 11,414 |  |  | 9.7 | % |  |  |  |  |  | \nEurope |  | 6,332 |  |  | 6,024 |  |  | 5.1 |  |  |  |  |  |  | \nWestern Hemisphere, excluding U.S. |  | 1,587 |  |  | 1,482 |  |  | 7.1 |  |  |  |  |  |  | \nAsia-Pacific, Africa |  | 4,310 |  |  | 4,506 |  |  | (4.3) |  |  |  |  |  |  | \nTotal |  | $ | 24,746 |  |  | 23,426 |  |  | 5.6 | % |  |  |  |  |  |   |  |  |  |  |  |  |  | \nProduct or product category |  | Number of Plaintiffs\nBody powders containing talc, primarily JOHNSON\u2019S Baby Powder |  | 40,330 | \nDePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System |  | 160 | \nPINNACLE Acetabular Cup System |  | 940 | \nPelvic meshes |  | 8,780 | \nETHICON PHYSIOMESH Flexible Composite Mesh |  | 2,070 | \nRISPERDAL |  | 520 | \nELMIRON |  | 2,070 | \nTYLENOL |  | 200 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | April 2, 2023 |  | April 3, 2022 |  | TotalChange |  | OperationsChange |  | CurrencyChange\nOTC(1) |  | $ | 1,642 |  |  | $ | 1,461 |  |  | 12.4 | % |  | 15.8 | % |  | (3.4) | %\nSkin Health/Beauty |  | 1,110 |  |  | 1,012 |  |  | 9.7 |  |  | 13.1 |  |  | (3.4) | \nOral Care |  | 361 |  |  | 366 |  |  | (1.3) |  |  | 2.1 |  |  | (3.4) | \nBaby Care |  | 359 |  |  | 355 |  |  | 1.0 |  |  | 6.5 |  |  | (5.5) | \nWomen\u2019s Health |  | 217 |  |  | 228 |  |  | (4.8) |  |  | 4.1 |  |  | (8.9) | \nWound Care/Other |  | 164 |  |  | 164 |  |  | (0.1) |  |  | 2.5 |  |  | (2.6) | \nTotal Consumer Health Sales |  | $ | 3,852 |  |  | $ | 3,586 |  |  | 7.4 | % |  | 11.3 | % |  | (3.9) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | April 2, 2023 |  | April 3, 2022 |  | TotalChange |  | OperationsChange |  | CurrencyChange\nImmunology |  | $ | 4,112 |  |  | $ | 4,119 |  |  | (0.2) | % |  | 2.5 | % |  | (2.7) | %\nREMICADE |  | 487 |  |  | 663 |  |  | (26.5) |  |  | (25.0) |  |  | (1.5) | \nSIMPONI/ SIMPONI ARIA |  | 537 |  |  | 571 |  |  | (5.8) |  |  | (1.9) |  |  | (3.9) | \nSTELARA |  | 2,444 |  |  | 2,288 |  |  | 6.8 |  |  | 9.6 |  |  | (2.8) | \nTREMFYA |  | 640 |  |  | 590 |  |  | 8.4 |  |  | 11.0 |  |  | (2.6) | \nOther Immunology |  | 3 |  |  | 6 |  |  | (51.3) |  | (51.3) |  | 0.0\nInfectious Diseases |  | 1,586 |  |  | 1,297 |  |  | 22.3 |  |  | 26.4 |  |  | (4.1) | \nCOVID-19 VACCINE |  | 747 |  |  | 457 |  |  | 63.4 |  |  | 70.8 |  |  | (7.4) | \nEDURANT/rilpivirine |  | 280 |  |  | 248 |  |  | 12.8 |  |  | 18.0 |  |  | (5.2) | \nPREZISTA/ PREZCOBIX/ REZOLSTA/SYMTUZA |  | 477 |  |  | 501 |  |  | (4.8) |  |  | (3.7) |  |  | (1.1) | \nOther Infectious Diseases |  | 82 |  |  | 91 |  |  | (9.8) |  |  | (8.0) |  |  | (1.8) | \nNeuroscience |  | 1,804 |  |  | 1,741 |  |  | 3.6 |  | 6.1 |  |  | (2.5) | \nCONCERTA/ methylphenidate |  | 206 |  |  | 157 |  |  | 31.4 |  |  | 38.2 |  |  | (6.8) | \nINVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/TREVICTA |  | 1,044 |  |  | 1,048 |  |  | (0.4) |  |  | 1.7 |  |  | (2.1) | \nSPRAVATO |  | 131 |  |  | 70 |  |  | 86.9 |  |  | 88.0 |  |  | (1.1) | \nOther Neuroscience(1) |  | 423 |  |  | 467 |  |  | (9.4) |  |  | (6.9) |  |  | (2.5) | \nOncology |  | 4,112 |  |  | 3,950 |  |  | 4.1 |  |  | 7.7 |  |  | (3.6) | \nCARVYKTI |  | 72 |  |  | \u2014 |  |  | * |  | * |  | \u2014 | \nDARZALEX |  | 2,264 |  |  | 1,856 |  |  | 22.0 |  |  | 25.7 |  |  | (3.7) | \nERLEADA |  | 542 |  |  | 400 |  |  | 35.6 |  |  | 40.3 |  |  | (4.7) | \nIMBRUVICA |  | 827 |  |  | 1,038 |  |  | (20.3) |  |  | (17.2) |  |  | (3.1) | \nZYTIGA/ abiraterone acetate |  | 245 |  |  | 539 |  |  | (54.5) |  |  | (50.9) |  |  | (3.6) | \nOther Oncology |  | 162 |  |  | 118 |  |  | 37.4 |  |  | 41.0 |  |  | (3.6) | \nPulmonary Hypertension |  | 872 |  |  | 852 |  |  | 2.4 |  |  | 5.0 |  |  | (2.6) | \nOPSUMIT |  | 440 |  |  | 443 |  |  | (0.7) |  |  | 2.3 |  |  | (3.0) | \nUPTRAVI |  | 362 |  |  | 325 |  |  | 11.4 |  |  | 12.4 |  |  | (1.0) | \nOther Pulmonary Hypertension |  | 70 |  |  | 83 |  |  | (16.1) |  |  | (9.3) |  |  | (6.8) | \nCardiovascular / Metabolism / Other |  | 927 |  |  | 910 |  |  | 1.8 |  |  | 3.0 |  |  | (1.2) | \nXARELTO |  | 578 |  |  | 508 |  |  | 13.7 |  |  | 13.7 |  |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nOther(2) |  | 349 |  |  | 402 |  |  | (13.2) |  |  | (10.5) |  |  | (2.7) | \nTotal Pharmaceutical Sales |  | $ | 13,413 |  |  | $ | 12,869 |  |  | 4.2 | % |  | 7.2 | % |  | (3.0) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | April 2, 2023 |  | April 3, 2022 |  | TotalChange |  | OperationsChange |  | CurrencyChange\nSurgery |  | $ | 2,434 |  |  | $ | 2,434 |  |  | 0.0 | % |  | 4.1 | % |  | (4.1) | %\nAdvanced |  | 1,118 |  |  | 1,146 |  |  | (2.5) |  |  | 1.6 |  |  | (4.1) | \nGeneral |  | 1,316 |  |  | 1,288 |  |  | 2.2 |  |  | 6.4 |  |  | (4.2) | \nOrthopaedics |  | 2,245 |  |  | 2,188 |  |  | 2.6 |  |  | 5.1 |  |  | (2.5) | \nHips |  | 390 |  |  | 389 |  |  | 0.4 |  |  | 2.7 |  |  | (2.3) | \nKnees |  | 368 |  |  | 339 |  |  | 8.7 |  |  | 11.3 |  |  | (2.6) | \nTrauma |  | 757 |  |  | 748 |  |  | 1.2 |  |  | 3.4 |  |  | (2.2) | \nSpine, Sports & Other |  | 729 |  |  | 712 |  |  | 2.4 |  |  | 5.2 |  |  | (2.8) | \nInterventional Solutions |  | 1,503 |  |  | 1,092 |  |  | 37.6 |  |  | 41.9 |  |  | (4.3) | \nElectrophysiology |  | 1,092 |  |  | 1,002 |  |  | 9.1 |  |  | 13.3 |  |  | (4.2) | \nAbiomed |  | 324 |  |  | \u2014 |  |  | * |  | * |  | \u2014 | \nOther Interventional Solutions |  | 87 |  |  | 90 |  |  | (3.9) |  |  | 1.1 |  |  | (5.0) | \nVision |  | 1,300 |  |  | 1,257 |  |  | 3.4 |  |  | 7.6 |  |  | (4.2) | \nContact Lenses/Other |  | 953 |  |  | 910 |  |  | 4.7 |  |  | 9.3 |  |  | (4.6) | \nSurgical |  | 347 |  |  | 347 |  |  | 0.1 |  |  | 3.1 |  |  | (3.0) | \nTotal MedTech Sales |  | $ | 7,481 |  |  | $ | 6,971 |  |  | 7.3 | % |  | 11.0 | % |  | (3.7) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nFiscal First Quarter |  |  |  |  |  | \n(Dollars in Billions)(Income)/Expense |  | 2023 |  | 2022 |  | Change\nLitigation related(1) |  | $ | 6.9 |  |  | 0.0 |  |  | 6.9 | \n |  |  |  |  |  | \nConsumer Health separation costs |  | 0.3 |  |  | 0.1 |  |  | 0.2 | \nCOVID-19 Vaccine related exit costs |  | 0.2 |  |  | 0.0 |  |  | 0.2 | \nChanges in the fair value of securities |  | 0.1 |  |  | 0.4 |  |  | (0.3) | \nEmployee benefit plan related |  | (0.4) |  |  | (0.3) |  |  | (0.1) | \nOther |  | 0.1 |  |  | (0.3) |  |  | 0.4 | \n |  |  |  |  |  | \n |  |  |  |  |  | \nTotal Other (Income) Expense, Net |  | $ | 7.2 |  |  | (0.1) |  |  | 7.3 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Income Before Tax |  | Segment Sales |  | Percent of Segment Sales\n(Dollars in Millions) |  | April 2, 2023 |  | April 3, 2022 |  | April 2, 2023 |  | April 3, 2022 |  | April 2, 2023 |  | April 3, 2022\nConsumer Health |  | $ | 776 |  |  | $ | 686 |  |  | $ | 3,852 |  |  | $ | 3,586 |  |  | 20.1 | % |  | 19.1 | %\nPharmaceutical |  | 4,444 |  |  | 3,924 |  |  | 13,413 |  |  | 12,869 |  |  | 33.1 |  |  | 30.5 | \nMedTech |  | 1,445 |  |  | 1,477 |  |  | 7,481 |  |  | 6,971 |  |  | 19.3 |  |  | 21.2 | \nSegment earnings before tax |  | 6,665 |  |  | 6,087 |  |  | 24,746 |  |  | 23,426 |  |  | 26.9 |  |  | 26.0 | \nLess: Expenses not allocated to segments(1) |  | 7,102 |  |  | 123 |  |  |  |  |  |  |  |  | \nLess: Consumer Health separation costs |  | 300 |  |  | 102 |  |  |  |  |  |  |  |  | \nWorldwide income/(loss) before tax |  | $ | (737) |  |  | $ | 5,862 |  |  | $ | 24,746 |  |  | $ | 23,426 |  |  | (3.0) | % |  | 25.0 | %  |  |  |  |  | \n(Dollars In Billions) | \n$ | 14.1 |  | Q4 2022 Cash and cash equivalents balance\n3.3 |  | net cash generated from operating activities\n3.3 |  | net cash generated from investing activities\n6.1 |  | net cash generated from financing activities\n0.1 |  | rounding\n | \n | \n$ | 26.9 |  | Q1 2023 Cash, cash equivalents and restricted cash balance  |  |  |  |  | \n(Dollars In Billions) | \n$ | (0.1) |  | Net Loss\n1.1 |  | non-cash expenses and other adjustments primarily for depreciation and amortization, stock-based compensation, asset write-downs and credit losses and accounts receivable allowances partially offset by the deferred tax provision and net gain on sale of assets/businesses\n | \n(0.6) |  | an increase in accounts receivable and inventories\n | \n(2.6) |  | a decrease in accounts payable and accrued liabilities\n(0.9) |  | an increase in other current and non-current assets\n6.3 |  | an increase in other current and non-current liabilities\n0.1 |  | Rounding\n$ | 3.3 |  | Cash Flow from operations  |  |  |  |  | \n(Dollars In Billions) | \n(0.9) |  | additions to property, plant and equipment\n | \n | \n4.0 |  | net sales of investments\n0.2 |  | credit support agreements activity, net\n | \n | \n$ | 3.3 |  | Net cash from investing activities  |  |  |  |  | \n(Dollars In Billions) | \n$ | (2.9) |  | dividends to shareholders\n(3.5) |  | repurchase of common stock\n5.2 | net proceeds from short term debt and repayment of long term debt\n7.7 |  | proceeds from Kenvue long term debt, net of issuance cost\n | \n | \n$ | (0.4) |  | other and rounding\n$ | 6.1 |  | Net cash from financing activities  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nFiscal Month Period |  | Total Numberof Shares Purchased(1) |  | Avg. PricePer Share |  | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs(2) |  | Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs\nJanuary 2, 2023 through January 29, 2023 |  | 2,507,585 |  |  | 176.23 |  |  | 635,911 |  |  | \u2014\nJanuary 30, 2023 through February 26, 2023 |  | 18,143,502 |  |  | 162.00 |  |  | 13,852,301 |  |  | \u2014\nFebruary 27, 2023 through April 2, 2023 |  | 996,230 |  |  | 156.52 |  |  | 646,230 |  |  | \u2014\nTotal |  | 21,647,317 |  |  | 163.39 |  |  | 15,134,442 |  |  | \u2014  |  |  |  |  |  |  |  | \nEX-101.INS |  | Instance Document - the instance document does not appear in the Interactive Data File because its                XBRL tags are embedded within the Inline XBRL document\nEX-101.SCH |  | Inline XBRL Taxonomy Extension Schema\nEX-101.CAL |  | Inline XBRL Taxonomy Extension Calculation Linkbase\nEX-101.LAB |  | Inline XBRL Taxonomy Extension Label Linkbase\nEX-101.PRE |  | Inline XBRL Taxonomy Extension Presentation Linkbase\nEX-101.DEF |  | Inline XBRL Taxonomy Extension Definition Document\n |  | \nExhibit 104: |  | Cover Page Interactive Data File\u2013\u2013the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.\n |  |   |  |  |  |  | \n | JOHNSON & JOHNSON(Registrant)\n | \nDate: April\u00a028, 2023 | By /s/ J. J. WOLK\n | J. J. WOLK\n | Executive Vice President, Chief Financial Officer (Principal Financial Officer)\n | \nDate: April\u00a028, 2023 | By /s/\u00a0R. J. DECKER Jr.\n | R. J. DECKER Jr.\n | Controller (Principal Accounting Officer)"}]}
{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For Johnson and Johnson, in 2023 Q2, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  |  |  |  |  |  |  |  |  |  |  |  |  | \n  |  |  |  |  |  |  |  | \n |  | \n\u2611 |  | Quarterly Report Pursuant to Section\u00a013 or 15(d) of the Securities Exchange Act of 1934  |  |  |  |  |  |  |  | \n |  | \n\u2610 |  | Transition Report Pursuant to Section\u00a013 or 15(d) of the Securities Exchange Act of 1934for the transition period from\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0to  |  |  |  |  |  |  |  | \nNew Jersey |  | 22-1024240\n(State or other jurisdiction ofincorporation or organization) |  | (I.R.S. EmployerIdentification No.)  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Large accelerated filer | \u2611 | Accelerated filer | \u2610\n | Non-accelerated filer | \u2610 | Smaller reporting company | \u2610\n | Emerging growth company | \u2610 |  |   |  |  |  |  |  |  |  | \nTitle of each class | Trading Symbol | Name of each exchange on which registered\nCommon Stock, Par Value $1.00 | JNJ | New York Stock Exchange\n0.650% Notes Due May 2024 | JNJ24C | New York Stock Exchange\n5.50% Notes Due November 2024 | JNJ24BP | New York Stock Exchange\n1.150% Notes Due November 2028 | JNJ28 | New York Stock Exchange\n1.650% Notes Due May 2035 | JNJ35 | New York Stock Exchange  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Page\n |  |  | No.\nPart I \u2014 Financial Information |  |  | 1\n |  |  | \nItem\u00a01. Financial Statements (unaudited) |  |  | 1\n |  |  | \nConsolidated Balance Sheets \u2014 July 2, 2023 and January 1, 2023 |  |  | 1\n |  |  | \nConsolidated Statements of Earnings for the Fiscal Second Quarters Ended July 2, 2023 and July 3, 2022 |  |  | 2\n |  |  | \nConsolidated Statements of Earnings for the Fiscal Six Months Ended July 2, 2023 and July 3, 2022 |  |  | 3\n |  |  | \nConsolidated Statements of Comprehensive Income for the Fiscal Second Quartersand Fiscal Six MonthsEnded July 2, 2023 and July 3, 2022 |  |  | 4\n |  |  | \nConsolidated Statements of Equity for the Fiscal Second Quarters and Fiscal Six Months Ended July 2, 2023 and July 3, 2022 |  |  | 5\n |  |  | \nConsolidated Statements of Cash Flows for the Fiscal Six Months Ended July 2, 2023 and July 3, 2022 |  |  | 7\n |  |  | \nNotes to Consolidated Financial Statements |  |  | 8\n |  |  | \n |  |  | \n |  |  | \nItem\u00a02. Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations |  |  | 43\n |  |  | \nItem\u00a03. Quantitative and Qualitative Disclosures About Market Risk |  |  | 61\n |  |  | \nItem\u00a04. Controls and Procedures |  |  | 61\n |  |  | \nPart II \u2014 Other Information |  |  | 61\n |  |  | \nItem\u00a01 - Legal Proceedings |  |  | 61\n |  |  | \nItem\u00a02 - Unregistered Sales of Equity Securities and Use of Proceeds |  |  | 61\n |  |  | \nItem\u00a06 - Exhibits |  |  | 62\n |  |  | \nSignatures |  |  | 63\n\n\n\n\n\n\n\n  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | July 2, 2023 |  | January 1, 2023\nASSETS\nCurrent assets: |  |  |  | \nCash and cash equivalents (Note 4) |  | $ | 21,183 |  |  | 14,127 | \n |  |  |  | \nMarketable securities |  | 7,322 |  |  | 9,392 | \nAccounts receivable, trade, less allowances $205(2022, $203) |  | 16,777 |  |  | 16,160 | \nInventories (Note 2) |  | 12,888 |  |  | 12,483 | \nPrepaid expenses and other |  | 2,397 |  |  | 3,132 | \n |  |  |  | \nTotal current assets |  | 60,567 |  |  | 55,294 | \nProperty, plant and equipment at cost |  | 51,218 |  |  | 49,253 | \nLess: accumulated depreciation |  | (30,642) |  |  | (29,450) | \nProperty, plant and equipment, net |  | 20,576 |  |  | 19,803 | \nIntangible assets, net (Note 3) |  | 46,246 |  |  | 48,325 | \nGoodwill (Note 3) |  | 45,440 |  |  | 45,231 | \nDeferred taxes on income (Note 5) |  | 8,779 |  |  | 9,123 | \nOther assets |  | 10,078 |  |  | 9,602 | \nTotal assets |  | $ | 191,686 |  |  | 187,378 | \nLIABILITIES AND SHAREHOLDERS\u2019 EQUITY\nCurrent liabilities: |  |  |  | \nLoans and notes payable |  | $ | 11,701 |  |  | 12,771 | \nAccounts payable |  | 10,443 |  |  | 11,703 | \nAccrued liabilities |  | 10,605 |  |  | 11,456 | \nAccrued rebates, returns and promotions |  | 15,672 |  |  | 14,417 | \nAccrued compensation and employee related obligations |  | 3,062 |  |  | 3,328 | \nAccrued taxes on income (Note 5) |  | 2,687 |  |  | 2,127 | \nTotal current liabilities |  | 54,170 |  |  | 55,802 | \nLong-term debt (Note 4) |  | 33,901 |  |  | 26,888 | \nDeferred taxes on income (Note 5) |  | 3,627 |  |  | 6,374 | \nEmployee related obligations (Note 6) |  | 6,461 |  |  | 6,767 | \nLong-term taxes payable (Note 5) |  | 2,536 |  |  | 4,306 | \nOther liabilities |  | 14,582 |  |  | 10,437 | \nTotal liabilities |  | $ | 115,277 |  |  | 110,574 | \nCommitments and Contingencies (Note 11) |  |  |  | \nShareholders\u2019 equity: |  |  |  | \nCommon stock \u2014 par value $1.00per share (authorized4,320,000,000shares; issued3,119,843,000shares) |  | $ | 3,120 |  |  | 3,120 | \nAccumulated other comprehensive income (loss) (Note 7) |  | (13,135) |  |  | (12,967) | \nRetained earnings and Additional paid-in capital |  | 129,381 |  |  | 128,345 | \nLess: common stock held in treasury, at cost (521,700,000and506,246,000shares) |  | 44,217 |  |  | 41,694 | \nTotal Johnson & Johnson shareholders\u2019 equity |  | 75,149 |  |  | 76,804 | \nEquity attributable to non-controlling interest (Note 12) |  | 1,260 |  |  | \u2014 | \nTotal equity |  | $ | 76,409 |  |  | 76,804 | \nTotal liabilities and shareholders\u2019 equity |  | $ | 191,686 |  |  | 187,378 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Second Quarter Ended\n |  | July 2,2023 |  | Percentto Sales |  | July 3,2022 |  | Percentto Sales\nSales to customers (Note 9) |  | $ | 25,530 |  |  | 100.0 | % |  | $ | 24,020 |  |  | 100.0 | %\nCost of products sold |  | 8,212 |  |  | 32.2 |  |  | 7,919 |  |  | 33.0 | \nGross profit |  | 17,318 |  |  | 67.8 |  |  | 16,101 |  |  | 67.0 | \nSelling, marketing and administrative expenses |  | 6,665 |  |  | 26.1 |  |  | 6,226 |  |  | 25.9 | \nResearch and development expense |  | 3,829 |  |  | 15.0 |  |  | 3,703 |  |  | 15.4 | \n |  |  |  |  |  |  |  | \nInterest income |  | (369) |  |  | (1.5) |  |  | (64) |  |  | (0.3) | \nInterest expense, net of portion capitalized |  | 346 |  |  | 1.4 |  |  | 38 |  |  | 0.2 | \nOther (income) expense, net* |  | (60) |  |  | (0.2) |  |  | 273 |  |  | 1.1 | \nRestructuring |  | 145 |  |  | 0.5 |  |  | 85 |  |  | 0.4 | \nEarnings before provision for taxes on income |  | 6,762 |  |  | 26.5 |  |  | 5,840 |  |  | 24.3 | \nProvision for taxes on income (Note 5) |  | 1,618 |  |  | 6.4 |  |  | 1,026 |  |  | 4.3 | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \nNET EARNINGS |  | $ | 5,144 |  |  | 20.1 | % |  | $ | 4,814 |  |  | 20.0 | %\n |  |  |  |  |  |  |  | \nNET EARNINGS PER SHARE (Note 8) |  |  |  |  |  |  |  | \nBasic |  | $ | 1.98 |  |  |  |  | $ | 1.83 |  |  | \nDiluted |  | $ | 1.96 |  |  |  |  | $ | 1.80 |  |  | \n |  |  |  |  |  |  |  | \nAVG. SHARES OUTSTANDING |  |  |  |  |  |  |  | \nBasic |  | 2,598.4 |  |  |  |  | 2,629.6 |  |  | \nDiluted |  | 2,625.7 |  |  |  |  | 2,667.9 |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Six Months Ended\n |  | July 2,2023 |  | Percentto Sales |  | July 3,2022 |  | Percentto Sales\nSales to customers (Note 9) |  | $ | 50,276 |  |  | 100.0 | % |  | $ | 47,446 |  |  | 100.0 | %\nCost of products sold |  | 16,607 |  |  | 33.0 |  |  | 15,517 |  |  | 32.7 | \nGross profit |  | 33,669 |  |  | 67.0 |  |  | 31,929 |  |  | 67.3 | \nSelling, marketing and administrative expenses |  | 12,803 |  |  | 25.5 |  |  | 12,164 |  |  | 25.6 | \nResearch and development expense |  | 7,392 |  |  | 14.7 |  |  | 7,165 |  |  | 15.1 | \nIn-process research and development impairments |  | 49 |  |  | 0.1 |  |  | 610 |  | 1.3 | \nInterest income |  | (604) |  |  | (1.2) |  |  | (86) |  |  | (0.2) | \nInterest expense, net of portion capitalized |  | 561 |  |  | 1.1 |  |  | 48 |  |  | 0.1 | \nOther (income) expense, net* |  | 7,168 |  |  | 14.3 |  |  | 171 |  |  | 0.4 | \nRestructuring |  | 275 |  |  | 0.5 |  |  | 155 |  |  | 0.3 | \nEarnings before provision for taxes on income |  | 6,025 |  |  | 12.0 |  |  | 11,702 |  |  | 24.7 | \nProvision for taxes on income (Note 5) |  | 949 |  |  | 1.9 |  |  | 1,739 |  |  | 3.7 | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \nNET EARNINGS |  | $ | 5,076 |  |  | 10.1 | % |  | $ | 9,963 |  |  | 21.0 | %\n |  |  |  |  |  |  |  | \nNET EARNINGS PER SHARE (Note 8) |  |  |  |  |  |  |  | \nBasic |  | $ | 1.95 |  |  |  |  | $ | 3.79 |  |  | \nDiluted |  | $ | 1.93 |  |  |  |  | $ | 3.73 |  |  | \n |  |  |  |  |  |  |  | \nAVG. SHARES OUTSTANDING |  |  |  |  |  |  |  | \nBasic |  | 2,601.9 |  |  |  |  | 2,629.4 |  |  | \nDiluted |  | 2,630.7 |  |  |  |  | 2,669.2 |  |  | \n |  |  |  |  |  |  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Fiscal Second Quarter Ended |  | Fiscal Six Months Ended\n | July 2, 2023 |  | July 3, 2022 |  | July 2, 2023 |  | July 3, 2022\n |  |  |  |  |  |  | \nNet earnings | $ | 5,144 |  |  | 4,814 |  |  | $ | 5,076 |  |  | 9,963 | \n |  |  |  |  |  |  | \nOther comprehensive income (loss), net of tax |  |  |  |  |  |  | \nForeign currency translation | (715) |  |  | (151) |  |  | (896) |  |  | (705) | \n |  |  |  |  |  |  | \nSecurities: |  |  |  |  |  |  | \nUnrealized holding gain (loss) arising during period | 4 |  |  | (20) |  |  | 21 |  |  | (33) | \nReclassifications to earnings | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \n |  |  |  |  |  |  | \nNet change | 4 |  |  | (20) |  |  | 21 |  |  | (33) | \n |  |  |  |  |  |  | \nEmployee benefit plans: |  |  |  |  |  |  | \nPrior service cost amortization during period | (36) |  |  | (20) |  |  | (71) |  |  | (73) | \nGain (loss) amortization during period | (34) |  |  | 86 |  |  | (67) |  |  | 303 | \n |  |  |  |  |  |  | \nNet change | (70) |  |  | 66 |  |  | (138) |  |  | 230 | \n |  |  |  |  |  |  | \nDerivatives & hedges: |  |  |  |  |  |  | \nUnrealized gain (loss) arising during period | (137) |  |  | 145 |  |  | 433 |  |  | (50) | \nReclassifications to earnings | (139) |  |  | (126) |  |  | (136) |  |  | (227) | \nNet change | (276) |  |  | 19 |  |  | 297 |  |  | (277) | \n |  |  |  |  |  |  | \nOther comprehensive income (loss) | (1,057) |  |  | (86) |  |  | (716) |  |  | (785) | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \nComprehensive income | $ | 4,087 |  |  | 4,728 |  |  | $ | 4,360 |  |  | 9,178 | \n |  |  |  |  |  |  |   |  | \nThe tax effects in other comprehensive income/(loss) for the fiscal second quarter were as follows for 2023 and 2022, respectively: Foreign Currency Translation: $32million and $533million; Securities: $1million and $6million; Employee Benefit Plans: $21million and $84million; Derivatives & Hedges: $74million and $5million.\n\nThe tax effects in other comprehensive income/(loss) for the fiscal six months were as follows for 2023 and 2022, respectively: Foreign Currency Translation: $266million and $678million; Securities: $6million and $9million; Employee Benefit Plans: $43million and $65million; Derivatives & Hedges: $80million and $73million.  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Total |  | RetainedEarnings and Additional paid-in capital |  | AccumulatedOtherComprehensiveIncome |  | Common StockIssued Amount |  | TreasuryStockAmount |  | Non-controlling interest (NCI) | \nBalance, April 2, 2023 | $ | 70,869 |  |  | 124,558 |  |  | (12,626) |  |  | 3,120 |  |  | (44,183) |  |  | \u2014 |  | \nNet earnings | 5,144 |  |  | 5,144 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  | \nCash dividends paid                   ($1.19per share) | (3,092) |  |  | (3,092) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  | \nEmployee compensation and stock option plans | 649 |  |  | 301 |  |  | \u2014 |  |  | \u2014 |  |  | 348 |  |  |  | \nRepurchase of common stock | (381) |  |  |  |  | \u2014 |  |  | \u2014 |  |  | (381) |  |  |  | \nOther | (1) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1) |  |  | \u2014 |  | \nKenvue IPO | 4,278 |  |  | 2,470 |  |  | 548 |  |  |  |  |  |  | 1,260 |  | *\nOther comprehensive income (loss), net of tax | (1,057) |  |  | \u2014 |  |  | (1,057) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  | \nBalance, July 2, 2023 | $ | 76,409 |  |  | 129,381 |  |  | (13,135) |  |  | 3,120 |  |  | (44,217) |  |  | 1,260 |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n | Total |  | RetainedEarnings and Additional paid-in capital |  | AccumulatedOtherComprehensiveIncome |  | Common StockIssued Amount |  | TreasuryStockAmount |  | Non-controlling interest (NCI) | \nBalance, January 1, 2023 | $ | 76,804 |  |  | 128,345 |  |  | (12,967) |  |  | 3,120 |  |  | (41,694) |  |  | \u2014 |  | \nNet earnings | 5,076 |  |  | 5,076 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  | \nCash dividends paid ($2.32per share) | (6,034) |  |  | (6,034) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  | \nEmployee compensation and stock option plans | 944 |  |  | (476) |  |  | \u2014 |  |  | \u2014 |  |  | 1,420 |  |  | \u2014 |  | \nRepurchase of common stock | (3,918) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (3,918) |  |  | \u2014 |  | \nOther | (25) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (25) |  |  | \u2014 |  | \nKenvue IPO | 4,278 |  |  | 2,470 |  |  | 548 |  |  | \u2014 |  |  | \u2014 |  |  | 1,260 |  | *\nOther comprehensive income (loss), net of tax | (716) |  |  | \u2014 |  |  | (716) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  | \nBalance, July 2, 2023 | $ | 76,409 |  |  | 129,381 |  |  | (13,135) |  |  | 3,120 |  |  | (44,217) |  |  | 1,260 |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Total |  | RetainedEarnings and Additional paid-in capital |  | AccumulatedOtherComprehensiveIncome |  | Common StockIssued Amount |  | TreasuryStockAmount\nBalance, April 3, 2022 | $ | 74,709 |  |  | 124,380 |  |  | (13,757) |  |  | 3,120 |  |  | (39,034) | \n |  |  |  |  |  |  |  |  | \nNet earnings | 4,814 |  |  | 4,814 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nCash dividends paid ($1.13per share) | (2,971) |  |  | (2,971) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nEmployee compensation and stock option plans | 864 |  |  | (7) |  |  | \u2014 |  |  | \u2014 |  |  | 871 | \nRepurchase of common stock | (973) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (973) | \n |  |  |  |  |  |  |  |  | \nOther comprehensive income (loss), net of tax | (86) |  |  | \u2014 |  |  | (86) |  |  | \u2014 |  |  | \u2014 | \nBalance, July 3, 2022 | $ | 76,357 |  |  | 126,216 |  |  | (13,843) |  |  | 3,120 |  |  | (39,136) | \n |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \nFiscal Six Months Ended July\u00a03, 2022\n | Total |  | RetainedEarnings |  | AccumulatedOtherComprehensiveIncome |  | Common StockIssued Amount |  | TreasuryStockAmount\nBalance, January 2, 2022 | $ | 74,023 |  |  | 123,060 |  |  | (13,058) |  |  | 3,120 |  |  | (39,099) | \n |  |  |  |  |  |  |  |  | \nNet earnings | 9,963 |  |  | 9,963 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nCash dividends paid ($2.19per share) | (5,758) |  |  | (5,758) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nEmployee compensation and stock option plans | 1,464 |  |  | (1,049) |  |  | \u2014 |  |  | \u2014 |  |  | 2,513 | \nRepurchase of common stock | (2,550) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (2,550) | \n |  |  |  |  |  |  |  |  | \nOther comprehensive income (loss), net of tax | (785) |  |  | \u2014 |  |  | (785) |  |  | \u2014 |  |  | \u2014 | \nBalance, July 3, 2022 | $ | 76,357 |  |  | 126,216 |  |  | (13,843) |  |  | 3,120 |  |  | (39,136) | \n |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Six Months Ended\n |  | July 2,2023 |  | July 3,2022\nCASH FLOWS FROM OPERATING ACTIVITIES |  |  |  | \nNet earnings |  | $ | 5,076 |  |  | 9,963 | \nAdjustments to reconcile net earnings to cash flows from operating activities: |  |  |  | \nDepreciation and amortization of property and intangibles |  | 3,814 |  |  | 3,513 | \nStock based compensation |  | 688 |  |  | 644 | \n |  |  |  | \n |  |  |  | \nAsset write-downs |  | 388 |  |  | 747 | \n |  |  |  | \nNet gain on sale of assets/businesses |  | (47) |  |  | (213) | \n |  |  |  | \nDeferred tax provision |  | (2,342) |  |  | (2,349) | \nCredit losses and accounts receivable allowances |  | \u2014 |  |  | (3) | \nChanges in assets and liabilities, net of effects from acquisitions and divestitures: |  |  |  | \nIncrease in accounts receivable |  | (599) |  |  | (1,386) | \nIncrease in inventories |  | (741) |  |  | (1,257) | \nDecrease in accounts payable and accrued liabilities |  | (1,061) |  |  | (1,170) | \n(Increase)/Decrease in other current and non-current assets |  | (1,144) |  |  | 3,527 | \nIncrease/(Decrease) in other current and non-current liabilities |  | 3,407 |  |  | (2,456) | \n |  |  |  | \nNET CASH FLOWS FROM OPERATING ACTIVITIES |  | 7,439 |  |  | 9,560 | \n |  |  |  | \nCASH FLOWS FROM INVESTING ACTIVITIES |  |  |  | \nAdditions to property, plant and equipment |  | (1,987) |  |  | (1,470) | \nProceeds from the disposal of assets/businesses, net (Note 10) |  | 116 |  |  | 314 | \nAcquisitions, net of cash acquired (Note 10) |  | \u2014 |  |  | (523) | \nPurchases of investments |  | (9,688) |  |  | (22,048) | \nSales of investments |  | 11,877 |  |  | 17,634 | \nCredit support agreements activity, net |  | (798) |  |  | (10) | \nOther (primarily licenses and milestones) |  | 19 |  |  | (170) | \n |  |  |  | \nNET CASH USED BY INVESTING ACTIVITIES |  | (461) |  |  | (6,273) | \n |  |  |  | \nCASH FLOWS FROM FINANCING ACTIVITIES |  |  |  | \nDividends to shareholders |  | (6,034) |  |  | (5,758) | \nRepurchase of common stock |  | (3,918) |  |  | (2,550) | \nProceeds from short-term debt (Note 4) |  | 12,221 |  |  | 4,371 | \nRepayment of short-term debt |  | (13,611) |  |  | (2,201) | \nProceeds from long-term debt, net of issuance costs (Note 4) |  | 7,674 |  |  | 2 | \nRepayment of long-term debt |  | (501) |  |  | (2,132) | \nProceeds from the exercise of stock options/employee withholding tax on stock awards, net |  | 254 |  |  | 820 | \nCredit support agreements activity, net |  | (126) |  |  | 813 | \nProceeds from Kenvue initial public offering (Note 12) |  | 4,241 |  |  | \u2014 | \nOther |  | (53) |  |  | (11) | \n |  |  |  | \nNET CASH FROM/(USED BY) FINANCING ACTIVITIES |  | 147 |  |  | (6,646) | \n |  |  |  | \nEffect of exchange rate changes on cash and cash equivalents |  | (69) |  |  | (145) | \nIncrease/(Decrease) in cash and cash equivalents |  | 7,056 |  |  | (3,504) | \nCash and Cash equivalents beginning of period |  | 14,127 |  |  | 14,487 | \nCASH AND CASH EQUIVALENTS, END OF PERIOD |  | $ | 21,183 |  |  | 10,983 | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \nAcquisitions |  |  |  | \nFair value of assets acquired |  | $ | \u2014 |  |  | 621 | \nFair value of liabilities assumed |  | \u2014 |  |  | (98) | \nNet cash paid for acquisitions |  | $ | \u2014 |  |  | 523 | \n |  |  |  | \n |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | July 2, 2023 |  | January 1, 2023\nRaw materials and supplies |  | $ | 2,419 |  |  | 2,070 | \nGoods in process |  | 1,944 |  |  | 1,700 | \nFinished goods |  | 8,525 |  |  | 8,713 | \nTotal inventories |  | $ | 12,888 |  |  | 12,483 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | July 2, 2023 |  | January 1, 2023\nIntangible assets with definite lives: |  |  |  | \nPatents and trademarks \u2014 gross |  | $ | 44,637 |  |  | 44,012 | \nLess accumulated amortization |  | (24,460) |  |  | (22,266) | \nPatents and trademarks \u2014 net |  | 20,177 |  |  | 21,746 | \nCustomer relationships and other intangibles \u2014 gross |  | 23,055 |  |  | 22,987 | \nLess accumulated amortization |  | (13,516) |  |  | (12,901) | \nCustomer relationships and other intangibles\u00a0\u2014 net(1) |  | 9,539 |  |  | 10,086 | \nIntangible assets with indefinite lives: |  |  |  | \nTrademarks |  | 6,834 |  |  | 6,807 | \nPurchased in-process research and development |  | 9,696 |  |  | 9,686 | \nTotal intangible assets with indefinite lives |  | 16,530 |  |  | 16,493 | \nTotal intangible assets \u2014 net |  | $ | 46,246 |  |  | 48,325 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | Consumer Health |  | Pharmaceutical |  | MedTech |  | Total\nGoodwill at January\u00a01, 2023 |  | $ | 9,184 |  |  | 10,184 |  |  | 25,863 |  |  | 45,231 | \nGoodwill, related to acquisitions |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nGoodwill, related to divestitures |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nCurrency translation/Other |  | (103) |  |  | 137 |  |  | 175 |  | * | 209 | \nGoodwill at July\u00a02, 2023 |  | $ | 9,081 |  |  | 10,321 |  |  | 26,038 |  |  | 45,440 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  |  |  |  |  | \n2023 |  | 2024 |  | 2025 |  | 2026 |  | 2027\n$4,800 |  | 4,600 |  | 3,800 |  | 3,200 |  | 2,600  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | July 2, 2023 | July 3, 2022\n(Dollars in Millions) | Sales | Cost of Products Sold | R&D Expense | Interest (Income) Expense | Other (Income)  Expense | Sales | Cost of Products Sold | R&D Expense | Interest (Income) Expense | Other (Income)  Expense\n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \nThe effects of fair value, net investment and cash flow hedging: |  |  |  |  |  |  |  |  |  | \nGain (Loss) on fair value hedging relationship: |  |  |  |  |  |  |  |  |  | \nInterest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nHedged items | $ | \u2014 |  | \u2014 |  | \u2014 |  | (175) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (241) |  | \u2014 | \nDerivatives designated as hedging instruments | \u2014 |  | \u2014 |  | \u2014 |  | 175 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 241 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nGain (Loss) on net investment hedging relationship: |  |  |  |  |  |  |  |  |  | \nCross currency interest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing | \u2014 |  | \u2014 |  | \u2014 |  | 33 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 44 |  | \u2014 | \nAmount of gain or (loss) recognized in AOCI | \u2014 |  | \u2014 |  | \u2014 |  | 33 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 44 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nGain (Loss) on cash flow hedging relationship: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) reclassified from AOCI into income | (15) |  | 56 |  | (12) |  | \u2014 |  | 3 |  | (17) |  | (6) |  | 42 |  | \u2014 |  | (39) | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in AOCI | (14) |  | 251 |  | 7 |  | \u2014 |  | 18 |  | (25) |  | 35 |  | 69 |  | \u2014 |  | (38) | \n |  |  |  |  |  |  |  |  |  | \nCross currency interest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) reclassified from AOCI into income | \u2014 |  | \u2014 |  | \u2014 |  | 74 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 102 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in AOCI | $ | \u2014 |  | \u2014 |  | \u2014 |  | (432) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 60 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | July 2, 2023 | July 3, 2022\n(Dollars in Millions) | Sales | Cost of Products Sold | R&D Expense | Interest (Income) Expense | Other (Income)  Expense | Sales | Cost of Products Sold | R&D Expense | Interest (Income) Expense | Other (Income)  Expense\n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \nThe effects of fair value, net investment and cash flow hedging: |  |  |  |  |  |  |  |  |  | \nGain (Loss) on fair value hedging relationship: |  |  |  |  |  |  |  |  |  | \nInterest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nHedged items | $ | \u2014 |  | \u2014 |  | \u2014 |  | (1,104) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (772) |  | \u2014 | \nDerivatives designated as hedging instruments | \u2014 |  | \u2014 |  | \u2014 |  | 1,104 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 772 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nGain (Loss) on net investment hedging relationship: |  |  |  |  |  |  |  |  |  | \nCross currency interest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing | \u2014 |  | \u2014 |  | \u2014 |  | 67 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 89 |  | \u2014 | \nAmount of gain or (loss) recognized in AOCI | \u2014 |  | \u2014 |  | \u2014 |  | 67 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 89 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nGain (Loss) on cash flow hedging relationship: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) reclassified from AOCI into income | (3) |  | (90) |  | (25) |  | \u2014 |  | 5 |  | (34) |  | (58) |  | 65 |  | \u2014 |  | (57) | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in AOCI | 10 |  | 396 |  | (29) |  | \u2014 |  | 4 |  | (3) |  | (59) |  | 102 |  | \u2014 |  | (111) | \n |  |  |  |  |  |  |  |  |  | \nCross currency interest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) reclassified from AOCI into income | \u2014 |  | \u2014 |  | \u2014 |  | 182 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 222 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in AOCI | $ | \u2014 |  | \u2014 |  | \u2014 |  | (15) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (68) |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLine item in the Consolidated Balance Sheet in which the hedged item is included |  | Carrying Amount of the Hedged Liability |  | Cumulative Amount of Fair Value Hedging Gain/ (Loss)  Included in the Carrying Amount of the Hedged Liability\n |  | \n(Dollars in Millions) |  | July 2, 2023 |  | January 1, 2023 |  | July 2, 2023 |  | January 1, 2023\n |  |  |  |  |  |  |  | \nLong-term Debt |  | $ | 8,662 |  |  | 8,665 |  |  | (1,443) |  |  | (1,435) | \n |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | \n |  |  |  | Gain/(Loss)Recognized InIncome on Derivative | Gain/(Loss)Recognized InIncome on Derivative | \n(Dollars in Millions) |  | Location of Gain /(Loss) Recognized in Income on Derivative |  | Fiscal Second Quarter Ended | Fiscal Six Months Ended | \nDerivatives Not Designated as Hedging Instruments |  |  |  | July 2, 2023 |  | July 3, 2022 | July 2, 2023 |  | July 3, 2022 | \nForeign Exchange Contracts |  | Other (income) expense |  | $ | 33 |  |  | 73 |  | 2 |  |  | 102 |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n\n |  | Gain/(Loss)Recognized InAccumulatedOCI |  | Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income |  | Gain/(Loss)                                                                                                                                                                                                                                  Reclassified FromAccumulated OCIInto Income\n(Dollars in Millions) |  | July 2, 2023 |  | July 3, 2022 |  |  |  | July 2, 2023 |  | July 3, 2022\nDebt |  | $ | 11 |  |  | 202 |  |  | Interest (income) expense |  | \u2014 |  |  | \u2014 | \nCross Currency interest rate swaps |  | $ | (24) |  |  | 313 |  |  | Interest (income) expense |  | \u2014 |  |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n\n |  | Gain/(Loss)Recognized InAccumulated OCI |  | Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income |  | Gain/(Loss)                                                                                                                                                                                                                                  Reclassified FromAccumulated OCIInto Income\n(Dollars in Millions) |  | July 2, 2023 |  | July 3, 2022 |  |  |  | July 2, 2023 |  | July 3, 2022\nDebt |  | $ | (66) |  |  | 270 |  |  | Interest (income) expense |  | \u2014 |  |  | \u2014 | \nCross Currency interest rate swaps |  | $ | 666 |  |  | 873 |  |  | Interest (income) expense |  | \u2014 |  |  | \u2014 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | January 1, 2023 |  |  |  |  |  | July 2, 2023 |  | \n |  | Carrying Value |  | Changes in Fair Value Reflected in Net Income(1) |  | Sales/ Purchases/Other(2) |  | Carrying Value |  | Non Current Other Assets\nEquity Investments with readily determinable value |  | $ | 576 |  |  | (30) |  |  | (53) |  |  | 493 |  |  | 493 | \n |  |  |  |  |  |  |  |  |  | \nEquity Investments without readily determinable value |  | $ | 698 |  |  | (26) |  |  | 75 |  |  | 747 |  |  | 747 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | July 2, 2023 |  |  |  | January 1, 2023\n(Dollars in Millions) |  | Level 1 |  | Level 2 |  | Level 3 |  | Total |  | Total(1)\nDerivatives designated as hedging instruments: |  |  |  |  |  |  |  |  |  | \nAssets: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts |  | $ | \u2014 |  |  | 893 |  |  | \u2014 |  |  | 893 |  |  | 629 | \nInterest rate contracts(2) |  | \u2014 |  |  | 1,310 |  |  | \u2014 |  |  | 1,310 |  |  | 1,534 | \n |  |  |  |  |  |  |  |  |  | \nTotal |  | \u2014 |  |  | 2,203 |  |  | \u2014 |  |  | 2,203 |  |  | 2,163 | \nLiabilities: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts |  | \u2014 |  |  | 446 |  |  | \u2014 |  |  | 446 |  |  | 511 | \nInterest rate contracts(2) |  | \u2014 |  |  | 3,691 |  |  | \u2014 |  |  | 3,691 |  |  | 2,778 | \n |  |  |  |  |  |  |  |  |  | \nTotal |  | \u2014 |  |  | 4,137 |  |  | \u2014 |  |  | 4,137 |  |  | 3,289 | \nDerivatives not designated as hedging instruments: |  |  |  |  |  |  |  |  |  | \nAssets: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts |  | \u2014 |  |  | 55 |  |  | \u2014 |  |  | 55 |  |  | 38 | \nLiabilities: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts |  | \u2014 |  |  | 22 |  |  | \u2014 |  |  | 22 |  |  | 68 | \nOther Investments: |  |  |  |  |  |  |  |  |  | \nEquity investments(3) |  | 493 |  |  | \u2014 |  |  | \u2014 |  |  | 493 |  |  | 576 | \nDebt securities(4) |  | \u2014 |  |  | 9,831 |  |  | \u2014 |  |  | 9,831 |  |  | 10,487 | \nOther Liabilities |  |  |  |  |  |  |  |  |  | \nContingent consideration(5) |  | $ | \u2014 |  |  | \u2014 |  |  | 1,142 |  |  | 1,142 |  |  | 1,120 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \nGross to Net Derivative Reconciliation |  | July 2, 2023 |  | January 1, 2023\n(Dollars in Millions) |  |  |  | \nTotal Gross Assets |  | $ | 2,258 |  |  | 2,201 | \nCredit Support Agreement (CSA) |  | (2,119) |  |  | (2,176) | \nTotal Net Asset |  | 139 |  |  | 25 | \n |  |  |  | \nTotal Gross Liabilities |  | 4,159 |  |  | 3,357 | \nCredit Support Agreement (CSA) |  | (3,890) |  |  | (3,023) | \nTotal Net Liabilities |  | $ | 269 |  |  | 334 | \n |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | \n |  | July 2, 2023 |  | July 3, 2022\n(Dollars in Millions) |  |  |  | \nBeginning Balance |  | $ | 1,120 |  |  | 533 | \nChanges in estimated fair value(6) |  | 25 |  |  | (88) | \nAdditions |  | \u2014 |  |  | 91 | \nPayments |  | (3) |  |  | \u2014 | \nEnding Balance |  | $ | 1,142 |  |  | 536 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) | Carrying Amount |  |  |  | Gain/(Loss) |  | Estimated Fair Value |  | Cash & Cash Equivalents |  | Current Marketable Securities\nCash | $ | 4,430 |  |  |  |  | \u2014 |  |  | 4,430 |  |  | 4,430 |  |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |  | \nNon-U.S. sovereign securities | 423 |  |  |  |  | \u2014 |  |  | 423 |  |  | 423 |  |  | \u2014 | \nU.S. reverse repurchase agreements | 8,991 |  |  |  |  | \u2014 |  |  | 8,991 |  |  | 8,991 |  |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |  | \nCorporate debt securities(1) | 641 |  |  |  |  | \u2014 |  |  | 641 |  |  | 368 |  |  | 273 | \nMoney market funds | 3,570 |  |  |  |  | \u2014 |  |  | 3,570 |  |  | 3,570 |  |  | \u2014 | \nTime deposits(1) | 619 |  |  |  |  | \u2014 |  |  | 619 |  |  | 619 |  |  | \u2014 | \nSubtotal | 18,674 |  |  |  |  | \u2014 |  |  | 18,674 |  |  | 18,401 |  |  | 273 | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | Unrealized Loss |  |  |  |  |  | \nU.S. Gov\u2019t securities | 9,416 |  |  |  |  | (5) |  |  | 9,411 |  |  | 2,729 |  |  | 6,682 | \nU.S. Gov\u2019t Agencies | 123 |  |  |  |  | (2) |  |  | 121 |  |  | \u2014 |  |  | 121 | \nOther sovereign securities | 9 |  |  |  |  | \u2014 |  |  | 9 |  |  | 7 |  |  | 2 | \nCorporate debt securities | 291 |  |  |  |  | (1) |  |  | 290 |  |  | 46 |  |  | 244 | \nSubtotal available for sale debt(2) | $ | 9,839 |  |  |  |  | (8) |  |  | 9,831 |  |  | 2,782 |  |  | 7,049 | \nTotal cash, cash equivalents and current marketable securities | $ | 28,513 |  |  |  |  | (8) |  |  | 28,505 |  |  | 21,183 |  |  | 7,322 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | Cost Basis |  | Fair Value\nDue within one year |  | $ | 9,823 |  |  | 9,815 | \nDue after one year through five years |  | 16 |  |  | 16 | \nDue after five years through ten years |  | \u2014 |  |  | \u2014 | \nTotal debt securities |  | $ | 9,839 |  |  | 9,831 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | Carrying Amount |  | Estimated Fair Value\n |  |  |  | \nFinancial Liabilities |  |  |  | \n |  |  |  | \nCurrent Debt |  | $ | 11,701 |  |  | 11,676 | \n |  |  |  | \nNon-Current Debt |  |  |  | \n |  |  |  | \n |  |  |  | \n5.50% Notes due 2024 (500MM GBP1.2605) |  | 629 |  |  | 627 | \n2.625% Notes due 2025 |  | 749 |  |  | 726 | \n0.55% Notes due 2025 |  | 926 |  |  | 914 | \n |  |  |  | \n2.45% Notes due 2026 |  | 1,997 |  |  | 1,890 | \n2.95% Notes due 2027 |  | 875 |  |  | 954 | \n |  |  |  | \n0.95% Notes due 2027 |  | 1,394 |  |  | 1,313 | \n2.90%\u00a0Notes due 2028 |  | 1,497 |  |  | 1,411 | \n1.150% Notes due 2028 (750MM Euro1.0873) |  | 811 |  |  | 728 | \n6.95% Notes due 2029 |  | 298 |  |  | 347 | \n1.30% Notes due 2030 |  | 1,605 |  |  | 1,435 | \n4.95% Debentures due 2033 |  | 498 |  |  | 525 | \n4.375% Notes due 2033 |  | 854 |  |  | 857 | \n1.650% Notes due 2035 (1.5B Euro1.0873) |  | 1,619 |  |  | 1,400 | \n3.55% Notes due 2036 |  | 840 |  |  | 901 | \n5.95% Notes due 2037 |  | 993 |  |  | 1,126 | \n3.625% Notes due 2037 |  | 1,334 |  |  | 1,355 | \n3.40%\u00a0Notes due 2038 |  | 992 |  |  | 889 | \n5.85% Debentures due 2038 |  | 697 |  |  | 783 | \n4.50% Debentures due 2040 |  | 541 |  |  | 539 | \n2.10% Notes due 2040 |  | 826 |  |  | 704 | \n4.85% Notes due 2041 |  | 297 |  |  | 299 | \n4.50% Notes due 2043 |  | 496 |  |  | 499 | \n3.70% Notes due 2046 |  | 1,977 |  |  | 1,758 | \n3.75% Notes due 2047 |  | 811 |  |  | 871 | \n3.50% Notes due 2048 |  | 743 |  |  | 640 | \n2.25% Notes due 2050 |  | 807 |  |  | 666 | \n2.45% Notes due 2060 |  | 1,053 |  |  | 811 | \n5.50% Debentures due 2025* |  | 748 |  |  | 752 | \n5.35% Debentures due 2026* |  | 747 |  |  | 756 | \n5.05% Debentures due 2028* |  | 994 |  |  | 1,006 | \n5.00% Debentures due 2030* |  | 992 |  |  | 1,006 | \n4.90% Debentures due 2033* |  | 1,240 |  |  | 1,264 | \n5.10% Debentures due 2043* |  | 741 |  |  | 763 | \n5.05% Debentures due 2053* |  | 1,476 |  |  | 1,531 | \n5.20% Debentures due 2063* |  | 738 |  |  | 765 | \nOther |  | 66 |  |  | 66 | \nTotal Non-Current Debt |  | $ | 33,901 |  |  | 32,877 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Second Quarter Ended |  | Fiscal Six Months Ended\n |  | Retirement Plans |  | Other Benefit Plans |  | Retirement Plans |  | Other Benefit Plans\n(Dollars in Millions) |  | July 2, 2023 |  | July 3, 2022 |  | July 2, 2023 |  | July 3, 2022 |  | July 2, 2023 |  | July 3, 2022 |  | July 2, 2023 |  | July 3, 2022\nService cost |  | $ | 216 |  |  | 319 |  |  | 69 |  |  | 80 |  |  | 428 |  |  | 640 |  |  | 137 |  |  | 160 | \nInterest cost |  | 373 |  |  | 229 |  |  | 55 |  |  | 27 |  |  | 727 |  |  | 459 |  |  | 109 |  |  | 53 | \nExpected return on plan assets |  | (694) |  |  | (693) |  |  | (2) |  |  | (2) |  |  | (1,362) |  |  | (1,392) |  |  | (3) |  |  | (4) | \nAmortization of prior service cost/(credit) |  | (46) |  |  | (46) |  |  | (1) |  |  | (2) |  |  | (92) |  |  | (92) |  |  | (1) |  |  | (3) | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nRecognized actuarial (gains) losses |  | (50) |  |  | 167 |  |  | 7 |  |  | 31 |  |  | (100) |  |  | 329 |  |  | 13 |  |  | 61 | \nCurtailments and settlements |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 1 |  |  | \u2014 |  |  | \u2014 | \nNet periodic benefit cost/(credit) |  | $ | (201) |  |  | (24) |  |  | 128 |  |  | 134 |  |  | (399) |  |  | (55) |  |  | 255 |  |  | 267 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  | Foreign |  | Gain/(Loss) |  | Employee |  | Gain/(Loss) |  | Total Accumulated\n |  | Currency |  | On |  | Benefit |  | On Derivatives |  | Other Comprehensive\n(Dollars in Millions) |  | Translation |  | Securities |  | Plans |  | & Hedges |  | Income (Loss)\nJanuary 1, 2023 |  | $ | (11,813) |  |  | (27) |  |  | (897) |  |  | (230) |  |  | (12,967) | \nNet change |  | (896) |  |  | 21 |  |  | (138) |  |  | 297 |  |  | (716) | \nAmount attributable to non-controlling interest |  | 548 |  |  |  |  |  |  |  |  | 548 | \nJuly 2, 2023 |  | $ | (12,161) |  |  | (6) |  |  | (1,035) |  |  | 67 |  |  | (13,135) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Second Quarter Ended |  | Fiscal Six Months Ended\n(Shares in Millions) |  | July 2, 2023 |  | July 3, 2022 |  | July 2, 2023 |  | July 3, 2022\nBasic net earnings per share |  | $ | 1.98 |  |  | 1.83 |  |  | 1.95 |  |  | 3.79 | \nAverage shares outstanding \u2014 basic |  | 2,598.4 |  |  | 2,629.6 |  |  | 2,601.9 |  |  | 2,629.4 | \nPotential shares exercisable under stock option plans |  | 95.2 |  |  | 143.7 |  |  | 96.9 |  |  | 141.8 | \nLess: shares which could be repurchased under treasury stock method |  | (67.9) |  |  | (105.4) |  |  | (68.1) |  |  | (102.0) | \n |  |  |  |  |  |  |  | \nAverage shares outstanding \u2014 diluted |  | 2,625.7 |  |  | 2,667.9 |  |  | 2,630.7 |  |  | 2,669.2 | \nDiluted net earnings per share |  | $ | 1.96 |  |  | 1.80 |  |  | 1.93 |  |  | 3.73 |   |  |  |  |  |  |  |  | \n\n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Second Quarter Ended |  | Fiscal Six Months Ended\n(Dollars in Millions) |  | July 2,2023 |  | July 3,2022 |  | PercentChange |  | July 2,2023 |  | July 3,2022 |  | Percent Change\n |  |  |  |  |  |  |  |  |  |  |  | \nCONSUMER HEALTH |  |  |  |  |  |  |  |  |  |  |  | \nOTC |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | $ | 712 |  |  | 663 |  |  | 7.5 | % |  | $ | 1,457 |  |  | 1,333 |  |  | 9.3 | %\nInternational |  | 947 |  |  | 818 |  |  | 15.7 |  |  | 1,844 |  |  | 1,609 |  |  | 14.6 | \nWorldwide |  | 1,659 |  |  | 1,482 |  |  | 12.0 |  |  | 3,301 |  |  | 2,943 |  |  | 12.2 | \nSkin Health/Beauty |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 650 |  |  | 629 |  |  | 3.4 |  |  | 1,267 |  |  | 1,173 |  |  | 8.0 | \nInternational |  | 498 |  |  | 497 |  |  | 0.3 |  |  | 991 |  |  | 965 |  |  | 2.7 | \nWorldwide |  | 1,148 |  |  | 1,126 |  |  | 2.0 |  |  | 2,258 |  |  | 2,138 |  |  | 5.6 | \nOral Care |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 173 |  |  | 170 |  |  | 1.7 |  |  | 332 |  |  | 313 |  |  | 6.2 | \nInternational |  | 225 |  |  | 224 |  |  | 0.3 |  |  | 427 |  |  | 447 |  |  | (4.7) | \nWorldwide |  | 398 |  |  | 394 |  |  | 0.9 |  |  | 759 |  |  | 760 |  |  | (0.2) | \nBaby Care |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 99 |  |  | 88 |  |  | 12.5 |  |  | 195 |  |  | 173 |  |  | 12.7 | \nInternational |  | 261 |  |  | 287 |  |  | (9.1) |  |  | 524 |  |  | 557 |  |  | (6.0) | \nWorldwide |  | 360 |  |  | 375 |  |  | (4.0) |  |  | 719 |  |  | 730 |  |  | (1.6) | \nWomen\u2019s Health |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 4 |  |  | 3 |  |  | (2.1) |  |  | 7 |  |  | 7 |  |  | (0.1) | \nInternational |  | 235 |  |  | 228 |  |  | 3.5 |  |  | 449 |  |  | 452 |  |  | (0.7) | \nWorldwide |  | 238 |  |  | 230 |  |  | 3.4 |  |  | 455 |  |  | 458 |  |  | (0.6) | \nWound Care/Other |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 149 |  |  | 133 |  |  | 12.3 |  |  | 264 |  |  | 245 |  |  | 7.9 | \nInternational |  | 58 |  |  | 65 |  |  | (10.3) |  |  | 107 |  |  | 117 |  |  | (8.4) | \nWorldwide |  | 207 |  |  | 197 |  |  | 4.9 |  |  | 371 |  |  | 361 |  |  | 2.6 | \nTOTAL CONSUMER HEALTH |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,787 |  |  | 1,687 |  |  | 6.0 |  |  | 3,522 |  |  | 3,244 |  |  | 8.6 | \nInternational |  | 2,224 |  |  | 2,118 |  |  | 5.0 |  |  | 4,341 |  |  | 4,147 |  |  | 4.7 | \nWorldwide |  | 4,011 |  |  | 3,805 |  |  | 5.4 |  |  | 7,863 |  |  | 7,391 |  |  | 6.4 | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPHARMACEUTICAL |  |  |  |  |  |  |  |  |  |  |  | \nImmunology |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 2,865 |  |  | 2,853 |  |  | 0.4 |  |  | 5,313 |  |  | 5,354 |  |  | (0.8) | \nInternational |  | 1,631 |  |  | 1,559 |  |  | 4.7 |  |  | 3,295 |  |  | 3,176 |  |  | 3.8 | \nWorldwide |  | 4,496 |  |  | 4,411 |  |  | 1.9 |  |  | 8,608 |  |  | 8,530 |  |  | 0.9 | \nREMICADE |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 277 |  |  | 391 |  |  | (29.3) |  |  | 553 |  |  | 749 |  |  | (26.2) | \nU.S. Exports |  | 33 |  |  | 44 |  |  | (24.9) |  |  | 74 |  |  | 124 |  |  | (40.3) | \nInternational |  | 152 |  |  | 212 |  |  | (28.2) |  |  | 322 |  |  | 437 |  |  | (26.2) | \nWorldwide |  | 462 |  |  | 647 |  |  | (28.6) |  |  | 949 |  |  | 1,310 |  |  | (27.5) | \nSIMPONI / SIMPONI ARIA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 285 |  |  | 301 |  |  | (5.1) |  |  | 556 |  |  | 588 |  |  | (5.4) | \nInternational |  | 244 |  |  | 266 |  |  | (8.2) |  |  | 510 |  |  | 549 |  |  | (7.1) | \nWorldwide |  | 529 |  |  | 566 |  |  | (6.6) |  |  | 1,066 |  |  | 1,137 |  |  | (6.2) | \nSTELARA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,817 |  |  | 1,731 |  |  | 4.9 |  |  | 3,268 |  |  | 3,110 |  |  | 5.1 | \nInternational |  | 981 |  |  | 868 |  |  | 13.0 |  |  | 1,974 |  |  | 1,777 |  |  | 11.1 | \nWorldwide |  | 2,797 |  |  | 2,599 |  |  | 7.6 |  |  | 5,241 |  |  | 4,887 |  |  | 7.2 | \nTREMFYA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 450 |  |  | 382 |  |  | 17.8 |  |  | 856 |  |  | 773 |  |  | 10.7 | \nInternational |  | 255 |  |  | 214 |  |  | 19.4 |  |  | 489 |  |  | 413 |  |  | 18.4 | \nWorldwide |  | 706 |  |  | 597 |  |  | 18.3 |  |  | 1,346 |  |  | 1,187 |  |  | 13.4 | \nOTHER IMMUNOLOGY |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 4 |  |  | 3 |  |  | 17.8 |  |  | 7 |  |  | 9 |  |  | (30.2) | \nInternational |  | 0 |  | 0 |  | \u2014 |  |  | 0 |  | 0 |  | \u2014\nWorldwide |  | 4 |  |  | 3 |  |  | 17.8 |  |  | 7 |  |  | 9 |  |  | (30.2) | \n |  |  |  |  |  |  |  |  |  |  |  | \nInfectious Diseases |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 395 |  |  | 415 |  |  | (4.9) |  |  | 787 |  |  | 876 |  |  | (10.2) | \nInternational |  | 727 |  |  | 901 |  |  | (19.4) |  |  | 1,920 |  |  | 1,737 |  |  | 10.5 | \nWorldwide |  | 1,121 |  |  | 1,316 |  |  | (14.8) |  |  | 2,707 |  |  | 2,613 |  |  | 3.6 | \nCOVID-19 VACCINE |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | \u2014 |  |  | 45 |  |  | * |  | \u2014 |  |  | 120 |  |  | *\nInternational |  | 285 |  |  | 499 |  |  | (43.0) |  |  | 1,032 |  |  | 881 |  |  | 17.1\nWorldwide |  | 285 |  |  | 544 |  |  | (47.7) |  |  | 1,032 |  |  | 1,001 |  |  | 3.0\nEDURANT / rilpivirine |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 8 |  |  | 9 |  |  | (9.0) |  |  | 17 |  |  | 18 |  |  | (5.3) | \nInternational |  | 258 |  |  | 215 |  |  | 19.9 |  |  | 529 |  |  | 454 |  |  | 16.4 | \nWorldwide |  | 266 |  |  | 225 |  |  | 18.6 |  |  | 546 |  |  | 473 |  |  | 15.6 | \nPREZISTA / PREZCOBIX /REZOLSTA / SYMTUZA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 382 |  |  | 355 |  |  | 7.6 |  |  | 760 |  |  | 724 |  |  | 5.0 | \nInternational |  | 109 |  |  | 110 |  |  | (0.2) |  |  | 208 |  |  | 242 |  |  | (13.9) | \nWorldwide |  | 491 |  |  | 464 |  |  | 5.8 |  |  | 968 |  |  | 965 |  |  | 0.3 | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nOTHER INFECTIOUS DISEASES |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 5 |  |  | 6 |  |  | (27.2) |  |  | 10 |  |  | 14 |  |  | (30.6) | \nInternational |  | 74 |  |  | 77 |  |  | (3.5) |  |  | 151 |  |  | 160 |  |  | (5.6) | \nWorldwide |  | 79 |  |  | 83 |  |  | (5.2) |  |  | 161 |  |  | 174 |  |  | (7.6) | \n |  |  |  |  |  |  |  |  |  |  |  | \nNeuroscience |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,029 |  |  | 896 |  |  | 14.9 |  |  | 2,007 |  |  | 1,739 |  |  | 15.4 | \nInternational |  | 764 |  |  | 837 |  |  | (8.8) |  |  | 1,590 |  |  | 1,735 |  |  | (8.4) | \nWorldwide |  | 1,793 |  |  | 1,734 |  |  | 3.5 |  |  | 3,597 |  |  | 3,475 |  |  | 3.5 | \nCONCERTA / methylphenidate |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 64 |  |  | 38 |  |  | 68.2 |  |  | 134 |  |  | 73 |  |  | 84.0 | \nInternational |  | 143 |  |  | 123 |  |  | 16.3 |  |  | 279 |  |  | 245 |  |  | 13.9 | \nWorldwide |  | 208 |  |  | 161 |  |  | 28.6 |  |  | 414 |  |  | 318 |  |  | 30.0 | \nINVEGA SUSTENNA / XEPLION / INVEGA   TRINZA / TREVICTA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 721 |  |  | 691 |  |  | 4.3 |  |  | 1,434 |  |  | 1,352 |  |  | 6.0 | \nInternational |  | 310 |  |  | 362 |  |  | (14.4) |  |  | 641 |  |  | 749 |  |  | (14.5) | \nWorldwide |  | 1,031 |  |  | 1,054 |  |  | (2.1) |  |  | 2,075 |  |  | 2,102 |  |  | (1.3) | \nSPRAVATO |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 144 |  |  | 74 |  |  | 93.2 |  |  | 255 |  |  | 135 |  |  | 88.3 | \nInternational |  | 25 |  |  | 11 |  |  | * |  | 45 |  |  | 20 |  |  | *\nWorldwide |  | 169 |  |  | 85 |  |  | 98.2 |  |  | 300 |  |  | 155 |  |  | 93.1 | \nOTHER NEUROSCIENCE(1) |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 100 |  |  | 93 |  |  | 9.3 |  |  | 184 |  |  | 179 |  |  | 3.1 | \nInternational |  | 286 |  |  | 341 |  |  | (16.4) |  |  | 625 |  |  | 721 |  |  | (13.4) | \nWorldwide |  | 386 |  |  | 433 |  |  | (10.9) |  |  | 809 |  |  | 900 |  |  | (10.1) | \n |  |  |  |  |  |  |  |  |  |  |  | \nOncology |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 2,069 |  |  | 1,679 |  |  | 23.2 |  |  | 3,958 |  |  | 3,261 |  |  | 21.4 | \nInternational |  | 2,329 |  |  | 2,362 |  |  | (1.4) |  |  | 4,552 |  |  | 4,731 |  |  | (3.8) | \nWorldwide |  | 4,398 |  |  | 4,042 |  |  | 8.8 |  |  | 8,510 |  |  | 7,992 |  |  | 6.5 | \nCARVYKTI |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 114 |  |  | 24 |  |  | * |  | 184 |  |  | 24 |  |  | *\nInternational |  | 3 |  |  | \u2014 |  |  | * |  | 5 |  |  | \u2014 |  |  | *\nWorldwide |  | 117 |  |  | 24 |  |  | * |  | 189 |  |  | 24 |  |  | *\nDARZALEX |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,322 |  |  | 1,021 |  |  | 29.5 |  |  | 2,513 |  |  | 1,974 |  |  | 27.3 | \nInternational |  | 1,110 |  |  | 965 |  |  | 15.0 |  |  | 2,182 |  |  | 1,868 |  |  | 16.8 | \nWorldwide |  | 2,431 |  |  | 1,986 |  |  | 22.4 |  |  | 4,695 |  |  | 3,842 |  |  | 22.2 | \nERLEADA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 241 |  |  | 233 |  |  | 3.6 |  |  | 490 |  | 439 |  | 11.8 | \nInternational |  | 326 |  |  | 218 |  |  | 49.7 |  |  | 619 |  | 412 |  | 50.3 | \nWorldwide |  | 567 |  |  | 450 |  |  | 25.9 |  |  | 1,109 |  |  | 850 |  | 30.4 | \nIMBRUVICA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 262 |  |  | 349 |  |  | (24.9) |  |  | 532 |  |  | 719 |  |  | (26.0) | \nInternational |  | 579 |  |  | 620 |  |  | (6.7) |  |  | 1,136 |  |  | 1,288 |  |  | (11.8) | \nWorldwide |  | 841 |  |  | 970 |  |  | (13.2) |  |  | 1,668 |  |  | 2,008 |  |  | (16.9) | \nZYTIGA/abiraterone acetate |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 9 |  |  | 19 |  |  | (55.2) |  |  | 25 |  |  | 38 |  |  | (34.7) | \nInternational |  | 218 |  |  | 486 |  |  | (55.1) |  |  | 447 |  |  | 1,006 |  |  | (55.6) | \nWorldwide |  | 227 |  |  | 505 |  |  | (55.1) |  |  | 472 |  |  | 1,044 |  |  | (54.8) | \nOTHER ONCOLOGY |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 122 |  |  | 33 |  |  | * |  | 214 |  |  | 67 |  |  | *\nInternational |  | 92 |  |  | 72 |  |  | 27.8 |  |  | 162 |  |  | 156 |  |  | 3.6 | \nWorldwide |  | 214 |  |  | 106 |  |  | * |  | 376 |  |  | 224 |  |  | 68.0 | \n |  |  |  |  |  |  |  |  |  |  |  | \nPulmonary Hypertension |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 684 |  |  | 560 |  |  | 22.0 |  |  | 1,284 |  |  | 1,132 |  |  | 13.4 | \nInternational |  | 289 |  |  | 284 |  |  | 2.0 |  |  | 561 |  |  | 563 |  |  | (0.4) | \nWorldwide |  | 972 |  |  | 843 |  |  | 15.3 |  |  | 1,844 |  |  | 1,695 |  |  | 8.8 | \nOPSUMIT |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 328 |  |  | 265 |  |  | 23.7 |  |  | 601 |  |  | 538 |  |  | 11.6 | \nInternational |  | 179 |  |  | 173 |  |  | 3.4 |  |  | 346 |  |  | 343 |  |  | 0.9 | \nWorldwide |  | 507 |  |  | 438 |  |  | 15.7 |  |  | 947 |  |  | 881 |  |  | 7.5 | \nUPTRAVI |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 338 |  |  | 272 |  |  | 24.2 |  |  | 642 |  |  | 541 |  |  | 18.7 | \nInternational |  | 61 |  |  | 56 |  |  | 10.0 |  |  | 119 |  |  | 112 |  |  | 6.6 | \nWorldwide |  | 399 |  |  | 328 |  |  | 21.8 |  |  | 761 |  |  | 653 |  |  | 16.6 | \nOTHER PULMONARY HYPERTENSION |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 18 |  |  | 23 |  |  | (23.8) |  |  | 41 |  |  | 53 |  |  | (23.0) | \nInternational |  | 48 |  |  | 55 |  |  | (10.9) |  |  | 95 |  |  | 108 |  |  | (11.7) | \nWorldwide |  | 66 |  |  | 78 |  |  | (14.7) |  |  | 136 |  |  | 161 |  |  | (15.5) | \n |  |  |  |  |  |  |  |  |  |  |  | \nCardiovascular / Metabolism / Other |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 776 |  |  | 757 |  |  | 2.6 |  |  | 1,491 |  |  | 1,429 |  |  | 4.3 | \nInternational |  | 174 |  |  | 215 |  |  | (19.0) |  |  | 386 |  |  | 453 |  |  | (14.7) | \nWorldwide |  | 950 |  |  | 972 |  |  | (2.2) |  |  | 1,877 |  |  | 1,882 |  |  | (0.3) | \nXARELTO |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 637 |  |  | 609 |  |  | 4.7 |  |  | 1,215 |  |  | 1,117 |  |  | 8.8 | \nInternational |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nWorldwide |  | 637 |  |  | 609 |  |  | 4.7 |  |  | 1,215 |  |  | 1,117 |  |  | 8.8 | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nOTHER(2) |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 138 |  |  | 148 |  |  | (6.3) |  |  | 275 |  |  | 312 |  |  | (11.8) | \nInternational |  | 174 |  |  | 215 |  |  | (19.0) |  |  | 386 |  |  | 453 |  |  | (14.7) | \nWorldwide |  | 313 |  |  | 363 |  |  | (13.8) |  |  | 662 |  |  | 765 |  |  | (13.5) | \n |  |  |  |  |  |  |  |  |  |  |  | \nTOTAL PHARMACEUTICAL |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 7,818 |  |  | 7,159 |  |  | 9.2 |  |  | 14,841 |  |  | 13,791 |  |  | 7.6 | \nInternational |  | 5,913 |  |  | 6,158 |  |  | (4.0) |  |  | 12,303 |  |  | 12,395 |  |  | (0.7) | \nWorldwide |  | 13,731 |  |  | 13,317 |  |  | 3.1 |  |  | 27,144 |  |  | 26,186 |  |  | 3.7 | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nMEDTECH |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nInterventional Solutions |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 908 |  |  | 525 |  |  | 73.1 |  |  | 1,771 |  |  | 1,019 |  |  | 73.8 | \nInternational |  | 712 |  |  | 525 |  |  | 35.7 |  |  | 1,352 |  |  | 1,123 |  |  | 20.5 | \nWorldwide |  | 1,620 |  |  | 1,049 |  |  | 54.4 |  |  | 3,123 |  |  | 2,141 |  |  | 45.8 | \nELECTROPHYSIOLOGY |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 609 |  |  | 499 |  |  | 22.0 |  |  | 1,180 |  |  | 969 |  |  | 21.7 | \nInternational |  | 587 |  |  | 469 |  |  | 25.1 |  |  | 1,109 |  |  | 1,001 |  |  | 10.8 | \nWorldwide |  | 1,196 |  |  | 968 |  |  | 23.5 |  |  | 2,288 |  |  | 1,970 |  |  | 16.2 | \nABIOMED(3) |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 272 |  |  | \u2014 |  |  | * |  | 536 |  |  | \u2014 |  |  | *\nInternational |  | 59 |  |  | \u2014 |  |  | * |  | 119 |  |  | \u2014 |  |  | *\nWorldwide |  | 331 |  |  | \u2014 |  |  | * |  | 655 |  |  | \u2014 |  |  | *\nOTHER INTERVENTIONAL SOLUTIONS |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 27 |  |  | 26 |  |  | 4.5 |  |  | 55 |  |  | 51 |  |  | 10.8 | \nInternational |  | 67 |  |  | 56 |  |  | 20.0 |  |  | 125 |  |  | 121 |  |  | 2.8 | \nWorldwide |  | 93 |  |  | 81 |  |  | 15.1 |  |  | 180 |  |  | 171 |  |  | 5.1 | \nOrthopaedics |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,388 |  |  | 1,338 |  |  | 3.7 |  |  | 2,751 |  |  | 2,627 |  |  | 4.7 | \nInternational |  | 878 |  |  | 820 |  |  | 7.0 |  |  | 1,759 |  |  | 1,719 |  |  | 2.3 | \nWorldwide |  | 2,265 |  |  | 2,157 |  |  | 5.0 |  |  | 4,510 |  |  | 4,345 |  |  | 3.8 | \nHIPS |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 250 |  |  | 240 |  |  | 4.1 |  |  | 491 |  |  | 465 |  |  | 5.6 | \nInternational |  | 147 |  |  | 148 |  |  | (0.8) |  |  | 296 |  |  | 312 |  |  | (5.1) | \nWorldwide |  | 397 |  |  | 388 |  |  | 2.2 |  |  | 787 |  |  | 777 |  |  | 1.3 | \nKNEES |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 221 |  |  | 216 |  |  | 2.4 |  |  | 447 |  |  | 417 |  |  | 7.2 | \nInternational |  | 142 |  |  | 133 |  |  | 6.3 |  |  | 284 |  |  | 271 |  |  | 4.8 | \nWorldwide |  | 363 |  |  | 349 |  |  | 3.9 |  |  | 731 |  |  | 688 |  |  | 6.3 | \nTRAUMA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 483 |  |  | 464 |  |  | 4.3 |  |  | 974 |  |  | 939 |  |  | 3.7 | \nInternational |  | 255 |  |  | 232 |  |  | 9.9 |  |  | 522 |  |  | 505 |  |  | 3.2 | \nWorldwide |  | 739 |  |  | 696 |  |  | 6.1 |  |  | 1,496 |  |  | 1,444 |  |  | 3.6 | \nSPINE, SPORTS & OTHER |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 433 |  |  | 418 |  |  | 3.5 |  |  | 839 |  |  | 805 |  |  | 4.1 | \nInternational |  | 334 |  |  | 306 |  |  | 9.0 |  |  | 657 |  |  | 630 |  |  | 4.2 | \nWorldwide |  | 766 |  |  | 724 |  |  | 5.8 |  |  | 1,495 |  |  | 1,436 |  |  | 4.2 | \nSurgery |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,015 |  |  | 992 |  |  | 2.2 |  |  | 1,990 |  |  | 1,913 |  |  | 4.0 | \nInternational |  | 1,580 |  |  | 1,458 |  |  | 8.4 |  |  | 3,039 |  |  | 2,971 |  |  | 2.3 | \nWorldwide |  | 2,594 |  |  | 2,450 |  |  | 5.9 |  |  | 5,028 |  |  | 4,884 |  |  | 3.0 | \nADVANCED |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 466 |  |  | 454 |  |  | 2.7 |  |  | 910 |  |  | 871 |  |  | 4.5 | \nInternational |  | 757 |  |  | 702 |  |  | 7.8 |  |  | 1,430 |  |  | 1,431 |  |  | 0.0\nWorldwide |  | 1,222 |  |  | 1,156 |  |  | 5.8 |  |  | 2,340 |  |  | 2,302 |  |  | 1.7 | \nGENERAL |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 548 |  |  | 538 |  |  | 1.9 |  |  | 1,079 |  |  | 1,042 |  |  | 3.6 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nInternational |  | 823 |  |  | 756 |  |  | 8.9 |  |  | 1,608 |  |  | 1,540 |  |  | 4.5 | \nWorldwide |  | 1,372 |  |  | 1,294 |  |  | 6.0 |  |  | 2,688 |  |  | 2,582 |  |  | 4.1 | \nVision |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 529 |  |  | 496 |  |  | 6.6 |  |  | 1,087 |  |  | 1,017 |  |  | 6.9 | \nInternational |  | 778 |  |  | 745 |  |  | 4.6 |  |  | 1,521 |  |  | 1,481 |  |  | 2.7 | \nWorldwide |  | 1,308 |  |  | 1,241 |  |  | 5.4 |  |  | 2,608 |  |  | 2,498 |  |  | 4.4 | \nCONTACT LENSES / OTHER |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 409 |  |  | 374 |  |  | 9.1 |  |  | 853 |  |  | 774 |  |  | 10.1 | \nInternational |  | 530 |  |  | 519 |  |  | 2.2 |  |  | 1,039 |  |  | 1,030 |  |  | 0.9 | \nWorldwide |  | 939 |  |  | 894 |  |  | 5.1 |  |  | 1,892 |  |  | 1,804 |  |  | 4.9 | \nSURGICAL |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 120 |  |  | 122 |  |  | (1.1) |  |  | 234 |  |  | 243 |  |  | (3.6) | \nInternational |  | 249 |  |  | 225 |  |  | 10.1 |  |  | 482 |  |  | 451 |  |  | 6.7 | \nWorldwide |  | 369 |  |  | 347 |  |  | 6.2 |  |  | 716 |  |  | 694 |  |  | 3.1 | \n |  |  |  |  |  |  |  |  |  |  |  | \nTOTAL MEDTECH |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 3,839 |  |  | 3,351 |  |  | 14.6 |  |  | 7,598 |  |  | 6,576 |  |  | 15.5 | \nInternational |  | 3,949 |  |  | 3,547 |  |  | 11.3 |  |  | 7,671 |  |  | 7,293 |  |  | 5.2 | \nWorldwide |  | 7,788 |  |  | 6,898 |  |  | 12.9 |  |  | 15,269 |  |  | 13,869 |  |  | 10.1 | \n |  |  |  |  |  |  |  |  |  |  |  | \nWORLDWIDE |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 13,444 |  |  | 12,197 |  |  | 10.2 |  |  | 25,961 |  |  | 23,611 |  |  | 10.0 | \nInternational |  | 12,086 |  |  | 11,823 |  |  | 2.2 |  |  | 24,315 |  |  | 23,835 |  |  | 2.0 | \nWorldwide |  | $ | 25,530 |  |  | 24,020 |  |  | 6.3 | % |  | $ | 50,276 |  |  | 47,446 |  |  | 6.0 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Second Quarter Ended |  | Fiscal Six Months Ended | \n(Dollars in Millions) |  | July 2,2023 |  | July 3,2022 |  | PercentChange |  | July 2,2023 |  | July 3,2022 |  | PercentChange |  |  |  |  | \nConsumer Health(1) |  | $ | 860 |  |  | 784 |  |  | 9.7 | % |  | $ | 1,636 |  |  | 1,470 |  |  | 11.3% |  |  |  |  | \nPharmaceutical(2) |  | 4,862 |  |  | 4,420 |  |  | 10.0 |  |  | 9,306 |  |  | 8,344 |  |  | 11.5 |  |  |  |  |  | \nMedTech(3) |  | 1,699 |  |  | 1,141 |  |  | 48.9 |  | 3,144 |  |  | 2,618 |  |  | 20.1 |  |  |  |  |  | \nSegment earnings before provision for taxes |  | 7,421 |  |  | 6,345 |  |  | 17.0 |  |  | 14,086 |  |  | 12,432 |  |  | 13.3 |  |  |  |  |  | \nLess: Expense not allocated to segments(4) |  | 377 |  |  | 237 |  |  |  |  | 7,479 |  |  | 360 |  |  |  |  |  |  |  | \nLess: Consumer Health separation costs |  | 282 |  |  | 268 |  |  |  |  | 582 |  |  | 370 |  |  |  |  |  |  |  | \nWorldwide income before tax |  | $ | 6,762 |  |  | 5,840 |  |  | 15.8% |  | $ | 6,025 |  |  | 11,702 |  |  | (48.5) | % |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Second Quarter Ended |  | Fiscal Six Months Ended\n(Dollars in Millions) |  | July 2, 2023 |  | July 3, 2022 |  | PercentChange |  | July 2, 2023 |  | July 3, 2022 |  | Percent Change\nUnited States |  | $ | 13,444 |  |  | 12,197 |  |  | 10.2 | % |  | $ | 25,961 |  |  | 23,611 |  |  | 10.0 | %\nEurope |  | 5,894 |  |  | 6,085 |  |  | (3.1) |  |  | 12,226 |  |  | 12,109 |  |  | 1.0 | \nWestern Hemisphere, excluding U.S. |  | 1,713 |  |  | 1,536 |  |  | 11.5 |  |  | 3,300 |  |  | 3,018 |  |  | 9.3 | \nAsia-Pacific, Africa |  | 4,479 |  |  | 4,202 |  |  | 6.6 |  |  | 8,789 |  |  | 8,708 |  |  | 0.9 | \nTotal |  | $ | 25,530 |  |  | 24,020 |  |  | 6.3 | % |  | $ | 50,276 |  |  | 47,446 |  |  | 6.0 | %  |  |  |  |  |  |  |  | \nProduct or product category |  | Number of Plaintiffs\nBody powders containing talc, primarily JOHNSON\u2019S Baby Powder |  | 40,480 | \nDePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System |  | 160 | \nPINNACLE Acetabular Cup System |  | 940 | \nPelvic meshes |  | 7,160 | \nETHICON PHYSIOMESH Flexible Composite Mesh |  | 910 | \nRISPERDAL |  | 240 | \nELMIRON |  | 2,130 | \nTYLENOL |  | 520 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | July 2, 2023 |  | July 3, 2022 |  | TotalChange |  | OperationsChange |  | CurrencyChange\nOTC |  | $ | 3,301 |  |  | $ | 2,943 |  |  | 12.2 | % |  | 14.8 | % |  | (2.6) | %\nSkin Health/Beauty |  | 2,258 |  |  | 2,138 |  |  | 5.6 |  |  | 8.0 |  |  | (2.4) | \nOral Care |  | 759 |  |  | 760 |  |  | (0.2) |  |  | 2.4 |  |  | (2.6) | \nBaby Care |  | 719 |  |  | 730 |  |  | (1.6) |  |  | 3.1 |  |  | (4.7) | \nWomen\u2019s Health |  | 455 |  |  | 458 |  |  | (0.6) |  |  | 7.1 |  |  | (7.7) | \nWound Care/Other |  | 371 |  |  | 361 |  |  | 2.6 |  |  | 4.9 |  |  | (2.3) | \nTotal Consumer Health Sales |  | $ | 7,863 |  |  | $ | 7,391 |  |  | 6.4 | % |  | 9.5 | % |  | (3.1) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | July 2, 2023 |  | July 3, 2022 |  | TotalChange |  | OperationsChange |  | CurrencyChange\nOTC |  | $ | 1,659 |  |  | $ | 1,482 |  |  | 12.0 | % |  | 13.9 | % |  | (1.9) | %\nSkin Health/Beauty |  | 1,148 |  |  | 1,126 |  |  | 2.0 |  |  | 3.5 |  |  | (1.5) | \nOral Care |  | 398 |  |  | 394 |  |  | 0.9 |  |  | 2.7 |  |  | (1.8) | \nBaby Care |  | 360 |  |  | 375 |  |  | (4.0) |  |  | (0.2) |  |  | (3.8) | \nWomen\u2019s Health |  | 238 |  |  | 230 |  |  | 3.4 |  |  | 10.0 |  |  | (6.6) | \nWound Care/Other |  | 207 |  |  | 197 |  |  | 4.9 |  |  | 6.8 |  |  | (1.9) | \nTotal Consumer Health Sales |  | $ | 4,011 |  |  | $ | 3,805 |  |  | 5.4 | % |  | 7.7 | % |  | (2.3) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | July 2, 2023 |  | July 3, 2022 |  | TotalChange |  | OperationsChange |  | CurrencyChange\nImmunology |  | $ | 8,608 |  |  | $ | 8,530 |  |  | 0.9 | % |  | 2.6 | % |  | (1.7) | %\nREMICADE |  | 949 |  |  | 1,310 |  |  | (27.5) |  |  | (26.3) |  |  | (1.2) | \nSIMPONI/ SIMPONI ARIA |  | 1,066 |  |  | 1,137 |  |  | (6.2) |  |  | (3.3) |  |  | (2.9) | \nSTELARA |  | 5,241 |  |  | 4,887 |  |  | 7.2 |  |  | 8.7 |  |  | (1.5) | \nTREMFYA |  | 1,346 |  |  | 1,187 |  |  | 13.4 |  |  | 15.0 |  |  | (1.6) | \nOther Immunology |  | 7 |  |  | 9 |  |  | (30.2) |  |  | (30.2) |  |  | \u2014 | \nInfectious Diseases |  | 2,707 |  |  | 2,613 |  |  | 3.6 |  |  | 4.7 |  |  | (1.1) | \nCOVID-19 VACCINE |  | 1,032 |  |  | 1,001 |  |  | 3.0 |  | 4.2 |  | (1.2)\nEDURANT/rilpivirine |  | 546 |  |  | 473 |  |  | 15.6 |  |  | 17.1 |  |  | (1.5) | \nPREZISTA/ PREZCOBIX/ REZOLSTA/ SYMTUZA |  | 968 |  |  | 965 |  |  | 0.3 |  |  | 0.7 |  |  | (0.4) | \nOther Infectious Diseases |  | 161 |  |  | 174 |  |  | (7.6) |  |  | (3.6) |  |  | (4.0) | \nNeuroscience |  | 3,597 |  |  | 3,475 |  |  | 3.5 |  |  | 5.8 |  |  | (2.3) | \nCONCERTA/methylphenidate |  | 414 |  |  | 318 |  |  | 30.0 |  |  | 35.3 |  |  | (5.3) | \nINVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA |  | 2,075 |  |  | 2,102 |  |  | (1.3) |  |  | 0.1 |  |  | (1.4) | \nSPRAVATO |  | 300 |  |  | 155 |  |  | 93.1 |  |  | 93.8 |  |  | (0.7) | \nOther Neuroscience(1) |  | 809 |  |  | 900 |  |  | (10.1) |  |  | (6.4) |  |  | (3.7) | \nOncology |  | 8,510 |  |  | 7,992 |  |  | 6.5 |  |  | 8.8 |  |  | (2.3) | \nCARVYKTI |  | 189 |  |  | 24 |  |  | * |  | * |  | *\nDARZALEX |  | 4,695 |  |  | 3,842 |  |  | 22.2 |  |  | 24.5 |  |  | (2.3) | \nERLEADA |  | 1,109 |  |  | 850 |  | 30.4 |  |  | 33.2 |  |  | (2.8) | \nIMBRUVICA |  | 1,668 |  |  | 2,008 |  |  | (16.9) |  |  | (15.0) |  |  | (1.9) | \nZYTIGA/ abiraterone acetate |  | 472 |  |  | 1,044 |  |  | (54.8) |  |  | (52.3) |  |  | (2.5) | \nOther Oncology |  | 376 |  |  | 224 |  |  | 68.0 |  |  | 70.4 |  |  | (2.4) | \nPulmonary Hypertension |  | 1,844 |  |  | 1,695 |  |  | 8.8 |  |  | 10.8 |  |  | (2.0) | \nOPSUMIT |  | 947 |  |  | 881 |  |  | 7.5 |  |  | 9.5 |  |  | (2.0) | \nUPTRAVI |  | 761 |  |  | 653 |  |  | 16.6 |  |  | 17.5 |  |  | (0.9) | \nOther Pulmonary Hypertension |  | 136 |  |  | 161 |  |  | (15.5) |  |  | (9.5) |  |  | (6.0) | \nCardiovascular / Metabolism / Other |  | 1,877 |  |  | 1,882 |  |  | (0.3) |  |  | 0.4 |  |  | (0.7) | \nXARELTO |  | 1,215 |  |  | 1,117 |  |  | 8.8 |  |  | 8.8 |  |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \nOther(2) |  | 662 |  |  | 765 |  |  | (13.5) |  |  | (11.9) |  |  | (1.6) | \nTotal Pharmaceutical Sales |  | $ | 27,144 |  |  | $ | 26,186 |  |  | 3.7 | % |  | 5.5 | % |  | (1.8) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | July 2, 2023 |  | July 3, 2022 |  | TotalChange |  | OperationsChange |  | CurrencyChange\nImmunology |  | $ | 4,496 |  |  | $ | 4,411 |  |  | 1.9 | % |  | 2.6 | % |  | (0.7) | %\nREMICADE |  | 462 |  |  | 647 |  |  | (28.6) |  |  | (27.6) |  |  | (1.0) | \nSIMPONI/ SIMPONI ARIA |  | 529 |  |  | 566 |  |  | (6.6) |  |  | (4.7) |  |  | (1.9) | \nSTELARA |  | 2,797 |  |  | 2,599 |  |  | 7.6 |  |  | 8.0 |  |  | (0.4) | \nTREMFYA |  | 706 |  |  | 597 |  |  | 18.3 |  |  | 18.9 |  |  | (0.6) | \nOther Immunology |  | 4 |  |  | 3 |  |  | 17.8 |  | 17.8 |  | \u2014\nInfectious Diseases |  | 1,121 |  |  | 1,316 |  |  | (14.8) |  |  | (16.6) |  |  | 1.8 | \nCOVID-19 VACCINE |  | 285 |  |  | 544 |  |  | (47.7) |  |  | (51.8) |  |  | 4.1 | \nEDURANT/rilpivirine |  | 266 |  |  | 225 |  |  | 18.6 |  |  | 16.2 |  |  | 2.4 | \nPREZISTA/ PREZCOBIX/ REZOLSTA/SYMTUZA |  | 491 |  |  | 464 |  |  | 5.8 |  |  | 5.6 |  |  | 0.2 | \nOther Infectious Diseases |  | 79 |  |  | 83 |  |  | (5.2) |  |  | 1.3 |  |  | (6.5) | \nNeuroscience |  | 1,793 |  |  | 1,734 |  |  | 3.5 |  | 5.5 |  |  | (2.0) | \nCONCERTA/ methylphenidate |  | 208 |  |  | 161 |  |  | 28.6 |  |  | 32.4 |  |  | (3.8) | \nINVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/TREVICTA |  | 1,031 |  |  | 1,054 |  |  | (2.1) |  |  | (1.5) |  |  | (0.6) | \nSPRAVATO |  | 169 |  |  | 85 |  |  | 98.2 |  |  | 98.5 |  |  | (0.3) | \nOther Neuroscience(1) |  | 386 |  |  | 433 |  |  | (10.9) |  |  | (5.8) |  |  | (5.1) | \nOncology |  | 4,398 |  |  | 4,042 |  |  | 8.8 |  |  | 9.7 |  |  | (0.9) | \nCARVYKTI |  | 117 |  |  | 24 |  |  | * |  | * |  | *\nDARZALEX |  | 2,431 |  |  | 1,986 |  |  | 22.4 |  |  | 23.4 |  |  | (1.0) | \nERLEADA |  | 567 |  |  | 450 |  |  | 25.9 |  |  | 26.9 |  |  | (1.0) | \nIMBRUVICA |  | 841 |  |  | 970 |  |  | (13.2) |  |  | (12.6) |  |  | (0.6) | \nZYTIGA/ abiraterone acetate |  | 227 |  |  | 505 |  |  | (55.1) |  |  | (53.8) |  |  | (1.3) | \nOther Oncology |  | 214 |  |  | 106 |  |  | * |  | * |  | *\nPulmonary Hypertension |  | 972 |  |  | 843 |  |  | 15.3 |  |  | 16.5 |  |  | (1.2) | \nOPSUMIT |  | 507 |  |  | 438 |  |  | 15.7 |  |  | 16.7 |  |  | (1.0) | \nUPTRAVI |  | 399 |  |  | 328 |  |  | 21.8 |  |  | 22.5 |  |  | (0.7) | \nOther Pulmonary Hypertension |  | 66 |  |  | 78 |  |  | (14.7) |  |  | (9.7) |  |  | (5.0) | \nCardiovascular / Metabolism / Other |  | 950 |  |  | 972 |  |  | (2.2) |  |  | (2.0) |  |  | (0.2) | \nXARELTO |  | 637 |  |  | 609 |  |  | 4.7 |  |  | 4.7 |  |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nOther(2) |  | 313 |  |  | 363 |  |  | (13.8) |  |  | (13.4) |  |  | (0.4) | \nTotal Pharmaceutical Sales |  | $ | 13,731 |  |  | $ | 13,317 |  |  | 3.1 | % |  | 3.8 | % |  | (0.7) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | July 2, 2023 |  | July 3, 2022 |  | TotalChange |  | OperationsChange |  | CurrencyChange\nSurgery |  | $ | 5,028 |  |  | $ | 4,884 |  |  | 3.0 | % |  | 6.3 | % |  | (3.3) | %\nAdvanced |  | 2,340 |  |  | 2,302 |  |  | 1.7 |  |  | 5.0 |  |  | (3.3) | \nGeneral |  | 2,688 |  |  | 2,582 |  |  | 4.1 |  |  | 7.4 |  |  | (3.3) | \nOrthopaedics |  | 4,510 |  |  | 4,345 |  |  | 3.8 |  |  | 5.4 |  |  | (1.6) | \nHips |  | 787 |  |  | 777 |  |  | 1.3 |  |  | 2.8 |  |  | (1.5) | \nKnees |  | 731 |  |  | 688 |  |  | 6.3 |  |  | 7.9 |  |  | (1.6) | \nTrauma |  | 1,496 |  |  | 1,444 |  |  | 3.6 |  |  | 4.9 |  |  | (1.3) | \nSpine, Sports & Other |  | 1,495 |  |  | 1,436 |  |  | 4.2 |  |  | 6.1 |  |  | (1.9) | \nInterventional Solutions |  | 3,123 |  |  | 2,141 |  |  | 45.8 |  |  | 49.3 |  |  | (3.5) | \nElectrophysiology |  | 2,288 |  |  | 1,970 |  |  | 16.2 |  |  | 19.5 |  |  | (3.3) | \nAbiomed |  | 655 |  |  | \u2014 |  |  | * |  | * |  | *\nOther Interventional Solutions |  | 180 |  |  | 171 |  |  | 5.1 |  |  | 9.5 |  |  | (4.4) | \nVision |  | 2,608 |  |  | 2,498 |  |  | 4.4 |  |  | 7.2 |  |  | (2.8) | \nContact Lenses/Other |  | 1,892 |  |  | 1,804 |  |  | 4.9 |  |  | 8.0 |  |  | (3.1) | \nSurgical |  | 716 |  |  | 694 |  |  | 3.1 |  |  | 5.4 |  |  | (2.3) | \nTotal MedTech Sales |  | $ | 15,269 |  |  | $ | 13,869 |  |  | 10.1 | % |  | 12.8 | % |  | (2.7) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | July 2, 2023 |  | July 3, 2022 |  | TotalChange |  | OperationsChange |  | CurrencyChange\nSurgery |  | $ | 2,594 |  |  | $ | 2,450 |  |  | 5.9 | % |  | 8.4 | % |  | (2.5) | %\nAdvanced |  | 1,222 |  |  | 1,156 |  |  | 5.8 |  |  | 8.4 |  |  | (2.6) | \nGeneral |  | 1,372 |  |  | 1,294 |  |  | 6.0 |  |  | 8.4 |  |  | (2.4) | \nOrthopaedics |  | 2,265 |  |  | 2,157 |  |  | 5.0 |  |  | 5.7 |  |  | (0.7) | \nHips |  | 397 |  |  | 388 |  |  | 2.2 |  |  | 3.0 |  |  | (0.8) | \nKnees |  | 363 |  |  | 349 |  |  | 3.9 |  |  | 4.5 |  |  | (0.6) | \nTrauma |  | 739 |  |  | 696 |  |  | 6.1 |  |  | 6.5 |  |  | (0.4) | \nSpine, Sports & Other |  | 766 |  |  | 724 |  |  | 5.8 |  |  | 7.0 |  |  | (1.2) | \nInterventional Solutions |  | 1,620 |  |  | 1,049 |  |  | 54.4 |  |  | 56.9 |  |  | (2.5) | \nElectrophysiology |  | 1,196 |  |  | 968 |  |  | 23.5 |  |  | 25.9 |  |  | (2.4) | \nAbiomed |  | 331 |  |  | \u2014 |  |  | * |  | * |  | *\nOther Interventional Solutions |  | 93 |  |  | 81 |  |  | 15.1 |  |  | 18.8 |  |  | (3.7) | \nVision |  | 1,308 |  |  | 1,241 |  |  | 5.4 |  |  | 6.9 |  |  | (1.5) | \nContact Lenses/Other |  | 939 |  |  | 894 |  |  | 5.1 |  |  | 6.6 |  |  | (1.5) | \nSurgical |  | 369 |  |  | 347 |  |  | 6.2 |  |  | 7.6 |  |  | (1.4) | \nTotal MedTech Sales |  | $ | 7,788 |  |  | $ | 6,898 |  |  | 12.9 | % |  | 14.7 | % |  | (1.8) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nFiscal Six Months |  |  |  |  |  | \n(Dollars in Billions)(Income)/Expense |  | 2023 |  | 2022 |  | Change\nLitigation related(1) |  | $ | 6.8 |  |  | 0.4 |  |  | 6.4 | \n |  |  |  |  |  | \nConsumer Health separation costs |  | 0.5 |  |  | 0.4 |  |  | 0.1 | \nCOVID-19 Vaccine related exit costs |  | 0.4 |  |  | 0.0 |  |  | 0.4 | \nChanges in the fair value of securities |  | 0.1 |  |  | 0.5 |  |  | (0.4) | \nEmployee benefit plan related |  | (0.7) |  |  | (0.6) |  |  | (0.1) | \nOther(2) |  | 0.1 |  |  | (0.5) |  |  | 0.6 | \n |  |  |  |  |  | \n |  |  |  |  |  | \nTotal Other (Income) Expense, Net |  | $ | 7.2 |  |  | 0.2 |  |  | 7.0 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nFiscal Second Quarter |  |  |  |  |  | \n(Dollars in Billions)(Income)/Expense |  | 2023 |  | 2022 |  | Change\n |  |  |  |  |  | \nConsumer Health separation costs |  | $ | 0.2 |  |  | 0.3 |  |  | (0.1) | \nCOVID-19 Vaccine related exit costs |  | 0.2 |  |  | 0.0 |  |  | 0.2 | \nEmployee benefit plan related |  | (0.4) |  |  | (0.3) |  |  | (0.1) | \nLitigation related(1) |  | (0.1) |  |  | 0.4 |  |  | (0.5) | \nChanges in the fair value of securities |  | 0.0 |  | 0.1 |  |  | (0.1) | \nOther(2) |  | 0.0 |  | (0.2) |  |  | 0.2 | \n |  |  |  |  |  | \n |  |  |  |  |  | \nTotal Other (Income) Expense, Net |  | $ | (0.1) |  |  | 0.3 |  |  | (0.4) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Income Before Tax |  | Segment Sales |  | Percent of Segment Sales\n(Dollars in Millions) |  | July 2, 2023 |  | July 3, 2022 |  | July 2, 2023 |  | July 3, 2022 |  | July 2, 2023 |  | July 3, 2022\nConsumer Health |  | $ | 1,636 |  |  | $ | 1,470 |  |  | $ | 7,863 |  |  | $ | 7,391 |  |  | 20.8 | % |  | 19.9 | %\nPharmaceutical |  | 9,306 |  |  | 8,344 |  |  | 27,144 |  |  | 26,186 |  |  | 34.3 |  |  | 31.9 | \nMedTech |  | 3,144 |  |  | 2,618 |  |  | 15,269 |  |  | 13,869 |  |  | 20.6 |  |  | 18.9 | \nSegment earnings before tax |  | 14,086 |  |  | 12,432 |  |  | 50,276 |  |  | 47,446 |  |  | 28.0 |  |  | 26.2 | \nLess: Expenses not allocated to segments(1) |  | 7,479 |  |  | 360 |  |  |  |  |  |  |  |  | \nLess: Consumer Health separation costs |  | 582 |  |  | 370 |  |  |  |  |  |  |  |  | \nWorldwide income before tax |  | $ | 6,025 |  |  | $ | 11,702 |  |  | $ | 50,276 |  |  | $ | 47,446 |  |  | 12.0 | % |  | 24.7 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Income Before Tax |  | Segment Sales |  | Percent of Segment Sales\n(Dollars in Millions) |  | July 2, 2023 |  | July 3, 2022 |  | July 2, 2023 |  | July 3, 2022 |  | July 2, 2023 |  | July 3, 2022\nConsumer Health |  | $ | 860 |  |  | $ | 784 |  |  | $ | 4,011 |  |  | $ | 3,805 |  |  | 21.4 | % |  | 20.6 | %\nPharmaceutical |  | 4,862 |  |  | 4,420 |  |  | 13,731 |  |  | 13,317 |  |  | 35.4 |  |  | 33.2 | \nMedTech |  | 1,699 |  |  | 1,141 |  |  | 7,788 |  |  | 6,898 |  |  | 21.8 |  |  | 16.5 | \nSegment earnings before tax |  | 7,421 |  |  | 6,345 |  |  | 25,530 |  |  | 24,020 |  |  | 29.1 |  |  | 26.4 | \nLess: Expenses not allocated to segments(1) |  | 377 |  |  | 237 |  |  |  |  |  |  |  |  | \nLess: Consumer Health separation costs |  | 282 |  |  | 268 |  |  |  |  |  |  |  |  | \nWorldwide income before tax |  | $ | 6,762 |  |  | $ | 5,840 |  |  | $ | 25,530 |  |  | $ | 24,020 |  |  | 26.5 | % |  | 24.3 | %  |  |  |  |  | \n(Dollars In Billions) | \n$ | 14.1 |  | Q4 2022 Cash and cash equivalents balance\n7.4 |  | net cash generated from operating activities\n(0.5) |  | net cash used by investing activities\n0.1 |  | net cash generated from financing activities\n0.1 |  | rounding\n | \n | \n$ | 21.2 |  | Q2 2023 Cash and cash equivalents  |  |  |  |  | \n(Dollars In Billions) | \n$ | 5.1 |  | Net earnings\n2.5 |  | non-cash expenses and other adjustments primarily for depreciation and amortization, stock-based compensation and asset write-downs partially offset by the deferred tax provision and net gain on sale of assets/businesses\n | \n(1.3) |  | an increase in accounts receivable and inventories\n | \n(1.1) |  | a decrease in accounts payable and accrued liabilities\n(1.1) |  | an increase in other current and non-current assets\n3.4 |  | an increase in other current and non-current liabilities\n(0.1) |  | Rounding\n$ | 7.4 |  | Cash Flow from operations  |  |  |  |  | \n(Dollars In Billions) | \n(2.0) |  | additions to property, plant and equipment\n0.1 |  | proceeds from the disposal of assets/businesses, net\n | \n2.2 |  | net sales of investments\n(0.8) |  | credit support agreements activity, net and other\n | \n | \n$ | (0.5) |  | Net cash used by investing activities  |  |  |  |  | \n(Dollars In Billions) | \n$ | (6.0) |  | dividends to shareholders\n(3.9) |  | repurchase of common stock\n(1.9) |  | net repayment of short and long term debt and other\n7.7 |  | proceeds from Kenvue long term debt, net of issuance cost\n | \n | \n4.2 |  | proceeds from Kenvue initial public offering\n | \n$ | 0.1 |  | Net cash from financing activities  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nFiscal Month Period |  | Total Numberof Shares Purchased(1) |  | Avg. PricePer Share |  | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs(2) |  | Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs\nApril 3, 2023 through April 30, 2023 |  | 1,011,500 |  |  | 162.35 |  |  | \u2014 |  |  | \u2014\nMay 1, 2023 through May 28, 2023 |  | 383,500 |  |  | 161.73 |  |  | \u2014 |  |  | \u2014\nMay 29, 2023 through July 2, 2023 |  | 962,825 |  |  | 160.35 |  |  | \u2014 |  |  | \u2014\nTotal |  | 2,357,825 |  |  | 161.44 |  |  | \u2014 |  |  | \u2014  |  |  |  |  |  |  |  | \nEX-101.INS |  | Instance Document - the instance document does not appear in the Interactive Data File because its                XBRL tags are embedded within the Inline XBRL document\nEX-101.SCH |  | Inline XBRL Taxonomy Extension Schema\nEX-101.CAL |  | Inline XBRL Taxonomy Extension Calculation Linkbase\nEX-101.LAB |  | Inline XBRL Taxonomy Extension Label Linkbase\nEX-101.PRE |  | Inline XBRL Taxonomy Extension Presentation Linkbase\nEX-101.DEF |  | Inline XBRL Taxonomy Extension Definition Document\n |  | \nExhibit 104: |  | Cover Page Interactive Data File\u2013\u2013the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.\n |  |   |  |  |  |  | \n | JOHNSON & JOHNSON(Registrant)\n | \nDate: July\u00a031, 2023 | By /s/ J. J. WOLK\n | J. J. WOLK\n | Executive Vice President, Chief Financial Officer (Principal Financial Officer)\n | \nDate: July\u00a031, 2023 | By /s/\u00a0R. J. DECKER Jr.\n | R. J. DECKER Jr.\n | Controller (Principal Accounting Officer)"}]}
{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For Johnson and Johnson, in 2023 Q3, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  |  |  |  |  |  |  |  |  |  |  |  |  | \n  |  |  |  |  |  |  |  | \n |  | \n\u2611 |  | Quarterly Report Pursuant to Section\u00a013 or 15(d) of the Securities Exchange Act of 1934  |  |  |  |  |  |  |  | \n |  | \n\u2610 |  | Transition Report Pursuant to Section\u00a013 or 15(d) of the Securities Exchange Act of 1934for the transition period from\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0to  |  |  |  |  |  |  |  | \nNew Jersey |  | 22-1024240\n(State or other jurisdiction ofincorporation or organization) |  | (I.R.S. EmployerIdentification No.)  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Large accelerated filer | \u2611 | Accelerated filer | \u2610\n | Non-accelerated filer | \u2610 | Smaller reporting company | \u2610\n | Emerging growth company | \u2610 |  |   |  |  |  |  |  |  |  | \nTitle of each class | Trading Symbol | Name of each exchange on which registered\nCommon Stock, Par Value $1.00 | JNJ | New York Stock Exchange\n0.650% Notes Due May 2024 | JNJ24C | New York Stock Exchange\n5.50% Notes Due November 2024 | JNJ24BP | New York Stock Exchange\n1.150% Notes Due November 2028 | JNJ28 | New York Stock Exchange\n1.650% Notes Due May 2035 | JNJ35 | New York Stock Exchange  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Page\n |  |  | No.\nPart I \u2014 Financial Information |  |  | 1\n |  |  | \nItem\u00a01. Financial Statements (unaudited) |  |  | 1\n |  |  | \nConsolidated Balance Sheets \u2014October1, 2023 and January 1, 2023 |  |  | 1\n |  |  | \nConsolidated Statements of Earnings for the FiscalThirdQuarters EndedOctober1, 2023 andOctober2, 2022 |  |  | 2\n |  |  | \nConsolidated Statements of Earnings for the FiscalNineMonths EndedOctober1, 2023 andOctober2, 2022 |  |  | 3\n |  |  | \nConsolidated Statements of Comprehensive Income for the FiscalThirdQuarters and FiscalNineMonths EndedOctober1, 2023 andOctober2, 2022 |  |  | 4\n |  |  | \nConsolidated Statements of Equity for the FiscalThirdQuarters and FiscalNineMonths EndedOctober1, 2023 andOctober2, 2022 |  |  | 5\n |  |  | \nConsolidated Statements of Cash Flows for the FiscalNineMonths EndedOctober1, 2023 andOctober2, 2022 |  |  | 7\n |  |  | \nNotes to Consolidated Financial Statements |  |  | 9\n |  |  | \n |  |  | \n |  |  | \nItem\u00a02. Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations |  |  | 43\n |  |  | \nItem\u00a03. Quantitative and Qualitative Disclosures About Market Risk |  |  | 58\n |  |  | \nItem\u00a04. Controls and Procedures |  |  | 58\n |  |  | \nPart II \u2014 Other Information |  |  | 59\n |  |  | \nItem\u00a01 - Legal Proceedings |  |  | 59\n |  |  | \nItem\u00a02 - Unregistered Sales of Equity Securities and Use of Proceeds |  |  | 59\n |  |  | \nItem 5 - Other Information |  |  | 59\n |  |  | \nItem\u00a06 - Exhibits |  |  | 60\n |  |  | \nSignatures |  |  | 61\n\n\n\n\n\n\n\n  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | October 1, 2023 |  | January 1, 2023\nASSETS\nCurrent assets: |  |  |  | \nCash and cash equivalents (Note 4) |  | $ | 19,728 |  |  | 12,889 | \n |  |  |  | \nMarketable securities |  | 3,783 |  |  | 9,392 | \nAccounts receivable, trade, less allowances $160(2022, $169) |  | 14,798 |  |  | 14,039 | \nInventories (Note 2) |  | 11,198 |  |  | 10,268 | \nPrepaid expenses and other |  | 4,196 |  |  | 2,876 | \nCurrent assets of discontinued operations (Note 12) |  | \u2014 |  |  | 5,830 | \nTotal current assets |  | 53,703 |  |  | 55,294 | \nProperty, plant and equipment at cost |  | 45,626 |  |  | 43,534 | \nLess: accumulated depreciation |  | (26,805) |  |  | (25,552) | \nProperty, plant and equipment, net |  | 18,821 |  |  | 17,982 | \nIntangible assets, net (Note 3) |  | 35,021 |  |  | 38,489 | \nGoodwill (Note 3) |  | 36,124 |  |  | 36,047 | \nDeferred taxes on income (Note 5) |  | 9,259 |  |  | 8,947 | \nOther assets |  | 13,133 |  |  | 9,212 | \nNoncurrent assets of discontinued operations (Note 12) |  | \u2014 |  |  | 21,407\nTotal assets |  | $ | 166,061 |  |  | 187,378 | \nLIABILITIES AND SHAREHOLDERS\u2019 EQUITY\nCurrent liabilities: |  |  |  | \nLoans and notes payable |  | $ | 3,870 |  |  | 12,756 | \nAccounts payable |  | 8,355 |  |  | 9,889 | \nAccrued liabilities |  | 10,101 |  |  | 10,719 | \nAccrued rebates, returns and promotions |  | 15,808 |  |  | 13,579 | \nAccrued compensation and employee related obligations |  | 3,337 |  |  | 3,049 | \nAccrued taxes on income (Note 5) |  | 2,899 |  |  | 2,220 | \nCurrent liabilities of discontinued operations (Note 12) |  | \u2014 |  |  | 3,590\nTotal current liabilities |  | 44,370 |  |  | 55,802 | \nLong-term debt (Note 4) |  | 26,051 |  |  | 26,886 | \nDeferred taxes on income (Note 5) |  | 2,623 |  |  | 3,991 | \nEmployee related obligations (Note 6) |  | 5,687 |  |  | 6,542 | \nLong-term taxes payable (Note 5) |  | 2,540 |  |  | 4,306 | \nOther liabilities |  | 13,562 |  |  | 10,146 | \nNoncurrent liabilities of discontinued operations (Note 12) |  | \u2014 |  |  | 2,901 | \nTotal liabilities |  | $ | 94,833 |  |  | 110,574 | \nCommitments and Contingencies (Note 11) |  |  |  | \nShareholders\u2019 equity: |  |  |  | \nCommon stock \u2014 par value $1.00per share (authorized4,320,000,000shares; issued3,119,843,000shares) |  | $ | 3,120 |  |  | 3,120 | \nAccumulated other comprehensive income (loss) (Note 7) |  | (8,780) |  |  | (12,967) | \nRetained earnings and Additional paid-in capital |  | 152,536 |  |  | 128,345 | \nLess: common stock held in treasury, at cost (712,665,000and506,246,000shares) |  | 75,648 |  |  | 41,694 | \nTotal shareholders\u2019 equity |  | $ | 71,228 |  |  | 76,804 | \nTotal liabilities and shareholders\u2019 equity |  | $ | 166,061 |  |  | 187,378 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Third Quarter Ended\n |  | October 1,2023 |  | Percentto Sales |  | October 2,2022 |  | Percentto Sales\nSales to customers (Note 9) |  | $ | 21,351 |  |  | 100.0 | % |  | $ | 19,996 |  |  | 100.0 | %\nCost of products sold |  | 6,606 |  |  | 30.9 |  |  | 6,172 |  |  | 30.9 | \nGross profit |  | 14,745 |  |  | 69.1 |  |  | 13,824 |  |  | 69.1 | \nSelling, marketing and administrative expenses |  | 5,400 |  |  | 25.3 |  |  | 4,975 |  |  | 24.9 | \nResearch and development expense |  | 3,447 |  |  | 16.2 |  |  | 3,485 |  |  | 17.4 | \nIn-process research and development impairments |  | 206 |  |  | 1.0 |  |  | \u2014 |  |  | \u2014 | \nInterest income |  | (374) |  |  | (1.7) |  |  | (150) |  |  | (0.8) | \nInterest expense, net of portion capitalized |  | 192 |  |  | 0.9 |  |  | 51 |  |  | 0.3 | \nOther (income) expense, net |  | 499 |  |  | 2.3 |  |  | 226 |  |  | 1.1 | \nRestructuring |  | 158 |  |  | 0.7 |  |  | 65 |  |  | 0.3 | \nEarnings before provision for taxes on income |  | 5,217 |  |  | 24.4 |  |  | 5,172 |  |  | 25.9 | \nProvision for taxes on income (Note\u00a05) |  | 908 |  |  | 4.2 |  |  | 862 |  |  | 4.3 | \nNet earnings from continuing operations |  | 4,309 |  |  | 20.2 | % |  | 4,310 |  |  | 21.6 | %\nNet earnings from discontinued operations, net of tax (Note 12) |  | 21,719 |  |  |  |  | 148 |  |  | \nNET EARNINGS |  | $ | 26,028 |  |  |  |  | $ | 4,458 |  |  | \n |  |  |  |  |  |  |  | \nNET EARNINGS PER SHARE (Note 8) |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \nContinuing operations - basic |  | $ | 1.71 |  |  |  |  | $ | 1.64 |  |  | \nDiscontinued operations - basic |  | $ | 8.61 |  |  |  |  | $ | 0.06 |  |  | \nTotal net earnings per share - basic |  | $ | 10.32 |  |  |  |  | $ | 1.70 |  |  | \n |  |  |  |  |  |  |  | \nContinuing operations - diluted |  | $ | 1.69 |  |  |  |  | $ | 1.62 |  |  | \nDiscontinued operations - diluted |  | $ | 8.52 |  |  |  |  | $ | 0.06 |  |  | \nTotal net earnings per share - diluted |  | $ | 10.21 |  |  |  |  | $ | 1.68 |  |  | \n |  |  |  |  |  |  |  | \nAVG. SHARES OUTSTANDING |  |  |  |  |  |  |  | \nBasic |  | 2,522.9 |  |  |  |  | 2,627.9 |  |  | \nDiluted |  | 2,549.7 |  |  |  |  | 2,661.3 |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Nine Months Ended\n |  | October 1,2023 |  | Percentto Sales |  | October 2,2022 |  | Percentto Sales\nSales to customers (Note 9) |  | $ | 63,764 |  |  | 100.0 | % |  | $ | 60,051 |  |  | 100.0 | %\nCost of products sold |  | 19,755 |  |  | 31.0 |  |  | 18,512 |  |  | 30.8 | \nGross profit |  | 44,009 |  |  | 69.0 |  |  | 41,539 |  |  | 69.2 | \nSelling, marketing and administrative expenses |  | 15,702 |  |  | 24.6 |  |  | 14,907 |  |  | 24.8 | \nResearch and development expense |  | 10,605 |  |  | 16.6 |  |  | 10,425 |  |  | 17.4 | \nIn-process research and development impairments |  | 255 |  |  | 0.4 |  |  | 610 |  | 1.0 | \nInterest income |  | (898) |  |  | (1.4) |  |  | (236) |  |  | (0.4) | \nInterest expense, net of portion capitalized |  | 621 |  |  | 1.0 |  |  | 99 |  |  | 0.2 | \nOther (income) expense, net |  | 7,055 |  |  | 11.1 |  |  | 15 |  |  | 0.0 | \nRestructuring |  | 433 |  |  | 0.6 |  |  | 200 |  |  | 0.4 | \nEarnings before provision for taxes on income |  | 10,236 |  |  | 16.1 |  |  | 15,519 |  |  | 25.8 | \nProvision for taxes on income (Note\u00a05) |  | 1,042 |  |  | 1.7 |  |  | 2,376 |  |  | 3.9 | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \nNet earnings from continuing operations |  | 9,194 |  |  | 14.4 | % |  | 13,143 |  |  | 21.9 | %\nNet earnings from discontinued operations, net of tax (Note 12) |  | 21,910 |  |  |  |  | 1,278 |  |  | \nNET EARNINGS |  | $ | 31,104 |  |  |  |  | $ | 14,421 |  |  | \n |  |  |  |  |  |  |  | \nNET EARNINGS PER SHARE (Note 8) |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \nContinuing operations - basic |  | $ | 3.57 |  |  |  |  | $ | 5.00 |  |  | \nDiscontinued operations - basic |  | $ | 8.51 |  |  |  |  | $ | 0.49 |  |  | \nTotal net earnings per share - basic |  | $ | 12.08 |  |  |  |  | $ | 5.49 |  |  | \n |  |  |  |  |  |  |  | \nContinuing operations - diluted |  | $ | 3.53 |  |  |  |  | $ | 4.93 |  |  | \nDiscontinued operations - diluted |  | $ | 8.42 |  |  |  |  | $ | 0.48 |  |  | \nTotal net earnings per share - diluted |  | $ | 11.95 |  |  |  |  | $ | 5.41 |  |  | \n |  |  |  |  |  |  |  | \nAVG. SHARES OUTSTANDING |  |  |  |  |  |  |  | \nBasic |  | 2,575.6 |  |  |  |  | 2,628.9 |  |  | \nDiluted |  | 2,603.4 |  |  |  |  | 2,667.5 |  |  | \n |  |  |  |  |  |  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended\n | October 1, 2023 |  | October 2, 2022 |  | October 1, 2023 |  | October 2, 2022\n |  |  |  |  |  |  | \nNet earnings | $ | 26,028 |  |  | 4,458 |  |  | $ | 31,104 |  |  | 14,421 | \n |  |  |  |  |  |  | \nOther comprehensive income (loss), net of tax |  |  |  |  |  |  | \nForeign currency translation | 448 |  |  | (1,252) |  |  | (448) |  |  | (1,957) | \n |  |  |  |  |  |  | \nSecurities: |  |  |  |  |  |  | \nUnrealized holding gain (loss) arising during period | 4 |  |  | (2) |  |  | 25 |  |  | (35) | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \nNet change | 4 |  |  | (2) |  |  | 25 |  |  | (35) | \n |  |  |  |  |  |  | \nEmployee benefit plans: |  |  |  |  |  |  | \nPrior service cost amortization during period | (36) |  |  | (37) |  |  | (107) |  |  | (110) | \nGain (loss) amortization during period | (34) |  |  | 151 |  |  | (101) |  |  | 454 | \nConsumer settlement/curtailment | 33 |  |  | \u2014 |  |  | 33 |  |  | \u2014 | \nNet change | (37) |  |  | 114 |  |  | (175) |  |  | 344 | \n |  |  |  |  |  |  | \nDerivatives & hedges: |  |  |  |  |  |  | \nUnrealized gain (loss) arising during period | (513) |  |  | (204) |  |  | (80) |  |  | (254) | \nReclassifications to earnings | (180) |  |  | (105) |  |  | (316) |  |  | (332) | \nNet change | (693) |  |  | (309) |  |  | (396) |  |  | (586) | \n |  |  |  |  |  |  | \nOther comprehensive income (loss) | (278) |  |  | (1,449) |  |  | (994) |  |  | (2,234) | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \nComprehensive income | $ | 25,750 |  |  | 3,009 |  |  | $ | 30,110 |  |  | 12,187 | \n |  |  |  |  |  |  |   |  | \nThe tax effects in other comprehensive income/(loss) for the fiscal third quarter were as follows for 2023 and 2022, respectively: Foreign Currency Translation: $335million and $181million; Securities: $1million and $0million; Employee Benefit Plans: $8million and $33million; Derivatives & Hedges: $185million and $82million.\n\nThe tax effects in other comprehensive income/(loss) for the fiscal nine months were as follows for 2023 and 2022, respectively: Foreign Currency Translation: $69million and $859million; Securities: $7million and $9million; Employee Benefit Plans: $51million and $98million; Derivatives & Hedges: $105million and $155million.  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Total |  | RetainedEarnings and Additional paid-in capital |  | AccumulatedOtherComprehensiveIncome |  | Common StockIssued Amount |  | TreasuryStockAmount |  | Non-controlling interest (NCI) | \nBalance, July 2, 2023 | $ | 76,409 |  |  | 129,381 |  |  | (13,135) |  |  | 3,120 |  |  | (44,217) |  |  | 1,260 |  | \nNet earnings | 26,028 |  |  | 26,028 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  | \nCash dividends paid                   ($1.19per share) | (2,871) |  |  | (2,871) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  | \nEmployee compensation and stock option plans | 948 |  |  | 41 |  |  | \u2014 |  |  | \u2014 |  |  | 907 |  |  |  | \nRepurchase of common stock | (920) |  |  |  |  | \u2014 |  |  | \u2014 |  |  | (920) |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nKenvue Separation (Note 12) | (28,088) |  |  | (43) |  |  | 4,633 |  |  | \u2014 |  |  | (31,418) |  |  | (1,260) |  | \nOther comprehensive income (loss), net of tax | (278) |  |  | \u2014 |  |  | (278) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  | \nBalance, October 1, 2023 | $ | 71,228 |  |  | 152,536 |  |  | (8,780) |  |  | 3,120 |  |  | (75,648) |  |  | \u2014 |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n | Total |  | RetainedEarnings and Additional paid-in capital |  | AccumulatedOtherComprehensiveIncome |  | Common StockIssued Amount |  | TreasuryStockAmount |  | Non-controlling interest (NCI) | \nBalance, January 1, 2023 | $ | 76,804 |  |  | 128,345 |  |  | (12,967) |  |  | 3,120 |  |  | (41,694) |  |  | \u2014 |  | \nNet earnings | 31,104 |  |  | 31,104 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  | \nCash dividends paid ($3.51per share) | (8,905) |  |  | (8,905) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  | \nEmployee compensation and stock option plans | 1,892 |  |  | (435) |  |  | \u2014 |  |  | \u2014 |  |  | 2,327 |  |  | \u2014 |  | \nRepurchase of common stock | (4,838) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (4,838) |  |  | \u2014 |  | \nOther | (25) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (25) |  |  | \u2014 |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nKenvue Separation/IPO (Note 12) | (23,810) |  |  | 2,427 |  |  | 5,181 |  |  | \u2014 |  |  | (31,418) |  |  | \u2014 |  | \nOther comprehensive income (loss), net of tax | (994) |  |  | \u2014 |  |  | (994) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  | \nBalance, October 1, 2023 | $ | 71,228 |  |  | 152,536 |  |  | (8,780) |  |  | 3,120 |  |  | (75,648) |  |  | \u2014 |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Total |  | RetainedEarnings and Additional paid-in capital |  | AccumulatedOtherComprehensiveIncome |  | Common StockIssued Amount |  | TreasuryStockAmount\nBalance, July 3, 2022 | $ | 76,357 |  |  | 126,216 |  |  | (13,843) |  |  | 3,120 |  |  | (39,136) | \n |  |  |  |  |  |  |  |  | \nNet earnings | 4,458 |  |  | 4,458 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nCash dividends paid ($1.13per share) | (2,970) |  |  | (2,970) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nEmployee compensation and stock option plans | 368 |  |  | 213 |  |  | \u2014 |  |  | \u2014 |  |  | 155 | \nRepurchase of common stock | (2,165) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (2,165) | \n |  |  |  |  |  |  |  |  | \nOther comprehensive income (loss), net of tax | (1,449) |  |  | \u2014 |  |  | (1,449) |  |  | \u2014 |  |  | \u2014 | \nBalance, October 2, 2022 | $ | 74,599 |  |  | 127,917 |  |  | (15,292) |  |  | 3,120 |  |  | (41,146) | \n |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \nFiscal nine Months Ended October\u00a02, 2022\n | Total |  | RetainedEarnings and Additional paid-in capital |  | AccumulatedOtherComprehensiveIncome |  | Common StockIssued Amount |  | TreasuryStockAmount\nBalance, January 2, 2022 | $ | 74,023 |  |  | 123,060 |  |  | (13,058) |  |  | 3,120 |  |  | (39,099) | \n |  |  |  |  |  |  |  |  | \nNet earnings | 14,421 |  |  | 14,421 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nCash dividends paid ($3.32per share) | (8,728) |  |  | (8,728) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nEmployee compensation and stock option plans | 1,832 |  |  | (836) |  |  | \u2014 |  |  | \u2014 |  |  | 2,668 | \nRepurchase of common stock | (4,715) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (4,715) | \n |  |  |  |  |  |  |  |  | \nOther comprehensive income (loss), net of tax | (2,234) |  |  | \u2014 |  |  | (2,234) |  |  | \u2014 |  |  | \u2014 | \nBalance, October 2, 2022 | $ | 74,599 |  |  | 127,917 |  |  | (15,292) |  |  | 3,120 |  |  | (41,146) | \n |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Nine Months Ended\n |  | October 1,2023 |  | October 2,2022\nCASH FLOWS FROM OPERATING ACTIVITIES |  |  |  | \nNet earnings |  | $ | 31,104 |  |  | 14,421 | \nAdjustments to reconcile net earnings to cash flows from operating activities: |  |  |  | \nDepreciation and amortization of property and intangibles |  | 5,643 |  |  | 5,198 | \nStock based compensation |  | 984 |  |  | 925 | \n |  |  |  | \n |  |  |  | \nAsset write-downs |  | 820 |  |  | 787 | \n |  |  |  | \nGain on Kenvue separation |  | (20,984) |  |  | \u2014 | \nNet gain on sale of assets/businesses |  | (117) |  |  | (213) | \n |  |  |  | \nDeferred tax provision |  | (1,782) |  |  | (2,488) | \nCredit losses and accounts receivable allowances |  | \u2014 |  |  | (14) | \nChanges in assets and liabilities, net of effects from acquisitions and divestitures: |  |  |  | \nIncrease in accounts receivable |  | (851) |  |  | (1,591) | \nIncrease in inventories |  | (1,447) |  |  | (1,877) | \nIncrease in accounts payable and accrued liabilities |  | 664 |  |  | 141 | \n(Increase)/Decrease in other current and non-current assets |  | (1,366) |  |  | 4,563 | \nIncrease/(Decrease) in other current and non-current liabilities |  | 2,260 |  |  | (4,008) | \n |  |  |  | \nNET CASH FLOWS FROM OPERATING ACTIVITIES |  | 14,928 |  |  | 15,844 | \n |  |  |  | \nCASH FLOWS FROM INVESTING ACTIVITIES |  |  |  | \nAdditions to property, plant and equipment |  | (2,954) |  |  | (2,422) | \nProceeds from the disposal of assets/businesses, net (Note 10) |  | 237 |  |  | 322 | \nAcquisitions, net of cash acquired (Note 10) |  | \u2014 |  |  | (522) | \nPurchases of investments |  | (9,981) |  |  | (31,163) | \nSales of investments |  | 15,787 |  |  | 26,324 | \nCredit support agreements activity, net |  | (917) |  |  | (305) | \nOther (primarily licenses and milestones) |  | (92) |  |  | (208) | \n |  |  |  | \nNET CASH FROM (USED BY) INVESTING ACTIVITIES |  | 2,080 |  |  | (7,974) | \n |  |  |  | \nCASH FLOWS FROM FINANCING ACTIVITIES |  |  |  | \nDividends to shareholders |  | (8,905) |  |  | (8,728) | \nRepurchase of common stock |  | (4,838) |  |  | (4,715) | \nProceeds from short-term debt (Note 4) |  | 12,462 |  |  | 7,099 | \nRepayment of short-term debt |  | (21,645) |  |  | (4,808) | \nProceeds from long-term debt, net of issuance costs (Note 4) |  | \u2014 |  |  | 1 | \nRepayment of long-term debt |  | (502) |  |  | (2,133) | \nProceeds from the exercise of stock options/employee withholding tax on stock awards, net |  | 907 |  |  | 907 | \nCredit support agreements activity, net |  | 62 |  |  | 1,678 | \nProceeds of short and long-term debt, net of issuance cost, related to the debt that transferred to Kenvue at separation |  | 8,047 |  |  | \u2014 | \nProceeds from Kenvue initial public offering (Note 12) |  | 4,241 |  |  | \u2014 | \nCash transferred to Kenvue at separation |  | (1,114) |  |  | \u2014 | \nOther |  | 115 |  |  | 128 | \n |  |  |  | \nNET CASH USED BY FINANCING ACTIVITIES |  | (11,170) |  |  | (10,571) | \n |  |  |  | \n |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Nine Months Ended\n |  | October 1,2023 |  | October 2,2022\nEffect of exchange rate changes on cash and cash equivalents |  | (237) |  |  | (431) | \nIncrease/(Decrease) in cash and cash equivalents |  | 5,601 |  |  | (3,132) | \nCash and cash equivalents from continuing operations, beginning of period |  | 12,889 |  |  | 13,309 | \nCash and cash equivalents from discontinued operations, beginning of period |  | 1,238 |  |  | 1,178 | \nCash and Cash equivalents beginning of period |  | 14,127 |  |  | 14,487 | \n |  |  |  | \nCash and cash equivalents from continuing operations, end of period |  | 19,728 |  |  | 10,347 | \nCash and cash equivalents from discontinued operations, end of period |  | \u2014 |  |  | 1,008 | \nCASH AND CASH EQUIVALENTS, END OF PERIOD |  | $ | 19,728 |  |  | 11,355 | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \nAcquisitions |  |  |  | \nFair value of assets acquired |  | $ | \u2014 |  |  | 620 | \nFair value of liabilities assumed |  | \u2014 |  |  | (98) | \nNet cash paid for acquisitions |  | $ | \u2014 |  |  | 522 | \n |  |  |  | \n |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | October 1, 2023 |  | January 1, 2023\nRaw materials and supplies |  | $ | 2,233 |  |  | 1,719 | \nGoods in process |  | 1,961 |  |  | 1,577 | \nFinished goods |  | 7,004 |  |  | 6,972 | \nTotal inventories |  | $ | 11,198 |  |  | 10,268 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | October 1, 2023 |  | January 1, 2023\nIntangible assets with definite lives: |  |  |  | \nPatents and trademarks \u2014 gross |  | $ | 39,284 |  |  | 39,388 | \nLess accumulated amortization |  | (23,052) |  |  | (20,616) | \nPatents and trademarks \u2014 net |  | 16,232 |  |  | 18,772 | \nCustomer relationships and other intangibles \u2014 gross |  | 19,844 |  |  | 19,764 | \nLess accumulated amortization |  | (12,159) |  |  | (11,363) | \nCustomer relationships and other intangibles\u00a0\u2014 net(1) |  | 7,685 |  |  | 8,401 | \nIntangible assets with indefinite lives: |  |  |  | \nTrademarks |  | 1,640 |  |  | 1,630 | \nPurchased in-process research and development |  | 9,464 |  |  | 9,686 | \nTotal intangible assets with indefinite lives |  | 11,104 |  |  | 11,316 | \nTotal intangible assets \u2014 net |  | $ | 35,021 |  |  | 38,489 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  |  |  | Innovative Medicine |  | MedTech |  | Total\nGoodwill at January\u00a01, 2023 |  |  |  | $ | 10,184 |  |  | 25,863 |  |  | 36,047 | \nGoodwill, related to acquisitions |  |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nGoodwill, related to divestitures |  |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nCurrency translation/Other |  |  |  | (35) |  |  | 112 |  | * | 77 | \nGoodwill at October\u00a01, 2023 |  |  |  | $ | 10,149 |  |  | 25,975 |  |  | 36,124 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  |  |  |  |  | \n2023 |  | 2024 |  | 2025 |  | 2026 |  | 2027\n$4,500 |  | 4,300 |  | 3,500 |  | 2,900 |  | 2,300  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | October 1, 2023 | October 2, 2022\n(Dollars in Millions) | Sales | Cost of Products Sold | R&D Expense | Interest (Income) Expense | Other (Income)  Expense | Sales | Cost of Products Sold | R&D Expense | Interest (Income) Expense | Other (Income)  Expense\n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \nThe effects of fair value, net investment and cash flow hedging: |  |  |  |  |  |  |  |  |  | \nGain (Loss) on fair value hedging relationship: |  |  |  |  |  |  |  |  |  | \nInterest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nHedged items | $ | \u2014 |  | \u2014 |  | \u2014 |  | (61) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (322) |  | \u2014 | \nDerivatives designated as hedging instruments | \u2014 |  | \u2014 |  | \u2014 |  | 61 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 322 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nGain (Loss) on net investment hedging relationship: |  |  |  |  |  |  |  |  |  | \nCross currency interest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing | \u2014 |  | \u2014 |  | \u2014 |  | 31 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 13 |  | \u2014 | \nAmount of gain or (loss) recognized in AOCI | \u2014 |  | \u2014 |  | \u2014 |  | 31 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 13 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nGain (Loss) on cash flow hedging relationship: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) reclassified from AOCI into income | 6 |  | 102 |  | (5) |  | \u2014 |  | 4 |  | (20) |  | (83) |  | 53 |  | \u2014 |  | 22 | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in AOCI | (11) |  | (166) |  | 49 |  | \u2014 |  | 38 |  | (45) |  | (94) |  | 91 |  | \u2014 |  | 36 | \n |  |  |  |  |  |  |  |  |  | \nCross currency interest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) reclassified from AOCI into income | \u2014 |  | \u2014 |  | \u2014 |  | 41 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 120 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in AOCI | $ | \u2014 |  | \u2014 |  | \u2014 |  | (454) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (205) |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | October 1, 2023 | October 2, 2022\n(Dollars in Millions) | Sales | Cost of Products Sold | R&D Expense | Interest (Income) Expense | Other (Income)  Expense | Sales | Cost of Products Sold | R&D Expense | Interest (Income) Expense | Other (Income)  Expense\n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \nThe effects of fair value, net investment and cash flow hedging: |  |  |  |  |  |  |  |  |  | \nGain (Loss) on fair value hedging relationship: |  |  |  |  |  |  |  |  |  | \nInterest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nHedged items | $ | \u2014 |  | \u2014 |  | \u2014 |  | (1,165) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (1,094) |  | \u2014 | \nDerivatives designated as hedging instruments | \u2014 |  | \u2014 |  | \u2014 |  | 1,165 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 1,094 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nGain (Loss) on net investment hedging relationship: |  |  |  |  |  |  |  |  |  | \nCross currency interest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing | \u2014 |  | \u2014 |  | \u2014 |  | 98 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 102 |  | \u2014 | \nAmount of gain or (loss) recognized in AOCI | \u2014 |  | \u2014 |  | \u2014 |  | 98 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 102 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nGain (Loss) on cash flow hedging relationship: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) reclassified from AOCI into income | 3 |  | 12 |  | (30) |  | \u2014 |  | 9 |  | (54) |  | (141) |  | 118 |  | \u2014 |  | (35) | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in AOCI | (1) |  | 230 |  | 20 |  | \u2014 |  | 42 |  | (48) |  | (153) |  | 193 |  | \u2014 |  | (75) | \n |  |  |  |  |  |  |  |  |  | \nCross currency interest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) reclassified from AOCI into income | \u2014 |  | \u2014 |  | \u2014 |  | 223 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 342 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in AOCI | $ | \u2014 |  | \u2014 |  | \u2014 |  | (469) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (273) |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLine item in the Consolidated Balance Sheet in which the hedged item is included |  | Carrying Amount of the Hedged Liability |  | Cumulative Amount of Fair Value Hedging Gain/ (Loss)  Included in the Carrying Amount of the Hedged Liability\n |  | \n(Dollars in Millions) |  | October 1, 2023 |  | January 1, 2023 |  | October 1, 2023 |  | January 1, 2023\n |  |  |  |  |  |  |  | \nLong-term Debt |  | $ | 8,589 |  |  | 8,665 |  |  | (1,523) |  |  | (1,435) | \n |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | \n |  |  |  | Gain/(Loss)Recognized InIncome on Derivative | Gain/(Loss)Recognized InIncome on Derivative | \n(Dollars in Millions) |  | Location of Gain /(Loss) Recognized in Income on Derivative |  | Fiscal Third Quarter Ended | Fiscal Nine Months Ended | \nDerivatives Not Designated as Hedging Instruments |  |  |  | October 1, 2023 |  | October 2, 2022 | October 1, 2023 |  | October 2, 2022 | \nForeign Exchange Contracts |  | Other (income) expense |  | $ | \u2014 |  |  | 109 |  | 2 |  |  | 211 |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n\n |  | Gain/(Loss)Recognized InAccumulatedOCI |  | Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income |  | Gain/(Loss)                                                                                                                                                                                                                                  Reclassified FromAccumulated OCIInto Income\n(Dollars in Millions) |  | October 1, 2023 |  | October 2, 2022 |  |  |  | October 1, 2023 |  | October 2, 2022\nDebt |  | $ | 101 |  |  | 208 |  |  | Interest (income) expense |  | \u2014 |  |  | \u2014 | \nCross Currency interest rate swaps |  | $ | 214 |  |  | 261 |  |  | Interest (income) expense |  | \u2014 |  |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n\n |  | Gain/(Loss)Recognized InAccumulated OCI |  | Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income |  | Gain/(Loss)                                                                                                                                                                                                                                  Reclassified FromAccumulated OCIInto Income\n(Dollars in Millions) |  | October 1, 2023 |  | October 2, 2022 |  |  |  | October 1, 2023 |  | October 2, 2022\nDebt |  | $ | 35 |  |  | 478 |  |  | Interest (income) expense |  | \u2014 |  |  | \u2014 | \nCross Currency interest rate swaps |  | $ | 880 |  |  | 1,134 |  |  | Interest (income) expense |  | \u2014 |  |  | \u2014 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | January 1, 2023 |  |  |  |  |  | October 1, 2023 |  | \n |  | Carrying Value |  | Changes in Fair Value Reflected in Net Income(1) |  | Sales/ Purchases/Other(2) |  | Carrying Value |  | Non Current Other Assets\nEquity Investments with readily determinable value* |  | $ | 576 |  |  | (813) |  |  | 4,260 |  |  | 4,023 |  |  | 4,023 | \n |  |  |  |  |  |  |  |  |  | \nEquity Investments without readily determinable value |  | $ | 613 |  |  | (24) |  |  | 96 |  |  | 685 |  |  | 685 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | October 1, 2023 |  |  |  | January 1, 2023\n(Dollars in Millions) |  | Level 1 |  | Level 2 |  | Level 3 |  | Total |  | Total(1)\nDerivatives designated as hedging instruments: |  |  |  |  |  |  |  |  |  | \nAssets: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts |  | $ | \u2014 |  |  | 901 |  |  | \u2014 |  |  | 901 |  |  | 629 | \nInterest rate contracts(2) |  | \u2014 |  |  | 1,534 |  |  | \u2014 |  |  | 1,534 |  |  | 1,534 | \n |  |  |  |  |  |  |  |  |  | \nTotal |  | \u2014 |  |  | 2,435 |  |  | \u2014 |  |  | 2,435 |  |  | 2,163 | \nLiabilities: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts |  | \u2014 |  |  | 577 |  |  | \u2014 |  |  | 577 |  |  | 511 | \nInterest rate contracts(2) |  | \u2014 |  |  | 3,669 |  |  | \u2014 |  |  | 3,669 |  |  | 2,778 | \n |  |  |  |  |  |  |  |  |  | \nTotal |  | \u2014 |  |  | 4,246 |  |  | \u2014 |  |  | 4,246 |  |  | 3,289 | \nDerivatives not designated as hedging instruments: |  |  |  |  |  |  |  |  |  | \nAssets: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts |  | \u2014 |  |  | 58 |  |  | \u2014 |  |  | 58 |  |  | 38 | \nLiabilities: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts |  | \u2014 |  |  | 47 |  |  | \u2014 |  |  | 47 |  |  | 68 | \nOther Investments: |  |  |  |  |  |  |  |  |  | \nEquity investments(3) |  | 4,023 |  |  | \u2014 |  |  | \u2014 |  |  | 4,023 |  |  | 576 | \nDebt securities(4) |  | \u2014 |  |  | 8,407 |  |  | \u2014 |  |  | 8,407 |  |  | 10,487 | \nOther Liabilities |  |  |  |  |  |  |  |  |  | \nContingent consideration(5) |  | $ | \u2014 |  |  | \u2014 |  |  | 1,178 |  |  | 1,178 |  |  | 1,120 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \nGross to Net Derivative Reconciliation |  | October 1, 2023 |  | January 1, 2023\n(Dollars in Millions) |  |  |  | \nTotal Gross Assets |  | $ | 2,493 |  |  | 2,201 | \nCredit Support Agreement (CSA) |  | (2,472) |  |  | (2,176) | \nTotal Net Asset |  | 21 |  |  | 25 | \n |  |  |  | \nTotal Gross Liabilities |  | 4,293 |  |  | 3,357 | \nCredit Support Agreement (CSA) |  | (4,174) |  |  | (3,023) | \nTotal Net Liabilities |  | $ | 119 |  |  | 334 | \n |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | \n |  | October 1, 2023 |  | October 2, 2022\n(Dollars in Millions) |  |  |  | \nBeginning Balance |  | $ | 1,120 |  |  | 533 | \nChanges in estimated fair value(6) |  | 62 |  |  | (85) | \nAdditions |  | \u2014 |  |  | 89 | \nPayments |  | (4) |  |  | (12) | \nEnding Balance |  | $ | 1,178 |  |  | 525 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) | Carrying Amount |  |  |  | Gain/(Loss) |  | Estimated Fair Value |  | Cash & Cash Equivalents |  | Current Marketable Securities\nCash | $ | 3,214 |  |  |  |  | \u2014 |  |  | 3,214 |  |  | 3,214 |  |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |  | \nNon-U.S. sovereign securities | 150 |  |  |  |  | \u2014 |  |  | 150 |  |  | 150 |  |  | \u2014 | \nU.S. reverse repurchase agreements | 7,261 |  |  |  |  | \u2014 |  |  | 7,261 |  |  | 7,261 |  |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |  | \nCorporate debt securities(1) | 228 |  |  |  |  | \u2014 |  |  | 228 |  |  | 78 |  |  | 150 | \nMoney market funds | 3,503 |  |  |  |  | \u2014 |  |  | 3,503 |  |  | 3,503 |  |  | \u2014 | \nTime deposits(1) | 748 |  |  |  |  | \u2014 |  |  | 748 |  |  | 748 |  |  | \u2014 | \nSubtotal | 15,104 |  |  |  |  | \u2014 |  |  | 15,104 |  |  | 14,954 |  |  | 150 | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | Unrealized Loss |  |  |  |  |  | \nU.S. Gov\u2019t securities | 8,062 |  |  |  |  | (1) |  |  | 8,061 |  |  | 4,728 |  |  | 3,333 | \nU.S. Gov\u2019t Agencies | 95 |  |  |  |  | (2) |  |  | 93 |  |  | \u2014 |  |  | 93 | \nOther sovereign securities | 6 |  |  |  |  | \u2014 |  |  | 6 |  |  | 2 |  |  | 4 | \nCorporate debt securities | 247 |  |  |  |  | \u2014 |  |  | 247 |  |  | 44 |  |  | 203 | \nSubtotal available for sale debt(2) | $ | 8,410 |  |  |  |  | (3) |  |  | 8,407 |  |  | 4,774 |  |  | 3,633 | \nTotal cash, cash equivalents and current marketable securities | $ | 23,514 |  |  |  |  | (3) |  |  | 23,511 |  |  | 19,728 |  |  | 3,783 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | Cost Basis |  | Fair Value\nDue within one year |  | $ | 8,400 |  |  | 8,397 | \nDue after one year through five years |  | 10 |  |  | 10 | \nDue after five years through ten years |  | \u2014 |  |  | \u2014 | \nTotal debt securities |  | $ | 8,410 |  |  | 8,407 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | Carrying Amount |  | Estimated Fair Value\n |  |  |  | \nFinancial Liabilities |  |  |  | \n |  |  |  | \nCurrent Debt |  | $ | 3,870 |  |  | 3,852 | \n |  |  |  | \nNon-Current Debt |  |  |  | \n |  |  |  | \n |  |  |  | \n5.50% Notes due 2024 (500MM GBP1.2190) |  | 609 |  |  | 609 | \n2.625% Notes due 2025 |  | 750 |  |  | 726 | \n0.55% Notes due 2025 |  | 947 |  |  | 916 | \n |  |  |  | \n2.45% Notes due 2026 |  | 1,997 |  |  | 1,879 | \n2.95% Notes due 2027 |  | 882 |  |  | 937 | \n |  |  |  | \n0.95% Notes due 2027 |  | 1,409 |  |  | 1,290 | \n2.90%\u00a0Notes due 2028 |  | 1,497 |  |  | 1,384 | \n1.150% Notes due 2028 (750MM Euro1.0534) |  | 786 |  |  | 705 | \n6.95% Notes due 2029 |  | 298 |  |  | 337 | \n1.30% Notes due 2030 |  | 1,604 |  |  | 1,377 | \n4.95% Debentures due 2033 |  | 499 |  |  | 507 | \n4.375% Notes due 2033 |  | 854 |  |  | 809 | \n1.650% Notes due 2035 (1.5B Euro1.0534) |  | 1,568 |  |  | 1,282 | \n3.55% Notes due 2036 |  | 831 |  |  | 852 | \n5.95% Notes due 2037 |  | 994 |  |  | 1,060 | \n3.625% Notes due 2037 |  | 1,321 |  |  | 1,261 | \n3.40%\u00a0Notes due 2038 |  | 993 |  |  | 823 | \n5.85% Debentures due 2038 |  | 697 |  |  | 735 | \n4.50% Debentures due 2040 |  | 541 |  |  | 502 | \n2.10% Notes due 2040 |  | 809 |  |  | 639 | \n4.85% Notes due 2041 |  | 297 |  |  | 282 | \n4.50% Notes due 2043 |  | 496 |  |  | 450 | \n3.70% Notes due 2046 |  | 1,977 |  |  | 1,555 | \n3.75% Notes due 2047 |  | 787 |  |  | 788 | \n3.50% Notes due 2048 |  | 743 |  |  | 564 | \n2.25% Notes due 2050 |  | 776 |  |  | 573 | \n2.45% Notes due 2060 |  | 1,025 |  |  | 695 | \nOther |  | 64 |  |  | 62 | \nTotal Non-Current Debt |  | $ | 26,051 |  |  | 23,599 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended\n |  | Retirement Plans |  | Other Benefit Plans |  | Retirement Plans |  | Other Benefit Plans\n(Dollars in Millions) |  | October 1, 2023 |  | October 2, 2022 |  | October 1, 2023 |  | October 2, 2022 |  | October 1, 2023 |  | October 2, 2022 |  | October 1, 2023 |  | October 2, 2022\nService cost |  | $ | 210 |  |  | 313 |  |  | 61 |  |  | 80 |  |  | 638 |  |  | 953 |  |  | 198 |  |  | 240 | \nInterest cost |  | 363 |  |  | 226 |  |  | 51 |  |  | 26 |  |  | 1,090 |  |  | 685 |  |  | 160 |  |  | 79 | \nExpected return on plan assets |  | (680) |  |  | (683) |  |  | (1) |  |  | (2) |  |  | (2,042) |  |  | (2,075) |  |  | (4) |  |  | (6) | \nAmortization of prior service cost/(credit) |  | (47) |  |  | (46) |  |  | \u2014 |  |  | (1) |  |  | (139) |  |  | (138) |  |  | (1) |  |  | (4) | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nRecognized actuarial (gains) losses |  | (50) |  |  | 163 |  |  | 4 |  |  | 30 |  |  | (150) |  |  | 492 |  |  | 17 |  |  | 91 | \nCurtailments and settlements |  | 72 |  |  | \u2014 |  |  | (9) |  |  | \u2014 |  |  | 72 |  |  | 1 |  |  | (9) |  |  | \u2014 | \nNet periodic benefit cost/(credit) |  | $ | (132) |  |  | (27) |  |  | 106 |  |  | 133 |  |  | (531) |  |  | (82) |  |  | 361 |  |  | 400 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  | Foreign Currency |  | Gain/(Loss) On |  | Employee Benefit |  | Gain/(Loss) On Derivatives |  | Total Accumulated Other Comprehensive\n(Dollars in Millions) |  | Translation |  | Securities |  | Plans |  | & Hedges |  | Income (Loss)\nJanuary 1, 2023 |  | $ | (11,813) |  |  | (27) |  |  | (897) |  |  | (230) |  |  | (12,967) | \nChange from continuing operations |  | (448) |  |  | 25 |  |  | (175) |  |  | (396) |  |  | (994) | \nKenvue Separation |  | 4,885 |  | ** | 0 |  | 296 | * | 0 |  | 5,181 | \n |  |  |  |  |  |  |  |  |  | \nNet change |  | 4,437 |  |  | 25 |  |  | 121 |  |  | (396) |  |  | 4,187 | \nOctober 1, 2023 |  | (7,376) |  |  | (2) |  |  | (776) |  |  | (626) |  |  | (8,780) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended\n(Shares in Millions) |  | October 1, 2023 |  | October 2, 2022 |  | October 1, 2023 |  | October 2, 2022\nBasic net earnings per share from continuing operations |  | $ | 1.71 |  |  | 1.64 |  |  | 3.57 |  |  | 5.00 | \nBasic net earnings per share from discontinued operations |  | 8.61 |  |  | 0.06 |  |  | 8.51 |  |  | 0.49 | \nTotal net earnings per share - basic |  | 10.32 |  |  | 1.70 |  |  | 12.08 |  |  | 5.49 | \nAverage shares outstanding \u2014 basic |  | 2,522.9 |  |  | 2,627.9 |  |  | 2,575.6 |  |  | 2,628.9 | \nPotential shares exercisable under stock option plans |  | 119.2 |  |  | 140.1 |  |  | 96.9 |  |  | 141.1 | \nLess: shares which could be repurchased under treasury stock method |  | (92.4) |  |  | (106.7) |  |  | (69.1) |  |  | (102.5) | \n |  |  |  |  |  |  |  | \nAverage shares outstanding \u2014 diluted |  | 2,549.7 |  |  | 2,661.3 |  |  | 2,603.4 |  |  | 2,667.5 | \nDiluted net earnings per share from continuing operations |  | 1.69 |  |  | 1.62 |  |  | 3.53 |  |  | 4.93 | \nDiluted net earnings per share from discontinuing operations |  | 8.52 |  |  | 0.06 |  |  | 8.42 |  |  | 0.48 | \nTotal net earnings per share - diluted |  | $ | 10.21 |  |  | 1.68 |  | 11.95 |  | 5.41  |  |  |  |  |  |  |  | \n\n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended\n(Dollars in Millions) |  | October 1,2023 |  | October 2,2022 |  | PercentChange |  | October 1,2023 |  | October 2,2022 |  | Percent Change\n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nINNOVATIVE MEDICINE |  |  |  |  |  |  |  |  |  |  |  | \nImmunology |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 3,193 |  |  | 2,876 |  |  | 11.0 |  |  | 8,506 |  |  | 8,230 |  |  | 3.3 | \nInternational |  | 1,656 |  |  | 1,411 |  |  | 17.4 |  |  | 4,951 |  |  | 4,587 |  |  | 7.9 | \nWorldwide |  | 4,849 |  |  | 4,287 |  |  | 13.1 |  |  | 13,457 |  |  | 12,817 |  |  | 5.0 | \nREMICADE |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 296 |  |  | 350 |  |  | (15.4) |  |  | 849 |  |  | 1,099 |  |  | (22.7) | \nU.S. Exports |  | 38 |  |  | 39 |  |  | (2.5) |  |  | 112 |  |  | 163 |  |  | (31.3) | \nInternational |  | 127 |  |  | 169 |  |  | (25.1) |  |  | 449 |  |  | 606 |  |  | (25.9) | \nWorldwide |  | 461 |  |  | 558 |  |  | (17.4) |  |  | 1,410 |  |  | 1,868 |  |  | (24.5) | \nSIMPONI / SIMPONI ARIA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 310 |  |  | 298 |  |  | 3.9 |  |  | 866 |  |  | 886 |  |  | (2.3) | \nInternational |  | 319 |  |  | 248 |  |  | 29.1 |  |  | 829 |  |  | 797 |  |  | 4.1 | \nWorldwide |  | 629 |  |  | 545 |  |  | 15.3 |  |  | 1,695 |  |  | 1,682 |  |  | 0.8 | \nSTELARA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,912 |  |  | 1,655 |  |  | 15.5 |  |  | 5,180 |  |  | 4,766 |  |  | 8.7 | \nInternational |  | 951 |  |  | 794 |  |  | 19.9 |  |  | 2,925 |  |  | 2,571 |  |  | 13.8 | \nWorldwide |  | 2,864 |  |  | 2,449 |  |  | 16.9 |  |  | 8,105 |  |  | 7,336 |  |  | 10.5 | \nTREMFYA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 634 |  |  | 530 |  |  | 19.6 |  |  | 1,490 |  |  | 1,303 |  |  | 14.4 | \nInternational |  | 258 |  |  | 200 |  |  | 29.0 |  |  | 747 |  |  | 613 |  |  | 21.9 | \nWorldwide |  | 891 |  |  | 729 |  |  | 22.2 |  |  | 2,237 |  |  | 1,916 |  |  | 16.8 | \nOTHER IMMUNOLOGY |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 2 |  |  | 5 |  |  | (47.1) |  |  | 9 |  |  | 14 |  |  | (36.1) | \nInternational |  | 0 |  | 0 |  | \u2014 |  |  | 0 |  | 0 |  | \u2014\nWorldwide |  | 2 |  |  | 5 |  |  | (47.1) |  |  | 9 |  |  | 14 |  |  | (36.1) | \n |  |  |  |  |  |  |  |  |  |  |  | \nInfectious Diseases |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 360 |  |  | 390 |  |  | (7.8) |  |  | 1,147 |  |  | 1,266 |  |  | (9.4) | \nInternational |  | 500 |  |  | 905 |  |  | (44.8) |  |  | 2,420 |  |  | 2,642 |  |  | (8.4) | \nWorldwide |  | 859 |  |  | 1,295 |  |  | (33.6) |  |  | 3,566 |  |  | 3,908 |  |  | (8.7) | \nCOVID-19 VACCINE |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  | \u2014 |  |  | 120 |  |  | *\nInternational |  | 41 |  |  | 489 |  |  | (91.5) |  |  | 1,073 |  |  | 1,370 |  |  | (21.6)\nWorldwide |  | 41 |  |  | 489 |  |  | (91.5) |  |  | 1,073 |  |  | 1,490 |  |  | (27.9)\nEDURANT / rilpivirine |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 9 |  |  | 9 |  |  | 10.2 |  |  | 26 |  |  | 27 |  |  | (0.5) | \nInternational |  | 287 |  |  | 237 |  |  | 21.4 |  |  | 816 |  |  | 691 |  |  | 18.2 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nWorldwide |  | 297 |  |  | 245 |  |  | 21.0 |  |  | 843 |  |  | 718 |  |  | 17.5 | \nPREZISTA / PREZCOBIX /REZOLSTA / SYMTUZA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 345 |  |  | 372 |  |  | (7.3) |  |  | 1,105 |  |  | 1,096 |  |  | 0.9 | \nInternational |  | 102 |  |  | 112 |  |  | (9.5) |  |  | 310 |  |  | 354 |  |  | (12.5) | \nWorldwide |  | 447 |  |  | 485 |  |  | (7.8) |  |  | 1,415 |  |  | 1,450 |  |  | (2.4) | \nOTHER INFECTIOUS DISEASES |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 5 |  |  | 10 |  |  | (42.7) |  |  | 15 |  |  | 24 |  |  | (35.5) | \nInternational |  | 69 |  |  | 68 |  |  | 2.0 |  |  | 220 |  |  | 228 |  |  | (3.4) | \nWorldwide |  | 74 |  |  | 77 |  |  | (3.6) |  |  | 235 |  |  | 251 |  |  | (6.4) | \n |  |  |  |  |  |  |  |  |  |  |  | \nNeuroscience |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,036 |  |  | 919 |  |  | 12.7 |  |  | 3,043 |  |  | 2,658 |  |  | 14.5 | \nInternational |  | 706 |  |  | 763 |  |  | (7.4) |  |  | 2,296 |  |  | 2,498 |  |  | (8.1) | \nWorldwide |  | 1,742 |  |  | 1,681 |  |  | 3.6 |  |  | 5,339 |  |  | 5,156 |  |  | 3.5 | \nCONCERTA / methylphenidate |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 57 |  |  | 41 |  |  | 38.1 |  |  | 191 |  |  | 114 |  |  | 67.4 | \nInternational |  | 133 |  |  | 117 |  |  | 13.6 |  |  | 412 |  |  | 362 |  |  | 13.8 | \nWorldwide |  | 189 |  |  | 158 |  |  | 20.0 |  |  | 603 |  |  | 476 |  |  | 26.7 | \nINVEGA SUSTENNA / XEPLION / INVEGA   TRINZA / TREVICTA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 730 |  |  | 684 |  |  | 6.8 |  |  | 2,164 |  |  | 2,036 |  |  | 6.3 | \nInternational |  | 299 |  |  | 348 |  |  | (14.0) |  |  | 940 |  |  | 1,097 |  |  | (14.3) | \nWorldwide |  | 1,029 |  |  | 1,031 |  |  | (0.2) |  |  | 3,104 |  |  | 3,132 |  |  | (0.9) | \nSPRAVATO |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 154 |  |  | 88 |  |  | 75.1 |  |  | 409 |  |  | 223 |  |  | 83.1 | \nInternational |  | 29 |  |  | 12 |  |  | * |  | 74 |  |  | 32 |  |  | *\nWorldwide |  | 183 |  |  | 100 |  |  | 82.1 |  |  | 483 |  |  | 255 |  |  | 88.8 | \nOTHER NEUROSCIENCE(1) |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 94 |  |  | 106 |  |  | (11.3) |  |  | 278 |  |  | 285 |  |  | (2.3) | \nInternational |  | 245 |  |  | 286 |  |  | (13.9) |  |  | 870 |  |  | 1,007 |  |  | (13.5) | \nWorldwide |  | 340 |  |  | 393 |  |  | (13.2) |  |  | 1,149 |  |  | 1,293 |  |  | (11.0) | \n |  |  |  |  |  |  |  |  |  |  |  | \nOncology |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 2,219 |  |  | 1,812 |  |  | 22.5 |  |  | 6,177 |  |  | 5,073 |  |  | 21.8 | \nInternational |  | 2,313 |  |  | 2,252 |  |  | 2.7 |  |  | 6,865 |  |  | 6,983 |  |  | (1.7) | \nWorldwide |  | 4,533 |  |  | 4,064 |  |  | 11.5 |  |  | 13,043 |  |  | 12,056 |  |  | 8.2 | \nCARVYKTI |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 140 |  |  | 55 |  |  | * |  | 324 |  |  | 79 |  |  | *\nInternational |  | 12 |  |  | \u2014 |  |  | * |  | 17 |  |  | \u2014 |  |  | *\nWorldwide |  | 152 |  |  | 55 |  |  | * |  | 341 |  |  | 79 |  |  | *\nDARZALEX |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,369 |  |  | 1,097 |  |  | 24.8 |  |  | 3,882 |  |  | 3,071 |  |  | 26.4 | \nInternational |  | 1,130 |  |  | 955 |  |  | 18.3 |  |  | 3,312 |  |  | 2,823 |  |  | 17.3 | \nWorldwide |  | 2,499 |  |  | 2,052 |  |  | 21.8 |  |  | 7,194 |  |  | 5,894 |  |  | 22.1 | \nERLEADA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 288 |  |  | 254 |  |  | 12.9 |  |  | 778 |  | 693 |  | 12.2 | \nInternational |  | 342 |  |  | 235 |  |  | 45.8 |  |  | 961 |  | 647 |  | 48.7 | \nWorldwide |  | 631 |  |  | 490 |  |  | 28.7 |  |  | 1,740 |  |  | 1,340 |  |  | 29.8 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nIMBRUVICA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 264 |  |  | 353 |  |  | (25.2) |  |  | 796 |  |  | 1,072 |  |  | (25.8) | \nInternational |  | 545 |  |  | 559 |  |  | (2.5) |  |  | 1,681 |  |  | 1,847 |  |  | (9.0) | \nWorldwide |  | 808 |  |  | 911 |  |  | (11.3) |  |  | 2,476 |  |  | 2,918 |  |  | (15.2) | \nZYTIGA/abiraterone acetate |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 16 |  |  | 16 |  |  | (2.8) |  |  | 41 |  |  | 54 |  |  | (24.9) | \nInternational |  | 199 |  |  | 440 |  |  | (54.9) |  |  | 646 |  |  | 1,446 |  |  | (55.3) | \nWorldwide |  | 214 |  |  | 456 |  |  | (53.0) |  |  | 686 |  |  | 1,500 |  |  | (54.2) | \nOTHER ONCOLOGY |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 143 |  |  | 37 |  |  | * |  | 357 |  |  | 104 |  |  | *\nInternational |  | 86 |  |  | 64 |  |  | 34.5 |  |  | 248 |  |  | 220 |  |  | 12.5 | \nWorldwide |  | 229 |  |  | 100 |  |  | * |  | 605 |  |  | 324 |  |  | 86.5 | \n |  |  |  |  |  |  |  |  |  |  |  | \nPulmonary Hypertension |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 680 |  |  | 604 |  |  | 12.6 |  |  | 1,964 |  |  | 1,736 |  |  | 13.1 | \nInternational |  | 274 |  |  | 247 |  |  | 10.5 |  |  | 835 |  |  | 810 |  |  | 3.0 | \nWorldwide |  | 954 |  |  | 852 |  |  | 12.0 |  |  | 2,798 |  |  | 2,547 |  |  | 9.9 | \nOPSUMIT |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 323 |  |  | 289 |  |  | 12.2 |  |  | 924 |  |  | 827 |  |  | 11.8 | \nInternational |  | 166 |  |  | 152 |  |  | 9.3 |  |  | 512 |  |  | 495 |  |  | 3.5 | \nWorldwide |  | 490 |  |  | 441 |  |  | 11.2 |  |  | 1,437 |  |  | 1,322 |  |  | 8.7 | \nUPTRAVI |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 336 |  |  | 283 |  |  | 18.9 |  |  | 978 |  |  | 824 |  |  | 18.7 | \nInternational |  | 66 |  |  | 50 |  |  | 30.9 |  |  | 185 |  |  | 162 |  |  | 14.1 | \nWorldwide |  | 402 |  |  | 333 |  |  | 20.7 |  |  | 1,163 |  |  | 986 |  |  | 18.0 | \nOTHER PULMONARY HYPERTENSION |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 20 |  |  | 33 |  |  | (37.1) |  |  | 61 |  |  | 86 |  |  | (28.4) | \nInternational |  | 42 |  |  | 46 |  |  | (7.5) |  |  | 137 |  |  | 154 |  |  | (10.5) | \nWorldwide |  | 63 |  |  | 78 |  |  | (19.8) |  |  | 199 |  |  | 239 |  |  | (16.9) | \n |  |  |  |  |  |  |  |  |  |  |  | \nCardiovascular / Metabolism / Other |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 763 |  |  | 837 |  |  | (8.8) |  |  | 2,254 |  |  | 2,266 |  |  | (0.5) | \nInternational |  | 194 |  |  | 198 |  |  | (2.1) |  |  | 580 |  |  | 651 |  |  | (10.8) | \nWorldwide |  | 957 |  |  | 1,034 |  |  | (7.5) |  |  | 2,834 |  |  | 2,916 |  |  | (2.8) | \nXARELTO |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 625 |  |  | 689 |  |  | (9.4) |  |  | 1,840 |  |  | 1,806 |  |  | 1.9 | \nInternational |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nWorldwide |  | 625 |  |  | 689 |  |  | (9.4) |  |  | 1,840 |  |  | 1,806 |  |  | 1.9 | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nOTHER(2) |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 139 |  |  | 147 |  |  | (6.1) |  |  | 414 |  |  | 459 |  |  | (9.9) | \nInternational |  | 194 |  |  | 198 |  |  | (2.1) |  |  | 580 |  |  | 651 |  |  | (10.8) | \nWorldwide |  | 332 |  |  | 345 |  |  | (3.8) |  |  | 994 |  |  | 1,110 |  |  | (10.5) | \n |  |  |  |  |  |  |  |  |  |  |  | \nTOTAL INNOVATIVE MEDICINE |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 8,249 |  |  | 7,438 |  |  | 10.9 |  |  | 23,090 |  |  | 21,229 |  |  | 8.8 | \nInternational |  | 5,644 |  |  | 5,776 |  |  | (2.3) |  |  | 17,947 |  |  | 18,171 |  |  | (1.2) | \nWorldwide |  | 13,893 |  |  | 13,214 |  |  | 5.1 |  |  | 41,037 |  |  | 39,400 |  |  | 4.2 | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nMEDTECH |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nInterventional Solutions |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 891 |  |  | 547 |  |  | 63.0 |  |  | 2,662 |  |  | 1,566 |  |  | 70.0 | \nInternational |  | 667 |  |  | 513 |  |  | 29.9 |  |  | 2,019 |  |  | 1,636 |  |  | 23.4 | \nWorldwide |  | 1,558 |  |  | 1,060 |  |  | 47.0 |  |  | 4,681 |  |  | 3,202 |  |  | 46.2 | \nELECTROPHYSIOLOGY |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 611 |  |  | 520 |  |  | 17.6 |  |  | 1,791 |  |  | 1,489 |  |  | 20.3 | \nInternational |  | 549 |  |  | 453 |  |  | 21.2 |  |  | 1,658 |  |  | 1,454 |  |  | 14.0 | \nWorldwide |  | 1,161 |  |  | 973 |  |  | 19.3 |  |  | 3,449 |  |  | 2,943 |  |  | 17.2 | \nABIOMED(3) |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 254 |  |  | \u2014 |  |  | * |  | 790 |  |  | \u2014 |  |  | *\nInternational |  | 57 |  |  | \u2014 |  |  | * |  | 176 |  |  | \u2014 |  |  | *\nWorldwide |  | 311 |  |  | \u2014 |  |  | * |  | 966 |  |  | \u2014 |  |  | *\nOTHER INTERVENTIONAL SOLUTIONS |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 26 |  |  | 27 |  |  | (3.2) |  |  | 81 |  |  | 77 |  |  | 5.9 | \nInternational |  | 61 |  |  | 60 |  |  | 1.0 |  |  | 186 |  |  | 181 |  |  | 2.2 | \nWorldwide |  | 87 |  |  | 87 |  |  | (0.3) |  |  | 267 |  |  | 258 |  |  | 3.3 | \nOrthopaedics |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,349 |  |  | 1,309 |  |  | 3.1 |  |  | 4,100 |  |  | 3,936 |  |  | 4.2 | \nInternational |  | 815 |  |  | 785 |  |  | 3.9 |  |  | 2,574 |  |  | 2,504 |  |  | 2.8 | \nWorldwide |  | 2,164 |  |  | 2,095 |  |  | 3.4 |  |  | 6,674 |  |  | 6,440 |  |  | 3.6 | \nHIPS |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 239 |  |  | 228 |  |  | 4.9 |  |  | 730 |  |  | 693 |  |  | 5.4 | \nInternational |  | 136 |  |  | 124 |  |  | 9.3 |  |  | 432 |  |  | 437 |  |  | (1.0) | \nWorldwide |  | 375 |  |  | 352 |  |  | 6.5 |  |  | 1,162 |  |  | 1,129 |  |  | 2.9 | \nKNEES |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 207 |  |  | 203 |  |  | 2.3 |  |  | 654 |  |  | 620 |  |  | 5.6 | \nInternational |  | 131 |  |  | 115 |  |  | 14.6 |  |  | 415 |  |  | 386 |  |  | 7.7 | \nWorldwide |  | 338 |  |  | 317 |  |  | 6.7 |  |  | 1,069 |  |  | 1,005 |  |  | 6.4 | \nTRAUMA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 488 |  |  | 473 |  |  | 3.2 |  |  | 1,462 |  |  | 1,412 |  |  | 3.5 | \nInternational |  | 253 |  |  | 244 |  |  | 4.2 |  |  | 775 |  |  | 749 |  |  | 3.5 | \nWorldwide |  | 742 |  |  | 717 |  |  | 3.5 |  |  | 2,238 |  |  | 2,161 |  |  | 3.5 | \nSPINE, SPORTS & OTHER |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 415 |  |  | 406 |  |  | 2.3 |  |  | 1,254 |  |  | 1,211 |  |  | 3.5 | \nInternational |  | 295 |  |  | 303 |  |  | (2.6) |  |  | 952 |  |  | 933 |  |  | 2.0 | \nWorldwide |  | 710 |  |  | 708 |  |  | 0.2 |  |  | 2,205 |  |  | 2,144 |  |  | 2.8 | \nSurgery |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 994 |  |  | 984 |  |  | 1.1 |  |  | 2,984 |  |  | 2,897 |  |  | 3.0 | \nInternational |  | 1,483 |  |  | 1,439 |  |  | 3.1 |  |  | 4,522 |  |  | 4,410 |  |  | 2.6 | \nWorldwide |  | 2,479 |  |  | 2,422 |  |  | 2.3 |  |  | 7,507 |  |  | 7,306 |  |  | 2.7 | \nADVANCED |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 455 |  |  | 457 |  |  | (0.4) |  |  | 1,365 |  |  | 1,328 |  |  | 2.8 | \nInternational |  | 709 |  |  | 701 |  |  | 1.0 |  |  | 2,139 |  |  | 2,132 |  |  | 0.3 | \nWorldwide |  | 1,164 |  |  | 1,158 |  |  | 0.5 |  |  | 3,504 |  |  | 3,460 |  |  | 1.3 | \nGENERAL |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 540 |  |  | 527 |  |  | 2.4 |  |  | 1,619 |  |  | 1,569 |  |  | 3.2 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nInternational |  | 775 |  |  | 737 |  |  | 5.1 |  |  | 2,383 |  |  | 2,277 |  |  | 4.7 | \nWorldwide |  | 1,314 |  |  | 1,264 |  |  | 4.0 |  |  | 4,002 |  |  | 3,846 |  |  | 4.1 | \nVision |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 512 |  |  | 517 |  |  | (1.0) |  |  | 1,599 |  |  | 1,534 |  |  | 4.2 | \nInternational |  | 744 |  |  | 689 |  |  | 8.1 |  |  | 2,265 |  |  | 2,170 |  |  | 4.4 | \nWorldwide |  | 1,256 |  |  | 1,206 |  |  | 4.2 |  |  | 3,864 |  |  | 3,704 |  |  | 4.3 | \nCONTACT LENSES / OTHER |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 399 |  |  | 405 |  |  | (1.2) |  |  | 1,252 |  |  | 1,179 |  |  | 6.2 | \nInternational |  | 529 |  |  | 503 |  |  | 4.9 |  |  | 1,568 |  |  | 1,533 |  |  | 2.3 | \nWorldwide |  | 928 |  |  | 908 |  |  | 2.2 |  |  | 2,820 |  |  | 2,712 |  |  | 4.0 | \nSURGICAL |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 112 |  |  | 112 |  |  | (0.1) |  |  | 346 |  |  | 355 |  |  | (2.5) | \nInternational |  | 216 |  |  | 186 |  |  | 16.6 |  |  | 698 |  |  | 637 |  |  | 9.6 | \nWorldwide |  | 328 |  |  | 298 |  |  | 10.3 |  |  | 1,044 |  |  | 992 |  |  | 5.3 | \n |  |  |  |  |  |  |  |  |  |  |  | \nTOTAL MEDTECH |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 3,747 |  |  | 3,356 |  |  | 11.6 |  |  | 11,345 |  |  | 9,932 |  |  | 14.2 | \nInternational |  | 3,711 |  |  | 3,426 |  |  | 8.3 |  |  | 11,382 |  |  | 10,719 |  |  | 6.2 | \nWorldwide |  | 7,458 |  |  | 6,782 |  |  | 10.0 |  |  | 22,727 |  |  | 20,651 |  |  | 10.0 | \n |  |  |  |  |  |  |  |  |  |  |  | \nWORLDWIDE |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 11,996 |  |  | 10,794 |  |  | 11.1 |  |  | 34,435 |  |  | 31,161 |  |  | 10.5 | \nInternational |  | 9,355 |  |  | 9,202 |  |  | 1.6 |  |  | 29,329 |  |  | 28,890 |  |  | 1.5 | \nWorldwide |  | $ | 21,351 |  |  | 19,996 |  |  | 6.8 | % |  | $ | 63,764 |  |  | 60,051 |  |  | 6.2 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended | \n(Dollars in Millions) |  | October 1,2023 |  | October 2,2022 |  | PercentChange |  | October 1,2023 |  | October 2,2022 |  | PercentChange |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nInnovative Medicine(1) |  | $ | 4,794 |  |  | 4,186 |  |  | 14.5 | % |  | $ | 14,008 |  |  | 12,424 |  |  | 12.7 | % |  |  |  |  | \nMedTech(2) |  | 1,185 |  |  | 1,090 |  |  | 8.7 |  | 4,265 |  |  | 3,641 |  |  | 17.1 |  |  |  |  |  | \nSegment earnings before provision for taxes |  | 5,979 |  |  | 5,276 |  |  | 13.3 |  |  | 18,273 |  |  | 16,065 |  |  | 13.7 |  |  |  |  |  | \nLess: Expense not allocated to segments(3) |  | 762 |  |  | 104 |  |  |  |  | 8,037 |  |  | 546 |  |  |  |  |  |  |  | \nWorldwide income before tax |  | $ | 5,217 |  |  | 5,172 |  |  | 0.9 | % |  | $ | 10,236 |  |  | 15,519 |  |  | (34.0) | % |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended\n(Dollars in Millions) |  | October 1, 2023 |  | October 2, 2022 |  | PercentChange |  | October 1, 2023 |  | October 2, 2022 |  | Percent Change\nUnited States |  | $ | 11,996 |  |  | 10,794 |  |  | 11.1 | % |  | $ | 34,435 |  |  | 31,161 |  |  | 10.5 | %\nEurope |  | 4,727 |  |  | 4,844 |  |  | (2.4) |  |  | 15,448 |  |  | 15,540 |  |  | (0.6) | \nWestern Hemisphere, excluding U.S. |  | 1,171 |  |  | 1,059 |  |  | 10.5 |  |  | 3,383 |  |  | 3,084 |  |  | 9.7 | \nAsia-Pacific, Africa |  | 3,457 |  |  | 3,299 |  |  | 4.8 |  |  | 10,498 |  |  | 10,266 |  |  | 2.2 | \nTotal |  | $ | 21,351 |  |  | 19,996 |  |  | 6.8 | % |  | $ | 63,764 |  |  | 60,051 |  |  | 6.2 | %  |  |  |  |  |  |  |  | \nProduct or product category |  | Number of Plaintiffs\nBody powders containing talc, primarily JOHNSON\u2019S Baby Powder |  | 52,220 | \nDePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System |  | 160 | \nPINNACLE Acetabular Cup System |  | 930 | \nPelvic meshes |  | 6,960 | \nETHICON PHYSIOMESH Flexible Composite Mesh |  | 720 | \nRISPERDAL |  | 220 | \nELMIRON |  | 2,150 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended\n(Dollars in Millions) |  | October 1, 2023(1) |  | October 2, 2022 |  | October 1, 2023(1) |  | October 2, 2022\nSales to customers |  | $ | 2,173 |  |  | 3,795 |  |  | 10,036 |  |  | 11,186 | \nCost of products sold |  | 911 |  |  | 1,635 |  |  | 4,369 |  |  | 4,812 | \nGross profit |  | 1,262 |  |  | 2,160 |  |  | 5,667 |  |  | 6,374 | \nSelling, marketing and administrative expenses |  | 584 |  |  | 1,114 |  |  | 3,085 |  |  | 3,346 | \nResearch and development expense |  | 24 |  |  | 112 |  |  | 258 |  |  | 337 | \nInterest Income |  | (37) |  |  | \u2014 |  |  | (117) |  |  | \u2014 | \nInterest expense, net of portion capitalized (Note\u00a04) |  | 67 |  |  | \u2014 |  |  | 199 |  |  | \u2014 | \nOther (income) expense, net |  | 406 |  |  | 267 |  |  | 1,018 |  |  | 649 | \nGain on separation of Kenvue |  | (20,984) |  |  | \u2014 |  |  | (20,984) |  |  | \u2014 | \nRestructuring |  | \u2014 |  |  | 17 |  |  | \u2014 |  |  | 37 | \nEarnings from Discontinued Operations Before Provision for Taxes on Income |  | 21,202 |  |  | 650 |  |  | 22,208 |  |  | 2,005 | \n(Benefit from)/Provision for taxes on income (Note\u00a05) |  | (517) |  |  | 502 |  |  | 298 |  |  | 727 | \nNet earnings from Discontinued Operations |  | 21,719 |  |  | 148 |  |  | 21,910 |  |  | 1,278 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Nine Months Ended\n(Dollars in Millions) |  | October 1, 2023 |  | October 2, 2022\nDepreciation and Amortization |  | 383 |  |  | 482 | \n |  |  |  | \nCapital expenditures |  | 162 |  |  | 178 |   |  |  |  |  |  | \n | January 1, 2023 | \nAssets |  | \nCurrent assets |  | \nCash and cash equivalents | $ | 1,238 |  | \nAccounts receivable trade, less allowances for doubtful accounts | 2,121 |  | \nInventories | 2,215 |  | \n |  | \nPrepaid expenses and other receivables | 256 |  | \nTotal current assets of discontinued operations | 5,830 |  | \nProperty, plant and equipment, net | 1,821 |  | \nIntangible assets, net | 9,836 |  | \nGoodwill | 9,184 |  | \nDeferred taxes on income | 176 |  | \nOther assets | 390 |  | \nTotal noncurrent assets of discontinued operations | $ | 21,407 |  | \n |  | \nLiabilities |  | \nLoans and notes payable | $ | 15 |  | \nAccounts payable | 1,814 |  | \nAccrued liabilities | 737 |  | \nAccrued rebates, returns and promotions | 838 |  | \nAccrued compensation and employee related obligations | 279 |  | \nAccrued taxes on income | (93) |  | \nTotal current liabilities of discontinued operations | 3,590 |  | \nLong-term debt | 2 |  | \nDeferred taxes on income | 2,383 |  | \nEmployee related obligations | 225 |  | \n |  | \nOther liabilities | 291 |  | \nTotal noncurrent liabilities of discontinued operations | $ | 2,901 |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Pre-tax Dollars in Millions) |  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended\nInnovative Medicine Segment(1) |  | $ | 149 |  |  | 424 | \nMedTech Segment(2) |  | 235 |  |  | 235 | \nTotal Programs |  | $ | 384 |  |  | 659 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | October 1, 2023 |  | October 2, 2022 |  | TotalChange |  | OperationsChange |  | CurrencyChange\nImmunology |  | $ | 13,457 |  |  | $ | 12,817 |  |  | 5.0 | % |  | 5.9 | % |  | (0.9) | %\nREMICADE |  | 1,410 |  |  | 1,868 |  |  | (24.5) |  |  | (23.6) |  |  | (0.9) | \nSIMPONI/ SIMPONI ARIA |  | 1,695 |  |  | 1,682 |  |  | 0.8 |  |  | 2.9 |  |  | (2.1) | \nSTELARA |  | 8,105 |  |  | 7,336 |  |  | 10.5 |  |  | 11.1 |  |  | (0.6) | \nTREMFYA |  | 2,237 |  |  | 1,916 |  |  | 16.8 |  |  | 17.4 |  |  | (0.6) | \nOther Immunology |  | 9 |  |  | 14 |  |  | (36.1) |  |  | (36.1) |  |  | \u2014 | \nInfectious Diseases |  | 3,566 |  |  | 3,908 |  |  | (8.7) |  |  | (9.3) |  |  | 0.6 | \nCOVID-19 VACCINE |  | 1,073 |  |  | 1,490 |  |  | (27.9) |  | (29.2) |  | 1.3\nEDURANT/rilpivirine |  | 843 |  |  | 718 |  |  | 17.5 |  |  | 15.8 |  |  | 1.7 | \nPREZISTA/ PREZCOBIX/ REZOLSTA/ SYMTUZA |  | 1,415 |  |  | 1,450 |  |  | (2.4) |  |  | (2.5) |  |  | 0.1 | \nOther Infectious Diseases |  | 235 |  |  | 251 |  |  | (6.4) |  |  | (2.6) |  |  | (3.8) | \nNeuroscience |  | 5,339 |  |  | 5,156 |  |  | 3.5 |  |  | 5.4 |  |  | (1.9) | \nCONCERTA/methylphenidate |  | 603 |  |  | 476 |  |  | 26.7 |  |  | 30.7 |  |  | (4.0) | \nINVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA |  | 3,104 |  |  | 3,132 |  |  | (0.9) |  |  | (0.1) |  |  | (0.8) | \nSPRAVATO |  | 483 |  |  | 255 |  |  | 88.8 |  |  | 88.7 |  |  | 0.1 | \nOther Neuroscience(1) |  | 1,149 |  |  | 1,293 |  |  | (11.0) |  |  | (7.1) |  |  | (3.9) | \nOncology |  | 13,043 |  |  | 12,056 |  |  | 8.2 |  |  | 9.3 |  |  | (1.1) | \nCARVYKTI |  | 341 |  |  | 79 |  |  | * |  | * |  | \u2014\nDARZALEX |  | 7,194 |  |  | 5,894 |  |  | 22.1 |  |  | 23.2 |  |  | (1.1) | \nERLEADA |  | 1,740 |  |  | 1,340 |  |  | 29.8 |  |  | 30.9 |  |  | (1.1) | \nIMBRUVICA |  | 2,476 |  |  | 2,918 |  |  | (15.2) |  |  | (14.2) |  |  | (1.0) | \nZYTIGA/ abiraterone acetate |  | 686 |  |  | 1,500 |  |  | (54.2) |  |  | (52.6) |  |  | (1.6) | \nOther Oncology |  | 605 |  |  | 324 |  |  | 86.5 |  |  | 87.4 |  |  | (0.9) | \nPulmonary Hypertension |  | 2,798 |  |  | 2,547 |  |  | 9.9 |  |  | 11.3 |  |  | (1.4) | \nOPSUMIT |  | 1,437 |  |  | 1,322 |  |  | 8.7 |  |  | 9.9 |  |  | (1.2) | \nUPTRAVI |  | 1,163 |  |  | 986 |  |  | 18.0 |  |  | 18.7 |  |  | (0.7) | \nOther Pulmonary Hypertension |  | 199 |  |  | 239 |  |  | (16.9) |  |  | (11.8) |  |  | (5.1) | \nCardiovascular / Metabolism / Other |  | 2,834 |  |  | 2,916 |  |  | (2.8) |  |  | (2.6) |  |  | (0.2) | \nXARELTO |  | 1,840 |  |  | 1,806 |  |  | 1.9 |  |  | 1.9 |  |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \nOther(2) |  | 994 |  |  | 1,110 |  |  | (10.5) |  |  | (9.8) |  |  | (0.7) | \nTotal Innovative Medicine Sales |  | $ | 41,037 |  |  | $ | 39,400 |  |  | 4.2 | % |  | 5.1 | % |  | (0.9) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | October 1, 2023 |  | October 2, 2022 |  | TotalChange |  | OperationsChange |  | CurrencyChange\nImmunology |  | $ | 4,849 |  |  | $ | 4,287 |  |  | 13.1 | % |  | 12.4 | % |  | 0.7 | %\nREMICADE |  | 461 |  |  | 558 |  |  | (17.4) |  |  | (17.1) |  |  | (0.3) | \nSIMPONI/ SIMPONI ARIA |  | 629 |  |  | 545 |  |  | 15.3 |  |  | 15.8 |  |  | (0.5) | \nSTELARA |  | 2,864 |  |  | 2,449 |  |  | 16.9 |  |  | 15.8 |  |  | 1.1 | \nTREMFYA |  | 891 |  |  | 729 |  |  | 22.2 |  |  | 21.5 |  |  | 0.7 | \nOther Immunology |  | 2 |  |  | 5 |  |  | (47.1) |  | (47.1) |  | \u2014\nInfectious Diseases |  | 859 |  |  | 1,295 |  |  | (33.6) |  |  | (37.8) |  |  | 4.2 | \nCOVID-19 VACCINE |  | 41 |  |  | 489 |  |  | (91.5) |  |  | (97.8) |  |  | 6.3 | \nEDURANT/rilpivirine |  | 297 |  |  | 245 |  |  | 21.0 |  |  | 13.3 |  |  | 7.7 | \nPREZISTA/ PREZCOBIX/ REZOLSTA/SYMTUZA |  | 447 |  |  | 485 |  |  | (7.8) |  |  | (9.0) |  |  | 1.2 | \nOther Infectious Diseases |  | 74 |  |  | 77 |  |  | (3.6) |  |  | (0.5) |  |  | (3.1) | \nNeuroscience |  | 1,742 |  |  | 1,681 |  |  | 3.6 |  | 4.6 |  |  | (1.0) | \nCONCERTA/ methylphenidate |  | 189 |  |  | 158 |  |  | 20.0 |  |  | 21.4 |  |  | (1.4) | \nINVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/TREVICTA |  | 1,029 |  |  | 1,031 |  |  | (0.2) |  |  | (0.3) |  |  | 0.1 | \nSPRAVATO |  | 183 |  |  | 100 |  |  | 82.1 |  |  | 81.0 |  |  | 1.1 | \nOther Neuroscience(1) |  | 340 |  |  | 393 |  |  | (13.2) |  |  | (8.7) |  |  | (4.5) | \nOncology |  | 4,533 |  |  | 4,064 |  |  | 11.5 |  |  | 10.4 |  |  | 1.1 | \nCARVYKTI |  | 152 |  |  | 55 |  |  | * |  | * |  | \u2014\nDARZALEX |  | 2,499 |  |  | 2,052 |  |  | 21.8 |  |  | 20.7 |  |  | 1.1 | \nERLEADA |  | 631 |  |  | 490 |  |  | 28.7 |  |  | 27.0 |  |  | 1.7 | \nIMBRUVICA |  | 808 |  |  | 911 |  |  | (11.3) |  |  | (12.6) |  |  | 1.3 | \nZYTIGA/ abiraterone acetate |  | 214 |  |  | 456 |  |  | (53.0) |  |  | (53.2) |  |  | 0.2 | \nOther Oncology |  | 229 |  |  | 100 |  |  | * |  | * |  | *\nPulmonary Hypertension |  | 954 |  |  | 852 |  |  | 12.0 |  |  | 12.4 |  |  | (0.4) | \nOPSUMIT |  | 490 |  |  | 441 |  |  | 11.2 |  |  | 10.9 |  |  | 0.3 | \nUPTRAVI |  | 402 |  |  | 333 |  |  | 20.7 |  |  | 21.1 |  |  | (0.4) | \nOther Pulmonary Hypertension |  | 63 |  |  | 78 |  |  | (19.8) |  |  | (16.6) |  |  | (3.2) | \nCardiovascular / Metabolism / Other |  | 957 |  |  | 1,034 |  |  | (7.5) |  |  | (8.0) |  |  | 0.5 | \nXARELTO |  | 625 |  |  | 689 |  |  | (9.4) |  |  | (9.4) |  |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nOther(2) |  | 332 |  |  | 345 |  |  | (3.8) |  |  | (5.3) |  |  | 1.5 | \nTotal Innovative Medicine Sales |  | $ | 13,893 |  |  | $ | 13,214 |  |  | 5.1 | % |  | 4.3 | % |  | 0.8 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | October 1, 2023 |  | October 2, 2022 |  | TotalChange |  | OperationsChange |  | CurrencyChange\nSurgery |  | $ | 7,507 |  |  | $ | 7,306 |  |  | 2.7 | % |  | 5.3 | % |  | (2.6) | %\nAdvanced |  | 3,504 |  |  | 3,460 |  |  | 1.3 |  |  | 3.8 |  |  | (2.5) | \nGeneral |  | 4,002 |  |  | 3,846 |  |  | 4.1 |  |  | 6.5 |  |  | (2.4) | \nOrthopaedics |  | 6,674 |  |  | 6,440 |  |  | 3.6 |  |  | 4.5 |  |  | (0.9) | \nHips |  | 1,162 |  |  | 1,129 |  |  | 2.9 |  |  | 3.8 |  |  | (0.9) | \nKnees |  | 1,069 |  |  | 1,005 |  |  | 6.4 |  |  | 7.2 |  |  | (0.8) | \nTrauma |  | 2,238 |  |  | 2,161 |  |  | 3.5 |  |  | 4.0 |  |  | (0.5) | \nSpine, Sports & Other |  | 2,205 |  |  | 2,144 |  |  | 2.8 |  |  | 4.0 |  |  | (1.2) | \nInterventional Solutions |  | 4,681 |  |  | 3,202 |  |  | 46.2 |  |  | 48.9 |  |  | (2.7) | \nElectrophysiology |  | 3,449 |  |  | 2,943 |  |  | 17.2 |  |  | 19.8 |  |  | (2.6) | \nAbiomed |  | 966 |  |  | \u2014 |  |  | * |  | * |  | \u2014\nOther Interventional Solutions |  | 267 |  |  | 258 |  |  | 3.3 |  |  | 6.8 |  |  | (3.5) | \nVision |  | 3,864 |  |  | 3,704 |  |  | 4.3 |  |  | 6.6 |  |  | (2.3) | \nContact Lenses/Other |  | 2,820 |  |  | 2,712 |  |  | 4.0 |  |  | 6.6 |  |  | (2.6) | \nSurgical |  | 1,044 |  |  | 992 |  |  | 5.3 |  |  | 6.6 |  |  | (1.3) | \nTotal MedTech Sales |  | $ | 22,727 |  |  | $ | 20,651 |  |  | 10.0 | % |  | 12.0 | % |  | (2.0) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | October 1, 2023 |  | October 2, 2022 |  | TotalChange |  | OperationsChange |  | CurrencyChange\nSurgery |  | $ | 2,479 |  |  | $ | 2,422 |  |  | 2.3 | % |  | 3.2 | % |  | (0.9) | %\nAdvanced |  | 1,164 |  |  | 1,158 |  |  | 0.5 |  |  | 1.5 |  |  | (1.0) | \nGeneral |  | 1,314 |  |  | 1,264 |  |  | 4.0 |  |  | 4.8 |  |  | (0.8) | \nOrthopaedics |  | 2,164 |  |  | 2,095 |  |  | 3.4 |  |  | 2.6 |  |  | 0.8 | \nHips |  | 375 |  |  | 352 |  |  | 6.5 |  |  | 5.8 |  |  | 0.7 | \nKnees |  | 338 |  |  | 317 |  |  | 6.7 |  |  | 5.7 |  |  | 1.0 | \nTrauma |  | 742 |  |  | 717 |  |  | 3.5 |  |  | 2.4 |  |  | 1.1 | \nSpine, Sports & Other |  | 710 |  |  | 708 |  |  | 0.2 |  |  | (0.2) |  |  | 0.4 | \nInterventional Solutions |  | 1,558 |  |  | 1,060 |  |  | 47.0 |  |  | 48.1 |  |  | (1.1) | \nElectrophysiology |  | 1,161 |  |  | 973 |  |  | 19.3 |  |  | 20.3 |  |  | (1.0) | \nAbiomed |  | 311 |  |  | \u2014 |  |  | * |  | * |  | \u2014\nOther Interventional Solutions |  | 87 |  |  | 87 |  |  | (0.3) |  |  | 1.6 |  |  | (1.9) | \nVision |  | 1,256 |  |  | 1,206 |  |  | 4.2 |  |  | 5.4 |  |  | (1.2) | \nContact Lenses/Other |  | 928 |  |  | 908 |  |  | 2.2 |  |  | 4.0 |  |  | (1.8) | \nSurgical |  | 328 |  |  | 298 |  |  | 10.3 |  |  | 9.5 |  |  | 0.8 | \nTotal MedTech Sales |  | $ | 7,458 |  |  | $ | 6,782 |  |  | 10.0 | % |  | 10.4 | % |  | (0.4) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nFiscal Nine Months |  |  |  |  |  | \n(Dollars in Billions)(Income)/Expense |  | 2023 |  | 2022 |  | Change\nLitigation related(1) |  | $ | 6.7 |  |  | 0.6 |  |  | 6.1 | \n |  |  |  |  |  | \nChanges in the fair value of securities(2) |  | 1.1 |  |  | 0.7 |  |  | 0.4 | \nCOVID-19 Vaccine related exit costs |  | 0.4 |  |  | 0.2 |  |  | 0.2 | \nEmployee benefit plan related |  | (1.1) |  |  | (0.9) |  |  | (0.2) | \nOther |  | (0.1) |  |  | (0.6) |  |  | 0.5 | \n |  |  |  |  |  | \n |  |  |  |  |  | \nTotal Other (Income) Expense, Net |  | $ | 7.0 |  |  | 0.0 |  |  | 7.0 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nFiscal Third Quarter |  |  |  |  |  | \n(Dollars in Billions)(Income)/Expense |  | 2023 |  | 2022 |  | Change\n |  |  |  |  |  | \nChanges in the fair value of securities(1) |  | $ | 1.0 |  |  | 0.2 |  |  | 0.8 | \nEmployee benefit plan related |  | (0.3) |  |  | (0.3) |  |  | \u2014 | \nLitigation related |  | (0.1) |  |  | 0.2 |  |  | (0.3) | \nCOVID-19 Vaccine related exit costs |  | 0.0 |  |  | 0.2 |  |  | (0.2) | \nOther |  | (0.1) |  |  | (0.1) |  |  | \u2014 | \n |  |  |  |  |  | \n |  |  |  |  |  | \nTotal Other (Income) Expense, Net |  | $ | 0.5 |  |  | 0.2 |  |  | 0.3 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Income Before Tax |  | Segment Sales |  | Percent of Segment Sales\n(Dollars in Millions) |  | October 1, 2023 |  | October 2, 2022 |  | October 1, 2023 |  | October 2, 2022 |  | October 1, 2023 |  | October 2, 2022\nInnovative Medicine |  | $ | 14,008 |  |  | $ | 12,424 |  |  | $ | 41,037 |  |  | $ | 39,400 |  |  | 34.1 | % |  | 31.5 | %\nMedTech |  | 4,265 |  |  | 3,641 |  |  | 22,727 |  |  | 20,651 |  |  | 18.8 |  |  | 17.6 | \nSegment earnings before tax |  | 18,273 |  |  | 16,065 |  |  | 63,764 |  |  | 60,051 |  |  | 28.7 |  |  | 26.8 | \nLess: Expenses not allocated to segments(1) |  | 8,037 |  |  | 546 |  |  |  |  |  |  |  |  | \nWorldwide income before tax |  | $ | 10,236 |  |  | $ | 15,519 |  |  | $ | 63,764 |  |  | $ | 60,051 |  |  | 16.1 | % |  | 25.8 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Income Before Tax |  | Segment Sales |  | Percent of Segment Sales\n(Dollars in Millions) |  | October 1, 2023 |  | October 2, 2022 |  | October 1, 2023 |  | October 2, 2022 |  | October 1, 2023 |  | October 2, 2022\nInnovative Medicine |  | $ | 4,794 |  |  | $ | 4,186 |  |  | $ | 13,893 |  |  | $ | 13,214 |  |  | 34.5 | % |  | 31.7 | %\nMedTech |  | 1,185 |  |  | 1,090 |  |  | 7,458 |  |  | 6,782 |  |  | 15.9 |  |  | 16.1 | \nSegment earnings before tax |  | 5,979 |  |  | 5,276 |  |  | 21,351 |  |  | 19,996 |  |  | 28.0 |  |  | 26.4 | \nLess: Expenses not allocated to segments(1) |  | 762 |  |  | 104 |  |  |  |  |  |  |  |  | \nWorldwide income before tax |  | $ | 5,217 |  |  | $ | 5,172 |  |  | $ | 21,351 |  |  | $ | 19,996 |  |  | 24.4 | % |  | 25.9 | %  |  |  |  |  | \n(Dollars In Billions) | \n14.1 |  | Q4 2022 Cash and cash equivalents balance\n14.9 |  | net cash generated from operating activities\n2.1 |  | net cash generated from investing activities\n(11.2) |  | net cash used by financing activities\n(0.2) |  | effect of exchange rate changes on cash and cash equivalents\n | \n | \n$ | 19.7 |  | Q3 2023 Cash and cash equivalents  |  |  |  |  | \n(Dollars In Billions) | \n$ | 31.1 |  | Net earnings\n(21.0) |  | gain on Kenvue separation\n5.5 |  | non-cash expenses and other adjustments primarily for depreciation and amortization, stock-based compensation and asset write-downs partially offset by the deferred tax provision and net gain on sale of assets/businesses\n(2.3) |  | an increase in accounts receivable and inventories\n2.9 |  | an increase in accounts payable and accrued liabilities and other current and non-current liabilities\n(1.4) |  | an increase in other current and non-current assets\n0.1 |  | Rounding\n$ | 14.9 |  | Cash Flow from operations  |  |  |  |  | \n(Dollars In Billions) | \n(3.0) |  | additions to property, plant and equipment\n0.2 |  | proceeds from the disposal of assets/businesses, net\n | \n5.8 |  | net sales of investments\n(0.9) |  | credit support agreements activity, net  other and rounding\n | \n | \n$ | 2.1 |  | Net cash used by investing activities  |  |  |  |  | \n(Dollars In Billions) | \n$ | (8.9) |  | dividends to shareholders\n(4.8) |  | repurchase of common stock\n(9.7) |  | net repayment of short and long term debt\n8.0 |  | Proceeds of short and long-term debt, net of issuance cost, related to the debt that transferred to Kenvue at separation\n4.2 |  | proceeds from Kenvue initial public offering\n(1.1) |  | Cash transferred to Kenvue at separation\n0.9 |  | proceeds from stock options exercised/employee withholding tax on stock awards, net\n0.1 |  | credit support agreements activity, net\n0.1 |  | other and rounding\n$ | (11.2) |  | Net cash from financing activities  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nFiscal Month Period |  | Total Numberof Shares Purchased(1) |  | Avg. PricePer Share |  | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs |  | Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs\nJuly 3, 2023 through July 30, 2023 |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014\nJuly 31, 2023 through August 27, 2023 |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014\nAugust 28, 2023 through October 1, 2023 |  | 5,690,272 |  |  | 161.68 |  |  | \u2014 |  |  | \u2014\nTotal |  | 5,690,272 |  |  | 161.68 |  |  | \u2014 |  |  | \u2014  |  |  |  |  |  |  |  | \nEX-101.INS |  | Instance Document - the instance document does not appear in the Interactive Data File because its                XBRL tags are embedded within the Inline XBRL document\nEX-101.SCH |  | Inline XBRL Taxonomy Extension Schema\nEX-101.CAL |  | Inline XBRL Taxonomy Extension Calculation Linkbase\nEX-101.LAB |  | Inline XBRL Taxonomy Extension Label Linkbase\nEX-101.PRE |  | Inline XBRL Taxonomy Extension Presentation Linkbase\nEX-101.DEF |  | Inline XBRL Taxonomy Extension Definition Document\n |  | \nExhibit 104: |  | Cover Page Interactive Data File\u2013\u2013the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.\n |  |   |  |  |  |  | \n | JOHNSON & JOHNSON(Registrant)\n | \nDate: October\u00a027, 2023 | By /s/ J. J. WOLK\n | J. J. WOLK\n | Executive Vice President, Chief Financial Officer (Principal Financial Officer)\n | \nDate: October\u00a027, 2023 | By /s/\u00a0R. J. DECKER Jr.\n | R. J. DECKER Jr.\n | Controller (Principal Accounting Officer)"}]}
